Total Synthesis of Hyperforin by Sparling, Brian Andrew
 Total Synthesis of Hyperforin
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation No citation.
Accessed February 19, 2015 1:29:10 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11181077
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
HARVARD
Graduate School
UNIVERSITY
of Arts and Sciences
DISSERTATION ACCEPTANCE CERTIFICATE
The undersigned, appointed by the
Department of Chemistry & Chemical Biology
have examined a dissertation entitled:
Total Synthesis of Hyper{orin
presented by : Brian Andrew Sparling
candidate for the degree of Doctor of Philosophy and hereby
certify that it is worthy of acceptance.
Signature
Typed name: Professor
Signature
Typed namei acobsen
Signature
Typed name'. Professor Andrew G. Myers
Date: 08 August 2013
 
 1 
 
 
 
 
Total Synthesis of Hyperforin 
 
 
 
 
A dissertation presented 
by 
Brian Andrew Sparling 
to 
The Department of Chemistry and Chemical Biology 
in partial fulfillment of the requirements 
for the degree of 
Doctor of Philosophy 
in the subject of  
Chemistry 
 
 
 
 
Harvard University 
Cambridge, Massachusetts 
August, 2013 
 
© 2013 by Brian Andrew Sparling 
 
All rights reserved.
 
iii 
Dissertation advisor: Professor Matthew D. Shair Brian Andrew Sparling 
 
Total Synthesis of Hyperforin 
 
Abstract 
Hyperforin (1) is the component of the medicinal herb St. John’s Wort (Hypericum perforatum) 
responsible for its antidepressant activity.  It works by blocking the reuptake of a variety of 
neurotransmitters through a unique mechanism of action and may be a critical lead for the treatment of 
depression and possibly other human diseases.  However, the therapeutic potential of hyperforin is 
severely handicapped by its poor water solubility, facile oxidative degradation, and potent activation of 
pregnane X receptor, leading to increased expression of many genes involved in xenobiotic metabolism.  
Access to a wide variety of hyperforin analogs is critical for mitigating these shortcomings while 
maintaining therapeutic activity.  While limited semisynthetic manipulation of isolated hyperforin is 
feasible, total synthesis is the only possible means of obtaining diverse hyperforin analogs.  
The goal of the work presented in this thesis was to devise a new enantioselective, versatile 
approach to hyperforin that would not only incorporate elements of modularity but also exploit latent 
symmetry within the natural product that would enable facile analog synthesis.  Early strategies that we 
explored included the carbocyclic cyclization of a polyketide and the electrocyclic cascade reaction 
involving an acylketene.  These strategies were inherently flawed, and we subsequently pursued an 
alternative approach involving a diastereoselective epoxide-opening cascade cyclization.  
This approach led to the enantioselective total synthesis of hyperforin.  The synthesis is 18 steps 
in its longest linear sequence and can be deconstructed as the stepwise fusion of six easily obtainable 
chemicals.  The key step in this sequence involved a group-selective, Lewis acid-mediated epoxide-
opening cyclization of 381, in which the strategically placed epoxide functionality relayed stereochemical 
information to the C1, C5, and C8 carbon centers of hyperforin, allowing 2 quaternary stereocenters and 
 
iv 
the bicyclic core of hyperforin to be established in a single transformation in forming 382.  Using this 18-
step sequence, we were able to synthesize over 40 mg of the natural product in a single batch. 
Further, a small library of analogs has been synthesized using the framework of the hyperforin 
synthesis.  These efforts have resulted in the first total synthesis of the natural product secohyperforin and 
the first enantioselective synthesis of (–)-nemorosone.   
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Chapter 1  
Polycyclic Polyprenylated Acylphloroglucinols: An Overview
1
 2 
Overview 
In 1971, a group of Soviet scientists studying the antibacterial properties of St. John’s wort 
(Hypericum perforatum, SJW) reported the discovery of a natural product hyperforin (1, Figure 1.1) from 
the medinical herb’s alcoholic extract.1 Using extensive chemical degradation methods, the flat structure 
of hyperforin was deduced four years later.2 Concurrent to these studies was the isolation and X-ray 
crystallography-guided elucidation of isoxanthochymol (2) from the Indian gamboge (Garcinia 
xanthochymus).3 Hyperforin and isoxanthochymol are the founding and prototypical members of a 
sprawling natural product family known as the polycyclic polyprenylated acylphloroglucinols (PPAPs),4 
of which there are 260 members to date. 
 
 
Figure 1.1. Structures of hyperforin (1) and isoxanthochymol (2).  
 
 
                                                      
1 Gurevic, A. I.; Dobrynin, V. N.; Kolosov, M. N.; Popravko, S. A.; Ryabova, I. D.; Chernov, B. K.; Derbentseva, 
N. A.; Aizenman, B. E.; Garagulya, A. D. Antibiotiki 1971, 16, 510-513. 
 
2 Bystrov, N. S.; Chernov, B. K.; Dobrynin, V. N.; Kolosov, M. N. Tetrahedron Lett. 1975, 16, 2791-2794. 
 
3 Karajgoaker, C. G.; Rama Rao, A. V.; Venkataraman, K.; Yemul, S. S.; Palmer, K. J. Tetrahedron Lett. 1973, 14, 
4977-4980. 
 
4 For reviews on the structural diversity of PPAP natural products, see: (a) Cuesta-Rubio, O.; Piccinelli, A. L.; 
Rastrelli, L. Stud. Nat. Prod. Chem. 2005, 32, 671-720. (b) Baggett, S.; Mazzola, E. P.; Kennelly, E. J. Stud. Nat. 
Prod. Chem. 2005, 32, 721-771. (c) Ciochina, R.; Grossman, R. B. Chem. Rev. 2006, 106, 3963-3986. (d) Singh, I. 
P.; Bharate, S. B. Nat. Prod. Rep. 2006, 23, 558-591. 
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A PPAP natural product may be defined as a bicyclo[3.3.1]nonane (or a larger bridged polycyclic 
containing a bicyclo[3.3.1]nonane element) bearing a C9 ketone (Figure 1.2).5,6 Aside from the C9 
position, oxidation is also found at the C2 and C4 positions, and in approximately 80% of PPAPs, these 
two oxidation sites are conjugated through C3 to form a β-hydroxyenone or β-alkoxyenone functionality 
array.  The periphery of this carbocyclic core is decorated with multiple isoprenoid groups at the C1, C3, 
C5, C7, and C8 positions.  In the great majority of instances, these substituents are derived from the 
following parent isoprenoids: prenyl in 75% of substituents; lavandulyl in 10% of substituents; and 
geranyl in 7.5% of substituents.  These isoprenoid substituents undergo secondary cyclization to form 
additional oxacyclic and carbocyclic rings in many PPAPs.  Nearly all of these natural products contain a 
quaternary center at the C8 position, and in 81% of PPAPs, this position is substituted with two methyl 
groups.   
 
 
Figure 1.2. Generic PPAP skeleton and typical substituents. 
 
 
                                                      
5 The general method of PPAP numbering used throughout is in accordance with IUPAC guidelines for bicyclic 
compounds.  For more information, see: Moss, G. P. Pure Appl. Chem. 1999, 71, 513-529.    
 
6 This definition excludes certain polycyclic polyprenylated acylphloroglucinol natural products that do not contain 
a bicyclo[3.3.1]nonane subunit.  For examples of “atypical PPAPs,” see: (a) Winkelmann, K.; Heilmann, J.; Zerbe, 
O.; Rali, T.; Sticher, O. J. Nat. Prod. 2000, 63, 104-108 (ialibinone A-E). (b) Wu, J.; Cheng, X.-F.; Harrison, L. J.; 
Goh, S.-H.; Sim, K.-Y. Tetrahedron Lett. 2004, 45, 9657-9659 (perforatumone). (c) Thoison, O.; Cuong, D. D.; 
Gramain, A.; Chiaroni, A.; Van Hung, N.; Sévenet, T. Tetrahedron 2005, 61, 8529-8525 (garcibracteatone). (d) 
Tanaka, N.; Kashiwada, Y.; Sekiya, M.; Ikeshiro, Y.; Takaishi, Y. Tetrahedron Lett. 2008, 49, 2799-2803 
(takaneone A-C). (e) Yang, X.-W.; Deng, X.; Liu, X.; Wu, C.-Y.; Li, X.-N.; Wu, B.; Luo, H.-R.; Li, Y.; Xu, H.-X.; 
Zhao, Q.-S.; Xu, G. Chem. Commun. 2012, 48, 5998-6000 (hypercohin A). 
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The placement of an acyl group around the bicyclic ring system is used to classify PPAPs into 
three different subgroups: (1) “Type A” PPAPs contain a C1 acyl substituent; (2) “Type B” PPAPs 
contain a C3 acyl substituent; and (3) “Type C” PPAPs contain a C5 acyl substituent.  Approximately 
52% of PPAPs are Type A, and 46% are Type B.  There are only three known Type C PPAPs, and an 
additional three PPAPs lack acyl substitution all together.  When an acyl group is present, it is either an 
isobutyryl (15%), 2-methylbutyryl (6%), isovaleryl (1.5%), benzoyl (36.5%), or an oxidized benzoyl 
(41%) group.  A comprehensive listing of all published PPAPs with references to chemotaxonomical, 
geographical, and spectroscopic data is found in Appendix A. 
Stereochemistry 
The absolute configurations of only a few PPAP natural products have been ascertained.  Since 
the most electron-rich atom found in all PPAPs is oxygen, anomalous scattering is not normally large 
enough to permit the refinement of the Flack parameter7 and thus absolute configuration during X-ray 
diffraction analysis.  To circumvent this issue, the crystal structures of PPAPs that have been appended 
with various brominated groups have been resolved, which now contain atoms with sufficient electron 
density to allow determination of the Flack parameter.  The absolute configurations of hyperforin,8 
isogarcinol,9 isoxanthochymol,10 and xanthochymol10,11 have been solved using this methodology.  Recent 
advancements using Bijvoet pair analysis and subsequent determination of the Hooft parameter allows for 
the determination of absolute structure at low temperatures without requiring the presence of heavy 
atoms.12 The absolute configuration of 7-epi-clusianone has been solved in this manner.13   
                                                      
7 Flack, H. D. Acta. Cryst. 1983, A39, 876-881.  
 
8 Brondz, I.; Greibrokk, T.; Groth, P.; Aasen, A. J. Acta Chem. Scand. A 1983, 37, 263-265. 
 
9 Marti, G.; Eparvier, V.; Moretti, C.; Susplugas, S.; Prado, S.; Grellier, P.; Retailleau, P.; Guéritte, F.; Litaudon, M. 
Phytochemistry 2009, 70, 75-85. 
 
10 Venkatswamy, G.; Yemul, S. S.; Rama Rao, A. V.; Palmer, K. J. Indian J. Chem. 1975, 13, 1355-1355. 
 
11 Blount, J. F.; Williams, T. H. Tetrahedron Lett. 1976, 17, 2921-2924. 
 
12 Hooft, R. W. W.; Straver, L. H.; Spek, A. L. J. Appl. Cryst. 2008, 41, 96-103. 
 
4
 5 
The absolute configurations of several PPAPs have been determined through comparison of 
spectroscopic data and direct semisynthetic conversion.  Isoxanthochymol and isogarcinol have identical 
spectroscopic properties except for optical rotations of opposite sign.  Through the observation of similar 
Cotton effects in the circular dichroism (CD) spectra of isogarcinol, the absolute configuration of 
isogarcinol 13-O-methyl ether14 and 13,14-didehydroxyisogarcinol15 were determined. The absolute 
configuration of guttiferone E (and thus its enantiomer, garcinol) was determined through acid- and heat-
mediated conversion to isoxanthochymol (2).16 Ozonolysis of sinaicone produced the previously 
characterized (2R,4R)-2,4-dimethylhexanoic acid.17  Through comparison of CD spectra with computed 
electronic circular dichroism (ECD) spectra calculated using density functional theory (DFT), the 
absolute configurations of 7-epi-guttiferone J,18 oxy-guttiferone K,19 guttiferone M,19 32-hydroxy-ent-
guttiferone M18 have been determined.   
In addition, several PPAPs have been isolated in both enantiomeric forms.  Specifically, these 
enantiomeric pairs are: chamuangone (cowanone) and guttiferone Q; cycloxanthochymol and ent-
cycloxanthochymol; garcinialiptone A and ent-garcinialiptone A; garcinielliptone I and hyperibone A; 
garcinol and guttiferone E; guttiferone G (guttiferone I2) and oblongifolin C; guttiferone O2 and 
oblongifolin F; hyperibone G and propolone D; isogarcinol and isoxanthochymol; and samponione G and 
ent-sampsonione G.   
                                                      
13 Christian, O. E.; Fronczek, F. R.; Ky, K.; Pradham, S.; Manandhar, A.; Richmond, C. Acta Cryst. 2012, E68, 
o3222-o3223. 
 
14 Ito, C.; Itoigawa, M.; Miyamoto, Y.; Onoda, S.; Rao, K. S.; Mukainaka, T.; Tokuda, H.; Nishino, H.; Furukawa, 
H. J. Nat. Prod. 2003, 66, 206-209. 
 
15 Chen, J.-J.; Ting, C.-W.; Hwang, T.-L.; Chen, I.-C. J. Nat. Prod. 2009, 72, 253-258. 
 
16 Gustafson, K. R.; Blunt, J. W.; Munro, M. H. G.; Fuller, R. W.; McKee, T. C.; Cardellina, J. H., II; McMahon, J. 
B.; Cragg, G. M.; Boyd, M. R. Tetrahedron 1992, 48, 10093-10102. 
 
17 Řezanka, T.; Sigler, K. Phytochemistry 2007, 68, 1272-1276. 
 
18 Acuña, U. M.; Figueroa, M.; Kavalier, A.; Jancovski, N.; Basile, M. J.; Kennelly, E. J. J. Nat. Prod. 2010, 73, 
1775-1779. 
 
19 Masullo, M.; Bassarello, C.; Bifulco, G.; Piacente, S. Tetrahedron 2010, 66, 139-145. 
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Distribution 
PPAPs have been isolated from 128 different plant species spanning 18 different genii in 6 
different families.  The great majority (257 out of 260) of PPAPs have been isolated from plants from the 
Clusiaceae (Guttifereae) and Hypericeae families, members of the Malpighiales order.20,21 The genii 
Clusia, Garcinia, and Hypericum are particularly prolific, having PPAPs isolated from 132 different 
subordinate species.22 Many PPAPs have been observed in multiple species; hyperforin alone has been 
detected in 38 distinct species.23 Only five PPAPs have been isolated outside of the Clusiaceae and 
Hypericeae families (Figure 1.3): dorstenpictanone (3) from Dorstenia picta (Moraceae);24 spiranthenones 
A-B (4,5) from Spiranthera odoratissima (Rutaceae);25 xanthochymol (6) from Endodesmia 
calophylloides (Calophyllaceae);26 and hyperforin (1) has been isolated from Apocynum venetum 
(Apocynaceae)27 and from Scutellaria baicalensis (Lamiaceae).28  
                                                      
20 Hypericeae has traditionally been regarded as a separate family, but recent phylogenic analysis based on the 
chloroplast gene rbcL has shown that it can be classified as a tribe (i.e., Hypericoideae) of the Clusiaceae family.  
For more information, see: Gustafsson, M. H. G.; Bittrich, V.; Stevens, P. F. Int. J. Plant Sci. 2002, 163, 1045-1054.   
 
21 Wurdack, K. J.; Davis, C. C. Am. J. Bot. 2009, 96, 1551-1570. 
 
22 For reviews of phytochemical and therapeutic aspects of the PPAPs from these genii, see: (a) Cuesta-Rubio, O.; 
Piccinelli, A. L.; Rastrelli, L. Stud. Nat. Prod. Chem. 2005, 32, 671-720. (b) Hemshekhar, M.; Sunitha, K.; 
Santhosh, M. S.; Devaraja, S.; Kemparaju, K.; Vishwanath, B. S.; Niranjana, S. R.; Girish, K. S. Phytochem. Rev. 
2011, 10, 325-351. 
 
23 For a review of the distribution of hyperforin amongst Hypericum species, see: Stojanović, G.; Đorđević, A.; 
Šmelcerović, A. Curr. Med. Chem. 2013, 20, 2273-2295. 
 
24 Hussain, H.; Vouffo, B.; Dongo, E.; Riaz, M.; Krohn, K. J. Asian Nat. Prod. Res. 2011, 13, 547-550. 
 
25 Albernaz, L. C.; Deville, A.; Dubost, L.; de Paula, J. E.; Bodo, B.; Grellier, P.; Espindola, L. S.; Mambu, L. 
Planta Med. 2012, 78, 459-464. 
 
26 Talontsi, F. M.; Islam, M. T.; Facey, P.; Douanla-Meli, C.; von Tiedemann, A.; Laatsch, H. Phytochem. Lett. 
2012, 5, 657-664. 
 
27 Zheng, M.; Fan, Y.; Shi, D.; Liu, C. J. Ethnopharmacol. 2013, 147, 108-113. 
 
28 Murch, S. J.; Rupasighe, H. P. V.; Goodenowe, D.; Saxena, P. K. Plant Cell Rep. 2004, 23, 419-425. 
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Figure 1.3. Structures of dorstenpictanone (3), spiranthenone A-B (4,5), and xanthochymol (6). 
 
 
While most species of the Clusiaceae family are found in tropical regions, Hypericeae species are 
found in temperate climes.  Given the fact that most PPAPs exhibit some degree of antibacterial 
properties, it is unsurprising that these compounds are isolated from the flowers and fruit rinds of these 
species, protecting vulnerable and sexually important organs from bacterial parasites.  Hyperforin may 
exist in concentrations up to 11% in the flowering parts of Hypericum perforatum,29 and its concentration 
generally decreases as the flowers develop and mature.30 Moreover, PPAPs are also found in the latex of 
many Clusiaceae species, protecting against the development of infections in injuries to these plants.  
Garcinol (7) and isogarcinol (8) were initially isolated in “surprisingly in large quantities” from the latex 
of Garcinia cambogia; garcinol comprised 37% of total mass of this material (Figure 1.4).31 
 
                                                      
29 Bergonzi, M. C.; Bilia, A. R.; Gallori, S.; Guerrini, D.; Vincieri, F. F. Drug Dev. Ind. Pharm. 2001, 27, 491-497. 
 
30 Büter, K. B.; Büter, B. J. Herbs Spices Med. Plants 2002, 9, 95-100. 
 
31 Rao, A. V. R.; Venkatswamy, G.; Pendse, A. D. Tetrahedron Lett. 1980, 21, 1975-1978. 
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Figure 1.4. Structures of garcinol (7) and isogarcinol (8). 
 
 
Species of both the Clusiaceae and Hypericeae families are also noted for their high degree of 
evolutionary plasticity, and this may be a direct result of adaptation to different methods of pollination.  
Further, while most flowers in general use nectar and pollen as pollinator rewards, a unique adaptation 
and defining feature of flowering plants from the Clusiaceae family is the additional use of resins as 
rewards.  Certain honeybees will use these resins to create a material known as propolis, which is used to 
patch holes in their hives as well as to embalm the carcasses of intruders.  Propolis is used widely in a 
variety of folk medicines, and its application traces back to the ancient Egyptians who used this substance 
in cadaver mummification.32 The contents of propolis vary according to geography and climate, and 
PPAPs are the dominant chemicals found in the propolis of New World bee colonies from as far north as 
the Caribbean islands to as far south as central Brazil.  It is interesting to note that while the majority of 
the 25 distinct PPAPs that have been isolated from these propola have also been found in nearby flora, the 
plant source of 7 propolis PPAPs have not been identified.   
Biosynthesis 
Very little evidence beyond conjecture is known specifically about PPAP biosynthesis.  The only 
PPAP that has undergone any biosynthetic experimental scrutiny is hyperforin (1); however, several 
generalizations about PPAP biosynthesis can be extrapolated from these studies.  In general, the 
biosynthesis of PPAPs can be broken down into three distinct phases: (1) polyketide synthesis of an 
                                                      
32 For reviews on propolis, see: (a) Salatino, A.; Teixeira, É. W.; Negri, G.; Message, D. Evid. Based Complement. 
Alternat. Med. 2005, 2, 33-38. (b) Miguel, M. G.; Antunes, M. D. J. Pharm. Bioallied Sci. 2011, 3, 479-495. (c) 
Watanabe, M. A. E.; Amarante, M. K.; Conti, B. J.; Sforcin, J. M. J. Pharm. Pharmacol. 2011, 63, 1378-1386. (d) 
Salatino, A.; Fernandes-Silva, C. C.; Righi, A. A.; Salatino, M. L. F. Nat. Prod. Rep. 2011, 28, 925-936. 
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acylphloroglucinol precursor; (2) alkylation of this core with isoprenoid side chains and subsequent 
cyclization to form the characteristic bicyclo[3.3.1]nonane core of PPAPs; and (3) secondary cyclizations, 
oxidations, and rearrangements. 
The first step in PPAP biosynthesis involves the stepwise, decarboxylative condensation of an 
alkoyl-SCoA or an aroyl-SCoA group (9) with three molecules of malonyl-CoA (10, Scheme 1.1).  This 
enzyme-bound linear tetraketide (11) then undergoes an intramolecular Claisen cyclization to form an 
acylphloroglucinol (12).  The enzymes that catalyze these reactions are members of the type III 
polyketide synthase (PKS) superfamily.  While type I and II PKSs contain acyl carrier proteins (ACPs) 
that shuttle the growing polyketide across modular functional domains (e.g., ketoreductase and 
dehydratase), type III PKSs lack ACPs and contain a single active site in which the growing polyketide 
chain is anchored.33   
 
 
Scheme 1.1. The first steps in PPAP biosynthesis. 
 
All known type III PKSs are homodimers and contain a highly conserved cysteine-histidine-
asparagine catalytic triad within the active site of each monomer.34 The cysteine acts as the polyketide 
attachment site, and the histidine and asparagine residues play critical roles in the decarboxylation of 
malonyl-CoA during chain extension.  Additionally, two generally conserved phenylalanine residues near 
the entrance of the active site facilitate some degree of substrate specificity; however, PKSs in general 
poorly differentiate starter units in vitro and rely upon compartmentalization within plant tissue and cells 
                                                      
33 For reviews of type III PKS, see: (a) Flores-Sanchez, I. J.; Verpoorte, R. Plant Physiol. Biochem. 2009, 47, 167-
174. (b) Beerhues, L.; Liu, B. Phytochemistry 2009, 70, 1719-1727.  
 
34 Jez, J. M.; Bowman, M. E.; Noel, J. P. Proc. Natl. Acad. Sci. USA 2002, 99, 5319-5324. 
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to engender a high degree of substrate selectivity.33a For PPAPs such as hyperforin (1) containing an 
isopropyl ketone moiety, isobutyrophenone synthase (BUS) is used to synthesize phlorisobutyrophenone 
(13, Figure 1.5).  PPAPs containing phenyl and isobutyl ketones utilize benzophenone synthase (BPS) 
and phlorisovalerophenone synthase (VPS) to synthesize 2,4,6-trihydroxybenzophenone (14) and 
phlorisovalerophenone (15), respectively.  Only two PKS systems utilized in PPAP biosynthesis have 
been characterized: the hyperforin and adhyperforin BUS from Hypericum calycinum35 and the 
hyperandrone A BPS from Hypericum androsaemum.36 In addition, the gene responsible the PKS 
involved in hyperforin and adhyperforin biosynthesis in Hypericum perforatum, named HpPKS1, has also 
been characterized.37  
 
 
Figure 1.5. Specific examples of intervening acylphloroglucinols in PPAP biosynthesis. 
 
For the biosynthesis of PPAPs, exactly three molecules of malonyl-CoA are condensed with a 
starter acyl-CoA subunit.  For type III PKSs, termination of polyketide chain length is determined by 
active site volume.  For example, if a Thr135Leu point mutation is introduced in the active site of the 
Hypericum androsaemum BPS, the subsequent decrease in active site volume causes this enzyme to 
become a phenylpyrone sythase without a decrease in catalytic efficiency, in which only two molecules of 
                                                      
35 Klingauf, P.; Beuerle, T.; Mellenthin, A.; El-Moghazy, S. A. M.; Boubakir, Z.; Beerhues, L. Phytochemistry 2005, 
66, 139-145. 
 
36 Liu, B.; Falkenstein-Paul, H.; Schmidt, W.; Beerhues, L. Plant J. 2003, 34, 847-855. 
 
37 Karppinen, K.; Hohtola, A. J. Plant Physiol. 2008, 165, 1079-1086. 
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malonyl-CoA are incorporated.38 This triketide then undergoes lactonization to form 6-phenyl-4-hydoxy-
2-pyrone (16, Scheme 1.2a) instead of 2,4,6-trihydroxybenzophenone (14, Scheme 1.2b).   
 
 
Scheme 1.2. (a) Phenylpyrone synthase activitiy of Thr135Leu H. androsaemum BPS and  
(b) benzophenone synthase activity of wild-type H. androsaemum BPS. 
 
The next step in PPAP biosynthesis involves polyisoprenylation of the acylphloroglucinol 
nucleus.  All isoprenoids are derived from the two C5 precursors: isopentenyl diphosphate (17) and 
dimethylallyl diphosphate (18).  Until the early 1990s, it was thought that these precursors were produced 
from a single pathway involving a melavonate (19) intermediate (Scheme 1.3).39 This pathway involves 
the condensation of three molecules of acetyl-CoA (20) to 3-hydroxy-3-methylglutaryl-CoA (21), and 
upon reduction to melavonate (19), pyrophosphorylation to 22, and decarboxylative elimination, 17 is 
synthesized, which can then be isomerized to 18.  Indeed, this is the pathway by which eukaryotes 
synthesize sterols and other important metabolites. 
 
 
Scheme 1.3. Melavonate pathway of terpene biosynthesis. 
 
                                                      
38 Klundt, T.; Bocola, M.; Beuerle, T.; Liu, B.; Beerhues, L. J. Biol. Chem. 2009, 284, 30957-30964. 
 
39 Bach, T. J. Lipids 1995, 30, 191-202.  
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However, in the early 1990s, inconsistencies regarding 13C-labelled intermediates led to the 
independent discoveries of a non-melavonate means of isoprenoid biosynthesis in plants and bacteria by 
the research groups of Rohmer and Arigoni.40 The absence of this pathway in humans has garnered 
significant attention as a means to develop novel anti-infective pharmaceutical agents.41 This 
deoxyxylulose phosphate pathway42 commences with the thiamine pyrophosphate (TPP) mediated 
decarboxylative coupling of pyruvate (23) to D-glyceraldehyde-3-phosphate (24) to form 1-deoxy-D-
xylulose-3-phosphate (25, Scheme 1.4).  A subsequent rearrangement with concomitant reduction affords 
2C-methyl-D-erythritol 4-phosphate (26).  Sequential cytidyl phosphorylation and phosphorylation yields 
4-diphosphocytidyl 2C-methyl-D-erythritol 2-phosphate (27).  Cytidyl monophosphate (CMP) is then 
released to form 2C-methyl-D-erythritol-2,4-cyclodiphosphate (28).  Single-electron transfer from an iron-
sulfur cluster cofactor mediates the reductive rearrangement of 28 to E-1-hydroxy-2-methyl-2-butenyl 
diphosphate (29) through an unknown mechanism of action.  Finally, another iron-sulfur cluster-
facilitated single-electron transfer process affords either 17 or 18, depending on the specific enzyme. 
 
 
Scheme 1.4. Deoxyxylulose phosphate pathway of terpene biosynthesis. 
 
 
                                                      
40 (a) Rohmer, M.; Knani, M.; Simonin, P.; Sutter, B.; Sahm, H. Biochem. J. 1993, 295, 517-524. (b) Arigoni, D.; 
Sagner, S.; Latzel, C.; Eisenreich, W.; Bacher, A.; Zenk, M. H. Proc. Natl. Acad. Sci. USA 1997, 94, 10600-10605. 
 
41 Gräwert, T.; Groll, M.; Rohdich, F.; Bacher, A.; Eisenreich, W. Cell. Mol. Life Sci. 2011, 68, 3797-3814. 
 
42 For reviews of the deoxyxylulose phosphate pathway, see ref. 41 and (a) Rohmer, M. Nat. Prod. Rep. 1999, 16, 
565-574. (b) Eisenreich, W.; Rohdich, F.; Bacher, A. Trends Plant Sci. 2001, 6, 78-84. (c) Hunter, W. M. J. Biol. 
Chem. 2007, 282, 21573-21577. 
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Higher plants utilize both the melavonate and deoxyxylulose pathways to synthesize terpenoids, 
and this is a reason for the relatively belated discovery of the latter.  In general, the melavonate route is 
used in the cytoplasm and mitochondria, and it is responsible for the synthesis of sesquiterpenoids and 
ubiquinones.  Other metabolites, such as hemiterpenes, monoterpenes, diterpenes, and carotenoids, are 
formed via the deoxyxylulose pathway localized in the plastids.43 Given the fact that most substituents on 
PPAPs are hemiterpenoid or monoterpenoid in origin, it is unsurprising that they are synthesized using 
the deoxyxylulose phosphate pathway.  Due to the presence of a skeletal rearrangement in this pathway 
(i.e., 25 to 26), the introduction of isotopically-labeled feedstocks may be used to differentiate between 
these pathways.  A feeding study of Hypericum perforatum sprouts performed in the dark utilizing both 
[1-13C]glucose and [U-13C6]glucose provided evidence for the involvement of the deoxyxylulose pathway 
in hyperforin biosynthesis.44  
Further, this study demonstrated that hyperforin is synthesized from the alkylation of 
phlorisobutyrophenone (13) with 3 molecules of dimethylallyl diphosphate (18) and 1 molecule of 
geranyl diphosphate (30).  Although the details concerning the specific order of alkylation remain scant, a 
reasonable biosynthetic sequence can be deduced for hyperforin (Scheme 1.5).  Originally proposed by 
Bystrov and coworkers in 1975,2 conversion of 13 to deoxycohumulone (31) followed by dearomative 
alkylation with 30 produces cyclohexadienone 32.  Prenylation of the proximal olefin present in the 
geranyl side chain of 32 with 18 with either concerted or stepwise cyclization affords hyperforin (1).   
                                                      
43 For more information on the biosynthesis of phytochemical terpenoids, see ref. 42b.  In some cases, both 
pathways may be operational in the biosynthesis of a single natural product.  For an example, see: Nabeta, K.; 
Ishikawa, T.; Kawae, T.; Okuyama, H. J. Chem. Soc., Chem. Commun. 1995, 681-682. 
 
44 Adam, P.; Arigoni, D.; Bacher, A.; Eisenreich, W. J. Med. Chem. 2002, 45, 4786-4793.  
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Scheme 1.5. Proposed biosynthesis of hyperforin (1) from phlorisobutyrophenone (13). 
 
The intermediates of this hyperforin biosynthesis bear resemblance to other families of natural 
products.  Polyprenylated acylphloroglucinols such as 31, also known as deoxycohumulone, were first 
isolated in hops in 1961.45 Hops are the female seed cones of Humulus lupulus (Cannabaceae) and have 
been extensively studied by the brewing industry due to the importance of hops in beer flavor and 
aroma.46 Deoxycohumulone (31) is a direct precursor of both colupulone (33),47 a typical hop β-acid, and 
cohumulone (34),48 a typical hop α-acid (Scheme 1.6).49 In the brewing of beer, hops are boiled with malt 
and wort in water.  Under these conditions, isomerization of cohumulone takes place to give bitter hop 
iso-α-acids, an important flavoring agent in beer.  While hop β-acids like colupulone are thought to 
                                                      
45 (a) Hübner, H.; Maier, J.; Riedl, W. Z. Physiol. Chem. 1961, 325, 224-228. (b) Lloyd, R. O. V.; Shannon, P. V. 
R.; Shaw, S. J. J. Inst. Brewing 1969, 75, 32-36. 
 
46 (a) Stevens, R.; Chem. Rev. 1967, 67, 19-71. (b) Palamand, S. R.; Aldenhoff, J. M. J. Agric. Food Chem. 1973, 
21, 535-543. 
 
47 Zuurbier, K. W. M.; Fung, S.-Y.; Scheffer, J. J. C.; Verpoorte, R. Phytochemistry 1995, 38, 77-82. 
 
48 (a) Fung, S.-Y.; Zuurbier, K. W. M.; Paniego, N. B.; Scheffer, J. J. C.; Verpoorte, R. Phytochemistry 1997, 44, 
1047-1053. (b) Goese, M.; Kammhuber, K.; Bacher, A.; Zenk, M. H.; Eisenreich, W. Eur. J. Biochem. 1999, 263, 
447-454. (c) Hecht, S.; Kammhuber, K.; Reiner, J.; Bacher, A.; Eisenrech, W. Phytochemistry 2004, 65, 1057-1060. 
 
49 Fung, S.-Y.; Brusee, J.; van der Hoeven, R. A. M.; Niessen, W. M. A.; Scheffer, J. J. C.; Verpoorte, R. J. Nat. 
Prod. 1994, 57, 452-459. 
Me
Me OPP
18
OH
OHHO
O
Me
Me
13
+  2 x
OH
OHHO
O
Me
Me
31
Me
Me
MeMe
+ Me
OPP
18
OHHO
OO Me
Me
Me
MeMe
Me
Me
Me
Me
Me
Me
OHO
OO Me
Me
Me
MeMe
Me
Me
Me
Me
Me
Me
OPP
32
Me
Me
30
1
14
 15 
mostly decompose during the wort boiling process, recent studies have shown that they also isomerize to 
bitter-tasting compounds that may further add to the complex composition of beer flavor.50 
 
 
Scheme 1.6. Deoxycohumulone (31) as a biosynthetic precursor to both colupulone (33) and cohumulone (34). 
 
 
The enzymes responsible for the isoprenylation en route to natural products such as PPAPs and 
hop acids are collectively known as prenyltransferases.51 In plants, prenyltransferase activity is mainly 
located in the plastids, and the alkylating terpenoid is derived from the deoxyxylulose pathway.  All 
known prenyltransferases require a divalent metal cation.  The prenyltransferases responsible for the 
conversion of phlorisobutyrophenone (13) to prenyl phlorisobutyrophenone (35, also known as 
“compound co-X”), which is the first prenylation step in the biosyntheses of hop bitter acids and 
hyperforin, has been characterized in both Humulus lupulus and Hypericum calycinum (Scheme 1.7).  The 
enzyme utilized in Humulus lupulus has an unusually wide substrate scope, and there are conflicting 
reports as to whether this enzyme is membrane-bound or not.52 All other plant prenyltransferases are 
membrane-bound.51 The analogous prenyltransferase utilized in hyperforin biosynthesis in Hypericum 
                                                      
50 (a) Haseleu, G.; Intelmann, D.; Hofmann, T. Food Chem. 2009, 116, 71-81. (b) Haseleu, G.; Intelmann, D.; 
Hofmann, T. J. Agric. Food Chem. 2009, 57, 7480-7489.   
 
51 For a review, see: Yazaki, K.; Sasaki, K.; Tsurumaru, Y. Phytochemistry 2009, 70, 1739-1745. 
 
52 (a) Zuurbier, K. W. M.; Fung, S.-Y.; Scheffer, J. J. C.; Verpoorte, R. (b) Tsurumaru, Y.; Sasaki, K.; Miyawaki, T.; 
Uto, Y.; Momma, T.; Umemoto, N.; Momose, M.; Yazaki, K. Biochem. Biophys. Res. Commun. 2012, 417, 393-
398.   
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calycinum has also been characterized as being non-membrane-bound.53 To date, the prenyltransferases 
involved in the formation of deoxycohumulone or the dearomative prenylation of deoxycohumulone have 
not been characterized.   
 
 
Scheme 1.7. The first prenylation step in hyperforin and hop bitter acid biosynthesis. 
 
After dearomative poly-isoprenylation of a polyketide acyphloroglucinol, a cascade cyclization 
takes place to form the characteristic bicyclo[3.3.1]nonane core of PPAP natural products.  Hop β-acids, 
such as colupulone (33) are alkylated54 to produce a tertiary carbocationic intermediate, which then is 
trapped through nucleophilic addition of the cyclohexadienone ring (e.g., see Scheme 1.5).  Several 
modes of nucleophilic addition are available to trap this carbocationic intermediate, as illustrated for 
grandone (36)55 in Scheme 1.8.  Following prenyl transfer and subsequent formation of the carbocation 
37, simple E1-type deprotonation may lead to the formation of weddellianone A (38, Scheme 1.8a), a 
lavandulyl-substituted hop β-acid that has been isolated from Clusia weddelliana (Clusiaceae).56 In 
addition, two different nucleophilic carbon centers in the cyclohexadienone ring of 37 may trap this 
carbocation, either at C1 or at C3, and this divergence leads to either a Type A or Type B PPAP, 
respectively.  If the carbocation is trapped at C1, the Type A PPAP nemorosone55b is generated (39, 
                                                      
53 Boubakir, Z.; Beuerle, T.; Liu, B.; Beerhues, L. Phytochemistry 2005, 66, 51-57.  
 
54 Note that two possible diastereomers may be generated at C7 from this alkylation event.  Only one diastereomer is 
depicted throughout Scheme 1.8. 
 
55 36 was first synthesized in 1971 in a study of hop β-acids: Collins, M.; Laws, D. R. J.; McGuinness, J. D.; 
Elvidge, J. A. J. Chem. Soc. C 1971, 3814-3818.  It was later isolated from Clusia grandiflora: de Oliveira, C. M. 
A.; Porto, A. M.; Bittrich, V.; Vencato, I.; Marsaioli, A. J. Tetrahedron Lett. 1996, 37, 6427-6430. 
 
56 Porto; A. L. M.; Machado, S. M. F.; de Oliveira, C. M. A.; Bittrich, V.; Amaral, M. do C. E.; Marsaioli, A. J. 
Phytochemistry 2000, 55, 755-768. 
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Scheme 1.8. Cyclization modes of grandone (36) after prenylation via intermediate 37: (a) deprotonation,  
(b) C1 cyclization, (c) C3 cyclization, and (d) etherification.  
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Scheme 1.8b), and if cyclization occurs at C3, the Type B PPAP 7-epi-clusianone57 is produced (40, 
Scheme 1.8c).  An oxygen atom, such as the ketone oxygen attached to C9, may also intercept this 
carbocation as depicted in Scheme 1.8d to generate benzopyran-type products like 41.  However, only a 
single analogous natural product that may involve such a cyclization has been isolated to date 
(bronianone, 42, Figure 1.6).58,59 
 
 
Figure 1.6. Structure of bronianone (42). 
 
 
Unlike Types A and B PPAPs, the relatively rare Type C PPAPs cannot be made via 
intermediates such as grandone (36) but rather an isomeric compound represented as 43 (Figure 1.7a).  
Only three Type C PPAPs have been isolated to date (Figure 1.7b), garcinielliptone K (44), L (45), and M 
(46), from Garcinia subelliptica.60 
 
                                                      
57 (a) Santos, M. H.; Speziali, N. L.; Nagem, T. J.; Oliveira, T. T. Acta Cryst. 1998, C54, 1990-1992. (b) Alves, T. 
M. de A.; Alves, R. de O.; Romanha, A. J.; dos Santos, M. H.; Nagem, T. J.; Zani, C. L. J. Nat. Prod. 1999, 62, 369-
371. 
 
58 (a) Ollis, W. D.; Redman, B. T.; Sutherland, I. O.; Jewers, K. J. Chem. Soc. D, Chem. Commun. 1969, 879-880. 
(b) Rama Rao, A. V.; Venkataraman, K.; Yemul, S. S. Tetrahedron Lett. 1973, 14, 4981-4982. 
 
59 The originally proposed structure of xanthochymol (6) was similar to 41 and 42 prior to revision.  See ref. 3. 
 
60 Weng, J.-R.; Tsao, L.-T.; Wang, J.-P.; Wu, R.-R.; Lin, C.-N. J. Nat. Prod. 2004, 67, 1796-1799. 
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Figure 1.7. (a) A possible intermediate in Type C PPAP biosynthesis and (b) the only known examples of Type C PPAPs. 
 
 
Following formation of the bicyclo[3.3.1]nonane ring, a variety of oxidations, cyclizations, and 
isomerizations may occur, further diversifying the family of PPAP natural products.  Many of these 
transformations are potentially facilitated by epoxidation of an isoprenoid side chain.  Examples of 
secondary cyclization are found in Scheme 1.9 involving plukenetione D/E (7-epi-nemorosone, 47)61 and 
its epoxidation product 48.  5-exo epoxide opening of the epoxide found in 48 by the oxygen attached to 
C4 leads to a PPAP containing a dihydrofuran ring, sampsonione O (49).62 A 6-endo cyclization 
(followed by elimination of the resulting alcohol) is also possible, illustrated by the natural products 
plukenetione F (50) and G (51).61 Carbocyclization involving the prenyl substituent at C7 is also possible, 
as evidenced by the formation of plukenetione B (52)61 from 48, exemplifying the formation of a 
tetracyclic PPAP bearing a homoadamantyl subunit.   
                                                      
61 Henry, G. E.; Jacobs, H.; Carrington, C. M. S.; McLean, S.; Reynolds, W. F. Tetrahedron 1999, 55, 1581-1596. 
 
62 Xiao, Z. Y.; Mu, Q.; Shiu, W. K. P.; Zeng, Y. H.; Gibbons, S. J. Nat. Prod. 2007, 70, 1779-1782. 
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Scheme 1.9. Formation of PPAPs through an epoxide intermediate of plukenetione D/E (47). 
 
 
While some PPAPs containing secondary cyclization may arise through enzymatic processes, 
some other PPAPs may simply be artifacts of the isolation process.  For example, simple treatment of 
xanthochymol (6) with acid or heat forms isoxanthochymol (2, Scheme 1.10).10 More in-depth analysis is 
necessary in order to further elucidate the later stages of PPAP biosynthesis.    
 
 
Scheme 1.10. Acid- or heat-mediated conversion of xanthochymol (6) to isoxanthochymol (2). 
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Bioactivity 
Widespread interest in the biological activity of PPAPs stems from the prevalence of these 
compounds in medicinally-relevant herbs used in a variety of traditional and ethnopharmaceutical 
treatments.  Rather than utilizing an organization based upon natural product, this section is organized 
into distinct disease areas in order to facilitate greater understanding of the relationship between PPAP 
structure and bioactivity.  The structures of PPAPs discussed herein may be found in Appendix A. 
Anti-infective Activity 
The anti-infective properties of PPAPs were one of the first types of bioactivity to be recognized.  
As mentioned previously, it has been theorized that plants biosynthesize PPAPs as a defense against 
infection.  A variety of PPAPs are effective antibacterial agents particularly amongst gram-positive 
bacteria (Table 1.1); however, some are active against gram-negative bacteria as well (Table 1.2).  While 
many of these bacteria are normally harmless and are intestinal commensals or found on normal skin flora 
(e.g., B. subtilis, E. faecalis, S. aureus, S. epidermidis), they may lead to often fatal infections in 
immunocompromised individuals, particularly in nosocomial environments.  Particularly effective, broad-
spectrum PPAPs include hyperforin, garcinol, and guttiferone A. 
21
 22 
Table 1.1. Evaluation of PPAPs against gram-positive bacteria. 
Bacterium Active PPAPs (MIC in µg/mL) Inactive PPAPs References 
Actinomyces naeslundii hyperibone A (1.65-3.3)  63 
Bacillus cereus 
garcinol (1.5), guttiferone A,a,b hyperatomarin (1.56), 
hyperpapuanone (8), isoxanthochymol (9.8), papuaforin 
A (64), papuaforin C (64), papuaforin D (130), 
papuaforin E (64) 
7-epi-clusianone, guttiferone G 64,65,66, 67,68,69 
Bacillus coagulans garcinol (2.0)  66 
Bacillus megaterium guttiferone G (0.61)b isoxanthochymol 67 
Bacillus mesentericus hyperforin (2)  1 
Bacillus mycoides hyperforin (0.2)  1 
Bacillus stearothermophilus isoxanthochymol (4.88)b guttiferone G 67 
Bacillus subtilis chamuangone (31), enervosanone (0.013), garcinol (0.05), hyperatomarin (3.1), hyperforin (0.2) 
methyl clusianone, furohyperforin, 
furohyperforin A, guttiferone G, 
isoxanthochymol, pyrohyperforin 
1,65,66,67, 
70,71,72, 
73,74 
Caryophanon latum hyperforin (1)  1 
Clavibacter michiganensis hyperforin (1)  1 
Corynebacterium diphtheriae hyperforin (1)  75 
                                                      
63 Castro, M. L.; do Nascimento, A. M.; Ikegaki, M.; Costa-Neto, C. M.; Alencar, S. M.; Rosalen, P. L. Bioorg. 
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74, 439-444.  
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Table 1.1 (continued). Evaluation of PPAPs against gram-positive bacteria. 
Bacterium Active PPAPs (MIC in µg/mL) Inactive PPAPs References 
Enterococcus faecalis guttiferone G (0.61),
b isogarcinol (32), xanthochymol 
(0.78) hyperforin, isoxanthochymol 
1,67,75, 
76,77 
Enterococcus spp. chamuangone (31)  74 
Listeria monocytogenes garcinol (25)  66 
Micrococcus luteus furohyperforin,
c furohyperforin A,c hyperatomarin 
(1.6), hyperpapuanone (16), papuaforin C (32) 
papuaforin A, papuaforin D, 
papuaforin E 64,78,79 
Mycobacterium B5 hyperforin (1)  1 
Rhodococcus equi  methyl clusianone 56 
Sarcina lutea hyperforin (0.1)  1 
Staphylococcus aureus 
(methicillin-sensitive) 
chamuangone (2-31), 7-epi-clusianone (0.6-1.2), 
cycloxanthochymol (25), enervosanone (0.013), 
furohyperforin A (50), garcinol (0.05-63),b guttiferone 
A (2.4-4.5), guttiferone E,d hyperatomarin (1.56), 
hyperforin (1.0), hyperibone A (0.73-1.4), hyperibone 
B,d hyperibone D,d isoxanthochymol (25), 
makandechamone,c nemorosone (8.1), scrobiculatone A 
(130), scrobiculatone B (130), xanthochymol (3.1)b 
furohyperforin, guttiferone G, 
hyperibone C, isogarcinol,  
isoxanthochymol, propolone A, 
pyrohyperforin 
1,56,63,65, 
66,67,68, 
71,72,73, 
74,75,78, 
79,80,81, 
82,83,84, 
85,86,87, 
88,89 
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Table 1.1 (continued). Evaluation of PPAPs against gram-positive bacteria. 
Bacterium Active PPAPs (MIC in µg/mL) Inactive PPAPs References 
Staphylococcus aureus 
(methicillin-resistant) 
chamuangone (0.5),b 7-epi-clusianone (3.7), 
cycloxanthochymol (25), garcinol (6.3-16),b hyperforin 
(1.0), hyperibone A,d hyperibone B,d hyperibone D,d 
isoxanthochymol, (25), peroxysampsone A (62) 
xanthochymol (25)b 
hyperibone C, isogarcinol, 
peroxysampsone B, plukenetione C 
62,75,81, 
89,90,91, 
92 
Staphylococcus epidermidis hyperpapuanone (8), papuaforin E (32), propolone A (100) 
guttiferone A, papuaforin A, 
papuaforin C, papuaforin D 64,69,82 
Streptococcus agalactiae hyperforin (1.0)  75 
Streptococcus gordonii hyperibone A (1.7-3.3)  63 
Streptococcus mutans 7-epi-clusianone (1.3-2.5),b hyperibone A (3.3-6.6)  63,93,94, 95,96 
Streptococcus oralis hyperibone A (1.7-3.3)  63 
Streptococcus pneumoniae garcinol (125)  80 
Streptococcus pyogenes hyperforin (1.0)  75 
Streptococcus sobrinus hyperibone A (1.7-3.3)  63 
Streptococcus viridans chamuangone (16), garcinol (130)  74,80 
Streptomyces aurantiogriseus propolone A (100)  82 
Streptomyces chartrensis propolone A (50)  82 
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Table 1.1 (continued). Evaluation of PPAPs against gram-positive bacteria. 
Bacterium Active PPAPs (MIC in µg/mL) Inactive PPAPs References 
Streptomyces griseus hyperforin (100)  97 
Strept. phaeochromogenes propolone A (100)  82 
Strept.violochromogenes propolone A (50)   82 
 
a See text.  
b More active or similar activity as positive control (e.g., vancomycin, chloramphenicol, chlorhexidine).  
c Reported to have activity in a diffusion assay.  
d Reported to have low to moderate activity in an antibiogram assay. 
 
Many PPAPs have been evaluated against bacteria involved in areas beyond nosocomial 
infections.  B. mesentericus and B. stearothermophilus are responsible for food spoilage (particularly 
bread),98 and hyperforin1 and isoxanthochymol67 show significant activity against these species, 
respectively.  Potato “ring rot” is a particular devastating infection caused by Clavibacter 
michiganensis,99 and hyperforin is effective against this bacterium.1 B. cereus is a leading cause of food-
borne illness, including “fried rice syndrome.”100 A variety of PPAPs show activity against this bacterium, 
including garcinol66,73 and hyperatomarin.65 Garcinol is effective against L. monocytogenes, a cause of 
listeriosis.66  
Given that honeybees will utilize Clusia plant species resins in propolis, it is unsurprising that 
both chamone I and nemorosone were active against Paenibacillus alvei and Paenibacillus larvae, two 
honeybee pathogens.56 Both of these PPAPs have been identified in Caribbean propola. 
A variety of PPAPs have also been evaluated against bacteria involved in tooth decay.  Typically, 
bacterial synthesis of extracellular glucans allows for biofilm formation, followed by acidification, plaque 
                                                      
97 Derbentseva, N. A.; Aizenman, B. Y.; Harahulya, O. O. Mikrobiologicheskii Zh. 1971, 33, 569-572. 
 
98 Thompson, J. M.; Dodd, C. E. R.; Waites, W. M. Int. Biodeter. Biodegr. 1993, 32, 55-66.  
 
99 van der Wolf, J. M.; van Beckhoven, J. R. C. M.; Hukkanen, A.; Karjalainen, R.; Müller, P. J. Phytopathol. 2005, 
153, 358-365. 
 
100 Drobniewski, F. C. Clin. Microbiol. Rev. 1993, 6, 324-338. 
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development, and the formation of dental caries.101 Hyperibone A is fairly effective against a range of 
bacteria involved in this process, including A. naeslundii, S. gordonii, S. mutans, S. oralis, and S. 
sobrinus.  Aside from hyperibone A, 7-epi-clusianone also displayed activity against S. mutans dental 
caries.94 Analyses of S. mutans in vitro have shown that this PPAP inhibits glucosyltransferases B and C, 
which are involved in glucan synthesis.93 In addition, it inhibited F-ATPase activity, preventing 
acidification without affecting bacterial viability.  Using a rodent model of dental caries, treatment with 7-
epi-clusianone alone or in combination with fluoride produced significant cariostatic effects by reducing 
the amount of extracellular glucans and disrupting biofilm development without any observed side effects 
in the treated rats.95 These cariostatic effects were attributed to glucosyltransferase inhibition as well as 
acidification prevention.96 
The mechanism of antibacterial activity of PPAPs remains largely unknown.  Lipophilicity may 
play an important role in determining antibacterial activity.  PPAPs containing a free β-hydroxyenone 
functionality at the C2–C4 bridge are more active than similar PPAPs that contain β-alkoxyenone at this 
site; for instance, garcinol and xanthochymol are more potent antibiotics than isogarcinol and 
isoxanthochymol, respectively.  A series of guttiferone A (53) derivatives have been synthesized with 
functionalization at the phenolic oxygen atoms (Figure 1.8).69 The analogs with cLogP (octanol/water) 
lower than guttiferone A (i.e., 54, 55, and 56) had more potent antibacterial activity than the parent 
compound across a range of bacteria and were more active than chloramphenicol, used as a positive 
control.  Analogs with higher lipophilicity (i.e., 57, 58, and 59) were less active.   
 
 
Figure 1.8. Guttiferone A and semisynthetic analogs. 
                                                      
101 Loesche, W. J. Microbiol. Rev. 1986, 50, 353-380. 
Me
O
O OH
Me
Me Me
Me
O
Me
Me
OR1
Me
Me
OR2 53: R1, R2 = H (guttiferone A)54: R1, R2 = Ac
55: R1, R2 = Ms
56: R1, R2 = Ts
57: R1 = Boc, R2 = H
58: R1, R2 = 4-chlorobenzoyl
59: R1, R2 = Bz
26
 27 
Also, it appears that bacterial resistance to PPAPs is orthogonal to that of known antibiotics, 
which has important implications considering the widespread use of SJW extract to treat depression.92 
Hyperforin has also been shown to act as an immunomodulatory agent towards bacterial phagocytosis in 
an in vitro model.102 At concentrations as low as 1 µg/mL, hyperforin activated human 
polymorphonuclear neutrophils towards either opsonized or non-opsonized E. coli.  
 
 
Table 1.2. Evaluation of PPAPs against gram-negative bacteria. 
Bacterium Active PPAPs (MIC in µg/mL) Inactive PPAPs References 
Citrobacter freundii guttiferone G (1.2)a isoxanthochymol 67 
Enterobacter aerogenes  guttiferone G, isoxanthochymol 67 
Enterobacter cloacae guttiferone G (1.2)a isoxanthochymol 67 
Escherichia coli 
cycloxanthochymol (25), enervosanone 
(0.013), garcinol (25-500), guttiferone E,b 
hyperforin (1), isogarcinol (25), 
isoxanthochymol (25) 
chamuangone, methyl clusianone, 7-epi-clusianone, 
furohyperforin, furohyperforin A, guttiferone A, 
guttiferone E, guttiferone G, nemorosone, 
pyrohyperforin, xanthochymol 
1,56,66,67, 
68,69,71,72, 
73,74,75,79, 
80,81,83,86, 
88,102 
Helicobacter pylori chamuangone (16), garcinolc  74,103 
Klebsiella pneumoniae isogarcinol (16), xanthochymol (1.6) garcinol, guttiferone G, isoxanthochymol 67,76,77 
Morganella morganii  guttiferone G, isoxanthochymol 67 
Neisseria gonorrhoeae garcinol (63)  80 
Proteus mirabilis guttiferone A (170) guttiferone G, isoxanthochymol 67,69 
Proteus vulgaris guttiferone G (1.2)a hyperforin, isoxanthochymol 1,67 
Pseudomonas aeruginosa enervosanone (0.013), garcinol (0.05-250), isogarcinol (16) 
guttiferone A, guttiferone G, hyperforin, 
isoxanthochymol 
1,67,69,72, 
73,75,77,80, 
97 
Salmonella enterica 
enterica isogarcinol (5) guttiferone G, isoxanthochymol 67,77 
Salmonella typhimurium guttiferone A (39)a guttiferone G, isoxanthochymol 67,69 
Serratia marcescens  garcinol 80 
Shigella dysenteriae  guttiferone G, isoxanthochymol 67 
Shigella flexneri garcinol (31), isogarcinol (16) guttiferone G, isoxanthochymol 67,77,80 
Shigella sonnei  chamuangone 74 
Yersinia enterocolitica   garcinol 66 
 
a More active or similar activity as positive control (e.g., chloramphenicol, gentamycin). 
b Reported to have activity in a diffusion assay. 
c See text. 
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The antiviral activity of several PPAPs has also been evaluated with limited success.  Garcinol 
was completely ineffective against viral infection of VERO cells with an adenovirus, coxsackievirus, 
herpes simplex virus type 1, measles, poliomyelitis virus type 1, and the Semliki forest virus.80 Garcinol 
was however active at preventing long-terminal repeat promoter activity of porcine endogenous 
retrovirus, which increases the likelihood of pig-to-human viral transplantation.104 Considering that this 
activity could be replicated using CpG methyltransferase, the antiretroviral activity of garcinol in this case 
may stem from its ability to act as an epigenetic modulator. 
A variety of PPAPs have been evaluated for activity against lentiviruses, particularly human 
immunodeficiency virus (HIV) strains.  HIV infection leads to a progressive failure of the immune 
system, otherwise known as acquired immunodeficiency syndrome (AIDS), which leaves infected 
individual susceptible to often fatal opportunistic infections and cancer.105 Similar to PPAP antibacterial 
activity, a free C2–C4 β-hydroxyenone moiety generally leads to greater activity against HIV 
pathophysiology.  Clusianone decreased HIV infection of 3T3.T4.CCR5 and Jurkat E6-1 cells in a dose-
dependent manner compared to control, while its O-methyl ether was inactive at all concentrations 
tested.106 Interestingly, ent-clusianone was similarly active against both cell lines (its O-methyl ether was 
also inactive).  Guttiferones A-E were found to have EC50 values in the range of 1-10 µg/mL against the 
cytopathic effects of CEM-SS cells infected HIV, although viral replication was not inhibited.16 
Isoxanthochymol, on the other hand, was in inactive in this assay.  It should be noted that these 
compounds were also found to be noncytotoxic to the CEM-SS cells used in this study.  Laxifloranone 
was also found to be active in this CEM-SS HIV assay (EC50 = 0.62 µg/mL); however, if the free 
carboxylic acid was blocked, all cytopathic effects were lost.107 In another assay involving C8166 cells, 
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aristophenone, clusianone, 7-epi-clusianone, nemorosone, and propolone A potently prevented HIV 
infection.108 Clusianone was the most effective PPAP screened, with an EC50 of 20 nM, but showed a 
TC50 value of 0.1 µM in uninfected C8166 cells.  The most selective PPAP test was propolone A, with an 
EC50 of 0.32 µM and a TC50 value of 5.0 µM.  Using an MT-4 cell line, guttiferone E, guttiferone O2, and 
isoxanthochymol did not inhibit HIV replication at subtoxic concentrations.109 
Further, it appears that PPAP anti-HIV activity may occur through several mechanisms of action.  
Plukenetione A and plukenetione D/E were both evaluated using CEMx174-SEAP cells as well as 
HEK293T cells infected with a simian immunodeficiency virus vector.110 While both compounds were 
found to be cytotoxic in the cell lines employed (ca. 4 µM), both were potent below 2 µM against 
lentiviral infection.  The activity of plukenetione A was primarily due to its inhibition of reverse 
transcriptase (IC50 = 1.75 µM), and the activity of plukenetione D/E was due to its interruption of the 
Akt/PKB signaling cascade.  Guttiferone F and 30-epi-isogarcinol were both active in an in vitro HIV 
protease assay, demonstrating that at least some PPAPs might target this enzyme.111 
The action of several PPAPs against the highly infectious, epidemic-causing influenza and 
hepatitis B viruses has also been reported.  The hepatitis B virus causes liver inflammation and while a 
vaccine is available in developed countries, a significant portion of the world population remains 
vulnerable to infection.112 Hypersampsones A-F demonstrated activity against hepatitis B e antigen 
secretion by infected MS-G2 cells at 10 µg/mL, but viral particle replication was not inhibited.113 
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Influenza, otherwise known as the flu, is a highly infectious disease and particularly dangerous owing to 
the ability of new strains to cross species barriers, incorporating genes from other mammals and birds.114 
Guttiferone E, guttiferone O2, and isoxanthochymol have been evaluated against influenza A-infected 
MDCK cells.109 All three PPAPs showed minimum cytotoxic concentrations of 4 µg/mL against these 
infected cells.  However, they were inactive at preventing replication of influenza A subtypes H1N1 and 
H3N2 and influenza B. 
Since several retroviruses use proteases during their reproductive cycle, protease inhibitors may 
be used in antiretroviral therapies.  The serine and cysteine protease inhibition ability of several PPAPs 
have been evaluated (Table 1.3).  While both 7-epi-clusianone and garciniaphenone modestly inhibited 
protease activity, guttiferone A moderately inhibited all four proteases screened. 
 
Table 1.3. Antiproteolytic activity of several PPAPs. 
 Protease IC50 (µM)  
PPAP Papain Trypsin Cathepsin B Cathepsin G References 
7-epi-clusianone 19.5 20.1 73.7-74.1 37.4-37.9 115,116 
garciniaphenone 130.8 103.5 102.0-103.5 97.6-98.8 115,116 
guttiferone A 1.9 9.4 2.1 2.7 115 
 
 
The antiparasitic properties of a variety of PPAPs have also been evaluated.  Malaria is a highly 
infectious disease spread by female Anopheles mosquitoes and is often caused by the protozoan 
Plasmodium falciparum.  There were an estimated 219 million cases of malaria reported in 2010, mostly 
in sub-Saharan Africa, resulting in 1.2 million deaths.117 A variety of PPAPs and semisynthetic analogs of 
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hyperforin (Figure 1.9) have been evaluated against P. falciparum (Table 1.4) and chloroquine-resistant 
P. falciparum (Table 1.5). 
   
Table 1.4. Evaluation of PPAPs against Plasmodium falciparum. 
PPAP IC50 (µM) References  PPAP IC50 (µM) References 
adhyperforin·HNCy2 1.4 118  spiranthenone B 32.1 25 
furohyperforin 1.7 118  60 7.8 118 
guttiferone A 0.5-3.0 88,119  61 >27 118 
hyperforin·HNCy2 1.5 118  62 4.8 118 
hyperforin, lithium salt 2.1 118  63 >27 118 
isoxanthochymol 2.2-4.5 120,121  64 0.6 118 
nemorosone 0.4 88  65 6.7 118 
oxyhyperforin 2.0 118  66·HNCy2 1.4 118 
spiranthenone A 8.2 25  66, lithium salt 2.7 118 
pyrohyperforin 8.6 118  67 2.1 119 
 
 
 
Figure 1.9. Semisynthetic analogs of hyperforin. 
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Table 1.5. Evaluation of PPAPs against chloroquine-resistant P. falciparum. 
PPAP IC50 (µM) References  PPAP IC50 (µM) References 
coccinone A 4.3 9  guttiferone A 3.17 88,122 
coccinone B 5.5 9  isogarcinol 3.5 9,123 
7-epi-coccinone B 3.3 124  7-epi-isogarcinol 3.2-5.1 9,124 
coccinone C 9.0 9  14-deoxy-7-epi-isogarcinol 2.5 124 
coccinone D 7.0 9  symphonone A 2.8 124 
coccinone E 4.9 9  symphonone B 3.3 124 
coccinone F 17.0 9  symphonone C 2.6 124 
coccinone G 19.2 9  symphonone D 2.1 124 
coccinone H 16.6 9  symphonone E 2.7 124 
cycloxanthochymol 2.1 9  symphonone F 3.2 124 
garcinol 12.6 9  symphonone G 2.1 124 
7-epi-garcinol 10.1 9,124  symphonone H 3.0 124 
14-deoxygarcinol 37.2 9   symphonone I 6.7 124 
 
Nemorosone and oxidized hyperforin analog 64 were most active against chloroquine-sensitive P. 
falciparum, and cycloxanthochymol and symphonones D and G were the most active against chloroquine-
resistant P. falciparum.  Nemorosone was found to be as active as chloroquine against P. falciparum.88 
Amongst the hyperforin derivatives, a limited degree of structural modification of the 
bicyclo[3.3.1]nonane core does not lead to significant changes in potency; analogs with C4 oxygen atom 
functionalization, with a quaternary center at C3, or hydrogenation of the pendant olefins had similar 
activity to that of hyperforin.118 The only inactive derivatives screened were 61 and 63.  A semisynthetic 
analog of guttiferone A, 67, was found to be more active than the parent PPAP (Figure 1.10).119 Also 
noteworthy is the potency trend within the coccinone and symphonone families of PPAPs.  Those that 
contain a free C2–C4 β-hydroxyenone (i.e., coccinones F-H) were significantly less potent than the other 
members, which bear a tetrahydropyran ring containing the C4 oxygen atom. 
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Figure 1.10. A semisynthetic analog of guttiferone A. 
 
Unfortunately, many PPAPs that exhibited antimalarial properties were found to be fairly 
cytotoxic.  Adhyperforin, guttiferone A, hyperforin, isoxanthochymol, octahydrohyperforin (66), and 67 
had cytotoxicity concentrations comparable to their antimalarial activity, but furohyperforin, and 
oxyhyperforin, and 62 were marginally less cytotoxic.  The only PPAPs screened for cytotoxicity that 
were significantly more potent than cytotoxic were spiranthenones A and B.    
In addition, several PPAPs have been evaluated for possible treatment of leishmaniasis.  This 
disease is caused by a variety of different protozoa belonging to the genus Leishmania, and is transmitted 
through the bite of sand flies from the subfamily Phleobotominae.125 During sand fly feeding, Leishmania 
promastigotes enter the body.  Upon macrophage phagocytosis, amastigotes are produced and proliferate.  
Leishmaniasis can take several forms, the most common of which involves skin sores, which appear 
weeks to months after initial exposure.  If the parasite migrates to vital organs, visceral leishmaniasis may 
occur, which is the second largest fatal parasitic disease in the world, after malaria.  Despite its 
prevalence, especially in developing countries, very few treatment options are available.  A summary of 
PPAPs evaluated for leishmanicidal activity is found in Table 1.6. 
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Table 1.6. Evaluation of PPAPs against various Leishmania species. 
Leishmania species  Life-cycle phase Evaluated PPAPs (IC50 in µM) References 
amastigotes 7-epi-clusianone (3.2),a garciniaphenone (inactive), guttiferone A (4.9) 126 
L. amazonensis 
promastigotes 7-epi-clusianone (6.6),
a garciniaphenone (11.6), garcinielliptone FC (42.8),  
guttiferone A (15.6-30.1), nemorosone (11.2) 88,126,127 
L. donovani amastigotes garcinol (0.82), guttiferone A (0.16),a guttiferone F (0.20),a isogarcinol (0.33)a 128 
amastigotes guttiferone A (13.5), isoxanthochymol (2.0), nemorosone (32.9) 88,121 
L. infantum 
promastigotes spiranthenone A (inactive), spiranthenone B (inactive) 25 
 
a More active or similarly active as a positive control (e.g., amphotericin B or miltefosine). 
 
In general, leishmanicidal activity is inversely related to hydrophobicity.  7-epi-Clusianone was 
one of the most active PPAPs screened, against both the amastigote and promastigote forms of the New 
World protozoan L. amazonensis, and it was found to be more potent than amphotericin B in both 
cases.126 Interestingly, garciniaphenone was active against the promastigote form of this Leishmania 
species but inactive against the amastigote form.  While isoxanthochymol was fairly potent against L. 
infantum amastigotes, it was found to be fairly cytotoxic towards MRC-5 cells.121 Guttiferones A and F 
and isogarcinol were the most effective leishmanicidal PPAPs screened against the Old World pathogen 
L. donovani.128 At 8.0 µM concentration, both guttiferone A and F inhibited parasite growth by 98%.  
Since guttiferone A was shown to be relatively noncytotoxic (CC50 = 17.8 µM in murine peritoneal 
macrophages),126 it may be a lead structure in the development of a treatment for Old World 
leishmaniasis.   
A variety of PPAPs has also been evaluated against trypanosomiasis, another parasitic protozoan 
disease.  There are two major forms of trypanosomiasis: (1) African trypanosomiasis, otherwise known as 
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sleeping sickness, and (2) Chagas disease.129 As the name suggests, African trypanosomiasis is most 
prevalent in sub-Saharan Africa, and it is caused by the protozoa of Trypanosoma brucei, transmitted by 
the tsetse fly.  Chagas disease is the most common form of trypanosomiasis in Latin America, in which 
Trypanosoma cruzi is transmitted by a variety of bloodsucking bugs, such as Rhodnius prolixus and 
Triatoma brasiliensis.   
A summary of the effects of several PPAPs on the viability of trypanosomiasis protozoa is found 
in Table 1.7.  Guttiferone A, isoxanthochymol, and nemorosone were found to be moderately active 
against both T. brucei and T. cruzei.  As mentioned earlier, isoxanthochymol is cytotoxic against MRC-5 
cells at a concentration similar to its concentration for effective trypanocidal outcomes.121 Guttiferone A 
and 67 suffer from similar problems.  One study established that guttiferone A had MC100 values against 
T. cruzi epimastigotes and typanomastigotes of 99.5 µM and 82.9 µM, respectively, and these values were 
well above the 10.7 µM IC50 value of the PPAP against murine periotoneal macrophages.126,130 7-epi-
Clusianone was also evaluated against T. cruzi; however, it was found to be ineffective in vivo in infected 
mice.131 Interestingly, nemorosone was also found to be non-cytotoxic against the predominant insect 
vector of Chagas disease, Rhodnius prolixus, but it displayed dose-dependent anti-molting effects.132 
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Table 1.7. Evaluation of PPAPs against Trypanosoma brucei and T. cruzi. 
  IC50 (µM)  
PPAP T. brucei T. cruzi References 
guttiferone A 3.0-13.5 11.8 88,119 
isoxanthochymol 1.9 2.7 121 
nemorosone 17.5 12.5 88 
spiranthenone A n.d. inactive 25 
spiranthenone B n.d. 211.3 25 
67 2.1 n.d. 119 
 
 
7-epi-Clusianone has also been evaluated for its molluscicidal effects upon Biomphalaria 
glabrata, a Brazilian freshwater snail and known carrier of Schistosoma mansoni, one of several parasitic 
worms responsible for schistosomiasis.131 However, this PPAP was found to be inactive in the snail 
toxicity assay.   
The antifungal properties of various PPAPs have also been explored, which is summarized in 
Table 1.8.  In general, the PPAPs evaluated were much less effective against fungi than against bacteria, 
viruses, and parasites, and generalizations about structure-activity relationships cannot be made.  
Guttiferone A was found to be most active across a wide range of fungi, including several Candida 
species responsible for infections in immunocompromised individuals, the cryptococcosis-causing 
Crytococcus neoformans, and two Trichophyton species involved in tinea-type skin infections.69 Two 
semisynthetic guttiferone A derivatives, 54 and 57, were generally more active than the parent PPAP, and 
other semisynthetic analogs, namely 55, 56, 58, and 59, were less active.  Unlike antibacterial activity, 
cLogP values did not correlate with fungicidal activity.  Isogarcinol and pyrohyperforin were found to be 
active against Candida albicans, the most common pathogen involved in yeast infections of the genitals 
and oral cavity.71,77 Xanthochymol was found to be active in a dose-dependent manner against Phomopsis 
viticola, a leading cause of grapevine dead arm (grape canker).26 Treatment with xanthochymol in the 1-
10 µg/mL range caused motility inhibition and lysis of Phomopsis viticola zoospores.  Only a few other 
PPAPs have been evaluated against phytopathogenic fungi (i.e., Aspergillus flavus, Aspergillus niger, 
36
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Cladosporium cucumerinium, and Fusarium avenaceum), and while garcinol has some phytopathogenic 
fungicidal activity,80 it would be interesting to see if other PPAPs exhibit activity against these fungi.    
 
Table 1.8. Evaluation of PPAPs against various fungi. 
Fungus Active PPAPs (MIC in µg/mL) Inactive PPAPs References 
Aspergillus flavus garcinol (100)  80 
Aspergillus fumigatus garcinol (100) xanthochymol 76,80 
Aspergillus niger garcinol (100)  80 
Candida albicans guttiferone A (40),
a isogarcinol 
(64), pyrohyperforin (25) 
7-epi-clusianone, furohyperforin, garcinol, 
guttiferone A, guttiferone E, guttiferone G, 
hyperforin, isoxanthochymol, nemorosone, 
xanthochymol 
1,67,68,69, 
71,75,76,77, 
80,86,88  
Candida glabrata guttiferone A (5.0)a guttiferone G, isoxanthochymol 67,69 
Candida krusei isogarcinol (64) guttiferone A, guttiferone G, isoxanthochymol 67,69,77 
Candida lusitaniae  isogarcinol 77 
Candida parapsilosis guttiferone A (20.0)a  69 
Candida tropicalis guttiferone A (20.0)a garcinol 69,80 
Cladosporium cucumerinum  hyperevolutin A, hyperevolutin B 133 
Cladosporium sphaerospermum  7-epi-clusianone 57 
Cryptococcus neoformans guttiferone A (5.0),
a  
isogarcinol (64)  69,77,80 
Fusarium avenaceum  hyperforin 1 
Microsporum gypseum guttiferone A (100)a  69 
Microsporum canis garcinol (100)  80 
Mucor plumbeus  hyperforin 1 
Penicillium chrysogenum  hyperforin 1 
Phomopsis viticola xanthochymolb  26 
Trichophyton ajelloi isogarcinol (64)  77 
Trichophyton interdigitale garcinol (100),  guttiferone A (20.0)a xanthochymol 69,76,80 
Trichophyton rubrum guttiferone A (11.8),
a 
isogarcinol (32) nemorosone 77,88 
 
a Value reported is IC50 (in µg/mL). 
 
b See text. 
 
Antioxidant and Anti-inflammatory Activity 
The antioxidant properties of PPAPs have also been explored in a variety of contexts, both in 
vitro and in vivo.  A summary of PPAP performance in various in vitro antioxidant assays is found in 
Table 1.9.  Unsurprisingly, PPAPs that bear a 3,4-dihydroxybenzoyl group at the C3 position were found 
to be the most active at scavenging radical or reactive oxygen species in these assays.  If one of the 
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phenolic hydroxyl groups is alkylated, as in the 13-O-methyl ethers of garcinol and isogarcinol, 
antioxidant potential is lost.14 The presence of a C2–C4 β-hydroxyenone was also important but not 
essential given the strong antioxidant properties of PPAPs such as guttiferone K2, isogarcinol, and 
isoxanthochymol.  A comparison of nemorosone and its O-methyl ether illustrates the significance of C2–
C4 β-hydroxyenone functionality.146  
 
Table 1.9. In vitro PPAP antioxidant activity. 
PPAP Antioxidant activitya,b References 
acuminophenone A DPPH (1.8), ABTS (3.4), TEAC (7.8) 134 
aristophenone DPPH (125) 135 
clusianone DPPH (inactive) 14 
7-epi-clusianone DPPH (inactive), ABTS (inactive) 18,136,137 
garcinielliptone A DPPH (150), ABTS (139.0), XO (53.8) 138 
garcinielliptone C XO (59.9) 139 
garcinielliptone F DPPH (inactive), ABTS (inactive), XO (inactive) 138 
garcinielliptone P XO (48.1) 140 
garcinielliptone S DPPH (inactive), ABTS (inactive), XO (inactive) 138 
garcinol DPPH (10.2), XO (52) 14,66,141 
garcinol 13-O-methyl ether DPPH (inactive) 14 
garsubellin A DPPH (inactive), ABTS (inactive), XO (inactive) 138 
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Table 1.9 (continued). In vitro PPAP antioxidant activity. 
PPAP Antioxidant activitya,b References 
guttiferone A DPPH (20.8-31.0), ABTS (12.5) 18,122,142,143 
guttiferone E DPPH (68) 86,135 
guttiferone F DPPH (42.8) 144 
guttiferone G DPPH (26.8) 145 
guttiferone H DPPH (64) 135 
7-epi-guttiferone J DPPH (inactive), ABTS (inactive) 18 
guttiferone K2 DPPH (3.9), ABTS (18.4), TEAC (2.5) 134 
32-hydroxy-ent-guttiferone M DPPH (38.3), ABTS (45.6) 18 
isogarcinol DPPH (13.3) 14 
isogarcinol 13-O-methyl ether DPPH (inactive) 14 
isoxanthochymol DPPH (4.6-5.8), ABTS (96.3), TEAC (3.7) 134,145 
nemorosone DPPH (44.1) 146 
nemorosone O-methyl ether DPPH (inactive) 146 
xanthochymol DPPH (53) 86,135 
 
a Assay abbreviations: DPPH, 2,2-diphenyl-1-picrylhydrazyl; ABTS, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid); 
XO, xanthine oxidase; TEAC, Trolox equivalent antioxidant capacity. 
b Values reported in parentheses refer to IC50 (in µM) for DPPH, ABTS, and XO assays, and Trolox equivalents for TEAC assay. 
 
 
 
Other than the results presented in Table 1.9, several other PPAPs have been evaluated for 
antioxidant properties in vitro.  Using an HPLC-DPPH assay system, hyperforin and adhyperforin were 
both identified as very active antioxidant components of alcoholic Hypericum perforatum extracts.147 
Similar results were obtained using partially purified HPLC fractions containing hyperforin, adhyperforin, 
hyperfirin, and adhyperfirin across a variety of tests, including the DPPH assay, FRAP, superoxide anion 
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test, NO radical inhibition assay, and the lipid peroxidation assay.148 A mixture of scrobiculatones A and 
B was found to be active in the DPPH assay.84 Guttiferone K and semsinone A were both active in the 
DPPH, ORAC, and anti-AGEs inhibition assays.143  
The reactions of garcinol with various radical systems were studied in order to further understand 
how this PPAP behaves as an antioxidant.149 Exposure of an acetone solution of garcinol (7) to DPPH in 
the dark afforded two oxidative cyclization products, 68 and 69 (Scheme 1.11a).150 Coincidentally, these 
two compounds were later isolated from Garcinia nujiangensis and named nujiangfolin A and B.151 A 
possible mechanistic manifold for this transformation is shown in Scheme 1.11b.  A resonance-stabilized 
enoxy radical 70 formed via hydrogen atom abstraction may cyclize onto the electron-rich aromatic ring 
to form 71, which after tautomerization provides 68 and 69.  The formation of these two oxidation 
products from garcinol provides evidence that the antioxidant properties of certain PPAPs may be derived 
from the 3,4-dihydroxybenzoyl and the C2–C4 β-hydroxyenone functional groups.  Similar results were 
observed when a heated acetone solution of garcinol (7) was exposed to AIBN, affording hydroperoxide 
72 and isogarcinol (8) as well as 68 and 69 (Scheme 1.11c).152 The formation of 72 likely involves radical 
6-endo-trig cyclization of the enoxy radical 70 onto the C1 prenyl group, followed by trapping with 
molecular oxygen.  The formation of isogarcinol may not involve radical intermediates, given that its 
heat-mediated formation from garcinol has been previously reported.31,153,154 
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Scheme 1.11. (a) The reaction of garcinol (7) with DPPH and (b) a possible mechanism, and 
(c) the reaction of garcinol (7) with AIBN. 
 
 
Several PPAPs have been evaluated in cell-based assays for antioxidant activity.  A St. John’s 
wort extract with standardized hyperforin content showed inverse dose-dependent superoxide inhibition 
in a XO-human placental vein assay.155 In other words, the most concentrated sample had a pro-oxidant 
effect, while the most dilute sample had the largest free radical inhibitory effect in this model, showing 
nearly an 80% decrease compared to control.  The radical scavenging ability of hyperforin was further 
explored in another study involving skin exposed to solar simulated radiation.156 Hyperforin was found to 
be more effective than Trolox (and without displaying phototoxicity) in a H2DCFDA irradiation assay 
involving HaCaT cells, with an EC50 value of 0.7 µM.  A cream containing 1.5% hyperforin was then 
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formulated and determined to have a radical scavenging ability of 200·1014 radicals/mg, corresponding to 
a radical protection factor of 39 (comparable to a good sunscreen).  After demonstrating that the cream 
reduced radical formation on irradiated porcine ear skin ex vivo, it was applied to 20 volunteers in a 
randomized, double-blind, vehicle-controlled clinical study.  The cream was well tolerated and 
successfully reduced ultraviolet B-induced erythema.  A later study also showed that a hyperforin-rich 
skin cream provided protection from radical formation in a 9-person study.157 These results contrast an 
earlier study, which found that hyperforin was a significant phototoxic component of St. John’s wort 
extracts in an assay involving photosensitized peroxidation of linoleic acid.158 
Several studies of the antioxidant properties of garcinol have been reported.  Aside from being 
almost three times more active by weight than vitamin E in the DPPH assay, it also displayed moderate 
activity against linoleic acid peroxidation and suppressed protein glycation in an in vitro bovine serum 
albumin/fructose system.159 Its free radical scavenging ability was also validated in Fenton reaction and 
H2O2/NaOH/DMSO systems, and in vivo by preventing indomethacin-induced acute gastric ulceration in 
rats through oral administration.160 Garcinol was also shown to protect DNA and neurons from radical-
induced damage.141 With an IC50 value of 0.32 µM, garcinol prevented pUC-19 supercoiled DNA from 
strand breakage under Fenton reaction conditions.   
While reactive oxygen species (ROS) are produced normally through metabolism or via immune 
system oxidative burst, if they accumulate too quickly, cell membrane damage may occur with the 
concomitant formation of mutagenic or carcinogenic lipid peroxides.161 Table 1.10 summarizes the 
activity of a variety of PPAPs against ROS formation in polymorphonuclear leukocytes (PMNs), rat 
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neutrophils, and human neutrophils stimulated with N-formylmethionine leucyl-phenylalanine (fMLP) 
alone or in combination with cytochalasin B (CB), opsonized zymosan (OZ), or phorbol 12-myristate 13-
acetate (PMA).  The garcimultiflorone family and 13,14-didehydroxyisogarcinol were found to be potent 
inhibitors of ROS generated from PMNs stimulated with fMLP/CB.15 7-epi-Clusianone also displayed 
dose-dependent decrease in ROS in PMNs stimulated with either fMLP or PMA.137 Most other PPAPs 
were either inactive or displayed marginal antioxidant activity, with the only exception being hyperforin, 
having an IC50 value of 1.8 µM against fMLP-stimulated PMNs.166 Later studies on hyperforin revealed 
that its ROS inhibition activity was lost when the PMNs were treated with PMA.167 This, combined with 
the observation that hyperforin decreased Ca2+ levels in resting PMNs and caused a decreased Ca2+ 
response to fMLP, led the authors to conclude that hyperforin targeted components of G protein signaling 
cascades involved in both Ca2+ homeostasis and inflammatory response.  The antioxidant properties 
garcinielliptone FC have also been investigated.162 Treatment of male mice with 2 mg/kg garcinielliptone 
FC caused a statistically significant increase in the activity of superoxide dismutase but not catalase.   
 
Table 1.10. Evaluation of PPAPs against ROS generation. 
PPAP Cell line Stimulation IC50 (µM) References 
garcimultiflorone A PMN fMLP/CB 5.6 15 
garcimultiflorone B PMN fMLP/CB 0.11 15 
13-hydroxygarcimultiflorone B PMN fMLP/CB 0.40 15 
garcimultiflorone C PMN fMLP/CB 7.2 15 
garcimultiflorone D2 PMN fMLP/CB 7.2 163 
garcinielliptone A rat neutrophil fMLP/CB inactive 164 
garcinielliptone A rat neutrophil PMA inactive 164 
garcinielliptone B rat neutrophil fMLP/CB inactive 164 
garcinielliptone B rat neutrophil PMA inactive 164 
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Table 1.10 (continued). Evaluation of PPAPs against ROS generation. 
PPAP Cell line Stimulation IC50 (µM) References 
garcinielliptone C rat neutrophil fMLP/CB 11.5 139 
garcinielliptone C rat neutrophil PMA inactive 139 
garcinielliptone F rat neutrophil fMLP/CB 17.0 165 
garcinielliptone F rat neutrophil PMA inactive 165 
garcinielliptone H rat neutrophil fMLP/CB inactive 165 
garcinielliptone H rat neutrophil PMA inactive 165 
garcinielliptone I rat neutrophil fMLP/CB inactive 165 
garcinielliptone I rat neutrophil PMA inactive 165 
garsubellin A rat neutrophil fMLP/CB inactive 164 
garsubellin A rat neutrophil PMA inactive 164 
hyperforin PMN fMLP 1.8 166 
hyperforin PMN OZ inactive 166 
hyperforin PMN PMA inactive 167 
hyperpapuanone PMN fMLP inactive 166 
hyperpapuanone PMN OZ inactive 166 
13,14-didehydroxyisogarcinol PMN fMLP/CB 0.88 15 
papuaforin A PMN fMLP inactive 166 
papuaforin A PMN OZ inactive 166 
papuaforin B PMN fMLP inactive 166 
papuaforin B PMN OZ inactive 166 
papuaforin C PMN fMLP inactive 166 
papuaforin C PMN OZ inactive 166 
papuaforin D PMN fMLP inactive 166 
papuaforin D PMN OZ inactive 166 
papuaforin E PMN fMLP 8.0 166 
papuaforin E PMN OZ inactive 166 
 
 
Several PPAPs have been evaluated against markers of inflammatory response aside from 
superoxide burst, such as the release of histamine, elastase, lysozyme, and β-glucuronidase as well as 
nitrite accumulation (Table 1.11).  Given the short half-life of nitric oxide, nitrite accumulation may be 
used to gauge its release during inflammatory response.  The garcimultiflorone family of PPAPs 
displayed fairly potent activity against elastase release in PMNs.15 However, to a large degree, the 
garcinielliptones showed little or no effect on these inflammatory response markers.   
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Table 1.11. Evaluation of PPAPs against several markers of inflammation. 
PPAP Cell line Stimulation Measured outcome IC50 (µM) Reference 
garcimultiflorone A PMN fMLP/CB elastase release 4.7 15 
garcimultiflorone B PMN fMLP/CB elastase release 0.14 15 
13-hydroxygarcimultiflorone B PMN fMLP/CB elastase release 0.86 15 
garcimultiflorone C PMN fMLP/CB elastase release 12.1 15 
garcimultiflorone D2 PMN fMLP/CB elastase release 6.0 163 
garcinielliptone A rat peritoneal mast cell compound 48/80 β-glucuronidase release inactive 164 
garcinielliptone A rat peritoneal mast cell compound 48/80 histamine release inactive 164 
garcinielliptone B rat peritoneal mast cell compound 48/80 β-glucuronidase release inactive 164 
garcinielliptone B rat peritoneal mast cell compound 48/80 histamine release inactive 164 
garcinielliptone C rat neutrophil fMLP/CB β-glucuronidase release 30.0 139 
garcinielliptone C rat neutrophil fMLP/CB lysozyme release 27.4 139 
garcinielliptone C RAW264.7 LPS TNF-α formation inactive 139 
garcinielliptone F rat neutrophil fMLP/CB β-glucuronidase release 26.9 165 
garcinielliptone F rat neutrophil fMLP/CB lysozyme release 20.0 165 
garcinielliptone F RAW264.7 LPS nitrite accumulation inactive 165 
garcinielliptone F N9 LPS/IFN-γ nitrite accumulation inactive 165 
garcinielliptone H rat neutrophil fMLP/CB β-glucuronidase release inactive 165 
garcinielliptone H rat neutrophil fMLP/CB lysozyme release inactive 165 
garcinielliptone H RAW264.7 LPS nitrite accumulation inactive 165 
garcinielliptone H N9 LPS/IFN-γ nitrite accumulation inactive 165 
garcinielliptone I rat neutrophil fMLP/CB β-glucuronidase release inactive 165 
garcinielliptone I rat neutrophil fMLP/CB lysozyme release inactive 165 
garcinielliptone I RAW264.7 LPS nitrite accumulation inactive 165 
garcinielliptone I N9 LPS/IFN-γ nitrite accumulation 7.4 165 
garcinielliptone L rat mast cell compound 48/80 β-glucuronidase release 22.9 60 
garcinielliptone L rat mast cell compound 48/80 histamine release inactive 60 
garcinielliptone L RAW264.7 LPS nitrite accumulation 22.7 60 
garcinielliptone L N9 LPS/IFN-γ nitrite accumulation 12.8 60 
garcinielliptone M rat mast cell compound 48/80 β-glucuronidase release 13.6 60 
garcinielliptone M rat mast cell compound 48/80 histamine release 19.0 60 
garcinielliptone M RAW264.7 LPS nitrite accumulation 15.3 60 
garcinielliptone M N9 LPS/IFN-γ nitrite accumulation inactive 60 
garsubellin A rat peritoneal mast cell compound 48/80 β-glucuronidase release 15.6 164 
garsubellin A rat peritoneal mast cell compound 48/80 histamine release inactive 164 
13,14-didehydroxyisogarcinol PMN fMLP/CB elastase release 1.2  15 
 
 
The effects of PPAPs on a variety of other markers of inflammation have been explored.  
Sundaicumones A and B were found to be weak activators of glucocorticoid receptor, which inhibits pro-
inflammatory transcription factors.168 Guttiferones O and P inhibited mitogen-activated protein kinase 
activated protein kinase 2 (MAPKAPK-2), a serine/threonine kinase involved in inflammation-response 
                                                      
168 Cao, S.; Low, K.-N.; Glover, R. P.; Crasta, S. C.; Ng, S.; Buss, A. D.; Butler, M. S. J. Nat. Prod. 2006, 69, 707-
709. 
45
 46 
transcriptional regulation, both with an IC50 value of 22.0 µM.169 Hyperforin has also been evaluated in 
several anti-inflammatory assays.  In human primary hepatocytes and intestinal epithelia, hyperforin 
induced interleukin-8 (IL-8) and intercellular adhesion molecule-1 (ICAM-1) expression.170 These effects 
were found to be dependent on extracellular signal-regulated kinase (ERK) 1 and 2 but independent of 
pregnane X receptor (PXR) and nuclear factor kappa B (NF-κB).  The dicyclohexylammonium salt of 
hyperforin also prevented fMLP-induced PMN chemotaxis and tissue infiltration in a dose-dependent 
manner (IC50 = 1 µM).171 The authors found that this was caused by decreased expression of the adhesion 
molecule integrin alpha M (ITGAM) and inhibition of matrix metalloproteinase-9 (MMP-9) activation.  
Subsequent studies found that hyperforin downregulated other markers in activated T cells (e.g., IFN-γ, 
T-box, CXCR3) and was successfully evaluated in a murine model of experimental allergic 
encephalomyelitis, an autoimmune disease of the central nervous system.172  
Hyperforin, garcinol, garcinielliptone FC, and guttiferone K were all found to potently inhibit 
lipid oxidation using the thiobarbituric acid reactive species (TBARS) assay.  Hyperforin prevented low-
density lipoprotein (LDL) oxidation in Cu2+- and nonmetal-mediated oxidation at concentrations as low as 
2.5 µM.173 Garcinol prevented LDL oxidation mediated by both Fe2+ (IC50 = 0.42 µM) and AAPH (IC50 = 
1.2 µM).174 This was more potent than vitamin E in both assays.  Garcinielliptone FC completely 
inhibited lipid peroxidation in the TBARS assay at 8.3 µM, and had an IC50 below 2 µM.175 Garcinol and 
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guttiferone K were found to protect human blood platelets from oxidative damage due to peroxynitrite, 
but these PPAPs did not prevent protein nitration.176 
Several PPAPs have been evaluated for their ability to inhibit general pro-inflammatory response.  
Garcinol displayed a neuroprotective effect in rat astrocytes exposed to LPS.141 Under normal 
circumstances, LPS exposure causes an inflammatory response including iNOS and COX-2 induction, 
which correlates with neurodegenerative processes.  It is believed that garcinol not only behaves as an 
antioxidant but also inhibits this inflammatory response.  In rats with carrageenan-induced paw edema 
and peritonitis, 7-epi-clusianone reduced inflammation in a dose-dependent manner, with oral doses of 5, 
10, and 15 mg/kg.177 Topical treatment of the dicyclohexylammonium salt of hyperforin as well as 
adhyperforin were similarly effective at the reduction of murine croton oil-induced ear edema as 
indomethacin, with EC50 values of 0.25 and 0.30 µmol/cm2.178 In an 8-person clinical trial, the anti-
inflammatory effects of hyperforin were found to at least be partly due to the ability of this PPAP to 
reduce the epidermal cells’ ability to recruit alloreactive T cells.179 These effects were similar to solar-
simulated radiation, a known immunosuppressive agent.  Hyperforin treatment was also well tolerated 
and was cosmetically acceptable.  When epidermal cells were treated with hyperforin in vitro, a dose-
dependent reduction of T cell and PMN proliferation was observed.  As a result, hyperforin therapy may 
be a possible treatment option for chronic atopic dermatitis or other skin conditions involving 
overreactive inflammatory response.   
Phagocyte activation of iNOS (inducible nitric oxide synthase) causes the release of nitric oxide; 
however, excessive NO production may lead to neurodegenerative disease.  Garcinielliptone FC was 
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found to be a potent scavenger of NO in a sodium nitroprusside decomposition assay.175 Hyperforin 
inhibited LPS-induced NO release in the 0.25-0.75 µM range in murine microglia by decreasing iNOS 
expression.180 These effects correlated with suppression of the activated states of NF-κB and cAMP 
response element-binding protein (CREB).  Prior results had suggested hypericin, and not hyperforin, was 
the component of St. John’s wort extracts responsible for inhibition of NF-κB.181 In rat aorta at 
concentrations below 10 µM, 7-epi-clusianone induced vasodilation via NO release.182 Interestingly, at 
concentrations above 10 µM, vasoconstriction was observed and was dependent on eicosanoid 
production.    
In addition, several PPAPs have been found to directly inhibit or modulate key proteins involved 
in the biosynthesis of pro-inflammatory eicosanoids.183 5-Lipoxygenase (5-LO) catalyzes the oxidation of 
arachidonic acid to arachidonic acid 5-hydroperoxide, an intermediate in the biosynthesis of 
leukotrienes.184 Arachidonic acid can also be oxidized by cyclooxygenases 1 and 2 (COX-1 and COX-2) 
to prostaglandin H2, the progenitor to prostanoids, prostacyclin, and thromboxanes.185 While several 
classes of drugs have been developed to broadly inhibit the action of these enzymes, the discovery and 
development of specific inhibitors of each of these pro-inflammatory enzymes is still actively pursued.186 
Several PPAPs are reported to be sub-micromolar inhibitors of proteins involved in eicosanoid 
biosynthesis.  Early studies with hyperforin established that it is an uncompetitive inhibitor of both 5-LO 
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and COX-1.187 Hyperforin inhibited purified 5-LO with an IC50 value of 90 nM and had an IC50 in the 
range of 1-2 µM in Ca2+ ionophore-stimulated (PMNs), which was comparable to the known 5-LO 
inhibitor zileuton.  COX-1 activity was also inhibited in stimulated platelet cells, with IC50 values ranging 
from 0.3 to 3 µM depending on the method of stimulation.  No COX-2 inhibition activity was observed.  
When RAW264.7 mouse marcophages188 and LPS-stimulated human blood samples189 were exposed to 
hyperforin, prostaglandin E2 biosynthesis was inhibited.  Aside from 5-LO and COX-1, hyperforin acts as 
an inhibitor of membrane-associated prostaglandin E synthetase-1 (mPGES-1) with an IC50 value of 1 
µM.189 Further, hyperforin may have a unique pharmacological profile compared to other known 5-LO 
inhibitors.  When carrageenan-treated rats were treated with hyperforin (4 mg/kg, intraperitoneal), 
suppression of leukotriene B4 was observed; however, when 5-LO point mutations were introduced 
(W13A-W75A-W102A) or phosphatidylcholine was present, the inhibitory activity of hyperforin was 
abolished.190 Other 5-LO inhibitors of different structural classes, ZM230487 and BWA4C, continued to 
inhibit leukotriene B4 production in the presence of the modifications.   
Given the distinctive nature of hyperforin 5-LO inhibition and moderate potency, a series of 
semisynthetic hyperforin analogs were evaluated against 5-LO in PMNs.191 Overall, oxidation of 
hyperforin produced more active 5-LO inhibitors, and alkylation or acylation produced less active 5-LO 
inhibitors (Table 1.12, Figure 1.11).  The most active analog found in the study was oxyhyperforin, which 
had an IC50 value of 40 nM.  Interestingly, analogs featuring a C9 carbinol were similarly active to those 
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containing a C9 ketone functionality.  Aside from hyperforin and its derivatives, garcinol also displayed 
inhibitory activity against various enzymes involved in eicosanoids.  Garcinol was found to be most 
active against 5-LO (IC50 = 0.1 µM), mPGES-1 (IC50 = 0.3 µM), and COX-1 (IC50 = 12 µM) but showed 
no activity against COX-2.192 
 
Table 1.12. 5-LO inhibition activity of semisynthetic hyperforin analogs.191 
Hyperforin derivative IC50 (µM) 
hyperforin 0.19 
furohyperforin 0.90 
oxyhyperforin 0.040 
hyperforin O-methyl ether (60) inactive 
63 inactive 
73 0.17 
74 inactive 
75 inactive 
 
 
Figure 1.11. Semisynthetic hyperforin analogs. 
 
Aside from being an inhibitor of several enzymes involved in eicosanoid biosynthesis, garcinol 
also acts as an anti-inflammatory agent by blocking pro-inflammatory protein expression.  In a study 
using LPS-activated RAW264.7 cells, it was found that garcinol (at 1 µM concentration) inhibited the 
phosphorylation of cytosolic phospholipase A2 (cPLA2).193 This phosphorylation activates cPLA2, which 
hydrolyzes phospholipids at the sn-2 position, releasing arachidonic acid.  On the other hand, hyperforin 
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was found to induce phosphorylation of cPLA2 with its activity more pronounced in cells with depleted 
intracellular Ca2+.194 The authors proposed that hyperforin inserts itself into lipid membranes and enables 
cPLA2 to access phospholipids and thus release arachidonic acid.  Along with cPLA2 inhibition, garcinol 
reduced iNOS expression and NO release in RAW264.7 cells at 1 µM concentration, presumably through 
inhibition of signal transducer and activator of transcription-1 (STAT-1) or NF-κB, master transcriptional 
regulators.195 Isogarcinol and semisynthetic garcinol derivatives 68 and 69 had similar effects to garcinol 
across these assays but were not as active.  Akin to garcinol, hyperforin has been shown to downregulate 
both STAT-1 and NF-κB in rat and human pancreatic islets in the 0.5-5 µM range, preventing the 
cytokine-induced apoptosis of insulin-secreting β-cells, a cause of type 1 diabetes.196 
7-epi-Clusianone and guttiferone A have also been evaluated for anti-inflammatory and 
antioxidant properties in other contexts.  7-epi-Clusianone inhibited carbachol- and histamine-induced 
guinea pig ileum spasms in a dose-dependent manner, with EC50 values in the 2-4 µM range.197 It also 
prevented allergen-induced contraction of guinea pig trachea at 10 µM, and these effects were replicated 
in an in vivo mouse model at 25-100 mg/kg oral dosing.198 The effects of 7-epi-clusianone were blocked 
by the addition of nitric oxide synthase inhibitors as well as cation channel blockers.  Guttiferone A dose-
dependently reduced the number of ulcerative lesions in a mouse model and was found to be as effective 
as omeprazole.199 This indicates that guttiferone A may impart gastroprotective effects. 
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Chemotherapeutic Activity 
Many PPAPs have been evaluated for their antiproliferative activity against a variety of cancer 
cell lines.  Overall, many PPAPs possess the ability to kill or modify cancer cells to a moderate extent, 
and a variety of underlying mechanisms have been explored.  In many instances, apoptosis activation 
leads to cell death.  A summary of the antiproliferative activity of PPAPs as well as several semisynthetic 
PPAP derivatives (Figure 1.12) against a variety of cancer cell lines is found in Table 1.13. 
 
Table 1.13. Evaluation of PPAPs against cancer cell proliferation. 
PPAP Cancer cell type Cell line IC50 (µM) References 
aristophenone human colon adenocarcinoma SW480 33 135 
clusianone human colorectal carcinoma HCT-116 3.2 200 
clusianone human cervical carcinoma HeLa 3-9.6 200,201 
clusianone human breast carcinoma MCF-7 5.7 201 
clusianone human pancreas carcinoma MIA PaCa-2 3.8 201 
clusianone human promyelocytic leukemia NB4 4.4 200 
clusianone human large cell lung carcinoma NCI-H460 8.3 200 
ent-clusianone human cervical carcinoma HeLa 5.8 201 
ent-clusianone human breast carcinoma MCF-7 8.3 201 
ent-clusianone human pancreas carcinoma MIA PaCa-2 5.2 201 
7-epi-clusianone human renal cell adenocarcinoma 786-0 6.9 116 
7-epi-clusianone human lung carcinoma A549 27.3 202 
7-epi-clusianone human squamous cell carcinoma CRL-1623 7.5 116 
7-epi-clusianone human squamous cell carcinoma CRL-1624 17.8 116 
7-epi-clusianone human Hodgkin's lymphoma HD-MY-Z 9.8 203 
7-epi-clusianone human myelogenous leukemia K562 11.8 203 
7-epi-clusianone human T cell leukemia KE-37 13.6 203 
7-epi-clusianone human breast carcinoma MCF-7 6.3-19.9 116,202 
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Table 1.13 (continued). Evaluation of PPAPs against cancer cell proliferation. 
PPAP Cancer cell type Cell line IC50 (µM) References 
7-epi-clusianone human breast carcinoma NCI-ADR 9.5 116 
7-epi-clusianone human large cell lung carcinoma NCI-H460 8.7 116 
7-epi-clusianone human ovarian carcinoma OVCAR 03 5.9 116 
7-epi-clusianone human prostate carcinoma PC-3 5.2 116 
7-epi-clusianone human malignant melanoma UACC-62 5.8 116 
cycloxanthochymol human lung carcinoma A549 7.5 204 
cycloxanthochymol human prostate carcinoma DU145 6.1 204 
cycloxanthochymol human nasopharyngeal carcinoma KB 8.3 204 
cycloxanthochymol human nasopharyngeal carcinoma KBvin 8.1 204 
cycloxanthochymol human colon adenocarcinoma SW480 16.6 135 
ent-cycloxanthochymol human lung carcinoma A549 7.5 204 
ent-cycloxanthochymol human prostate carcinoma DU145 7.8 204 
ent-cycloxanthochymol human nasopharyngeal carcinoma KB 8.1 204 
ent-cycloxanthochymol human nasopharyngeal carcinoma KBvin 8.6 204 
garcicowin A human colorectal carcinoma HCT-116 inactive 205 
garcicowin B human colorectal carcinoma HCT-116 inactive 205 
garcicowin C human colorectal carcinoma HCT-116 > 5 205 
garcicowin C human cervical carcinoma HeLa-C3 inactive 206 
garcicowin D human colorectal carcinoma HCT-116 > 5 205 
garcimultiflorone D human cervical carcinoma HeLa-C3 17.5 207 
18-hydroxygarcimultiflorone D human cervical carcinoma HeLa-C3 23.0 207 
garcimultiflorone E human cervical carcinoma HeLa-C3 14.3 207 
garcimultiflorone F human cervical carcinoma HeLa-C3 14.9 207 
isogarcimultiflorone F human cervical carcinoma HeLa-C3 12.4 207 
garciniagifolone A human cervical carcinoma HeLa 25.3 208 
garciniagifolone A human hepatocellular carcinoma HepG2 40.0 208 
garciniagifolone A human gastric adenocarcinoma SGC-7901 9.7 208 
garcinialiptone A human lung carcinoma A549 7.0 204 
garcinialiptone A human prostate carcinoma DU145 6.8 204 
garcinialiptone A human nasopharyngeal carcinoma KB 9.5 204 
garcinialiptone A human nasopharyngeal carcinoma KBvin 9.3 204 
ent-garcinialiptone A human lung carcinoma A549 7.0 204 
ent-garcinialiptone A human prostate carcinoma DU145 7.0 204 
ent-garcinialiptone A human cervical carcinoma HeLa inactive 209 
ent-garcinialiptone A human nasopharyngeal carcinoma KB 7.3 204 
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Table 1.13 (continued). Evaluation of PPAPs against cancer cell proliferation. 
PPAP Cancer cell type Cell line IC50 (µM) References 
ent-garcinialiptone A human nasopharyngeal carcinoma KBvin 8.8 204 
ent-garcinialiptone A human breast carcinoma MCF-7 inactive 209 
garcinialiptone C human nasopharyngeal carcinoma KBvin 7.9 204 
garcinialiptone D human lung carcinoma A549 7.3 204 
garcinialiptone D human prostate carcinoma DU145 5.5 204 
garcinialiptone D human nasopharyngeal carcinoma KB 6.5 204 
garcinialiptone D human nasopharyngeal carcinoma KBvin 7.6 204 
garciniaphenone human renal cell adenocarcinoma 786-0 5.1 116 
garciniaphenone human squamous cell carcinoma CRL-1623 15.3 116 
garciniaphenone human squamous cell carcinoma CRL-1624 20.1 116 
garciniaphenone human breast carcinoma MCF-7 10.3 116 
garciniaphenone human breast carcinoma NCI-ADR 12.7 116 
garciniaphenone human large cell lung carcinoma NCI-H460 8.3 116 
garciniaphenone human ovarian carcinoma OVCAR 03 6.4 116 
garciniaphenone human prostate carcinoma PC-3 6.6 116 
garciniaphenone human malignant melanoma UACC-62 6.1 116 
garcinielliptone FB human hepatocellular carcinoma Hep3B 10.2 210 
garcinielliptone FB human colorectal adenocarcinoma HT-29 18.1 210 
garcinielliptone FB human breast carcinoma MCF-7 11.0 210 
garcinielliptone FC human larynx carcinoma HEp-2 5.0 127 
garcinielliptone FC human promyelocytic leukemia  HL-60 2.3 127 
garcinielliptone FC human pulmonary carcinoma NCI-H292 5.0 127 
garcinielliptone FC human bladder carcinoma NTUB1 13.5 138 
garcinielliptone I human colorectal carcinoma HCT-116 inactive 200 
garcinielliptone I human cervical carcinoma HeLa inactive 200 
garcinielliptone I human promyelocytic leukemia NB4 inactive 200 
garcinielliptone I human large cell lung carcinoma NCI-H460 inactive 200 
garcinol human pancreatic adenocarcinoma BXPC-3 a 211 
garcinol human colorectal carcinoma HCT-116 10.5-12.0 200,205,212 
garcinol human cervical carcinoma HeLa 9.8-30.4 200,208 
garcinol human hepatocellular carcinoma HepG2 inactive 208,213 
garcinol human promyelocytic leukemia  HL-60 9.4-17 150,152,214 
garcinol human colorectal adenocarcinoma HT-29 11.4-12.0 212 
garcinol human breast carcinoma MCF-7 a 215 
garcinol human breast adenocarcinoma MDA-MB-231 a 215 
garcinol murine liver hepatoma MH1C1 < 10 213 
garcinol human promyelocytic leukemia NB4 9.2 200 
garcinol human large cell lung carcinoma NCI-H460 8.5 200 
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Table 1.13 (continued). Evaluation of PPAPs against cancer cell proliferation. 
PPAP Cancer cell type Cell line IC50 (µM) References 
garcinol murine leukemia P388 8.1 216 
garcinol human gastric adenocarcinoma SGC-7901 28.6 208 
72 human promyelocytic leukemia  HL-60 inactive 152 
guttiferone A human ovarian carcinoma A2780 8.3-13.3 217,218 
guttiferone A human lung carcinoma A549 3.3 143 
guttiferone A human prostate carcinoma DU145 6.4 143 
guttiferone A human colorectal carcinoma HCT-116 5.0-5.9 200,219 
guttiferone A human cervical carcinoma HeLa 11.6 200 
guttiferone A human colorectal adenocarcinoma HT-29 5 219 
guttiferone A human nasopharyngeal carcinoma KB 7.4 143 
guttiferone A human nasopharyngeal carcinoma KBvin 6.9 143 
guttiferone A human promyelocytic leukemia NB4 5.7 200 
guttiferone A human large cell lung carcinoma NCI-H460 4.2 200 
guttiferone A human colon adenocarcinoma SW480 21 219 
guttiferone B human colorectal carcinoma HCT-116 > 5 205 
guttiferone E human colorectal carcinoma HCT-116 6.4-9 200,220 
guttiferone E human cervical carcinoma HeLa 11.3 200 
guttiferone E human cervical carcinoma HeLa-C3 inactive 206 
guttiferone E human colorectal adenocarcinoma HT-29 14 220 
guttiferone E human promyelocytic leukemia NB4 10.4 200 
guttiferone E human large cell lung carcinoma NCI-H460 5.4 200 
guttiferone E human colon adenocarcinoma SW480 7.5-17 135,220 
guttiferone F human cervical carcinoma HeLa 20.0 221 
guttiferone F human breast carcinoma MCF-7 18.4 221 
guttiferone F human large cell lung carcinoma NCI-H460 19.7 221 
guttiferone G  human ovarian carcinoma A2780 10.1 217 
guttiferone G human cervical carcinoma HeLa 17.1 209 
guttiferone G  human cervical carcinoma HeLa-C3 inactive 206 
guttiferone G  human nasopharyngeal carcinoma KB 7.0 222 
guttiferone G human breast carcinoma MCF-7 17.8 209 
guttiferone H human colorectal carcinoma HCT-116 9 220 
guttiferone H human colorectal adenocarcinoma HT-29 13 220 
guttiferone H human colon adenocarcinoma SW480 12-16 135,220 
guttiferone I human ovarian carcinoma A2780 7.8 218 
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Table 1.13 (continued). Evaluation of PPAPs against cancer cell proliferation. 
PPAP Cancer cell type Cell line IC50 (µM) References 
guttiferone I human cervical carcinoma HeLa 28.5 221,223 
guttiferone I human breast carcinoma MCF-7 31.2 221,223 
guttiferone I human large cell lung carcinoma NCI-H460 23.9 221,223 
guttiferone J human nasopharyngeal carcinoma KB 8.5 222 
guttiferone K human ovarian carcinoma A2780 6.0 224 
guttiferone K human lung carcinoma A549 4.4 143 
guttiferone K human prostate carcinoma DU145 4.6 143 
guttiferone K human colorectal carcinoma HCT-116 10 205,219 
guttiferone K human colorectal adenocarcinoma HT-29 5.4-25 219,225 
guttiferone K human nasopharyngeal carcinoma KB 5.2 143 
guttiferone K human nasopharyngeal carcinoma KBvin 5.3 143 
guttiferone K human colon adenocarcinoma SW480 23 219 
guttiferone K2 human cervical carcinoma HeLa-C3 inactive 206 
guttiferone L human ovarian carcinoma A2780 4.8 224 
guttiferone Q human cervical carcinoma HeLa 6.0 223 
guttiferone Q human breast carcinoma MCF-7 5.5 223 
guttiferone Q human large cell lung carcinoma NCI-H460 8.0 223 
guttiferone R human cervical carcinoma HeLa inactive 223 
guttiferone R human breast carcinoma MCF-7 inactive 223 
guttiferone R human large cell lung carcinoma NCI-H460 inactive 223 
guttiferone S human cervical carcinoma HeLa inactive 223 
guttiferone S human breast carcinoma MCF-7 inactive 223 
guttiferone S human large cell lung carcinoma NCI-H460 inactive 223 
guttiferone T human cervical carcinoma HeLa 19.9 209 
guttiferone T human breast carcinoma MCF-7 14.3 209 
hyperatomarin human stage II bladder carcinoma 5637 1.2 226 
hyperatomarin human endometrioid carcinoma DOHH-2 0.14 227 
hyperatomarin human endometrioid carcinoma EJ 8.8 227 
hyperatomarin human Hodgkin's lymphoma HD-MY-Z 5 227 
hyperatomarin human promyelocytic leukemia  HL-60 2.2 226 
hyperatomarin human promyelocytic leukemia  HL-60Dox 1.8 226 
hyperatomarin human myelogenous leukemia K562 15.7 227 
hyperatomarin human acute myelogenous leukemia KG-1 12.7 226 
hyperatomarin human chronic myeloid leukemia LAMA-84 12.7 227 
hyperatomarin human breast carcinoma MCF-7 0.79 227 
hyperatomarin human breast adenocarcinoma MDA-MB-231 0.86 226 
hyperatomarin human neuroblastoma Neuro-2a 9.4 227 
hyperatomarin human primary osteosarcoma Saos-2 1.2 227 
hyperatomarin human T cell leukemia SKW-3 3 227 
hyperatomarin human B cell malignant myeloma U266 0.49 227 
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Table 1.13 (continued). Evaluation of PPAPs against cancer cell proliferation. 
PPAP Cancer cell type Cell line IC50 (µM) References 
hyperevolutin A human colon carcinoma Co-115 1.5 133 
hyperevolutin B human colon carcinoma Co-115 1.5 133 
hyperfoliatin  human lung carcinoma A549 inactive 202 
hyperfoliatin  human breast carcinoma MCF-7 35.7 202 
hyperforin human melanoma 1F6 8.4 228 
hyperforin human squamous carcinoma A431 8.4 228 
hyperforin murine pancreatic tumor ARIP 4.1 228 
hyperforin murine prostatic carcinoma AT-2.1 3.5 228 
hyperforin murine fibrosarcoma BDX2 74.5 228 
hyperforin human malignant melanoma HT144 11.2 228 
hyperforin human T cell leukemia Jurkat 12.1 228 
hyperforin human myelogenous leukemia K562 14.9 229 
hyperforin human glioblastoma LN-229 19.2 229 
hyperforin murine prostatic carcinoma MAT-Lu 16.8 228 
hyperforin human breast carcinoma MCF-7 2.8 228 
hyperforin human breast adenocarcinoma MDA-MB-468 3.7 228 
hyperforin murine breast carcinoma MT-450 2.8 228 
hyperforin human melanoma MV3 4.7 228 
hyperforin murine bladder carcinoma NBT-II inactive 230 
hyperforin murine glioblastoma RG2 4.7 228 
hyperforin human melanoma SB1 8.4 228 
hyperforin human melanoma SB3 8.4 228 
hyperforin human ovarian adenocarcinoma SK-OV-3 5.6 228 
hyperforin human bladder carcinoma T24 inactive 230 
hyperforin human histiocytic leukemia U937 15.8 229 
hyperforin·HNCy2 human malignant melanoma A375 12.4 231
 
hyperforin·HNCy2 human lung carcinoma A549 3.7 231 
hyperforin·HNCy2 murine melanoma B16-LU8 5-8 232 
hyperforin·HNCy2 murine colon adenocarcinoma C-26 5-8 232 
hyperforin·HNCy2 human cervical carcinoma HeLa 3.1 231 
hyperforin·HNCy2 human hepatocellular carcinoma HepG2 2.7 231 
hyperforin·HNCy2 human fibrosarcoma HT1080 5-8 232 
hyperforin·HNCy2 human myelogenous leukemia K562 8.6-9.9b 231,233 
hyperforin·HNCy2 human myelogenous leukemia K562 3.2c 233 
hyperforin·HNCy2 human myelogenous leukemia K562ADR 14.3 231 
hyperforin·HNCy2 human breast carcinoma MCF-7 2.8 231 
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Table 1.13 (continued). Evaluation of PPAPs against cancer cell proliferation. 
PPAP Cancer cell type Cell line IC50 (µM) References 
hyperforin·HNCy2 human breast adenocarcinoma MDA-MB-231 5 234 
hyperforin·HNCy2 human neuroblastoma SK-N-BE inactive 232 
hyperforin·HNCy2 murine prostate adenocarcinoma TRAMP-C1 inactive 232 
hyperforin O-acetate human malignant melanoma A375 50.6 231 
hyperforin O-acetate human lung carcinoma A549 41.4 231 
hyperforin O-acetate human cervical carcinoma HeLa 17.3 231 
hyperforin O-acetate human hepatocellular carcinoma HepG2 58.9 231 
hyperforin O-acetate human myelogenous leukemia K562 34.3 231 
hyperforin O-acetate human myelogenous leukemia K562ADR 41.6 231 
hyperforin O-acetate human breast carcinoma MCF-7 21.7 231 
octahydrohyperforin (66) human breast adenocarcinoma MDA-MB-231 9 234 
octahydrohyperforin O-acetate human malignant melanoma A375 inactive 231 
octahydrohyperforin O-acetate human lung carcinoma A549 inactive 231 
octahydrohyperforin O-acetate human cervical carcinoma HeLa inactive 231 
octahydrohyperforin O-acetate human hepatocellular carcinoma HepG2 inactive 231 
octahydrohyperforin O-acetate human myelogenous leukemia K562 inactive 231 
octahydrohyperforin O-acetate human myelogenous leukemia K562ADR inactive 231 
octahydrohyperforin O-acetate human breast carcinoma MCF-7 inactive 231 
tetrahydrohyperforin (76) human breast adenocarcinoma MDA-MB-231 2 234 
hyperibone A human cervical carcinoma HeLa 0.176 63 
hyperibone B human colorectal carcinoma HCT-116 inactive 200 
hyperibone B human cervical carcinoma HeLa inactive 200 
hyperibone B human promyelocytic leukemia NB4 inactive 200 
hyperibone B human large cell lung carcinoma NCI-H460 inactive 200 
hyperibone K human lung carcinoma A549 27.4 202 
hyperibone K human breast carcinoma MCF-7 20.0 202 
hyperibone L human lung carcinoma A549 20.5 202 
hyperibone L human breast carcinoma MCF-7 33.4 202 
hyperpapuanone human nasopharyngeal carcinoma KB 7.7 64 
hypersampsone G human lung carcinoma A549 inactive 235 
hypersampsone H human lung carcinoma A549 inactive 235 
isogarcinol human colorectal carcinoma HCT-116 6-8 212 
isogarcinol human cervical carcinoma HeLa-C3 inactive 206 
isogarcinol human promyelocytic leukemia  HL-60 16-17 152 
isogarcinol human colorectal adenocarcinoma HT-29 6-8 212 
30-epi-isogarcinol human colorectal carcinoma HCT-116 5 205 
30-epi-isogarcinol human cervical carcinoma HeLa-C3 inactive 206 
30-epi-isogarcinol human breast carcinoma MCF-7 25.9 221 
30-epi-isogarcinol human large cell lung carcinoma NCI-H460 22.6 221 
isoxanthochymol human lung carcinoma A549 7.3 204 
isoxanthochymol human colon carcinoma Colo-320-DM 4.9 236 
isoxanthochymol human prostate carcinoma DU145 7.0 204 
isoxanthochymol human nasopharyngeal carcinoma KB 7.5 204 
isoxanthochymol human nasopharyngeal carcinoma KBvin 8.6 204 
isoxanthochymol human breast carcinoma MCF-7 2.9 236 
isoxanthochymol murine leukemia P388 2.4 216 
isoxanthochymol human colon adenocarcinoma SW480 16.6 135 
isoxanthochymol human liver carcinoma WRL-68 15.5 236 
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Table 1.13 (continued). Evaluation of PPAPs against cancer cell proliferation. 
PPAP Cancer cell type Cell line IC50 (µM) References 
nemorosone human ovarian carcinoma A2780 18.3 237 
nemorosone human ovarian carcinoma A2780CP 12.4 237 
nemorosone human ovarian carcinoma A2780Dox 13.4 237 
nemorosone human conjuctival melanoma CRMM-1 25.3 238 
nemorosone human conjuctival melanoma CRMM-2 12.9 238 
nemorosone human colorectal carcinoma HCT-116 6.8 200 
nemorosone human colorectal adenocarcinoma HCT-8 8.4 237 
nemorosone human colorectal adenocarcinoma HCT-8Ral 8.8 237 
nemorosone human colorectal adenocarcinoma HCT-8SN-38 8.1 237 
nemorosone human cervical carcinoma HeLa 3.3-5.2 146,200,201 
nemorosone human larynx carcinoma HEp-2 3.1 146 
nemorosone human colorectal adenocarcinoma HT-29 10.4 237 
nemorosone human colorectal adenocarcinoma HT-295-FU 10.3 237 
nemorosone human colorectal adenocarcinoma HT-29SN-38 7.0 237 
nemorosone human T cell leukemia Jurkat 92 237 
nemorosone human myelogenous leukemia K562 8.4 237 
nemorosone human neuroblastoma KELLY 5.2 239 
nemorosone human neuroblastoma LAN-1 4.1-16.3 237,239 
nemorosone human neuroblastoma LAN-15-FU 4.1-16.4 237,239 
nemorosone human neuroblastoma LAN-1ADR  4.9-5.0 237,239 
nemorosone human neuroblastoma LAN-1CP 4.2-16.8 237,239 
nemorosone human neuroblastoma LAN-1ETO 18.3 237 
nemorosone human prostate adenocarcinoma  LNCaP 4.2 237 
nemorosone human prostate adenocarcinoma  LNCaPETO  3.6 237 
nemorosone human stomach carcinoma M51 11.3 237 
nemorosone human stomach carcinoma M51CP 9.5 237 
nemorosone human breast carcinoma MCF-7 6.5-8.7 201,237 
nemorosone human breast carcinoma MCF-75-FU 6.6 237 
nemorosone human breast carcinoma MCF-7Dox 8.5 237 
nemorosone human pancreas carcinoma MIA PaCa-2 3.4 201 
nemorosone human promyelocytic leukemia NB4 4.8 200 
nemorosone human stage III neuroblastoma NB69 3.1 239 
nemorosone human large cell lung carcinoma NCI-H460 5.0-8.4 200,237 
nemorosone human prostate carcinoma PC-3 4.0-7.2 146,237 
nemorosone human neuroblastoma SK-N-AS 6.3 239 
nemorosone human neuronal glioblastoma U251 3.9 146 
ent-nemorosone human cervical carcinoma HeLa 3.4 201 
ent-nemorosone human breast carcinoma MCF-7 8 201 
ent-nemorosone human pancreas carcinoma MIA PaCa-2 3.5 201 
nemorosone O-methyl ether human cervical carcinoma HeLa 57.1 146 
nemorosone O-methyl ether human larynx carcinoma HEp-2 94.5 146 
nemorosone O-methyl ether human prostate carcinoma PC-3 85.1 146 
nemorosone O-methyl ether human neuronal glioblastoma U251 32.9 146 
nujiangefolin A human malignant melanoma A375 inactive 151 
nujiangefolin A human lung carcinoma A549 inactive 151 
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Table 1.13 (continued). Evaluation of PPAPs against cancer cell proliferation. 
PPAP Cancer cell type Cell line IC50 (µM) References 
nujiangefolin A human gastric adenocarcinoma AGs inactive 151 
nujiangefolin A human pancreatic adenocarcinoma BXPC-3 inactive 151 
nujiangefolin A human colorectal carcinoma HCT-116 3.2-5.9 212 
nujiangefolin A human hepatocellular carcinoma HepG2 inactive 151 
nujiangefolin A human promyelocytic leukemia  HL-60 8.4-17 150,152 
nujiangefolin A human colorectal adenocarcinoma HT-29 3.2-5.9 212 
nujiangefolin A human breast carcinoma MCF-7 inactive 151 
nujiangefolin A human breast adenocarcinoma MDA-MB-231 inactive 151 
nujiangefolin A human lung adenocarcinoma NCI-H2126 inactive 151 
nujiangefolin A human pancreatic carcinoma PANC-1 inactive 151 
nujiangefolin A human hepatocellular carcinoma SMMC-7721 inactive 151 
nujiangefolin A human primary glioblastoma U87 inactive 151 
nujiangefolin B human malignant melanoma A375 inactive 151 
nujiangefolin B human lung carcinoma A549 inactive 151 
nujiangefolin B human gastric adenocarcinoma AGs inactive 151 
nujiangefolin B human pancreatic adenocarcinoma BXPC-3 inactive 151 
nujiangefolin B human colorectal carcinoma HCT-116 3-7 212 
nujiangefolin B human hepatocellular carcinoma HepG2 inactive 151 
nujiangefolin B human promyelocytic leukemia  HL-60 8-18 150,152 
nujiangefolin B human colorectal adenocarcinoma HT-29 3-7 212 
nujiangefolin B human breast carcinoma MCF-7 inactive 151 
nujiangefolin B human breast adenocarcinoma MDA-MB-231 inactive 151 
nujiangefolin B human lung adenocarcinoma NCI-H2126 inactive 151 
nujiangefolin B human pancreatic carcinoma PANC-1 inactive 151 
nujiangefolin B human hepatocellular carcinoma SMMC-7721 inactive 151 
nujiangefolin B human primary glioblastoma U87 inactive 151 
nujiangefolin C human malignant melanoma A375 inactive 151 
nujiangefolin C human lung carcinoma A549 inactive 151 
nujiangefolin C human gastric adenocarcinoma AGs inactive 151 
nujiangefolin C human pancreatic adenocarcinoma BXPC-3 inactive 151 
nujiangefolin C human hepatocellular carcinoma HepG2 inactive 151 
nujiangefolin C human breast carcinoma MCF-7 inactive 151 
nujiangefolin C human breast adenocarcinoma MDA-MB-231 inactive 151 
nujiangefolin C human lung adenocarcinoma NCI-H2126 inactive 151 
nujiangefolin C human pancreatic carcinoma PANC-1 inactive 151 
nujiangefolin C human hepatocellular carcinoma SMMC-7721 inactive 151 
nujiangefolin C human primary glioblastoma U87 inactive 151 
oblongifolin B human colorectal carcinoma HCT-116 < 5 205 
oblongifolin B human cervical carcinoma HeLa-C3 inactive 240 
oblongifolin C human colorectal carcinoma HCT-116 7.3 205,241 
oblongifolin C human colorectal carcinoma HCT-116MDR 9.8 241 
oblongifolin C human breast carcinoma MCF-7 7.7 241 
oblongifolin C human breast carcinoma MCF-7HER2 9.7 241 
oblongifolin D human colorectal carcinoma HCT-116 < 5 205 
oblongifolin D human cervical carcinoma HeLa-C3 inactive 240 
 
                                                      
240 Xu, G.; Feng, C.; Zhou, Y.; Han, Q.-B.; Qiao, C.-F.; Huang, S.-X.; Chang, D. C.; Zhao, Q.-S.; Luo, K. Q.; Xu, 
H.-X. J. Agric. Food Chem. 2008, 56, 11144-11150. 
 
241 Feng, C.; Zhou, L.-Y.; Yu, T.; Xu, G.; Tain, H.-L.; Xu, J.-J.; Xu, H.-X.; Luo, K. Q. Int. J. Cancer 2012, 131, 
1445-1454. 
 
60
 61 
Table 1.13 (continued). Evaluation of PPAPs against cancer cell proliferation. 
PPAP Cancer cell type Cell line IC50 (µM) References 
ochrocarpinone A human ovarian carcinoma A2780 12.9 242 
ochrocarpinone B human ovarian carcinoma A2780 14.3 242 
ochrocarpinone C human ovarian carcinoma A2780 15.8 242 
oxy-thorelione A human breast carcinoma MCF-7 17.3 221 
oxy-thorelione A human large cell lung carcinoma NCI-H460 51.3 221 
papuaforin A human nasopharyngeal carcinoma KB 18.2 64 
papuaforin C human nasopharyngeal carcinoma KB 11.5 64 
papuaforin D human nasopharyngeal carcinoma KB 13.7 64 
papuaforin E human nasopharyngeal carcinoma KB 11.3 64 
paucinone A human cervical carcinoma HeLa 10 243 
paucinone B human cervical carcinoma HeLa 8.2 243 
paucinone C human cervical carcinoma HeLa 24.3 243 
paucinone D human cervical carcinoma HeLa 5.8 243 
plukenetione A human ovarian carcinoma A2780 25.8 237 
plukenetione A human ovarian carcinoma A2780CP 31.8 237 
plukenetione A human ovarian carcinoma A2780Dox 28.9 237 
plukenetione A human colorectal adenocarcinoma HCT-8 25.8 237 
plukenetione A human colorectal adenocarcinoma HCT-8Ral 24.2 237 
plukenetione A human colorectal adenocarcinoma HCT-8SN-38 23.3 237 
plukenetione A human colorectal adenocarcinoma HT-29 24.0 237 
plukenetione A human colorectal adenocarcinoma HT-295-FU 28.4 237 
plukenetione A human colorectal adenocarcinoma HT-29SN-38 26.6 237 
plukenetione A human T cell leukemia Jurkat 10.5 237 
plukenetione A human prostate adenocarcinoma  LNCaP 4.0 237 
plukenetione A human prostate adenocarcinoma  LNCapETO 3.4 237 
plukenetione A human stomach carcinoma M51 13.0 237 
plukenetione A human stomach carcinoma M51CP 15.2 237 
plukenetione A human breast carcinoma MCF-7 32.5 237 
plukenetione A human breast carcinoma MCF-75-FU 20.0 237 
plukenetione A human breast carcinoma MCF-7Dox 30.0 237 
plukenetione A human large cell lung carcinoma NCI-H460 26.8 237 
plukenetione D/E human prostate carcinoma DU145 7.3 244 
plukenetione D/E human prostate carcinoma DU145MDR 6.8 244 
plukenetione D/E human prostate adenocarcinoma  LNCaP 4.1 244 
plukenetione D/E human prostate adenocarcinoma  LNCaPETO 4.8 244 
plukenetione D/E human prostate carcinoma PC-3 5.0 244 
plukenetione D/E human prostate carcinoma PC-3ETO 5.1 244 
15,16-dihydro-16-hydroperoxy-plukentione F human ovarian carcinoma A2780 15.7 242 
prolifenone A human gastric adenocarcinoma AGs inactive 245 
prolifenone A human colorectal carcinoma HCT-116 inactive 245 
prolifenone A human breast carcinoma MCF-7 inactive 245 
prolifenone A human large cell lung carcinoma NCI-H460 inactive 245 
prolifenone A human astrocytoma SF-268 inactive 245 
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Table 1.13 (continued). Evaluation of PPAPs against cancer cell proliferation. 
PPAP Cancer cell type Cell line IC50 (µM) References 
prolifenone B human gastric adenocarcinoma AGs inactive 245 
prolifenone B human colorectal carcinoma HCT-116 inactive 245 
prolifenone B human breast carcinoma MCF-7 inactive 245 
prolifenone B human large cell lung carcinoma NCI-H460 inactive 245 
prolifenone B human astrocytoma SF-268 inactive 245 
propolone A human colorectal carcinoma HCT-116 4.4 200 
propolone A human cervical carcinoma HeLa 10.8 200 
propolone A human promyelocytic leukemia NB4 6.8 200 
propolone A human large cell lung carcinoma NCI-H460 6.3 200 
propolone B human colorectal carcinoma HCT-116 16.4 200 
propolone B human cervical carcinoma HeLa inactive 200 
propolone B human promyelocytic leukemia NB4 inactive 200 
propolone B human large cell lung carcinoma NCI-H460 23 200 
propolone C human colorectal carcinoma HCT-116 16.3 200 
propolone C human cervical carcinoma HeLa inactive 200 
propolone C human promyelocytic leukemia NB4 inactive 200 
propolone C human large cell lung carcinoma NCI-H460 inactive 200 
propolone D human colorectal carcinoma HCT-116 inactive 200 
propolone D human cervical carcinoma HeLa inactive 200 
propolone D human promyelocytic leukemia NB4 inactive 200 
propolone D human large cell lung carcinoma NCI-H460 inactive 200 
propolone D peroxide human colorectal carcinoma HCT-116 inactive 200 
propolone D peroxide human cervical carcinoma HeLa inactive 200 
propolone D peroxide human promyelocytic leukemia NB4 inactive 200 
propolone D peroxide human large cell lung carcinoma NCI-H460 inactive 200 
sampsonione A murine leukemia P388 22.2 246 
sampsonione I murine leukemia P388 11.8 247 
sampsonione J murine leukemia P388 inactive 247 
semsinone A human lung carcinoma A549 12.5 143 
semsinone A human prostate carcinoma DU145 16.4 143 
semsinone A human nasopharyngeal carcinoma KB 5.9 143 
semsinone A human nasopharyngeal carcinoma KBvin 13.9 143 
thorelione A human cervical carcinoma HeLa 15.4 221 
thorelione A human breast carcinoma MCF-7 12.3 221 
thorelione A human large cell lung carcinoma NCI-H460 17.6 221 
uralodin B human hepatocellular carcinoma HepG2 171.0 248 
uralodin B human promyelocytic leukemia  HL-60 21.8 248 
uralodin B human myelogenous leukemia K562 171 248 
uralodin B human gastric adenocarcinoma SGC-7901 63.7 248 
uralodin C human hepatocellular carcinoma HepG2 28.5 248 
uralodin C human promyelocytic leukemia  HL-60 14.3 248 
uralodin C human myelogenous leukemia K562 32.1 248 
uralodin C human gastric adenocarcinoma SGC-7901 26.1 248 
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Table 1.13 (continued). Evaluation of PPAPs against cancer cell proliferation. 
PPAP Cancer cell type Cell line IC50 (µM) References 
xanthochymol human lung carcinoma A549 6.6 204 
xanthochymol human colon carcinoma Colo-320-DM 0.62 236 
xanthochymol human prostate carcinoma DU145 6.6 204 
xanthochymol human colorectal carcinoma HCT-116 10 220 
xanthochymol human colorectal adenocarcinoma HT-29 15 220 
xanthochymol human nasopharyngeal carcinoma KB 8.3 204 
xanthochymol human nasopharyngeal carcinoma KBvin 8.1 204 
xanthochymol human breast carcinoma MCF-7 0.475 236 
xanthochymol human colon adenocarcinoma SW480 8.3-17 135,220 
xanthochymol human liver carcinoma WRL-68 2.5 236 
octahydroxanthochymol (77) human nasopharyngeal carcinoma KB 20 249 
 
a Antiproliferative activity was observed, but no IC50 value was reported. 
b IC50 value after 48 h of incubation with the compound. 
c IC50 value after 72 h of incubation with the compound. 
 
 
Figure 1.12. Semisynthetic PPAP analogs tetrahydrohyperforin (76) and octahydroxanthochymol (77). 
 
 
Overall, the presence of a relatively acidic hydroxyl group (either an enolic or phenolic –OH) is 
imperative for antiproliferative activity.  A common feature of inactive PPAPs found in Table 1.13 is the 
presence of a tetrahydrofuran ring encompassing the C4 (or C2) enolic oxygen atom, such as 
garcinielliptone I, guttiferone R, hyperibone B, and propolone D.  These PPAPs lack any phenolic 
hydroxyl functionality, as well.  Interestingly, while hyperforin O-acetate maintains moderate activity 
across a variety of cell lines, octahydrohyperforin O-acetate is inactive.231 A decrease in the activity of 
nemorosone as its O-methyl ether also demonstrates the importance of this free acidic hydroxyl group to 
antiproliferative activity.146 In addition to the PPAPs listed in Table 1.13, the tin complex of 7-epi-
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clusianone [SnClPh3(7-epi-clusianone)], has been evaluated against HN-5 cells, however with 
inconclusive results.250 
In some instances, the underlying mechanisms by which PPAPs affect cancer cells have been 
explored.  Several studies have provided evidence that hyperforin influences cancer survival and 
proliferation through a variety of pathways.251 An early study by Schempp and coworkers with MT-450 
cells established that hyperforin induces apoptosis through caspase activation.228 The addition of the 
nonspecific caspase inhibitor Z-VAD-FMK prevented hyperforin-induced apoptosis.  Aside from caspase 
activation, hyperforin also caused a loss of the mitochondrial transmembrane potential.  Given that this 
latter effect occurred in the presence of Z-VAD-FMK and that hyperforin treatment induced cytochrome c 
release from isolated mitochondria, the authors concluded that hyperforin’s ability to increase 
mitochondrial membrane permeability caused caspase activation and ultimately cell death through 
apoptosis.  Similar results were found in a later study using K562 cells treated with hyperforin·HNCy2.233  
In leukemia cells, hyperforin upregulates the pro-apoptotic regulator Noxa in addition to caspase 
mediated pathways.  In cells taken from CLL patients, Noxa upregulation was observed upon treatment 
with hyperforin, leading to apoptosis.252 siRNA-mediated Noxa silencing partially reduced the effects of 
hyperforin in these cells.  Studies involving various AML cell lines also demonstrated Noxa-induced 
apoptosis.253 In U937 cells, Noxa upregulation was accompanied with downregulation of anti-apoptotic 
Bcl-2, an increase in mitochondrial permeability, and inhibition of the kinase activity of the survival 
factor PKB. 
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In addition to acting as a pro-apoptotic, hyperforin also acts as an anti-angiogenic agent and an 
inhibitor of cancer metastasis.  In an in vitro assay involving BAE cells, treatment with 1-10 µM 
hyperforin strongly inhibited proliferation.254 Zymographic analysis revealed that hyperforin significantly 
inhibited urokinase and MMP-2 production.  Similar results were observed in a later study involving a 
panel of murine and human cancer cell lines,232 as well as HDMECs and in vivo with rats injected with 
MT-450 cells.255 In cultured B-CLL cells taken from patients, hyperforin inhibited the secretion of MMP-
9, with IC50 values below 10 µM, and inhibited the formation of microtubules of human bone marrow 
endothelial cells cultured on Matrigel.256 Along with decreased secretion of urokinase, MMP-2, and 
MMP-9, hyperforin·HNCy2 inhibited elastase noncompetitively (IC50 = 3 µM).  In mouse models 
involving both B16-LU8 and C-26, sub-cytotoxic administration of hyperforin·HNCy2 significantly 
reduced tumor metastasis and infiltration.  Capillary-like structure development of HUVECs was also 
inhibited, and hyperforin treatment prevented the proliferation of the highly angiogenic Kaposi’s sarcoma 
cell line.257 In the latter instance, significant reduction of vascularization and tumor size was observed 
compared to control.  In contrast to these results, sub-micromolar concentrations of hyperforin actually 
increased VEGF expression in DAOY cells.258 No effect was observed in U87 cells, which overexpresses 
VEGF. 
Due to the instability of pure hyperforin, several semisynthetic analogs have been prepared and 
their antiproliferative properties have been studied.  While alkylation of the C4 enolic oxygen atom 
imparts stability, this may worsen the already marginal water solubility of hyperforin.  To address these 
issues, the semisynthetic derivative aristoforin (78) was synthesized in two steps from hyperforin 
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(Scheme 1.12).259 Not only was aristoforin more stable and more water-soluble than hyperforin, it also 
possessed very similar antiproliferative and pro-apoptotic properties as the parent natural product in MT-
450 tumor assays.  A loss of activity was observed with octahydroaristoforin, the hydrogenolysis product 
of aristoforin.  Both hyperforin and aristoforin were similarly active at suppressing tumor-induced 
lymphangiogenesis in vivo at concentrations below 10 µM.260 Above 10 µM, both compounds induced 
apoptosis in lymphatic endothelial cells through increased mitochondrial membrane permeability and 
induction of caspase 9. 
 
 
Scheme 1.12. Synthesis of aristoforin from hyperforin.a 
a Conditions: (a) BrCH2CO2Et, K2CO3, acetone; (b) NaOH, H2O, MeOH, 0 ºC to rt, 37% (2 steps). 
 
 
A variety of oxidized and reduced hyperforin derivatives have also been evaluated, and some of 
the results are shown in Table 1.13.  Both octahydrohyperforin (66) tetrahydrohyperforin (76) were found 
to be similarly effective towards MDA-MB-231 cells.234 Tetrahydrohyperforin displayed antiangiogenic 
properties comparable to hyperforin·HNCy2 in a BAE cell growth assay and the Matrigel tubule-like 
structure formation assay.  Several other semisynthetic derivatives, including furohyperforin, 
oxyhyperforin, 79, 80, and 81 (Figure 1.13), were also evaluated but were ineffective at inhibiting 
angiogenesis.  This illustrates the importance of the enolic C4 oxygen atom for anti-angiogenic activity.  
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As mentioned previously, a significant loss of antiproliferative activity was observed with hyperforin O-
acetate and octahydrohyperforin O-acetate across a variety of cancer cell lines.231 
 
 
Figure 1.13. Semisynthetic hyperforin derivatives lacking C4 functionality. 
 
 
Garcinol is another PPAP that has undergone rather extensive mechanistic studies, and it has been 
found to promote apoptosis and inhibit cancer proliferation, angiogenesis, and metastasis in a variety of 
ways.261 Similar to hyperforin, garcinol activates apoptosis in certain cancer cell lines by increasing 
mitochondrial membrane permeability.  This loss of membrane potential was observed in three different 
leukemia cell lines and led to activation of caspase 3.262 In this study, similar activity was observed with 
isogarcinol but not xanthochymol.  The addition of the caspase 3 inhibitor Z-DEVD-FMK prevented 
garcinol-induced apoptotic DNA fragmentation.214 Later studies involving pancreatic211 and breast215 
cancer cell lines found that garcinol suppressed NF-κB.  In HT-29 cells, 10 µM garcinol induced 
apoptosis and prevented migration by inhibiting the phosphorylation of FAK as well as preventing the 
activation of the MAPK and PI3K/Akt signaling pathways.263 Downregulation of STAT-3 was observed 
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in a variety of cancer cell lines and in an MDA-MD-231 mouse xenograft model.264 In another study 
involving the MDA-MD-231 and the BT-549 breast carcinoma cell lines, garcinol treatment reversed the 
epithelial-to-mesenchymal transition and increased phosphorylation of β-catenin.265 These results were 
also validated in a xenograft mouse model.  Breast cancer proliferation may also be inhibited through the 
ability of garcinol to downregulate the expression of cyclin D3, which is highly upregulated in cancer 
cells compared to nearby normal tissue.266 Treatment with 1 µM garcinol in a nicotine-induced MDA-
MD-231 cell line prevented cancer proliferation.  Garcinol has also been shown to be particularly 
cytotoxic to cells expressing PDGFRs, kinases implicated in several forms of cancer including 
medulloblastoma.267 Inhibition of PDGFRs in several cell lines by garcinol led to apoptosis; however, 
PDGFR-negative MEF cells were not affected by garcinol treatment.   
In addition to increased mitochondrial membrane permeability, garcinol may also promote 
apoptosis through the accumulation of ROS within cancer cells.  In garcinol-treated (50 µM) p53-negative 
Hep3B cells, this ROS accumulation was observed along with increased expression of endoplasmic 
reticulum stress modulator GADD153 and loss of mitochondrial membrane potential, leading to cell 
death.268 Interestingly, an independent study found that while high concentrations of garcinol caused 
apoptosis in HT-29 and HCT-116 cells, low concentrations (<1 µM) actually promoted cancer cell 
proliferation.212 This latter effect may be mediated by ROS; in the presence of superoxide dismutase and 
catalase and with concentrations of garcinol 0.5-1 µM, cell growth was inhibited.   
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Administration of garcinol has been shown to prevent carcinogenesis in several animal models. 
Dietary feeding of garcinol (0.01-0.05% of diet) caused a significant reduction of the formation of 
azoxymethane-induced colonic aberrant crypt foci (ACF) in rats compared to control.269 Rats were given 
a garcinol-laden diet 1 week prior to the induction of ACF and during the next four weeks.  Up to 40% 
reduction of ACF frequency was observed (with the 0.05% dietary garcinol cohort).  Dietary feeding of 
garcinol (0.01-0.05%) also prevented 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.270 Rats 
were given garcinol either for 10 weeks during carcinogen administration or for 22 weeks following 
exposure, and in both instances, the frequency of tongue lesions were significantly reduced.  Topical 
treatment of garcinol also prevented 7,12-dimethylbenz[a]anthracene-induced hamster cheek pouch 
carcinogenesis.271 Both short- and long-term application of garcinol prevented inflammation, lesion 
formation, and tumor size.  In these three studies reported, a possible explanation for the suppression of 
carcinogenesis by garcinol may be due to its ability to decrease the expression of enzymes involved in 
inflammation response, such as iNOS, COX-2, and 5-LO. 
Nemorosone also displays anti-cancer properties and may operate in a similar manner to 
hyperforin and garcinol.  Nemorosone, in concentrations of 50-500 nM, has been shown to increase 
membrane permeability in mitochondria isolated from rat livers.272 The authors hypothesized that 
nemorosone acted as a proton shuttle across the mitochondrial membrane, thus dissipating membrane 
potential.  Indeed, nemorosone was found to be cytotoxic to HepG2 cells in 1-25 µM concentrations.  In 
various breast cancer cell lines, nemorosone was selectively cytotoxic to cells expressing estrogen 
receptor 1, and when an estrogen receptor antagonist was used in conjunction with nemorosone, these 
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effects were enhanced.273 Nemorosone was also found to be cytotoxic toward the neuroblastoma cell line 
LAN-1.239 Significant decreases in Akt and ERK activity were observed and may be the cause of 
apoptosis in this cell line.  Aside from facilitating apoptosis in pancreatic cells via mitochondrial 
membrane potential dissipation and caspase activation, transcription profiling revealed that nemorosone 
altered the expression of many proteins involved in unfolded protein response.274 This cellular stress 
response mechanism may be one avenue by which nemorosone facilitates apoptosis in cancer cells.   
The mechanisms by which several other PPAPs inhibit cancer cell proliferation have been 
explored.  Unsurprisingly, guttiferone A also increases mitochondrial membrane permeability and caused 
apoptosis of the pancreatic cancer cell line HepG2.275 Plukenetione A promoted apoptosis in a variety of 
cancer cell lines, and this may be due to its ability to repress the expression of topoisomerase I and DNA 
polymerase.237 In its ability to facilitate LNCaP prostate carcinoma cell apoptosis, 7-epi-nemorosone may 
inhibit MAPK, similar to garcinol.244 The ability of guttiferone K to promote apoptosis may also be due to 
MAPK inhibition.225 The addition of a JNK (a type of MAPK) inhibitor partially rescued HT-29 cells 
from guttiferone K-induced apoptosis.  Oblongifolin C promoted apoptosis in HeLa cells via caspase and 
Bax activation.241 In the presence of a pan-caspase inhibitor or the anti-apoptotic protein Bcl-xL, 
apoptosis was prevented.  Caspase activation has also been noted in hyperatomarin-induced cancer cell 
apoptosis.226 Cathepsin inhibition has been implicated as a major factor in the antiproliferative properties 
of 7-epi-clusianone and garcinaphenone.116 
Further, several other PPAPs have been evaluated specifically for antimutagenic and antimitotic 
activity.  Nemorosone displayed modest inhibitory activity in the Ames mutagenicity assay involving 
various Salmonella typhimurium strains, especially against mitomycin C- and aflatoxin B1-induced 
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mutagenesis.276 Garcinielliptone FC facilitated DNA damage and cleavage in the presence of Cu2+, 
possibly involving the formation of ROS.277 While garcinol, guttiferone B, and oblongifolins A-D were 
found to be ineffective at microtubule disassembly inhibition, they inhibited tubulin assembly, with IC50 
values ranging from 50-100 µM.278 Guttiferones G and J222 as well as a mixture of cycloxanthochymol 
and isoxanthochymol249 showed no effect on tubulin assembly. 
Several studies have addressed whether certain PPAPs can be used in concert with other 
therapeutic agents to treat cancer.  When hyperforin was combined with hypericin or procyanidin B2, 
synergistic cytotoxic effects were observed in K562 and U937 cells upon treatment.229 Thus, the authors 
of the study purport that the crude St. John’s wort extract may be a viable therapeutic option for various 
leukemias.  In another study, an enhancement of activity was observed in hypericin-mediated 
photodynamic therapy of HT-29 cells when hyperforin or aristoforin was present.279 In leukemia cells, 
hyperforin has been shown to impair the activity of P-gp and BCRP, ATP-binding cassette transporters 
responsible for the development of multidrug resistance in several cancer cell lines.280 Hyperforin’s 
ability to inhibit drug efflux from cancer cells may find use in chemotherapies in which drug resistance 
develops.   
Other than hyperforin, garcinol may be useful as a co-therapeutic in cancer treatment.  By 
inhibiting DNA repair via non-homologous end joining, garcinol has been shown to radiosensitize cancer 
cells.281 Garcinol may prevent this DNA damage repair by acting as a histone acetyltransferase inhibitor.  
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Garcinol’s ability to change gene expression has also been applied to the sensitization of pancreatic 
cancer cells to the chemotherapeutic gemcitabine.282 A synergistic effect was noted when garcinol and 
gemcitabine were co-applied to pancreatic cancer cells.  Synergistic antiproliferative and apoptotic effects 
were also noted between garcinol and curcumin in the pancreatic cancer cell lines BXP-3 and PANC-1.283 
Potency of a combination of the two agents was 2- to 10-fold greater than the individual potency of each 
agent.   
Activity against Neurological Disorders 
Diseases and disorders of the central nervous system have also been targeted with PPAP-based 
therapeutics.  The most studied PPAP in this area is hyperforin, a component of the medicinal herb St. 
John’s wort, and much work has been done to elucidate its effects on clinical depression.284 For over 
2,000 years, St. John’s wort has been used to treat a variety of ailments, and several ancient Greek and 
Roman historians and doctors have recorded the medicinal use of an herb called hyperikon that matches 
the description of Hypericum perforatum.285 Indeed, hyperikon is derived from the Latin words hyper 
(meaning “over”) and eikon (meaning “apparition”), which in the pre-modern medicine era may refer to 
depression.  A traditional English proverb below effectively summarizes the use of St. John’s wort prior 
to the advent of modern medicine: 
St. John’s wort doth charm all the witches away,  
If gathered at midnight on the saint's holy day,  
And devils and witches have no power to harm  
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Those that do gather the plant for a charm 
Rub the lintels and post with that red juicy flower  
No thunder nor tempest will then have the power  
To hurt or to hinder your houses; and bind  
Round your neck a charm of a similar kind.286 
To this day, SJW extract remains a popular therapeutic for depression in European countries; 
during the period between April 2007 and March 2008, over 9.5 million units of SJW were sold, mostly 
in Germany, Russia, and Poland.287 In Germany, standardized SJW extracts are one of the most prescribed 
antidepressants, with sales comparable to synthetic antidepressants.  In the United States, sales of SJW 
peaked in the late 1990’s, reaching upwards of an estimated $310 million.288 However, the discovery of 
side effects (to be discussed in the next section) has led to a decrease in SJW sales, with 2007 numbers an 
estimated $8.1 million, making it the tenth most popular herbal dietary supplement sold in the country 
that year.289 Dozens of clinical trials involving SJW treatment of depression have appeared in the 
literature enlisting over 5,000 patients.  A Cochrane Collaboration meta-analysis of 29 double-blind, 
randomized trials involving 5,489 patients found that SJW was indeed effective for treatment of major 
depression with efficacy comparable to standard antidepressants.290 Importantly, fewer adverse side 
effects were encountered with SJW extract use than with other antidepressants.   
Given the long history of use, efficacy, and safety of SJW extract, identification of the active 
component has received considerable attention.  Chemicals found in the extract fall into three distinct 
categories: phloroglucinols, flavonoids, and naphthodianthrones.291 An early study purported that the 
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active antidepressant component of herb was hypericin (82, Figure 1.14), a naphthodianthrone polyketide 
that had monoamine oxidase (MAO) inhibition activity, with IC50 values of 68 nM and 420 nM for type A 
and B MAOs, respectively.292 However, there are several reasons to doubt that hypericin, by itself, is the 
active principle of SJW.  Attempts to replicate these original findings have been unsuccessful, using 
either pure hypericin or crude SJW extracts.293 In fact, the flavonoid-containing fraction of the extract was 
the only component to show mild MAO inhibition ability at all.  Also, it appears that hypericin does not 
cross the blood-brain barrier.  When rats were orally administered with either SJW extract (1600 mg/kg) 
or pure hypericin (5 mg/kg), no hypericin was detected in the brain above the detection threshold (16 
pmol/g).294  
 
 
Figure 1.14. Structure of hypericin. 
 
 
Upon further analysis of the compounds found in SJW extract, multiple sources found that 
hyperforin was indeed the primary component responsible for its antidepressant activity.295 While it had 
been known since the 1970’s that hyperforin is a significant constituent of the herb,1 comprising 2-4% of 
                                                      
 
292 Suzuki, O.; Katsumata, Y.; Oya, M.; Bladt, S.; Wagner, H. Planta Med. 1984, 50, 272-274. 
 
293 (a) Thiede, H.-M.; Walper, A. J. Geriatr. Psychiatry Neurol. 1994, 7 (Suppl. 1), 54-56. (b) Bladt, S.; Wagner, H. 
J. Geriatr. Psychiatry Neurol. 1994, 7 (Suppl. 1), 57-59. (c) Yu, P. H. Pharmacopsychiatry 2000, 33, 60-65. 
 
294 Paulke, A.; Schubert-Zsilavecz, M.; Wurglics, M. Monatsh. Chem. 2008, 139, 489-494. 
 
295 For a review of the antidepressant properties of hyperforin, see: (a) Müller, W. E. Pharmacol. Res. 2003, 47, 101-
109. (b) Wurglics, M.; Schubert-Zsilavecz, M. Clin. Pharmacokinet. 2006, 45, 449-468. (c) Hussain, S.; Ansari, Z. 
H.; Arif, M. Int. J. Health Res. 2009, 2, 15-22. 
 
O
O
Me
Me
OH
HO
HO
OH OH
OH
hypericin (82)
74
 75 
the dry weight of its aerial parts,296 it had been largely disregarded due to its chemical instability.  In fact, 
the inconsistencies of SJW clinical trials may be due to hyperforin instability; prior to the realization of 
the significance of hyperforin, the PPAP was found in variable amounts in SJW medical preparations.297  
Upon exposure to light and air, hyperforin rapidly converts to furohyperforin, among other 
oxidation products.  Furohyperforin is observed when air is bubbled through a methanolic solution of 
hyperforin for 6.5 h.298 Upon standing neat exposed to air at 40 ºC, or dissolved in nonpolar solvents (e.g., 
hexane, benzene, petroleum ether), furohyperforin, 33-deoxy-33-hydroperoxy-furohyperforin, 
oxyhyperforin, oxepahyperforin, furohyperforin isomers 1 and 2, and a variety of monocyclic 
cyclohexanones were observed.299 Similar degradation products are found when hyperforin is 
photochemically irradiated in acetonitrile300 or exposed to peroxide oxidants.301 Despite its apparent 
instability upon exposure to light, oxidants, and nonpolar solvents, hyperforin may be stabilized in polar 
protic solvents.  In general, the half-life of hyperforin increases with increasing solvent polarity.  After 30 
days at 20 ºC in the dark, over 70% of hyperforin remains in ethanol, methanol, or methanol/water 
suspensions.302 Storage below –20 ºC under nitrogen also prevents degradation of hyperforin; after 8 
months, only marginal decomposition of hyperforin occurred.303 Overall, despite the fact that hyperforin 
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may readily decompose upon exposure to light and air, relatively straightforward precautions can be taken 
in order to preserve hyperforin either as a pure substance or as found in SJW extracts.   
The discovery that hyperforin was the principle antidepressant component of SJW came in 1998 
with a seminal paper by Müller and coworkers.304 Using two murine models for depression, the 
behavioral despair test and the learned helplessness test, it was found that the antidepressant potency of 
SJW extracts correlated with hyperforin content.  More importantly, isolated hyperforin inhibited the 
uptake of tritiated neurotransmitters into isolated murine synaptosomes in a dose-dependent manner.  IC50 
values for these in vitro experiments ranged from 0.011-3.35 µM and have been confirmed in later studies 
(Table 1.14).305 Unlike synthetic antidepressants, which selectively block the selective reuptake of 
individual neurotransmitters, hyperforin appeared to block the reuptake of a variety of neurotransmitters, 
possibly signifying a novel mechanistic paradigm for the treatment of depression. 
  
Table 1.14. Inhibition of synaptosomal [3H]neurotransmitter uptake by hyperforin. 
Neurotransmitter IC50 (µM) References 
[3H]serotonin 0.12-3.35 304,306,307,308,309,310 
[3H]noradrenaline 0.033-0.080 304,308 
[3H]dopamine 0.011-0.102 304,308 
[3H]γ-aminobutyric acid 0.184 304,311 
[3H]L-glutamate 0.143-0.829 304,311 
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Subsequent to the realization that hyperforin may be responsible for the antidepressant activity of 
SJW, ensuing preclinical and clinical studies provided more evidence to verify this hypothesis.  In the 
behavioral despair and elevated plus-maze murine models of depression, treatment with pure hyperforin 
led to more favorable outcomes compared to the ethanolic and supercritical CO2 SJW extracts, which 
contained 4.5% and 38.8% hyperforin, respectively.312 Hyperforin was significantly effective in the 
elevated plus-maze test at concentrations as low as 1 mg/kg, and 3-day 20 mg/kg treatment with pure 
hyperforin in the force swim test caused a 40% reduction of immobilization time compared to vehicle.  
Using the same ethanolic and CO2 SJW extracts as above, positive outcomes in a variety of other murine 
models of depression were shown to correlate with hyperforin content, including rat resperine syndrome, 
muricidal rat behavior, 5-hydroxytryptophan-induced mouse head twitches, L-dopa-induced mouse 
behavior, apomorphine-induced rat stereotypy, and post-swim mouse grooming response.313 In rats that 
were chronically exposed to unavoidable stress, escape deficit developed along with an anhedonia-type 
behavior towards palatable food.  When these conditioned rats were exposed to SJW extracts or pure 
hyperforin, this escape deficit behavior diminished and the rats displayed favorable appetitive behavior.314 
In addition, pure hyperforin was significantly more potent than the SJW extracts used.  Hyperforin 
administration also displayed positive outcome in the murine passive avoidance test.315 
A variety of clinical trials has also shown that hyperforin is a critical antidepressant component of 
SJW extracts.  In a randomized, 147 out-patient, 42-day, double-blind multicenter study of persons 
suffering from mild to moderate depression,316 the treatment group receiving an extract containing a 
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standardized 5% amount of hyperforin exhibited significantly larger positive endpoint when compared to 
treatment groups receiving either placebo or an extract with 0.5% hyperforin.317 Patients were given three 
300 mg tablets per day.  In particular, more severely depressed patients responded particularly well to the 
5% treatment.  In a Phase I trial, 18 healthy volunteers were given one 900 mg tablet a day for 8 days, 
containing placebo or SJW extract (0.5% or 5% hyperforin), and monitored via quantitative topographic 
electroencephalography.318 Significant pharmacodynamic effects were seen with both non-placebo 
treatment groups, peaking 4-8 hours after administration, and the treatment group receiving the higher 
dose of hyperforin saw more pronounced changes in electrical activity.  In a 12-man study involving a 
SJW extract standardized to hypericin, no significant endpoint was achieved, providing further evidence 
that hyperforin, and not hypericin, is the active component of SJW.319  
One important note concerning outpatient clinical trials involving SJW is that results may be 
exacerbated by the readily available nature of its extracts, leading to patient noncompliance and 
confounding results.  The highly publicized Hypericum Depression Trial Study,320 which found no 
difference between SJW and placebo for major depression, was replicated three years later with the 
addition of monitoring plasma hyperforin levels.321 In this study, involving a total of 340 outpatients, one 
out of every six taking placebo had significant plasma hyperforin, and one-sixth of patients taking the 
SJW extract had no detectable hyperforin in their blood. 
Interest in the underlying antidepressant mechanism of hyperforin and its biomolecular targets 
has led to numerous studies.  Aside from inhibiting the uptake of neurotransmitters by synaptosomes as 
previously discussed, intraperitoneal injection of hyperforin (10 mg/kg) also was found to increase the 
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extracellular concentration of a variety of neurotransmitters in the rat locus coeruleus.322 Presumably, 
hyperforin caused the release of synaptic vesicles containing these neurotransmitters into the synaptic 
cleft and prevented reuptake.  This hypothesis was confirmed in a later study in which neurons in rat brain 
slices were preloaded with radiolabeled serotonin and dopamine.323 Hyperforin dose-dependently caused 
release of these amines.  Similar results were obtained with human blood platelets preloaded with 
[14C]serotonin; treatment with 300 nM hyperforin caused store depletion of this monoamine.324 
The above results do not support the idea that hyperforin works through direct interaction with 
reuptake enzymes.  Michaelis–Menten kinetic analysis reveals that hyperforin blocks serotonin uptake via 
noncompetitive inhibition in mouse brain synaptosomes.306 Indeed, rat brain cortical synaptosomes 
pretreated with hyperforin did not prevent binding of tritiated citalopram, a selective serotonin reuptake 
inhibitor.307 Further, hyperforin failed to inhibit monoamine binding across a wide variety of 
neurotransmitter transporters and receptors in in vitro binding assays.325 Hyperforin, while inhibiting the 
uptake of radiolabeled monoamines in rat forebrain homogenates, did not affect binding of 
[3H]dihydrotetrabenazine, a known selective vesicular monoamine transporter ligand.326 Interestingly, 
SJW extracts do seem to competitively inhibit monoamine receptors in guinea pig hippocampal slices; 
however, when purified hyperforin was subjected to this ex vivo assay, no inhibition was observed.327 
Instead of directly binding to neurotransmitter transports and receptors, numerous studies indicate 
that hyperforin increases intracellular ion levels, and this mediates not only monoamine uptake inhibition 
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but also vesicular monoamine release.  A wide variety of neurotransmitter transports rely on co-transport 
of sodium cations, and the presence of a sodium ion gradient across the cellular membrane facilitates this 
process.328 By diminishing this ion gradient, hyperforin indirectly inhibits monoamine reuptake.  
Accordingly, treatment of human platelets with 50 µM hyperforin caused an increase in intracellular 
[Na+] over basal levels.306 A similar effect was observed when a known cation transporter monensin was 
used; however, hyperforin did not elevate [Na+]i to extracellular levels, as in the case of monensin, 
indicating a different transport mechanism.  The addition of benzamil, an amiloride derivative and potent 
Na+ ion channel inhibitor, further differentiated hyperforin- and monensin-based pathways.311 Benzamil 
attenuated hyperforin-based uptake inhibition but had no effect on monensin’s activity.  In addition, Ca2+ 
entry or electrical current may facilitate the release of neurotransmitters.  In rat cortical synaptosomes, the 
release of glutamate induced by hyperforin was preceded by an increase of intracellular [Ca2+], indicating 
that hyperforin-mediated ion influx appears to be nonselective.329 Dose-dependent Ca2+ influx was also 
observed when 0.6-18.6 µM hyperforin was added to hamster vas deferens smooth muscle.330 pH gradient 
was also dissipated across the membranes of synaptic vesicles isolated from rat striatum and 
hypothalamus by inhibiting the action of vacuolar H+-ATPase with an IC50 value of 0.19 µM.331 This 
facilitated the release of radiolabeled serotonin from preloaded vesicles.  In addition, ion influx induces 
an electrical current across the cell membrane.  Using patch clamp techniques, hyperforin caused a dose- 
and time-dependent inward current in isolated hippocampal pyramidal neurons and cerebellar rat Purkinje 
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neurons through ion influx.332 Low concentrations of hyperforin (100-800 nM) also modulated the 
activity of P-type calcium channels in Purkinje neurons in a voltage-dependent manner.333  
To summarize the evidence presented above, the ability of hyperforin to inhibit the reuptake and 
promote the release of neurotransmitters from neurons may be reliant on nonselective inward ion influx.  
Taken together, these data suggest that hyperforin may activate an ion channel expressed on neuronal 
membranes, and elucidation of this ion channel protein may represent a new target for developing 
antidepressants.334 Indeed, tetrodotoxin, a potent sodium channel blocker, inhibited hyperforin-mediated 
monoamine release from mouse cortical neurons.335 Similar inhibition was observed in human platelets 
and PC12 cells with both SKF-96365 and LOE 908, two inhibitors of nonselective cation channels.336 The 
addition of La3+ and Gd3+ ions also inhibited the activity of hyperforin in these cells, and these cations are 
known blockers of the canonical transient receptor potential protein (TRPC) channel family.  
TRPC channels are members of the transient receptor potential protein superfamily that can be 
broadly described as cell-surface ion channels involved in many aspects of sensation and response to 
physical or chemical stimulation.337 TRPC channels were the first members of this family discovered, and 
all contain six transmembrane domains.  They assemble into either homo- or hetero-tetramers, and cation 
selectivity is determined by the size of the pore loop.  Several proteins may be anchored onto the 
cytoplasmic end of the S6 domain, providing control elements to regulate the activity of the cation 
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channel.  There are seven known TRPC proteins, and they may be activated by diacylglycerol, 
phospholipase C, or tyrosine kinases.338 
Further analysis determined that hyperforin selectively activates TRPC6.339 Hyperforin (10 µM) 
induced nonselective ion entry into PC12 cells expressing TRPC6.  Furthermore, the entry of Ca2+ ions 
when TRPC6 was activated by hyperforin (0.1-0.3 µM) caused neurite outgrowth in these cells, similar to 
the effects of adding nerve growth factor.  Cation influx was suppressed in PC12 cells by expressing a 
dominant negative mutant of TRPC6.  This is noteworthy given that the cell expression of related TRPC 
proteins remained unaffected, such as TRPC3 and TRPC7, which share approximately 75% sequence 
homology to TRPC6.340 Given the similarity of TRPC6 to other members of the TRPC family, it seems 
unlikely that hyperforin interacts directly with TRPC6.  When PC12 cells were pre-incubated with 
various tyrosine kinase and phospholipase C inhibitors, the effects of hyperforin were mitigated, possibly 
indicating that hyperforin interacts with a protein involved in TRPC6 activation.341  
Regardless of the nature of hyperforin’s interaction with TRPC6, its ability to act as a TRPC6 
molecular probe has furthered understanding of this protein in particular and of ion homeostasis in 
general.  When internal stores of Ca2+ are depleted from a cell, various ion channels are activated via the 
store-operated Ca2+ entry (SOCE) pathway.342 In murine brain cortical embryonic neurons from which 
internal Ca2+ stores were depleted using thapsigargin, SOCE became activated.343 Addition of the TRPC3-
selective inhibitor Pyr3 potently prevented Ca2+ entry; however, the addition of hyperforin facilitated Ca2+ 
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entry presumably through TRPC6 activation.  This indicates that while TRPC3 participates in SOCE, 
TRPC6 does not.344 Additionally, the activity of hyperforin was attenuated through the Zn2+ chelator 
TPEN, but SOCE-mediated Ca2+ entry remained unaffected.  Further studies established that hyperforin 
also promoted the release of Ca2+ and Zn2+ stores from isolated brain mitochondria.345 The ability of 
hyperforin to increase the permeability of mitochondrial membrane has been documented.346 Beyond 
increasing mitochondrial membrane permeability, chronic hyperforin treatment (1 µM treatment for 3 
days) has been shown to increase the gene expression of metallothioneins and thus Zn2+ storage capacity 
in cortical neurons.347 Metallothioneins are cysteine-rich proteins and bind to Zn2+ among other cationic 
species.  Chronic intraperitoneal injection of rats with hyperforin (4 mg/kg/day) has similar effects, 
increasing the Zn2+ storage capabilities of their brain tissue.  Increased intracellular Zn2+ stores were also 
achieved by expressing TRPC6 in HEK293 cells, but not with TRPC3 expression.348 These data suggest 
that TRPC6 is capable of acting as a Zn2+-conducting channel. 
Prior studies have suggested that TRPC proteins in general and TRPC6 in particular play crucial 
roles in neuronal differentiation, plasticity, and outgrowth.349 This may be one avenue by which 
hyperforin acts as an antidepressant and alters nerve tissue in the brain.  Oral dosing (15 mg/kg) of the 
sodium salt of hyperforin in rats caused changes in the morphology of their brain membranes.350 Another 
study established that hyperforin treatment of neural stem/progenitor cells promoted the maturation of 
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oligodendrocytes without affecting the proliferation of the progenitor cells.351 Oligodendrocyte 
dysfunction may play a role in the pathogenesis of major depressive disorder.352 Hyperforin, via TRPC6 
activation, caused changes in dendritic spine morphology in pyramidal neurons in rat hippocampal 
slices.353 These effects were blocked by the addition of La3+, indicating the importance of TRPC6 
channels on hyperforin-induced morphological effects.  Hyperforin has also been shown to generate 
neuroprotective effects in neurons through the activation of CREB in a tissue-specific manner.  Rats 
treated with daily hyperforin injections (4 mg/kg) for 4 weeks had increased cortical expression of 
TRPC6 and TrkB, a brain-derived neurotrophic factor receptor.354 Immediately following a middle 
cerebral artery occlusion in the brains of rats, direct injection of hyperforin into the brain reduced total 
cell death and increased TRPC6 and CREB activity.355 One day after the ischemic stroke, the rats treated 
with hyperforin also displayed higher neurologic scores than the control group.  Interestingly, expression 
of TrkB in the hippocampus remained unaffected.  Similar effects were observed in a rat model of status 
epilepticus, a prolonged seizure event that results in significant brain tissue damage.356 In such an event, 
TRPC6 expression decreases in affected tissue, ultimately leading to neuronal cell death;357 however, 
prior hyperforin treatment prevented this downregulation and subsequently prevents neurodegeneration.  
Conversely, hyperforin has also engendered neuroprotective effects by the downregulation of TRPC6 and 
CREB expression in certain situations.  As discussed earlier, hyperforin decreased activated CREB levels 
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in mouse microglia by decreasing iNOS expression.180 In PC12 cells that had been previously activated 
with NGF, hyperforin actually downregulated TRPC6 expression.358 Decreased expression of TRPC6 in 
this instance may have promoted neuroprotection by regulating the rate of neurite outgrowth.  
 Due to its expression throughout the human body, TRPC6 may be a unique target for the 
treatment of a variety of diseases.  Many inflammatory skin conditions are characterized by over-
proliferating skin cells, and TRPC6 has been associated with Ca2+-induced keratinocyte differentiation.359 
Additionally, skin creams formulated with SJW extracts have shown efficacy in several half-side clinical 
trials involving inflammatory skin diseases,360 including pressure ulcers,361 psoriasis,362 and atopic 
dermatitis.363 When HaCaT cells were treated with hyperforin (1 µM), an influx of Ca2+ was observed and 
differentiation was triggered, and these effects were mimicked through the addition of a high 
concentration of extracellular Ca2+.364 When TRPC6 was knocked down, both hyperforin- and Ca2+-
induced differentiation was not observed.  TRPC6 is also abnormally expressed in several breast cancer 
cell lines (e.g., MCF-7, MCF 10A, MDA-MB-231), and the antiproliferative effect of hyperforin on these 
cell lines may be in part due to its interaction with TRPC6 or its effects on TRPC6 expression.365 In 
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vascular smooth muscle, TRPC6 plays an important role in regulating vascular tone.366 Hyperforin caused 
dose- and time-dependent smooth muscle constriction in aortic segments taken from mice.  In aortic 
segments taken from TRPC6-knockout mice, no such constriction was observed.  In the lung, TRPC6 
expression is associated with the induction of platelet-activating factor-induced vascular leakage leading 
to lung edema.367 Treatment of mouse lungs with hyperforin caused effects similar to platelet-activating 
factor, including increased intracellular [Ca2+] and weight gain due to fluid entry.  TRPC6 malfunction 
has also been implicated in certain instances of focal segmented glomerulosclerosis, a significant cause of 
renal disease.368 
In addition to TRPC6 and neuronal monoamine receptors, several other potential biomolecular 
targets of hyperforin have been explored.  Both hyperforin and its dicyclohexylamine salt were found to 
be potent inhibitors of substance P-induced interleukin-6 release in human astrocytoma cells with an IC50 
value of 1.6 µM.369 Hypersecretion of interleukin-6 and other cytokines may be involved with the 
pathophysiology of depression.  β-Adrenergic receptors may also be involved in depression since 
downregulation of these proteins correlate with the antidepressant effects of other medicines.370 When rats 
were treated with methanolic and CO2 SJW extracts, a significant decrease in β-adrenergic receptor levels 
was observed in the frontal cortex region of the brain.371 In rat C6 glioblastoma cells, treatment with 
hyperforin led to a decrease in β2-adrenergic receptor expression, indicating that hyperforin was one of 
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the primary components of the extracts responsible for this activity.372 Hyperforin treatment was later 
shown to also decrease β1-adrenergic receptor in this cell line.373 
While hyperforin is considered the chief antidepressant component of SJW extracts, it is not 
exclusively responsible for the herb’s antidepressant activity; other chemicals isolated from the extract 
have shown efficacy in various in vitro and in vivo models.  Hypericin and pseudohypericin374 as well as 
the biflavonoid amentoflavone375 and various xanthones376 inhibited monoamine receptor binding.  
Interestingly, SJW extracts devoid of hyperforin displayed antidepressant-like outcomes in a variety of 
murine behavioral models, including the elevated plus maze,377 tail suspension test, and the forced swim 
test.378 In other behavioral models, positive outcomes were observed even when no detectable amount of 
hyperforin was present in the brain.379 Flavonoids,380 such as rutin381 and quercetin,382 were found to be 
active in these behavioral models.  Amentoflavone was the most active component of the extract at 
stopping stress-induced hyperthermia in mice.383 Quercetin also displayed potent, selective inhibition of 
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monoamine oxidase A, with an IC50 value of 10 nM.384 Modulation of the hypothalamic-pituitary-adrenal 
axis may be a therapeutic option in the treatment of depression, and while hyperforin did not alter gene 
expression in brain areas involved with axis control in rats,385 various flavonoids386 and 
pseudohypericin387 present in SJW extracts modulated axis function.  Overall, while hyperforin is the 
consensus active principle of SJW, various other components display activity across a range of 
biochemical systems implicated in depression. 
 Aside from hyperforin, very few PPAPs have been evaluated for antidepressant activity.  
Adhyperforin is also isolated from SJW, usually in concentrations one-seventh that of hyperforin.312 
Unsurprisingly, this PPAP also potently inhibits neurotransmitter uptake in the synaptosome uptake assay 
with IC50 values lower than hyperforin to some extent (Table 1.15).  Hyperfoliatin (hyperibone J) has also 
been evaluated in synaptosomal reuptake assays but was several orders of magnitude less active than 
hyperforin and adhyperforin (Table 1.15). Like hyperforin, adhyperforin and hyperfoliatin do not bind 
directly to monoamine receptors.308,388 In addition, hyperfoliatin reduced the immobility time of the forced 
swim test in rats.  Hyperatomarin has also been evaluated for uptake inhibition, but was found to be only 
weakly active against serotonin reuptake (IC50  = 16.8 µM), and was actually one of the least potent 
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components of Hypericum annulatum evaluated in this study.389 Furohyperforin was reported to have one-
tenth the activity of hyperforin against synaptosomal serotonin uptake.390 
 
Table 1.15. Inhibition of synaptosomal [3H]neurotransmitter uptake by adhyperforin.a 
PPAP [3H]serotonin [3H]noradrenaline [3H]dopamine [3H]L-glutamate References 
adhyperforin 0.027-0.32 0.014-0.67 0.003 2.40 308,391 
hyperfoliatin 3.5 1.8 1.2 n.d. 388 
 
a All data reported are IC50 values (in µM). 
 
 
Several semisynthetic hyperforin analogs have been evaluated for antidepressant activity.  Crude 
SJW extracts containing hyperforin and adhyperforin conjugates still retained significant activity in the 
forced swim test, even though they did not contain detectable hyperforin or adhyperforin.392 In studies 
involving more resolved hyperforin analogs, hyperforin esters generally show favorable antidepressant 
activity whereas oxidation products display decreased activity.  Across four different animal models of 
depression (i.e., forced swim test, learned helplessness test, elevated plus maze, and light-dark test), 
hyperforin O-acetate at 3-5 mg/kg dosing showed efficacy.393 Hyperforin O-3,4,5-trimethoxybenzoate 
(61) also shortened immobility time during the forced swim test when injected at 3.1-6.3 mg/kg 
concentrations.394 At these concentrations, plasma levels of this analog were 30-50 µM and brain levels 
were found to be 0.3 µM.  While both of these analogs were active in animal models of depression, 
neither possessed the ability to inhibit in vitro synaptosomal neurotransmitter uptake.309,394 A variety of 
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other hyperforin analogs were found to be inactive in this uptake assay, including hyperforin O-methyl 
ether (60), hyperforin O-2,4-dinitrobenzoate, 63, 64, oxyhyperforin, pyrohyperforin, and 83 (Figure 
1.15).309 It should be noted that various diacylphloroglucinol derivatives have been developed as TRPC6-
selective inhibitors, but these compounds bear little resemblance to hyperforin.395 
 
 
Figure 1.15. A semisynthetic hyperforin analog evaluated for antidepressant activity. 
 
 
Several PPAPs have been evaluated for their activity against neurological disorders beyond 
clinical depression.396 Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are possible targets 
for the treatment of various neurological diseases, such as Alzheimer’s disease, glaucoma, and 
myasthenia gravis.397 Various PPAPs exhibit fairly potent inhibition activity against both of these 
enzymes in an in vitro assay (Table 1.16).128 At a concentration of 10 µM, garsubellin A increased choline 
acetyltransferase activity by 154% in P10 rat septal neurons.398 Mice injected with 1-10 mg/kg hyperforin 
caused an increase of acetocholine release, and at the highest concentration tested, a significant decrease 
in locomotor activity was observed.399 The former results could be explained by the ability of hyperforin 
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to activate ion channels in neurons, and the latter result may indicate that very high, chronic doses of 
hyperforin may lead to Parkinson’s disease.  A subsequent study found that hyperforin-induced 
acetylcholine release in the rat hippocampus is indeed Ca2+-dependent.400 
 
Table 1.16. AChE and BChE inhibition activity of several PPAPs. 
PPAP AChE IC50 (µM) BChE IC50 (µM) 
garcinol 0.66 7.39 
guttiferone A 0.88 2.77 
guttiferone F 0.95 3.50 
isogarcinol 1.13 8.30 
 
 
Hyperforin and its reduced derivative tetrahydrohyperforin (76) have been evaluated for their 
ability to affect β-amyloid (Aβ) biochemistry, a poorly understood but important component of the 
pathophysiology of Alzheimer’s disease.401 In rat PC12 cells, hyperforin treatment accelerated the 
proteolysis of amyloid precursor protein.402 The activity of hyperforin was distinct from other, known 
activators of amyloid precursor protein proteolytic secretion.  Hyperforin also significantly decreased the 
formation of amyloid deposits in rats injected with amyloid fibrils.403 The rats also displayed more 
favorable outcomes in the circular water maze test compared to control and decreased Aβ-related 
neurotoxicity in hippocampal neurons.  Similar in vivo effects were observed for tetrahydrohyperforin 
(76).404 In amyloid precursor protein-transgenic mice, tetrahydrohyperforin caused a reduction in Aβ 
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plaque formation, possibly due to the release of AChE from the precursor fibril assemblies405 or the 
prevention of AChE association with amyloid plaques.406 Later studies established that this semisynthetic 
hyperforin derivate dose-dependently prevented cognitive deficit and memory impairment in this 
transgenic mouse model as well as a decrease in neurotoxicity and an increase in hippocampal 
neurogenesis.407 Part of this activity could be explained by the inhibition of the proteolytic processing of 
amyloid precusor protein to Aβ peptide.  In addition to affecting Aβ generation and plaque formation, the 
ability of hyperforin to upregulate P-gp and thus increase clearance of Aβ peptide from the brain may also 
be effective in preventing the onset of Alzheimer’s disease.408 
Deficit of prepulse inhibition is common phenomenon in patients suffering from a variety of 
neurological disorders including Alzheimer’s disease and schizophrenia.  Since inhibition of monoamine 
receptors may be involved in disruption of prepulse inhibition, it is unsurprising that hyperforin caused a 
significant decrease in rat startle amplitude in the acoustic startle response test.409 Given its effects on 
prepulse inhibition, hyperforin may exacerbate the symptoms of several mental disorders. 
Both garcinol and hyperforin have been evaluated for their effects on the acquisition of new 
memories.  Treatment of mice and rats with the sodium salt of hyperforin (1.25 mg/kg/day) for 7 days 
caused significant increases in learned responses in the conditioned avoidance test.410 After 9 days 
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following the last dose of hyperforin, the learned response was retained in the animals.  Hyperforin also 
showed improvement after a single dose in the passive avoidance test and reversed scopolamine-induced 
amnesia.  In another study, direct injection of garcinol into the rat lateral amygdala immediately following 
fear conditioning reduced the consolidation of the Pavlovian fear memory.411 Similarly, garcinol also 
prevented the reconsolidation of a fear memory following fear memory retrieval.  This property of 
garcinol may be useful for the treatment of post-traumatic stress disorder.   
Hyperforin has also been evaluated for the treatment of other neurological conditions.  When rats 
were injected with hyperforin (10 mg/kg) once a day for 7 days, they showed significantly less aggression 
across four behavioral models: foot shock-induced aggression, isolation-induced aggression, resident-
intruder aggression, and the water competition test.412 In a study in which rats were given access to 
alcohol, injection of SJW extracts containing hyperforin caused a reduction of ethanol consumption that 
was proportional to the amount of hyperforin in the extracts.413 Similar dose-dependent results were found 
using a breed of mice that preferred alcohol.414 These effects may be due hyperforin-based N-methyl-D-
aspartate-induced (NMDA) antagonism.  NMDA receptors overactivity has been noted in alcohol 
withdrawal, often causing agitation and seizures in some cases.415 Hyperforin (at a 10 µM concentration) 
inhibited NMDA-induced Ca2+ influx in isolated rat cortical neurons and blocked the NMDA receptor-
induced release of phospholipid-based choline in rat hippocampal slices.416 These effects may contribute 
to apparent reduction alcohol consumption observed with hyperforin treatment. 
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In addition to hyperforin, garcinol and guttiferone have displayed neuroprotective effects.  
Garcinol has been shown to promote the development of neurons.417 Cortical progenitor cells taken from 
embryonic rats developed into neurospheres upon treatment of garcinol, and this may be facilitated by 
Ca2+ entry through the extracellular signal-regulated kinase pathway, which also promoted neuronal 
survival.  The neuroprotective effects of guttiferone A are most likely derived from its ability to scavenge 
free radicals.  Incubation of PC12 cells with guttiferone A garnered protection from Fe3+ auto-oxidation418 
as well as from various reactive oxygen species.142 
Given its ability to inhibit neurotransmitter reuptake by neurons, hyperforin has also been 
evaluated for its effects on neuroendocrine response.  Injection of 9.3 mg/kg hyperforin into rats increased 
plasma corticosterone, and lowered haloperidol-induced plasma prolactin levels.419 Since ketanserin but 
not WAY-100635 inhibited hyperforin-induced plasma corticosterone effects, 5-HT2 receptors may be 
involved in this response.  A small-scale, single-blind study involving 12 healthy volunteers found that a 
hyperforin-enriched SJW extract (at 600, 900, and 1200 mg/kg daily oral dosing over 4 days) stimulated 
adenocorticotropic hormone, while cortisol and prolactin levels remained unaffected.420 Several patients 
experienced an increase in growth hormone release, but this effect was not statistically significant 
compared to placebo. 
The analgesic properties of several PPAPs have also been evaluated.  Through analyzing the 
components of SJW extracts individually, it was discovered that both hypericin and hyperforin displayed 
antinociceptive properties in murine models of neuropathic pain.421 Hyperforin was particularly effective 
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at the prevention of thermally induced pain.  This pain inhibition was abolished by the addition of 
naloxone, indicating hyperforin’s effects are most likely opioid-dependent.  The analgesic effects of 7-
epi-clusianone were not limited to thermally induced pain in mouse models, imparting antinociceptive 
effects in tests including acetic acid-induced writhing, hot plate exposure, the formalin subplantar 
injection.177 In the acetic acid-induced writhing model, guttiferone A dose-dependently reduced 
abdominal constrictions with an EC50 value of 4.5 mg/kg.422 
Other Bioactivity 
As the popularity of SJW extracts grew in the late 1990’s, several instances of alarming side 
effects were reported.423 By the end of 1999, more than 8 reported cases suggested that SJW extracts may 
cause increased hepatic metabolism of prescribed medication.424 In particular, women consuming SJW 
extracts experienced a significant decrease in co-medicated theophylline, cyclosporin, warfarin, and 
ethinylestradiol.425 A subsequent study conducted by the NIH in 16 healthy volunteers found that SJW 
extract caused a decrease in indivanir,426 and two German heart transplant patients suffered acute 
transplant rejection due to SJW extract-accelerated cyclosprorine metabolism.427 These alarming 
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observations led the FDA to issue a public healthy advisory428 and the British Medicines Control Agency 
to issue a reminder to doctors.429 
It was soon discovered independently by two different groups that hyperforin is the component of 
SJW that potently activates pregnane X receptor (PXR, steroid X receptor).430 PXR is a transcription 
factor that serves as a key regulator of many enzymes involved in xenobiotic metabolism, such as 
cytochrome P450s and P-gp.  It contains a DNA-binding domain and a ligand-binding domain, the latter 
of which is substantially flexible and allows for the binding of structurally diverse compounds (i.e., 
xenobiotics).  For instance, the compound SR12813 binds to PXR in three distinct orientations.431 With an 
EC50 value of 23 nM, hyperforin is the most potent PXR activator discovered.430b Using tritiated SR12813 
in a competition binding assay, it was also discovered that hyperforin binds directly to PXR.  A resolved 
crystal structure of hyperforin bound to PXR provided unambiguous proof of direct interaction (Figure 
1.16a).432 Compared to an earlier crystal structure of the ligand-binding domain of PXR in its apo form, 
hyperforin caused a 250 Å3 increase in binding site volume.  In addition, most of the contacts hyperforin 
makes to PXR are through hydrophobic interactions of its prenyl side-chains (Figure 1.16b).  
                                                      
428 (a) Lumpkin, M. M.; Alpert, S. Public Health Advisory; U.S. Food and Drug Administration, February 10, 2000. 
(b) Henney, J. E. J. Am. Med. Assoc. 2000, 283, 1679-1679. 
 
429 Committee on Safety of Medicines, Medicines Control Agency, Curr. Prob. Pharmacovigilance 2000, 26, 6-7. 
 
430 (a) Wentworth, J. M.; Agostini, M.; Love, J.; Schwabe, J. W.; Chatterjee, V. K. K. J. Endocrinol. 2000, 166, 
R11-R16. (b) Moore, L. B.; Goodwin, B.; Jones, S. A.; Wisely, G. B.; Serabjit-Singh, C. J.; Willson, T. M.; Collins, 
J. L.; Kliewer, S. A. Proc. Natl. Acad. Sci. USA 2000, 97, 7500-7502. 
 
431 Watkins, R. E.; Wisely, G. B.; Moore, L. B.; Collins, J. L.; Lambert, M. H.; Williams, S. P.; Willson, T. M.; 
Kliewer, S. A.; Rebindo, M. R. Science 2001, 292, 2329-2333. 
 
432 Watkins, R. E.; Maglich, J. M.; Moore, L. B.; Wisely, G. B.; Noble, S. M.; Davis-Searles, P. R.; Lambert, M. H.; 
Kliewer, S. A.; Rebindo, M. R. Biochemistry 2003, 42, 1430-1438.  
96
 97 
 
Figure 1.16. (a) Detail of hyperforin bound to the ligand-binding domain of PXR and (b) schematic highlighting the contacts 
between hyperforin and PXR (solid lines indicate nonpolar contacts, and dotted lines indicate hydrogen bonding). 
 
 
 
Further, hyperforin-induced PXR activation directly results in the upregulation of genes involved 
in xenobiotic metabolism and drug efflux.  Treatment of primary human hepatocytes with hyperforin 
induced increased CYP3A4 expression.430b CYP2C9 induction was also noted in the hyperforin treatment 
of HepG2 cells.433 The increased expression of these cytochrome P450s is significant since CYP3A4 and 
CYP2C9 are responsible for the metabolism of approximately 50% and 20% of all known drugs, 
respectively.434 While CYP3A4 and CYP2C8 expression did increase upon hyperforin exposure in primary 
human hepatocytes,435 CYP24A1 and CYP27B1 levels remained unchanged.436 In another study, CYP1A1, 
CYP1A2, and gene for the monooxygenase FMO5 were upregulated in HepG2 cells, while CYP4F2 and 
NQO2 were downregulated.437 Hyperforin also caused tissue-specific activation of the ATP-binding 
cassette transporters, which play important roles in controlling the passage of drugs and xenobiotics 
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across intracellular and extracellular membranes.  Using porcine brain capillary endothelial cells 
(PBCECs) as a model for the blood-brain barrier in humans, hyperforin treatment caused significant 
increases in mRNA levels for P-gp438 and both ABCG1 and 2.439 P-gp expression also significantly 
increased in LS180440 and T84441 cells, demonstrating that hyperforin may accelerate the excretion of 
drugs.  Interestingly, while hyperforin caused upregulation of CYP3A4 in Caco-2 cells, P-gp expression 
actually decreased.442 Aside from regulating xenobiotic metabolism, PXR may also play a role in other 
areas of human health. Hyperforin-induced PXR activation may prevent liver steatosis, given that 
hyperforin treatment of HepG2 cells overexpressing PXR exacerbated steatogenic effects in these cells.443 
PXR may be important in bone homeostasis and thus prevent osteoporosis; treatment of primary 
osteocytes with vitamin K2 or hyperforin activated PXR and led to an increase in bone marker 
expression.444 However, chronic activation of PXR may lead to osteomalacia via increased CYP24A1 
expression, leading to vitamin D deficiency.445 
It is also important to note that activation of PXR is species-specific.  As mentioned previously, 
porcine PXR is hyperforin-sensitive.438 It is unclear whether mouse PXR is a hyperforin target.  One 
study found that hyperforin did not induce cytochrome P450 expression in Swiss Webster mice,446 but 
another study found that hyperforin·HNCy2 increased CYP3A-mediated hepatic erythomycin-N-
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demethylase activity in CD-1 mice.447 The cynomolgus monkey (i.e., crab-eating macaque) response to 
hyperforin is very similar to that of humans, making this species an effective animal model for predicting 
downstream metabolic enzyme induction via PXR activation.448 Unlike mouse PXR, rat PXR is 
unambiguously unaffected by hyperforin exposure.449 In order to study which residues in rat PXR confer 
hyperforin insensitivity, a variety of rat-human PXR cDNA chimeras were prepared.450 Rat PXR 
hyperforin sensitivity was conferred by converting Phe305 to leucine, and human PXR was rendered 
hyperforin insensitive via mutagenesis of Leu308 to phenylalanine.  
Further evidence for hyperforin activation of xenobiotic metabolism was provided through a 
variety of drug-specific, small-scale clinical trials involving SJW extracts containing variable amounts of 
the PPAP.  In a study involving 10 renal transplant patients, only those that took SJW extracts with 
significant hyperforin experienced a cyclosporine drug interaction.451 Similar herb-drug interactions were 
encountered in studies involving healthy volunteers taking digoxin,452,453 theophylline,454 alprazolam,453 
caffeine,453 tolbutamide,453 midazolam,455 ethinylestradiol,456 and 3-ketodesogestrel.456 SJW extracts with 
little to no hyperforin content failed to increase cytochrome P450 expression in several studies.457  
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Apart from hyperforin, the binding affinity of other PPAPs to PXR has not been explored.  The 
only other PPAP reported to interact with a nuclear receptor is guttiferone G.458 Guttiferone G 
preferentially binds to the liver X receptor α isoform (LXR-α) with an IC50 value of 3.4 µM, having little 
to no interaction with LXR-β (IC50 > 15 µM).  Since LXRs play important roles in cholesterol 
homeostasis, guttiferone G may be a lead structure in the development of cholesterol regulation therapy. 
Aside from increasing their expression levels via PXR activation, hyperforin appears to inhibit 
several proteins involved in xenobiotic metabolism.  An early study found that hyperforin 
noncompetitively inhibited CYP2D6 with a Ki of 1.5 µM and competitively inhibited CYP3A4 (Ki = 0.48 
µM) and CYP2C9 (Ki = 1.8 µM) in in vitro binding assays.459 Hyperforin also potently inhibited cDNA-
expressed CYP1A2, CYP2C9, and CYP2C19 with IC50 values of 3.9, 0.01, and 0.02 µM, respectively.460 
CYP1A1 was also inhibited by hyperforin (Ki = 1.1 µM, IC50 = 1.2 µM), and this was demonstrated by 
the prevention of the carcinogen formation from CYP1A1-mediated benzo[a]pyrene-7,8-dihydrodiol 
epoxidation.461 While hyperforin inhibited CYP3A4 with an IC50 value of 0.63 µM, three of its naturally 
occurring analogs were found to be more potent inhibits of the cytochrome P450 isoform (IC50 values in 
parentheses): furoadhyperforin (0.072 µM), furohyperforin isomer 1 (0.079 µM), furohyperforin isomer 2 
(0.23 µM).462 Furohyperforin was also found to inhibit CYP3A4 with an IC50 value of 1.3 µM.  P-gp 
activity was also moderately inhibited by hyperforin (IC50 = 30 µM), ascertained by monitoring the active 
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efflux of daunorubicin from NIH-3T3 cells expressing P-gp.463 P-gp and ABCG2 inhibition was also 
observed in leukemia cell lines.464 Using PBCECs and freshly isolated porcine brain capillaries as models 
for the blood-brain barrier, hyperforin was found to directly inhibit P-gp activity.465 Hyperforin also 
partially inhibited paclitaxel efflux from xenopus oocytes expressing the liver-specific organic anion 
transporting polypeptide isoform 1B3.466  
Several preclinical and small-scale clinical trials were performed to determine hyperforin’s 
pharmacokinetic profile in various orally available forms.467 This is particularly intriguing considering 
that hyperforin on one hand activates PXR and on the other inhibits various cytochrome P450s.  In rats 
given a SJW extract containing 5% hyperforin (300 mg/kg) orally, hyperforin plasma levels reached a 
maximum of 370 ng/mL (approximately 690 nM) after a single dose.468 After dosing either an extract 
containing 4.5% or with pure hyperforin·HNCy2 once a day for 12 days in mice, plasma concentrations of 
hyperforin were significantly lower than after a single dose.447 These data are unsurprising given the fact 
that hyperforin may increase xenobiotic metabolism through activation of PXR in mice.  When a 5% 
hyperforin extract was co-medicated with the CYP3A4 inhibitor ritonavir (20 mg/kg) in mice, a 
significant increase in hyperforin bioavailability was observed. 467 Co-medication with the P-gp inhibitor 
valspodar did not have any effect on hyperforin AUC.  Another study established that hyperforin does 
indeed cross the blood-brain barrier in mice.469,470 While treatment with the purified sodium salt of 
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hyperforin (15 mg/kg) produced a 28.8 ng/g brain concentration, treatment with 300 mg/kg SJW extract 
containing 5% hyperforin only gave a 15.8 ng/g concentration.  Hyperforin rat brain concentrations were 
increased through co-medication with borneol or through electroacupuncture, two techniques that have 
shown some positive results in increasing blood-brain barrier permeability.471 
Hyperforin pharmacokinetics have been determined in humans through various small-scale 
studies, and the results of several single- and multiple-dose studies involving various SJW ethanolic 
extract preparations are shown in Table 1.17.  A large degree of pharmacokinetic parameter variation is 
observed, and this is in part due to the variable nature of the extracts and inherent metabolite ratios as well 
as inter-individual differences in response to treatment.  In general, Cmax is rapidly attained within 3-4 
hours and follows a linear relationship to the amount of hyperforin administered in single-dose studies.  
Overall, hyperforin plasma concentrations peaked in the range of 0.16-0.81 M.  Single-dose AUC also 
follows a linear relationship up to about 40 mg hyperforin, and at higher concentrations, lower than 
expected bioavailability is observed.  Elimination half-life remained fairly consistent across dosing 
regimens. 
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Table 1.17. Hyperforin pharmacokinetics following oral dosing of SJW extracts.a 
Extract dose 
(mg x day) Participants
b Hyperforin 
per dose (mg) tmax (h) Cmax (ng/mL) AUC (ng/mL·h) t1/2 (h) References 
600 x 1 18 M 13.5 4.4 (1.5) 84 (28) 1009 (203) 19.6 (6.3) 472 
600 x 14 18 M 13.5 4.3 (1.0) 97 (30) 826 (176) 4.3 (1.0) 472 
300 x 1 6 M 14.8 3.6 (0.6) 153 (21) 1336 (145) 9.5 (1.1) 468 
300 x 1 6 M, 6 F 15 3.1 (0.8) 84 (36) 586 (240) n.d. 473 
300c x 1 6 M, 6 F 15 2.5 (0.8) 168 (58) 1483 (897) n.d. 473 
900 x 1 18 M 17.2 4.5 (1.2) 122 (46) 1550 (371) 17.5 (4.5) 474 
900 x 14 18 M 17.2 3.9 (1.3) 87 (37) 769 (235) n.d. 474 
600 x 1 6 M 28.6 3.5 (0.3) 302 (47) 2215 (279) 8.5 (0.7) 468 
900 x 1 7 M, 2 F 42.8 2.9 (0.3) 300 (23) 3352 (329) 7.2 (0.3) 468 
900 x 8 7 M, 2 F 42.8 3.1 (0.4) 246 (22) 2336 (303) 11.2 (1.0) 468 
900 x 1 3 M, 9 Fd 55.1 4.0 (n.d.) 1500 (200) 13600 (2400) 16.6 (1.9) 475 
900 x 14e 3 M, 9 Fd 55.1 3.0 (n.d.) 1300 (200) 10900 (2200) 14.7 (2.2) 475 
1200 x 1 6 M 59.2 2.8 (0.3) 437 (101) 3378 (670) 9.7 (0.8) 468 
 
a Pharmacokinetic data are reported as means (± standard error). 
b Listed are the number of male (M) and female (F) participants.  Unless noted, all participants were healthy volunteers. 
c A softgel capsule formulation was used. 
d Patients in these studies were diagnosed with clinical depression prior to treatment.  See text below. 
e The SJW extract was co-medicated with the antidepressant amitriptyline (75 mg twice daily). 
 
 
While most of the data presented in Table 1.17 is derived from studies involving healthy 
volunteers, one study utilized patients suffering from clinical depression, with initial scores ranging from 
10-34 in the Hamilton Rating Scale for Depression.475 Intriguingly, hyperforin exposure was significantly 
higher for these patients than in healthy patients consuming similar amounts of hyperforin.  Formulation 
of the SJW extract also appears to have an effect on oral bioavailability; a softgel capsule formulation led 
to significant increases in Cmax and AUC when directly compared to a traditional two-piece hard gelatin 
capsule.473  
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Multiple-dose hyperforin pharmacokinetics were also investigated.468,472,474 In all three instances, 
significantly lower AUC at the end of the treatment regimen was observed and can be explained by 
hyperforin’s ability to activate PXR and thus upregulate xenobiotic metabolism.  Similar results were 
observed upon co-medication of amitriptyline with hyperforin; aside from decreased amitriptyline plasma 
concentrations, the concentrations of all hydroxylated metabolites of amitriptyline decreased significantly, 
indicating increased drug efflux.475 A study involving five mothers taking SJW extract daily (containing 
22.4 mg hyperforin) demonstrated that hyperforin is present in breast milk, but at low levels.476 In two 
breastfed infants, the plasma concentration of hyperforin was present, albeit at the lowest limit of 
detection (0.1 ng/mL).   
The only other PPAP to have undergone pharmacological studies is xanthochymol.76 Doses of 
1.0-10.0 mg/kg given to anesthetized cats did not lead to cardiovascular side effects.  In mice, the LD50 of 
xanthochymol was determined to be 1000 mg/kg, and no detrimental nervous system effects were 
observed at one-fifth the LD50.  
The packaging and unpackaging of eukaryotic DNA around histones largely determines the 
extent to which genes are expressed.  Modifications of these histone proteins, such as through acetylation, 
alter chromatin structure and regulates transcription.477 The enzymes responsible for histone acetylation 
and deacetylation are called histone acetyltransferases (HATs) and histone deacetylases (HDACs), 
respectively, and alteration of HAT and HDAC activity has been implicated in a variety of diseases, such 
as cancer and neuodegeneration.478 Given the ability of a variety of PPAPs to penetrate cell membranes 
and perturb a variety of biochemical processes, their ability to modulate HAT/HDAC activity has been 
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actively investigated.479 Early studies found that hyperforin altered protein expression in hamster smooth 
muscle cells480 and that garcinol altered gene expression in rat livers,481 implying that these PPAPs may 
be interacting with epigenetic modulators. 
Indeed, garcinol was later found to dose-dependently inhibit two HATs, p300 (IC50 = 7 µM) and 
PCAF (IC50 = 5 µM) both in in vitro assay studies as well as in vivo studies involving HeLa cells.482 Over 
a hundred genes were affected in HeLa cells treated with garcinol, and apoptosis was observed.  Kinetic 
analysis revealed that garcinol acted as a competitive inhibitor for both enzymes.  However, garcinol also 
exhibited considerable cytotoxicity.  In order to find a HAT inhibition-specific molecular probe, nearly 50 
semisynthetic garcinol derivatives were screened for p300 inhibition activity.483 Isogarcinol inhibited 
p300 activity but was also cytotoxic.  Three derivatives of garcinol, 84, 85, and 86, were identified as 
non-cytotoxic, p300-specific inhibitors with IC50 values in the range of 5-7 µM (Figure 1.17).  T cells 
treated with 84 were not only viable but also experienced histone acetylation inhibition after HIV 
infection, thus preventing viral replication.  Subsequent mechanistic studies found that the inhibition of 
p300 HAT activity by 84 is dissimilar to that of garcinol and isogarcinol.484 Using in silico docking 
methods, garcinol and isogarcinol were found to bind p300 in two distinct sites, including the ATP-
binding pocket, but 84 bound to a single, allosteric site.  These data were supported by experimental 
isothermal calorimetric data.  
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Figure 1.17. Garcinol and several semisynthetic derivatives. 
 
 
The ability of garcinol to alter gene expression has been applied across several settings relevant to 
human health.  When garcinol was co-administered with the apoptosis-inducing cytokine TRAIL, several 
cancer cell lines resistant to TRAIL became sensitive.485 Garcinol increased expression of death receptors 
4 and 5, receptors of TRAIL, and also decreased the expression of various proteins involved in cell 
survival.  In addition, the epigenetic changes mediated by garcinol and 84 in inhibiting MCF-7 cell 
proliferation were elucidated.486 Increased levels of H4K16 acetylation and H4K20 trimethylation 
accompanied significant reduction in H3K18 acetylation.  A major but limited source of hematopoietic 
stem cells is human cord blood, and when human cord blood cells were treated with either garcinol or 
isogarcinol in the presence of thrombopoietin, a significant increase in cell proliferation was observed.487 
This stem cell expansion may be due to the ability of these PPAPs to inhibit HAT activity.  In 3T3-L1 
preadipocytes, garcinol treatment prevented adipogenesis and lowered expression levels of proteins 
associated with this differentiation process, including leptin, resistin, and fatty acid synthase.488 This 
epigenetically-induced anti-adipogenic effect of garcinol may be one avenue for the treatment and 
prevention of obesity.   
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Aside from garcinol and its derivatives, a variety of other PPAPs have been evaluated for HAT 
and HDAC activity.  While garcinielliptone, hyperibone B, propolones A-D, and propolone D peroxide 
had no significant interaction with p300, guttiferones A and E as well as clusianone inhibited p300 HAT 
activity with IC50 values in the 5-10 µM range.489 Interestingly, nemorosone was a potent activator of 
p300 HAT activity.  Surface plasmon resonance established that guttiferones A and E, clusianone, and 
nemorosone all interact directly with p300.  Aside from modulating HAT activity, oblongifolin C, 
hyperforin, and the semisynthetic hyperforin derivative aristoforin (78) inhibited HDAC activity of 
sirtuins SIRT1 and SIRT2 (Table 1.18).490 Both oblongifolin C and aristoforin were less cytotoxic toward 
HUVECs than hyperforin. 
 
Table 1.18. Inhibition of sirtuins by oblongifolin C, hyperforin, and aristoforin.490 
PPAP SIRT1 IC50 (µM) SIRT2 IC50 (µM) 
oblongifolin C 9 22 
hyperforin 15 28 
aristoforin (78) 7 21 
 
 
Hyperforin has been evaluated for the ability to modulate contractility.  Overactive bladder 
contractions causes a loss of urine control and leads to incontinence.  At concentrations as low as 10 µM, 
hyperforin inhibited electric field stimulated contractions in isolated rat bladder strips.491 Naloxone but 
not neurotransmitter receptor inhibitors and ion channel blockers abrogated the ability of hyperforin to 
inhibit contractions.  This suggests the involvement of opioid receptors.  In contrast, at low concentration 
(10 nM), hyperforin caused a slight increase in carbachol-induced contractions.492 Orally dosed 
hyperforin delayed acetocholine-induced gastric emptying with an EC50 value of about 1 µM in a rat 
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model, which may lead to drug-drug interactions since gastric motility plays an important role in drug 
uptake.493 Overactive contractions of the vas deferens smooth muscle may lead to premature ejaculation.  
An early study found that hyperforin, in concentrations as low as 0.6 µM, inhibited neurotransmitter-
induced contractions of hamster vas deferens smooth muscle tissue.330 Similar inhibition was observed in 
phenylephrine-induced contractions of both isolated rat and human vas deferens tissue.494 A hyperforin-
enriched supercritical CO2 SJW extract was shown to prevent chemically-induced ejaculation acceleration 
in anesthetized rats, the first instance of hyperforin showing efficacy against premature ejaculation in an 
animal model.495 
Synthesis Strategies 
Owing to their fascinating biological activity and unique structural features, PPAPs have been 
popular targets over the past fifteen years, and many strategies have been developed for their synthesis.496  
Several salient features of PPAP structure apropos to bond construction are summarized in Scheme 1.13.  
All PPAPs contain a heavily substituted bicyclo[3.3.1]nonane core in which one component carbocycle is 
highly oxygenated and the other carbocycle contains stereochemically-rich functionalization.  In 
particular, a synthetically challenging C7–C8–C1 stereoarray includes contiguous quaternary centers.  All 
studies toward PPAP total synthesis may be broken down into two general strategic camps: (1) a “bottom-
up” approach and (2) a “top-down” approach.  Bottom-up tactics rely on the synthesis of a functionalized 
cyclohexanone followed by attachment of a 1,3-propanedial synthon.  Likewise, top-down strategies 
typically involve the construction of a functionalized phloroglucinol (or cyclohexane-1,3-dione) which 
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then undergoes dearomative annulation497 or stepwise alkylation-cyclization with a 3-carbon electrophile.  
An overview of the PPAP synthesis literature is provided below, following this general framework. 
 
 
Scheme 1.13. General PPAP synthesis strategies. 
 
 
Several 1,3-dielectrophiles have been utilized in “bottom-up” annulation approaches (Figure 
1.18).  Malonyl dichloride (87) is especially useful for the synthesis of PPAPs considering that annulation 
would directly afford the correct oxidation state of the C2–C4 bridge.  Malonyl dichloride was first used 
to synthesize bicyclo[3.3.1]nonanes by Effenberger in 1984; however, a fourfold excess of 1-methoxy-1-
cyclohexene was required in this initial report.498 Stoltz demonstrated that silyl enol ethers may be utilized 
in addition to alkyl enol ethers and that an excess of malonyl dichloride may be used instead of the enol 
ether component in this Effenberger annulation.499 Nicolaou has utilized methacrylaldehyde (88) in acid-
mediated annulation reactions to create a series of bicyclic medium-sized rings, including 
bicyclo[3.3.1]nonanes.500 Kraus has explored several strategies toward the construction of PPAP model 
systems, using the electrophiles vinylsulfone 89501 and methyl acrylate 90.502 Simpkins also attempted to 
utilize diaryl malonate 91 but to no avail.503 
                                                      
497 For a review that features dearomative annulation and cyclization approaches to PPAPs, see: Roche, S. P.; Porco, 
J. A., Jr. Angew. Chem. Int. Ed. 2011, 50, 4068-4093. 
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Figure 1.18. Various electrophiles utilized in “bottom-up” approaches to PPAPs. 
 
 
A total synthesis of (±)-clusianone (rac-92) by Simpkins utilizing an Effenberger annulation 
strategy is shown in Scheme 1.14.504 Starting with 2-methoxycyclohexenone 93, α-prenylation followed 
by methyl lithium addition afforded enone 94.  Conjugate addition of methyl cuprate and subsequent 
methyl enol ether formation afforded 95.505 Exposure of enol ether 95 to malonyl dichloride and 
subsequent treatment of the product with trimethyl orthoformate afforded vinylogous ester 96 in 24% 
yield over 2 steps.  LDA-mediated bridgehead lithiation and alkylation with prenyl bromide gave 97, and 
subsequent benzoylation afforded rac-clusianone O-methyl ether 98.  Lithium hydroxide-facilitated 
demethylation revealed rac-clusianone.  By replacing LDA with a chiral bis-lithium amide in the 
bridgehead lithiation reaction of 96, a kinetic resolution allowed 96 to be recovered with 98% ee and 
facilitated the synthesis of ent-clusianone (ent-92).506 Effenberger annulations are also utilized in Delpech 
and Marazano’s synthesis of rac-92,507 and Coltart has synthesized ent-92 using a chiral auxiliary to 
                                                      
 
502 Kraus, G. A.; Jeon, I. Tetrahedron Lett. 2008, 49, 286-288. 
 
503 Ahmad, N. M.; Rodeschini, V.; Simpkins, N. S.; Ward, S. E.; Blake, A. J. J. Org. Chem. 2007, 72, 4803-4815. 
 
504 Rodeschini, V.; Ahmad, N. M.; Simpkins, N. S. Org. Lett. 2006, 8, 5283-5285. 
 
505 Prior to 1999, the only synthesis studies directed toward a PPAP are found in a graduate thesis from the 
Univeristy of Arizona: Heidt, J. C. Thesis, University of Arizona, Tucson, Arizona, United States of America, 1988.  
A compound similar to 95 was the most advanced intermediate synthesized in an approach to hyperforin.  
 
506 Rodeschini, V.; Simpkins, N. S.; Wilson, C. J. Org. Chem. 2007, 72, 4265-4267. 
 
507 (a) Nuhant, P.; David, M.; Pouplin, T.; Delpech, B.; Marazano, C. Org. Lett. 2007, 9, 287-289. (b) Tolon, B.; 
Delpech, B.; Marazano, C. Arkivoc 2009 (Part xiii), 252-264.   
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establish absolute stereocontrol.106,508 Mehta has utilized an Effenberger annulation in studies directed 
toward prolifenones A and B.509 
 
 
Scheme 1.14. Total synthesis of (±)-clusianone by Simpkins (ref. 504).a 
a Conditions: (a) LDA, prenyl bromide, THF, –78 ºC; (b) MeLi, THF, –78 ºC; HCl, 88% (2 steps); (c) MeMgBr, CuBr·Me2S, 
TMSCl, HMPA, THF, –78 to –30 ºC, 88%; (d) t-BuOK, DMSO; Me2SO4, 87% (mixture of enol ethers, dominant enol ether 
shown); (e) malonyl dichloride (87), Et2O, –20 ºC; KOH, BnEt3NCl, H2O; (f) HC(OMe)3, p-TsOH, MeOH, 50 ºC, 24% (2 steps); 
(g) LDA, THF, –78 ºC; prenyl bromide, –78 ºC, 91% (h) LiTMP, THF, –78 ºC; BzCl, 91%; (i) LiOH, H2O, dioxane, 90 ºC, 90%. 
 
 
A prominent feature of Simpkins’s total synthesis of clusianone is the bridgehead lithiation and 
subsequent alkylation of intermediate 96.  The reaction involves the formation of a somewhat unusual 
pyramidalized carbanionic species from a bridgehead methine whose trajectory limits hyperconjugative 
delocalization into the neighboring carbonyl π* molecular orbitals.  In the context of PPAP total 
synthesis, the scope and limitations of bridgehead functionalization has been studied in detail.503 In 
Scheme 1.14, the bridgehead alkylation occurs at the C5 position of 96.  Bridgehead substitutions at the 
C1 position, which is proximal to the C8 quaternary center, are understandably more challenging due to 
its steric environment, and only a limited number of electrophiles have been utilized to functionalize this 
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position.  Simpkins’s total synthesis of racemic nemorosone (rac-39) illustrates the difficulties of direct 
C1 bridgehead substitution (Scheme 1.15).503,510 Starting from enone 99,499 α-prenylation followed by 
conjugate methyl addition accessed cyclohexanone 100.503 Sequential silylation, Effenberger annulation 
with malonyl dichloride (87), and methylation revealed 101, which was silylated at the C3 position to 
yield 102.  
 
 
Scheme 1.15. Total synthesis of (±)-nemorosone by Simpkins (ref. 510).a 
a Conditions: (a) LDA, prenyl bromide, THF, –78 ºC, 77%; (b) MeMgBr, CuI, THF, Me2S, 0 ºC, 88%; (c) TBSCl, NEt3, NaI, 
MeCN, reflux, 87%; (d) malonyl dichloride (87), Et2O, –20 ºC; BnEt3NCl, KOH, H2O; (e) Me2SO4, K2CO3, acetone, reflux 
(19%, 2 steps); (f) LiTMP, THF, –78 ºC; TMSCl, 94%; (g) LDA, TMSCl, THF, –78 to 0 ºC; I2, 0 ºC, 65%; (h) BuLi, THF, –78 
ºC; BzCl, 63%; (i) TBAF, THF, 81%; (j) LiTMP, THF; Li(2-Th)CuCN; prenyl bromide, 55%; (k) LiCl, DMSO, 120 ºC, >99%. 
 
 
A more direct route to nemorosone would involve C3 prenylation; however, such an intermediate 
would not undergo bridgehead lithiation owing to an acidic bisallylic methylene subunit.503 A variety of 
conditions for the bridgehead functionalization of 102, including the use of several carbogenic 
electrophiles, did not provide any desired products.  This illustrates the difficulty of performing 
bridgehead substitution chemistry at the C1 position relative to the C5 position when compared to the 
efficient conversion of 96 to 97 in Scheme 1.14.  In the end, metalation of 102 with LDA followed by 
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trapping with iodine provided bridgehead iodide 103.  Having installed a functional handle at C1, 
metalation with butyllithium, trapping with benzoyl chloride, and desilylation provided phenyl ketone 
104.  Finally, installation of the C3 prenyl group was facilitated by sequential deprotonation, 
transmetalation with Lipshutz’s cuprate,511 and prenyl bromide alkylation, and demethylation with lithium 
chloride provided (±)-nemorosone (rac-39). 
Aside from using 1,3-dielectrophiles, several groups have explored the use of an intramolecular 
aldol reaction to construct the PPAP bicyclo[3.3.1]nonane core.  Shibasaki has utilized this reaction in his 
total synthesis of ent-hyperforin (ent-1), the first enantioselective total synthesis of a PPAP (Scheme 
1.16).512 Starting with diene 105 (available in 7 steps from propargyl bromide)513 and oxazolidinone 106, 
a catalytic, enantioselective Diels–Alder reaction involving FeBr3 and pybox ligand 107 (Figure 1.19) 
afforded siloxycyclohexene 108.  This is a particularly effective transformation for the construction of the 
cyclohexanone carbocycle of PPAPs, since both the C7 and C8 stereocenters of hyperforin are established 
in a single step.  Removal of the oxazolidinone ring and silyl groups of 108 revealed cyclohexanone 109, 
and a subsequent series of reactions including a Barbier reaction produced 110 containing the carbon 
framework of the isopropyl ketone of hyperforin.  α-Prenylation gave 111 as a single epimer at the C5 
position.  After C5 epimerization and functional group manipulations, O-allylation afforded 112, and 
heating a toluene solution of 112 quantitatively yielded 113 in a high diastereomeric ratio at the newly 
formed quaternary C1 stereocenter.  The high degree of diastereocontrol in this transformation may be 
rationalized by assuming the C5 prenyl group of 112 directs the carbon-carbon bond formation to the 
opposite face of the cyclohexene ring.  Hydroboration of the olefin present in 113 followed by DMP-
mediated oxidation provided aldehyde 114.  Exposure of this aldehyde to sodium ethoxide in ethanol 
  
                                                      
511 Lipshutz, B. H.; Koerner, M.; Parker, D. A. Tetrahedron Lett. 1987, 28, 945-948. 
 
512 (a) Shimizu, Y.; Shi, S.-L.; Usuda, H.; Kanai, M.; Shibasaki, M. Angew. Chem. Int. Ed. 2010, 49, 1103-1106. (b) 
Shimizu, Y.; Shi, S.-L.; Usuda, H.; Kanai, M.; Shibasaki, M. Tetrahedron 2010, 66, 6569-6584. 
 
513 (a) Apparu, M.; Barrelle, M. Bull. Soc. Chim. Fr. II 1983, 83-86. (b) Usuda, H.; Kuramochi, A.; Kanai, M.; 
Shibasaki, M. Org. Lett. 2004, 6, 4387-4390. 
113
 114 
 
Scheme 1.16. Total synthesis of ent-hyperforin by Shibasaki (ref. 512).a 
a Conditions: (a) 107, FeBr3, AgSbF6, 5Å MS, CH2Cl2, –70 ºC, 93%, 98% ee; (b) EtSLi, THF, 96%; (c) LAH, THF, 99%; (d) 
MOMCl, TBAI, i-Pr2NEt, CH2Cl2, 94%; (e) TBAF, HOAc, THF; (f) HF·pyr, pyr, THF, 91% (2 steps); (g) TMSCl, NEt3, 
CH2Cl2; (h) TIPSOTf, i-Pr2NEt, CH2Cl2; (i) K2CO3, MeOH; (j) TPAP, NMO, 4Å MS, MeCN, CH2Cl2; (k) i-PrBr, Li, THF; (l) 
TBAF, HOAc, THF, 58% (6 steps); (m) TMSCl, imid, DMF, 94%; (n) LDA, HMPA, prenyl bromide, THF, 89%; (o) LDA, THF, 
NH4Cl, H2O, 88%; (p) HF·pyr, pyr, THF; (q) DMP, CH2Cl2, 96% (2 steps); (r) NaHMDS, allyl bromide, HMPA, THF, >99%; 
(s) PhMe, N,N-diethylaniline, 170 ºC, >99%, 12:1 dr; (t) (Sia)2BH, THF; H2O2, NaOH, H2O, EtOH, 81%; (u) DMP, CH2Cl2, 
91%; (v) EtONa, EtOH; (w) DMP, CH2Cl2, 86% (2 steps); (x) CSA, MeOH, 66% (3 cycles); (y) (COCl)2, DMSO, CH2Cl2; NEt3, 
95%; (z) vinylmagnesium bromide, THF, 92%; (aa) Ac2O, DMAP, i-Pr2NEt, CH2Cl2, 98%; (bb) Pd(PPh3)4, HCO2NH4, PhMe, 
95%; (cc) 117, 2-methyl-2-butene, CH2Cl2, >99%; (dd) TMSCl, NEt3, DMAP, CH2Cl2, 84%; (ee) Pd(OAc)2, DMSO, O2, >99%; 
(ff) NaBH4, MeOH, 95%; (gg) CS2, NaH, THF; MeI, >99%; (hh) PhMe, 150 ºC; (ii) EtSLi, THF; MeI, NEt3, 98% (2 steps); (jj) 
NaBO3·4H2O, HOAc, 95%; (kk) TFAA, DTBMP, CH2Cl2, –40 ºC; H2O, 65%; (ll) H2O2, HFIP, 87%; (mm) DMP, CH2Cl2, 86%; 
(nn) Amberlyst-15DRY, PhMe, 55%; (oo) LiH, allyl alcohol, 67%; (pp) [Pd2(dba)3]·CHCl3, (S)-tol-BINAP, THF; Ac2O, pyr, 
50%; (qq) 117, 2-methyl-2-butene, CH2Cl2, 34%; (rr) K2CO3, MeOH, 94%.  
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facilitated the key aldol cyclization reaction,514 and subsequent DMP-mediated oxidation afforded 115, 
which contains the bicyclo[3.3.1]nonane core of hyperforin with all key stereocenters established. 
 
 
Figure 1.19. A Pybox ligand and an olefin metathesis catalyst, both utilized in the total synthesis of ent-hyperforin. 
 
 
At this point in the synthesis, the only remaining tasks were the installation of the C3 and C7 
prenyl groups as well as the 1,3-diketone oxidation state about the C2–C4 bridge.  First, the C7 prenyl 
group was installed via sequential MOM group removal, oxidation, and vinylmagnesium bromide 
addition of 115 to afford allylic alcohol 116 as a mixture of epimers.  Deoxygenation was then 
accomplished via stepwise acetylation and Pd-catalyzed allylic reduction, and a resulting olefin cross 
metathesis with 2-methyl-2-butene utilizing Hoveyda–Grubbs second-generation catalyst (117, Figure 
1.19) afforded 118.  It is noteworthy that the C8 homoprenyl olefin was previously protected as a tertiary 
methyl ether; if a homoprenyl group was present during this cross metathesis, the authors observed ring-
closing metathesis.   After considerable experimentation, installation of the C2–C4 1,3-diketone oxidation 
was accomplished through a vinylogous Pummerer rearrangement.  First, a Saegusa oxidation of 118 
followed by 1,2-reduction and xanthate formation led to 119.  Thermal [1,3]-rearrangement of the 
xanthate functionality, thiolysis, S-methylation, and S-oxidation yielded the rearrangement precursor 120.  
Exposure of 120 to trifluoroacetic anhydride and 2,6-di-tert-butyl-4-methylpyridine followed by 
hydrolysis afforded a product, 121, bearing oxygenation at both the C2 and C4 positions.  S-Oxidation, 
DMP-mediated oxidation, elimination of the homoprenyl protecting group, and addition-elimination 
                                                      
514 This intramolecular aldol strategy for the construction of hyperforin was first revealed in 2007: Shimizu, Y.; 
Kuramochi, A.; Usuda, H.; Kanai, M.; Shibasaki, M. Tetrahedron Lett. 2007, 48, 4173-4177. 
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afforded allylic ether 122.  Finally, intramolecular Pd-catalyzed allyl transfer, acetylation, cross 
metathesis, and deacetylation revealed ent-hyperforin (ent-1). 
Other groups have utilized an intramolecular aldol strategy in their studies toward PPAP natural 
products.  Grossman’s approach involved a Pb(OAc)4-mediated α-alkynylation of β-ketoester 123 with 
stannane 124, and subsequent hydrosilylation of an insipient Co2(CO)6 complex to reveal enal 125, which 
upon exposure to aqueous acid afforded allylic alcohol 126 (Scheme 1.17a).515 Mehta has reported the 
DIBAL reduction of tetrahydrochromene 127 to bicyclo[3.3.1]nonane 128, which may proceed through 
an intermediate hemiacetal 129 that undergoes formal [1,3] rearrangement via aldehyde 130 (Scheme 
1.17b).516 Very similar reductive rearrangements have been reported by Shibasaki517 and Delpech.518 In 
studies toward hyperforin, Chen has reported the synthesis of aldehyde 131 via sequential Pd-catalyzed 
hydrostannylation of alkyne 132 followed by oxidative cleavage (Scheme 1.17c).519 Exposure of this 
aldehyde to NaOEt in EtOH afforded bicyclo[3.3.1]nonane 133. 
                                                      
515 Ciochina, R.; Grossman, R. B. Org. Lett. 2003, 5, 4619-4621.   
 
516 (a) Mehta, G.; Bera, M. K. Tetrahedron Lett. 2006, 47, 689-692. (b) Mehta, G.; Bera, M. K. Tetrahedron Lett. 
2008, 49, 1417-1420. (c) Mehta, G.; Bera, M. K. Tetrahedron Lett. 2009, 50, 3519-3522. (d) Mehta, G.; Das, M.; 
Kundu, U. K. Tetrahedron Lett. 2012, 53, 4538-4542. (e) Mehta, G.; Bera, M. K. Tetrahedron 2013, 69, 1815-1821. 
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Scheme 1.17. Intramolecular aldol approaches to PPAPs by (a) Grossman, (b) Mehta, and (c) Chen.a 
a Conditions: (a) 124, Pb(OAc)4, THF, –30 ºC to rt, 48%; (b) HCO2H, 71%; (c) Co2(CO)8, CH2Cl2, 0 ºC, 87%; (d) Et3SiH, 
bis(trimethylsilyl)acetylene, DCE, 65 ºC, 94%, (e) HCl, H2O, 72%; (f) DIBAL, CH2Cl2, 0 ºC, 52%; (g) PdCl2(PPh3)2, Bu3SnH, 
THF; OsO4, NMO, H2O; (h) Pb(OAc)4, CH2Cl2, 79% (2 steps); (i) NaOEt, EtOH, 0 ºC to rt; (j) DMP, NaHCO3, CH2Cl2, 70% (2 
steps). 
 
 
In addition to the aldol strategies outlined previously, Plietker has utilized an intramolecular 
Dieckmann cyclization approach for the synthesis of (±)-7-epi-clusianone (rac-40, Scheme 1.18).520 
Starting with acetylacetone (134), stepwise prenylation and deacylative aldol methylenation provided 
enone 135.  Treatment of this enone with dimethyl acetonedicarboxylate (136) afforded cyclohexenone 
137 as a result of a tandem Michael addition-Knoevenagel condensation.  Sequential regioselective 
methyllithium 1,2-addition, α-prenylation, and conjugate methylation afforded cyclohexanone 138.  In 
order to facilitate the key Dieckmann cyclization step, stereoselective prenylation at the C1 position of 
138 was required in order to position the methyl ketone and methyl ester upon the same face of the 
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cyclohexanone ring.  After some experimentation, a Fe-catalyzed allylation521 using methyl prenyl 
carbonate (139) afforded cyclization precursor 140.  Treatment with KOt-Bu followed by BzCN directly 
afforded (±)-7-epi-clusianone (rac-40).  Further, Plietker was able to synthesize racemic hyperpapuanone, 
hyperibone L, and oblongifolin A, highlighting the utility of this methodology to obtain Type B PPAPs 
bearing an exo C7 substituent.   
 
 
Scheme 1.18. Total synthesis of (±)-7-epi-clusianone by Plietker (ref. 520).a 
a Conditions: (a) NaH, EtOH, 0 ºC; prenyl bromide, 0 ºC to rt; CH2O, K2CO3, H2O, 60%; (b) MeMgCl, 136, THF, MeOH, 60 ºC, 
89%, (c) NaH, THF, 0 ºC; MeLi, 0 ºC; (d) NaH, 18-crown-6, THF, 0 ºC; prenyl bromide, 0 ºC to rt, 61% (2 steps); (e) MeMgBr, 
CuI, TMSCl, LiCl, THF, –78 ºC, 96%; (f) t-AmOK, 1,3-dimesitylimidazolin-2-ylidene hexafluorophosphate, MTBE, 60 ºC; 
Bu4N[Fe(CO)3(NO)], rt to 60 ºC; 138, LiH, THF, 0 ºC to rt; (139, 100 ºC, 86%; (g) t-BuOK, THF, 0 ºC; BzCN, 0 to 45 ºC, 78%. 
 
 
Other “bottom-up” approaches involve the use of transition metals or cycloaddition chemistry to 
facilitate the formation of the bicyclo[3.3.1]nonane core of PPAPs.  Garsubellin A was the first PPAP to 
be synthesized, and Shibasaki utilized ring-closing metathesis to establish the C2–C4 bridge.522 Kraus has 
utilized a Mn(OAc)3-mediated oxidative free-radical cyclization to facilitate to formation of the PPAP 
                                                      
521 Plietker, B. Angew. Chem. Int. Ed. 2006, 45, 1469-1473. 
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14201. 
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core in several model systems.523 Mehta has also synthesized a model bicyclo[3.3.1]nonane524 using a Pd-
catalyzed Kende cyclization.525 In an approach to hyperevolutin A, Young utilized an allene-nitrile oxide 
[3+2] cycloaddition reaction (Scheme 1.19).526 Treatment of 141 with PhNCO facilitated the 
cycloaddition to form isoxazoline 142, presumably through intermediate nitrile oxide 143.  Only a single 
C4 epimer of 142 was isolated, indicating that only one diastereomer of 143 underwent cyclization.  
Reduction of 142 using Raney Ni quantitatively afforded enamine 144 through cleavage of the 
isoxazoline ring.   
 
 
Scheme 1.19. Young's [3+2] allene-nitrile oxide cycloaddition approach to hyperevolutin A (ref. 526).a 
a Conditions: (a) PhNCO, NEt3, 40%; (b) Raney Ni, H2, MeOH, >99%. 
 
 
 
Contrasting “bottom-up” strategies, “top-down” approaches to PPAP synthesis typically involve 
dearomatization of an oxidized benzene ring through the attachment of the C6–C8 bridge.  Many of these 
strategies are inspired by the proposed biosynthesis of PPAPs, involving the dearomative alkylation of an 
acylphloroglucinol (e.g., Scheme 1.5).  As previously discussed, a challenge of many “bottom-up” 
strategies is the oxidation of the C2–C4 subunit; in “top-down” strategies, establishing this oxidation very 
                                                      
523 (a) Kraus, G. A.; Dneprovskaia, E.; Nguyen, T. H.; Jeon, I. Tetrahedron 2003, 59, 8975-8978. (b) Kraus, G. A.; 
Nguyen, T. H.; Jeon, I. Tetrahedron Lett. 2003, 44, 659-661. 
 
524 Mehta, G.; Bera, M. K. Tetrahedron Lett. 2004, 45, 1113-1116. 
 
525 (a) Kende, A. S.; Roth, B.; Sanfilippo, P. J. J. Am. Chem. Soc. 1982, 104, 1784-1785. (b) Kende, A. S.; Roth, B.; 
Sanfilippo, P. J.; Blacklock, T. J. J. Am. Chem. Soc. 1982, 104, 5808-5810. 
 
526 Young, D. G. J.; Zeng, D. J. Org. Chem. 2002, 67, 3134-3137. 
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early in the synthesis circumvents this problem.  Likewise, a difficulty of latter approaches is the 
installation of stereochemical elements at a late stage.   
Many of these principles were incorporated in the total synthesis of (±)-garsubellin A (rac-145) 
by Danishefsky (Scheme 1.20).527 Starting with phloroglucinol triether 146,528 regioselective ortho 
lithiation-prenylation, dihydroxylation, acetonide formation, and desilylation afforded phloroglucinol 
diether 147.  The reaction of this electron-rich phenol and allyl methyl carbonate under Pd- and Ti-
cocatalysis provided divinylogous carbonate 148 via a dearomative allylation reaction.529 A possible 
mechanism for this transformation involves Lewis acid-activation of the phenolic hydroxyl group 
followed by direct para C-allylation.  Treatment of 148 with perchloric acid facilitated the formation of 
alcohol 149 as a single diastereomer, bearing the tetrahydrofuran ring of garsubellin A.  Cross metathesis 
with 2-methyl-2-butene facilitated by Grubbs second-generation catalyst (150) afforded 151.  Exposure of 
151 to iodine not only provided the desired bicyclo[3.3.1]nonane core through a iodocarbocyclization 
reaction but also promoted iodination at the C1 position, which after treatment with iodine and CAN 
provided triiodide 152.  Aside from a tandem desired magnesium-iodine exchange with subsequent 
allylation at the C3 position of 152, a transannular Wurtz cyclopropanation yielded 153.  Iodide 1,5-
addition to the activated cyclopropane in 153 was accomplished by treatment with TMSI, affording 154.  
The synthesis of C7 prenylation product 155 was accomplished in two steps: (1) a AIBN-mediated Keck 
radical allylation530 with allyltributylstannane and (2) cross-metathesis with 2-methyl-2-butene.  At this 
juncture, only C1 acylation was necessary to complete the total synthesis; however, direct bridgehead 
lithiation-acylation of 155 was not feasible.  Accordingly, bridgehead iodination was accomplished using 
LDA and iodine to afford iodide 156.  Magnesium-iodide exchange, trapping with isobutyraldehyde, 
DMP-mediated oxidation, and desilylation subsequently afforded (±)-garsubellin A (rac-145).  In 
                                                      
527 Siegel, D. R.; Danishefsky, S. J. J. Am. Chem. Soc. 2006, 128, 1048-1049. 
 
528 Landi, J. J., Jr.; Ramig, K. Synth. Commun. 1991, 21, 167-171. 
 
529 Satoh, T.; Ikeda, M.; Miura, M.; Nomura, M. J. Org. Chem. 1997, 62, 4877-4879. 
 
530 Keck, G. A.; Enholm, E. J.; Yates, J. B.; Wiley, M. R. Tetrahedron 1985, 41, 4079-4094. 
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addition, these strategies were later utilized in racemic total syntheses of both nemorosone and 
clusianone.531 
 
 
Scheme 1.20. Total synthesis of (±)-garsubellin A by Danishefsky (ref. 527).a 
a Conditions: (a) BuLi, Et2O, 0 ºC; prenyl bromide; (b) K2OsO4·2H2O, K2CO3, K3[Fe(CN)6], MeSO2NH2, t-BuOH, H2O; (c) p-
TsOH·H2O, 2,2-dimethoxypropane, acetone; (d) TBAF, THF, 70% (4 steps); (e) Pd(OAc)2, PPh3, Ti(Oi-Pr)4, allyl methyl 
carbonate, PhH, 80 ºC, 62%; (f) HClO4, H2O, dioxane, 60 ºC, 71%; (g) 150, 2-methyl-2-butene, CH2Cl2, 40 ºC, 68%; (h) I2, KI, 
KHCO3, THF, H2O, 85%; (i) I2, CAN, MeCN, 50 ºC, 77%; (j) i-PrMgCl, THF, –78 ºC; Li2CuCl4, allyl bromide, –78 to 0 ºC, 
67%; (k) TMSI, CH2Cl2, 0 ºC; HCl, H2O, 0 ºC, 98%; (l) AIBN, allyltributylstannane, PhH, 80 ºC, 82%; (m) 150, 2-methyl-2-
butene, CH2Cl2, 40 ºC, 73%; (n) LDA, TMSCl, THF, –78 ºC; I2, –78 to 0 ºC, 25-36%; (o) i-PrMgCl, THF, –78 ºC; i-PrCHO, –78 
to 0 ºC, 72%; (p) DMP, CH2Cl2; (q) Et3N(HF)3, THF, 88% (2 steps). 
 
 
Other groups have utilized activated-olefin carbocyclization as key steps in their studies toward 
PPAP natural products.  Jacobsen employed a Claisen rearrangement of enol ether 157, catalyzed by 
guanidinium catalyst 158, to yield 159, in one step garnering the highly congested C1–C8 bond of 
hyperforin flanked by two stereogenic quaternary centers (Scheme 1.21a).532 Enol ether hydrolysis 
                                                      
531 Tsukano, C.; Siegel, D. R.; Danishefsky, S. J. Angew. Chem. Int. Ed. 2007, 46, 8840-8844. 
 
532 Uyeda, C.; Rötheli, A. R.; Jacobsen, E. N. Angew. Chem. Int. Ed. 2010, 49, 9753-9756. 
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followed by treatment with iodine yielded bicyclic diiodide 160.  In studies toward garsubellin A, 
Nicolaou performed a Lewis acid-mediated selenocarbocyclization upon 161 using N-
(phenylseleno)phthalamide (162), yielding bicyclo[3.3.1]nonane 163 (Scheme 1.21b).533 Couladorous 
reported a dearomative C-alkylation of deoxycohumulone (31) with allyl chloride 164 to yield 
cyclohexadienone 165 (Scheme 1.21c).534 Following monoacetylation to give 166, exposure to MsCl 
afforded SN1-type alkylation product 167.  However, a substantial amount of O-alkylation product 168 
was produced in addition to the desired C-alkylation product.  SnCl4-mediated carbocyclization of a 
prenylated phloroglucinol derivative has also been reported by Marazano; however, this reaction formed a 
variety of products.535  
 
                                                      
 
533 (a) Nicolaou, K. C.; Pfefferkorn, J. A.; Kim, S.; Wei, H. X. J. Am. Chem. Soc. 1999, 121, 4724-4725. (b) 
Nicolaou, K. C.; Pfefferkorn, J. A.; Cao, G.-Q.; Kim, S.; Kessabi, J. Org. Lett. 1999, 1, 807-810. 
 
534 Couladouros, E. A.; Dakanali, M.; Demadis, K. D.; Vidali, V. P. Org. Lett. 2009, 11, 4430-4433. 
 
535 Raikar, S. B.; Nuhant, P.; Delpech, B.; Marazano, C. Eur. J. Org. Chem. 2008, 1358-1369. 
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Scheme 1.21. Carbocyclization approaches to PPAPs by (a) Jacobsen, (b) Nicolaou, and (c) Couladouros.a 
a Conditions: (a) 158, hexane, 30 ºC, 81%, 7:1 dr, 81% ee; (b) HCl, THF, 90%; (c) I2, KI, NHCO3, THF, H2O, 65%; (d) 162, 
SnCl4, CH2Cl2, –23 ºC, 95%. (e) 164, KOH, Aliquat 336, PhCl, H2O, 81%; (f) Ac2O, pyr, acetone, 89%; (g) MsCl, NEt3, THF, –
40 ºC, 89% (total yield).   
 
 
Other unique dearomatization strategies have been explored.  Njardarson has pursued an 
oxidative dearomatization-double radical cyclization strategy for the synthesis of Type B PPAPs (Scheme 
1.22a).536 Hypervalent iodine-mediated oxidative deraromatization of 169 afforded cyclohexadienone 
170, and exposure of this compound to BEt3 gave bicyclo[3.3.1]nonane 171, the result of two 5-exo-trig 
cyclizations.  Simpkins has utilized an unusual rearrangement of the flavonoid catechin (172) to 
catechinic acid (173), a reaction previously reported by Sears in 1974 (Scheme 1.22b).537 
 
                                                      
536 McGrath, N. A.; Binner, J. R.; Markopoulos, G.; Brichacek, M.; Njardarson, J. T. Chem. Commun. 2011, 47, 
209-211.   
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Scheme 1.22. Other dearomative carbocyclization approaches by (a) Njardarson and (b) Simpkins.a 
a Conditions: (a) PhI(OAc)2, MeOH, 75%; (b) BEt3, (TMS)3SiH, air, PhMe, 73%; (c) NaOH, H2O, reflux, 91%. 
 
Nakada has explored an alternative approach to PPAPs involving a Birch reduction-
cyclopropanation-cyclopropane opening sequence,538 exemplified by the racemic total synthesis of 
hyperforin (Scheme 1.23).539 Starting with methyl 2,6-dimethoxybenzoate (174), Birch reduction with 
concommitant allylation followed by reduction and silylation produced cyclohexadiene 175.540 The allyl 
moiety in 175 was converted to a methyl ketone using a three step protocol involving dihydroxylation and 
oxidative cleavage followed by methyl addition mediated with AlMe3 with an ensuing Oppenauer 
oxidation, affording 176.  Subsequent trifluoracetylation of this compound followed by diazo transfer 
yielded α-diazoketone 177.  Exposure of 177 to [Cu(OTf)]2 in the presence of achiral bisoxazoline ligand 
178 facilitated an intramolecular cyclopropanation reaction, forming 179.  Unfortunately, the use of chiral 
ligands did not lead to high levels of absolute stereocontrol.538c Stepwise α-alkylation of ketone 179 with 
allyl iodide and iodomethane followed by acid-mediated cyclopropane opening led to isolation of 180, a 
bicyclo[3.3.1]nonane core containing the key C1 and C8 vicinal stereogenic quaternary centers of 
hyperforin.  Formal silanolysis of the allyl group of 180, formation of an enol triflate at the C7 position, 
                                                      
538 (a) Abe, M.; Nakada, M. Tetrahedron Lett. 2006, 47, 6347-6351. (b) Abe, M.; Nakada, M. Tetrahedron Lett. 
2007, 48, 4873-4877. (c) Abe, M.; Saito, A.; Nakada, M. Tetrahedron Lett. 2010, 51, 1298-1302. 
 
539 Uwamori, M.; Nakada, M. Tetrahedron Lett. 2013, 54, 2022-2025. 
 
540 Uwamori, M.; Saito, A.; Nakada, M. J. Org. Chem. 2012, 77, 5098-5107. 
OH
O
Br
Br
Ph
a. PhI(OAc)2,
    MeOH
O
MeO
O
Ph
O
OMeO
Br
Br
Ph
b. BEt3
(75%) (73%)
OHO
OH
OH
OH
OH c. NaOH
O OH
O OH
HO
HO(91%)
169 170 171
172 173
a.
b.
124
 125 
and subsequent Pd-mediated carbonylation led to ester 181.  Crabtree’s catalyst facilitated stereoselective 
hydrogenation of the C6–C7 olefin, and subsequent functional group manipulations afforded acetate 182.  
Allylic oxidation mediated by TBHP and Pearlman’s catalyst afforded β-methoxyenone 183.  Mono-
desilylation and Wittig homologation produced 184, and a subsequent aldehyde Wittig homologation 
yielded enol ether 185.  Hydrolysis of this enol ether, another Wittig homologation, and C5 bridgehead 
allylation gave 186.  Deprotonation at C3, followed by transmetalation with Lipshutz’s cuprate,511 and 
alkylation with allyl bromide yielded 187.  Conversion of the C1 hydroxymethylene of 187 to an 
isopropyl ketone afforded 188, and subsequent global cross metathesis and C2 methyl ether cleavage 
revealed (±)-hyperforin (rac-1).  A similar strategy was utilized in the total synthesis of (±)-nemorosone 
by Nakada.540 
  
125
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Scheme 1.23. Racemic total synthesis of (±)-hyperforin by Nakada (ref. 539).a 
a Conditions: (a) Na, NH3, t-BuOH, Et2O, –78 ºC; allyl bromide; (b) LAH, Et2O, 0 ºC; (c) TIPSOTf, NEt3, CH2Cl2, 0 ºC, 74% (3 
steps); (d) K2OsO4·H2O, K3[Fe(CN)6], K2CO3, (DHQD)2PHAL, t-BuOH, H2O; (e) NaIO4, MeOH, H2O, 81% (2 steps); (f) 
Me3Al, PhMe, 0 ºC; 3-nitrobenzaldehyde, PhMe, 0 ºC to rt, 85%; (g) LHMDS, THF, –78 ºC; CF3CO2CH2CF3; 4-
nitrobenzenesulfonyl azide, NEt3, 0 to 40 ºC, 85%; (h) [Cu(OTf)]2·PhMe, 178, PhMe; (i) KHMDS, HMPA, PhMe, THF, –78 ºC; 
allyl iodide, –78 to 0 ºC; (j) KHMDS, HMPA, PhMe, THF, –78 ºC; MeI, –78 ºC to 0 ºC; HCl, H2O, THF, 88% (3 steps); (k) 
(Sia)2BH, THF, –20 ºC; NaOH, H2O2, H2O, 78%; (l) TBSCl, NEt3, DMAP, CH2Cl2, 99%; (m) Comins’ reagent, KHMDS, PhMe, 
THF, 78 ºC, 90%; (n) CO, Pd(OAc)2, dppf, MeOH, DMF, 50 ºC, 93%; (o) H2, Crabtree’s catalyst, DCE, reflux, 97%; (p) 
DIBAL, CH2Cl2, –78 ºC; (q) Ac2O, DMAP, NEt3, CH2Cl2; (r) DMP, NaHCO3, CH2Cl2, 89% (3 steps); (s) TBHP, Pd(OH)2/C, 
K2CO3, CH2Cl2, 69%; (t) CSA, MeOH, CH2Cl2; (u) DMP, NaHCO3, CH2Cl2; (v) PPh3CH3Br, t-BuOK, THF, 0 ºC, 74% (3 
steps); (w) K2CO3, MeOH; (x) DMP, NaHCO3, CH2Cl2, 93% (2 steps); (y) PPh3(Cl)CH2OCH3, KHMDS, THF, 0 ºC, 79%; (z) p-
TsOH, acetone, H2O, 40 ºC; (aa) PPh3CH3Br, t-BuOK, THF, 0 ºC, 79% (2 steps); (bb) LiTMP, HMPA, THF, –78 ºC; allyl 
bromide, 84%; (cc) LiTMP, THF, –78 ºC; Li(2-Th)CuCN; allyl bromide, 90%; (dd) TBAF, THF; (ee) DMP, CH2Cl2, 84% (2 
steps); (ff) i-PrMgCl, CeCl3·2LiCl, THF, –78 ºC; (gg) DMP, NaHCO3, CH2Cl2, 71% (2 steps); (hh) 150, isobutene, 120 ºC, 93%; 
(ii) LiCl, DMSO, 120 ºC, 62%. 
 
 
While these dearomative alkylation approaches to PPAP natural products are useful and have 
successfully led to the synthesis of several PPAPs, a more direct strategy would involve annulation of a 
C6–C8 carbon bridge directly onto an aromatic nucleus.  However this strategy is not without its 
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challenges, especially concerning the control of absolute and C7–C8 relative stereochemistry.  Both 
Takagi and Porco have explored such dearomative annulation strategies, utilizing electrophiles such as 
acrylates 189,541 190,542 and 191543 as well as enals 192544 and 193545 and vinylsulfone 194544 (Figure 
1.20). 
 
 
Figure 1.20. Various electrophiles utilized in “top-down” annulation strategies. 
 
The total synthesis of ent-hyperibone K (ent-195) by Porco exemplifies the dearomative 
annulation strategy for PPAP construction (Scheme 1.24).545 bis-Prenylation of 2,4,6-
trihydroxybenzophenone (14)546 using basic, aqueous conditions provided the natural acylphloroglucinol 
clusiaphenone B (196).547 Upon exposure of 196 to enal 193 in the presence of Cinchona alkaloid-derived 
phase-transfer catalyst 197, adamantane 198 was produced enantioselectively.  This is a remarkable 
reaction, considering that two quaternary stereocenters are formed along with the characteristic PPAP 
bicyclo[3.3.1]nonane core.  Initially, this annulation was performed using enal 192, but shorter reaction 
times and higher enantioselectivity was garnered using 193.  A mechanistic model for this transformation 
                                                      
541 Takagi, R.; Nerio, T.; Miwa, Y.; Matsumura, S.; Ohkata, K. Tetrahedron Lett. 2004, 45, 7401-7405. 
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545 Qi, J.; Beeler, A. B.; Zhang, Q.; Porco, J. A., Jr. J. Am. Chem. Soc. 2010, 132, 13642-13644. 
 
546 14 is available in 2 steps from 1,3,5-trimethoxybenzene: Mondal, M.; Puranik, V. G.; Argade, N. P. J. Org. 
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involves the formation of a tight ion pair between 196 and 197 in which only one face of 196 is available 
to engage in binding interactions with the enal electrophile.  The remaining C–C bond required for the 
synthesis of hyperibone K from intermediate 198 was installed via deprotonation with LDA, revealing an 
aldehyde from a retro-aldol reaction, and trapping with 2-methyl-1-propenylmagnesium bromide, forming 
alcohol 199.  Exposure of this alcohol to Sc(OTf)3 yielded the enantiomer of hyperibone K (ent-195).  
This represents one of the only two total syntheses of adamantyl PPAPs reported to date.  Using this 
synthesis strategy, Porco has successfully prepared (±)-clusianone,544 (±)-plukenetione A,548 and (±)-
plukenetione D/E (7-epi-nemorosone).549 
 
  
Scheme 1.24. Total synthesis of ent-hyperibone K by Porco (ref. 545).a 
a Conditions: (a) prenyl bromide, KOH, H2O, 0 ºC, 45%; (b) 193, 197, CsOH·H2O, 4Å MS, CH2Cl2, –50 ºC, 71%, 90% ee; (c) 
LDA, 2-methyl-1-propenylmagnesium bromide, THF, –78 to –55 ºC; (d) Sc(OTf)3, CH3NO2, 50% (2 steps). 
 
 
Aside from the approaches outlined above that were developed specifically for PPAP synthesis, 
more general strategies toward the construction of bicyclo[3.3.1]nonanes have been developed.550 Several 
                                                      
548 Zhang, Q.; Mitasev, B.; Qi, J.; Porco, J. A., Jr. J. Am. Chem. Soc. 2010, 132, 14212-14215. 
 
549 Zhang, Q.; Porco, J. A., Jr. Org. Lett. 2012, 14, 1796-1799. 
 
550 For a review of bicyclo[3.3.1]nonane synthesis, see: Butkus, E. Synlett 2001, 1827-1835. 
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tactics include intramolecular conjugate addition reactions to both enones551 and ynones.552 Intermolecular 
cascade annulations involving unsaturated carbonyl systems have also been explored.553  Rhenium-,554 
gold-,555 and copper-mediated556 additions of cyclohexanones and their enol ether derivatives have yielded 
bicyclo[3.3.1]nonane systems.  Barriault has reported the use of a Prins-pinacol reaction to fashion a 
variety of bicyclic ring scaffolds.557 An SN2-type cyclization involving primary tosylate displacement has 
been explored.558  
Apart from cyclization strategies, Tadano has developed a zinc-mediated Barbier-type allylation 
reaction utilizing sugar-based aldehydes to construct stereogenic quaternary carbon centers that resemble 
the C8 center of PPAPs that bear differential substitution at that position (e.g., hyperforin).559 
 
                                                      
551 Srikrishna, A.; Kumar, P. P.; Reddy, T. J. Arkivoc 2003 (Part iii), 55-66. 
 
552 Klein, A.; Miesch, M. Tetrahedron Lett. 2003, 44, 4483-4485.  
 
553 (a) Barboni, L.; Gabrielli, S.; Palmieri, A.; Femoni, C.; Ballini, R. Chem. Eur. J. 2009, 15, 7867-7870. (b) Zhao, 
Y.-L.; Chen, L.; Yang, S.-C.; Tian, C.; Liu, Q. J. Org. Chem. 2009, 74, 5622-5625. (c) Wang, D.; Crowe, W. E. 
Org. Lett. 2010, 12, 1232-1235. 
 
554 Kuninobu, Y.; Morita, J.; Nishi, M.; Kawata, A.; Takai, K. Org. Lett. 2009, 11, 2535-2537. 
 
555 (a) Barabé, F.; Bétournay, G.; Bellavance, G.; Barriault, L. Org. Lett. 2009, 11, 4236-4238. (b) Sow, B.; 
Bellavance, G.; Barabé, F.; Barriault, L. Beilstein J. Org. Chem. 2011, 7, 1007-1013. 
 
556 Zhang, C.; Hu, X.-H.; Wang, Y.-H.; Zheng, Z.; Xu, J.; Hu, X.-P. J. Am. Chem. Soc. 2012, 134, 9585-9588. 
 
557 Lavigne, R. M. A.; Riou, M.; Girardin, M.; Morency, L.; Barriault, L. Org. Lett. 2005, 7, 5921-5923. 
 
558 Majumber, A.; Mandal, A.; Ghosh, P. J. Atoms Mol. 2012, 2, 176-181.   
 
559 Takao, K.-i.; Miyashita, T.; Akiyama, N.; Kurisu, T.; Tsunoda, K.; Tadano, K.-i. Heterocycles 2012, 86, 147-
153. 
129
 130 
Chapter 2  
Strategies Toward Hyperforin Synthesis  
130
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Synthesis Overview  
As elaborated above, hyperforin displays a broad spectrum of biological activity.560 Moreover, 
hyperforin is believed to be the component of St. John’s wort that is responsible for its antidepressant 
activity.  This is particularly noteworthy given hyperforin’s unique mechanism of action and absence of 
deleterious side effects that often accompany the use of other clinical antidepressants.  However, 
hyperforin’s therapeutic potential is handicapped by several factors:  (1) its poor water-solubility; (2) its 
fragility, readily decomposing in the presence of light and air;561 and (3) its potent activation of PXR, 
causing increases in gene expression levels of many proteins involved in xenobiotic metabolism.   
In order to mitigate these shortcomings while maintaining potential salutary benefits, access to a 
broad spectrum of hyperforin analogs is necessary.  While semisynthetic manipulation of hyperforin has 
led to a limited number of such derivatives,562 total synthesis is the only means by which diverse 
hyperforin analogs may be obtained.  Even though several synthesis endeavors have led to the total 
synthesis of both racemic and ent-hyperforin,563 the considerable length of these routes renders analog 
synthesis impractical.  Therefore, our goal was to devise a short, enantioselective approach to hyperforin 
that would be amenable to the synthesis of a variety of hyperforin mimetics and enable the first full 
structure-activity relationship study of hyperforin.   
Further, we rationalized that latent symmetry elements in hyperforin may be exploited to expedite 
total synthesis.  Imbedded within the hyperforin bicyclo[3.3.1]nonane core is a 1,3,5-cyclohexanetrione 
subunit (highlighted in blue in Scheme 2.1a).  Retrosynthetic cleavage of the C5–C6 bond in hyperforin 
(1) via intramolecular SN2-type displacement-cyclization would reveal monocyclic intermediate 200.  
                                                      
560 For reviews of hyperforin biological activity, see: (a) Barnes, J.; Anderson, L. A.; Phillipson, J. D. J. Pharm. 
Pharmacol. 2001, 53, 583-600. (b) Zanoli, P. CNS Drug Rev. 2004, 10, 203-218. (c) Vollmer, J. J.; Rosenson, J. J. 
Chem. Ed. 2004, 81, 1450-1456. (d) Medina, M. A.; Martínez-Poveda, B.; Amores-Sánchez, M. I.; Quesada, A. R. 
Life Sci. 2006, 79, 105-111. (e) Beerhues, L. Phytochemistry 2006, 67, 2201-2207. 
 
561 See discussion on page 75.  
 
562 For examples of semisynthetic hyperforin analogs, see refs. 259 and 309, and: Bombardelli, E.; Morazzoni, P.; 
Riva, A.; Fuzzati, N. US Patent 2005/0222274 A1, October, 6, 2005. 
 
563 See discussion on page 108. 
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Given the substitution pattern around this cyclohexanetrione ring, the C1 quaternary center of 200 is 
prostereogenic owing to a plane of symmetry intersecting the C1 and C4 atoms.  C1 stereochemistry is 
introduced during the subsequent alkylation event, in which two possible nucleophilic carbon atoms (i.e., 
C3 and C5) may engage the electrophilic C6.  We rationalized that the C7 prenyl substituent 
stereochemistry would bias the formation of a C5–C6 bond over C3–C6 bond formation (Scheme 2.1b).  
The former situation would lead to transition state 201, bearing a pseudoequatorial C7 prenyl substituent, 
whereas the latter bond-forming event would lead to transition state 202 containing a pseudoaxial C7 
prenyl moiety whose orientation begets two syn-pentane-like interactions with the C1–C9 and C3–C4 
bonds. 
 
 
Scheme 2.1. (a) Retrosynthetic analysis of hyperforin and (b) transition-state analysis of key cyclization event. 
 
Polyketide Cyclization Approach 
Prior to evaluating the plausibility of using this cyclization to construct hyperforin, synthesis of 
monocyclic precursor 200 was required.  In order to evaluate the feasibility of synthesizing 200, a model 
system in which the C8 stereogenic center of hyperforin was replaced with a tert-butyl group (203) was 
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established (Scheme 2.2).  We hypothesized that 203 would be accessed via dienylketene 204 via either a 
Dieckmann cyclization or a 6π electrocyclization.  Conjugated dienylketenes are known to undergo 
cyclization under fairly mild conditions,564 even to form nonaromatic carbocyclic products.565 This 
dienylketene would be accessed via tetraketide 205, the product of the coupling reaction between 
acylketene 206 with β-ketocarbonyl species 207.  This route was particularly appealing owing to the lack 
of oxidation-state changes and protecting group manipulations.  
 
 
Scheme 2.2. Retrosynthesis of model system 203 via tetraketide 205. 
 
Initially, we explored the feasibility of constructing several tetraketide-type species similar to 205  
(Figure 2.1).  Moreover, we chose to explore the coupling chemistry of the previously characterized and 
prepared tert-butylcarbethoxyketene566 (208) before exploring the synthesis of the potentially unstable α-
ketoketene 206.  Due to both the stabilizing effect of the conjugated ester and the steric nature of the tert-
                                                      
564 For reviews, see: (a) Harris, T. M.; Harris, C. M. Tetrahedron 1977, 33, 2159-2185. (b) Harris, T. M.; Harris, C. 
M. Pure Appl. Chem. 1986, 58, 283-294. 
 
565 For examples of nonaromatic cyclizations of polyketide-type products, see: (a) Griffiths, J.; Hart, H. J. Am. 
Chem. Soc. 1968, 90, 3297-3298. (b) Dannenberg, W.; Perst, H.; Seifert, W. J. Tetrahedron Lett. 1975, 16, 3481-
3484. (c) Fishbein, P. L.; Moore, H. W. J. Org. Chem. 1985, 50, 3226-3228. (d) Hsung, R. P.; Wulff, W. D. J. Am. 
Chem. Soc. 1994, 116, 6449-6450. 
 
566 (a) Newman, M. S.; Zuech, E. A. J. Org. Chem. 1962, 27, 1436-1438. (b) Evans, A. R.; Hafiz, M.; Taylor, G. A. 
J. Chem. Soc., Perkin Trans. 1 1984, 1241-1245. 
Me
Me
OO
OO
Me
Me
Me
Me Me
Me
Me
X
200
Me
Me
Me
OO
O
Me
O
Me
Me Me
Me
Me
Me
Me
203
model system for 200
8
204
•
O
OHHO
t-Bu
Me Me
Me
MeO
Me
Me
O O
t-Bu
O O
X
Me
Me
Me Me MeMe
O O
X
Me Me MeMe
+
t-Bu
• O
O
Me
Me
205
206
207
8
133
 134 
butyl substituent, 208 can be isolated and distilled in the absence of solvent.  Several candidate  
dienylketene precursors were explored.  An α-oxoketene may be generated from the thermolysis of a 
dioxinone,567 such as 209.  α-Oxoketenes may also be generated from the elimination of alcohols and 
thiols from β-ketoesters and β-ketothioesters, respectively, which also led us to pursue 210 and 211.568  
 
 
Figure 2.1. Carbethoxyketene 208 and several potential dienylketene precursors. 
 
We first explored the synthesis of dioxinone 209 (Scheme 2.3).  Magnesium-iodine exchange of 
iododioxinone 212569 followed by CuBr-mediated transmetalation and trapping with prenyl bromide 
afforded intermediate 213.  Deprotonation using LDA and trapping with a second equivalent of prenyl 
bromide afforded 214.  However, numerous attempts of the coupling of anions derived from 209 as well 
as its silyl dienyl ether only led to recovery of 214 and hydrolysis of ketene 208.  We concluded that the 
nucleophilic derivatives of 209 were not reactive enough to engage ketene 208. 
 
                                                      
567 For a review of dioxinone chemistry, see: Kaneko, C.; Sato, M.; Sakaki, J.-i.; Abe, Y. J. Heterocyclic Chem. 
1990, 27, 25-30. 
 
568 For reviews on the synthesis and chemistry of α-oxoketenes, see: (a) Moore, H. W.; Decker, O. H. W. Chem. 
Rev. 1986, 86, 821-830. (b) Seikaly, H. R.; Tidwell, T. T. Tetrahedron 1986, 42, 2587-2613. (c) Tidwell, T. T. Acc. 
Chem. Res. 1990, 23, 273-279. (d) Wentrup, C.; Heilmeyer, W.; Kollenz, G. Synthesis 1994, 1219-1248. 
 
569 Iwaoka, T.; Murohashi, T.; Katagiri, N.; Sato, M.; Kaneko, C. J. Chem. Soc., Perkin Trans. 1 1992, 1393-1397. 
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Scheme 2.3. Attempted Synthesis of dioxinone 209.a 
a Conditions: (a) i-PrMgCl, THF, –30 ºC; CuBr, LiCl, –30 ºC; prenyl bromide, –30 ºC, 84%; (b) LDA, DMPU, THF, 0 ºC; 214, 0 
ºC; prenyl bromide, –40 ºC to rt, 46%.  
 
 
While we failed to observe reactivity using monoanions derived from 214, we hypothesized that 
more nucleophilic, Weiler-type dianions generated from β-ketocarbonyl-type systems would react with 
ketene 208.570 Indeed, both tetraketides 210 and 211 were synthesized (Scheme 2.4). Prenylation of the 
dianion generated from acetoacetate 215571 yielded 216.  The reaction of the dianion generated from this 
acetoacetate with ketene 208 afforded adduct 210 as a complex mixture of diastereomers and tautomers.  
Likewise, the synthesis of 211 proceeded in similar fashion.  Stepwise prenylation of tert-butyl 
acetothioacetate572 (217) led to the isolation of 218.  The use of DME as solvent in these alkylations was 
crucial in preventing the formation of byproducts.573 Coupling with ketene 208 was achieved, affording 
key tetraketide 211.  
 
                                                      
570 (a) Hucklin, S. N.; Weiler, L. J. Am. Chem. Soc. 1974, 96, 1082-1087. (b) Huckin, S. N.; Weiler, L. Can. J. 
Chem. 1974, 52, 1343-1351. 
 
571 Yang, D.; Gao, Q.; Lee, O.-Y. Org. Lett. 2002, 4, 1239-1241.  
 
572 Sakaki, J.-i.; Kobayashi, S.; Sato, M.; Kaneko, C. Chem. Pharm. Bull. 1990, 38, 2262-2264. 
 
573 (a) Booth, P. M.; Fox, C. M. J.; Ley, S. V. Tetrahedron Lett. 1983, 24, 5143-5146. (b) Booth, P. M.; Fox, C. M. 
J.; Ley, S. V. J. Chem. Soc., Perkin Trans. 1 1987, 121-129. 
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Scheme 2.4. Synthesis of tetraketides 210 and 211.a 
a Conditions: (a) K2CO3, prenyl bromide, DMF, acetone, reflux, 64%; (b) NaH, THF, 0 ºC; BuLi, 0 ºC; 208, 0 ºC to rt, 55%; (c) 
NaH, DME, 0 ºC; BuLi, –30 ºC; prenyl bromide, –30 ºC to rt, 61%; (d) NaH, DME, 0 ºC; prenyl bromide, 0 ºC to rt, 75%; (e) 
NaH, DME, 0 ºC; BuLi, –30 ºC; 208, –30 ºC to rt, 39%. 
 
 
Unfortunately, all attempts at the generation of dienylketene 219 from either 210 or 211 en route 
to carbocycle 203 were unsuccessful (Scheme 2.5).  Treatment of these tetraketides with acid or base in 
order to directly generate a ketene intermediate led to decomposition.  While it was possible to obtain the 
extremely unstable carboxylic acid 220, any attempts to activate this intermediate (e.g., formation of an 
acid chloride) led to facile decarboxylation. 
 
 
Scheme 2.5. Attempted ketene generation from tetraketides 210 and 211. 
 
 
Concurrent to these studies, we also assessed the feasibility of synthesizing and coupling 
ketoketene 206 (Scheme 2.6).  First, i-PrMgCl addition to carbethoxyketene 208 gave β-ketoester 221.  
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Stepwise saponification, acid chloride formation, and treatment with NEt3 afforded ketoketene 206 as a 
volatile liquid that was stable in the absence of solvent.  Upon coupling of β-ketothioester 218 with 206, 
we were surprised to isolate α-pyrone 222.  Upon careful analysis of the reaction conditions, it was 
discovered that the direct product of the coupling reaction was linear polyketide 223, which upon acidic 
workup afforded pyrone 222.  Performing a basic aqueous workup gave decreased amounts of this 
product.  Similar acid-mediated heterocyclizations of triketothioacids have been reported.574 While the 
formation of pyrone 222 was undesirable, Harris has reported the conversion of 6-acyl-4-hydroxy-2-
pyrones, such as product 222, to acylphloroglucinols through the use of non-nucleophilic bases, such as 
LDA or LiH, possibly proceeding through a dienylketene intermediate similar to 204.575 
 
 
Scheme 2.6. Synthesis of ketene 206 and coupling with β-ketothioester 218.a 
a Conditions: (a) i-PrMgCl, THF, 0 ºC to rt, >99%; (b) NaOH, MeOH, H2O; (c) PCl5, Et2O, reflux, 73% (2 steps); (d) NEt3, PhH, 
51%; (e) NaH. 
 
 
 
We hypothesized that the conversion of 6-acyl-4-hydroxy-2-pyrone 222 to key intermediate 203 
would proceed through deprotonation of the internal, doubly conjugated methine to reveal extended 
enolate 224 (Scheme 2.7a).  Upon bond rotation and carbon-carbon bond formation, cyclohexanetrione 
203 would be accessed, an overall internal O-to-C acyl migration process.  Despite screening a variety of 
                                                      
574 Harris, T. M.; Harris, C. M. Tetrahedron 1969, 25, 2687-2691. 
 
575 Harris, T. M.; Wachter, M. P. Tetrahedron 1970, 26, 5255-5263. 
t-Bu
• O
O
EtO
208
t-Bu
O O
OEt
221
Me
Me t-Bu
• O
O
206
Me
Me
a. i-PrMgCl
b. NaOH
c. PCl5
d. NEt3
(37%, 3 steps)
(>99%)
St-Bu
OO
Me Me MeMe
218
e. NaH; BuLi;
    206
O
O
t-Bu
O
Me
Me
Me Me
HO
Me
Me
(55%)
222
O
O
t-Bu
O
Me
Me
Me Me
O
Me
Me
223
St-Bu
NH4Cl, H2O
137
 138 
non-nucleophilic bases, we were not able to achieve this transformation (Scheme 2.7b).  In most cases, 
222 was recovered.  Deuterium quench experiments indicated that the isopropyl methine and the pyrone 
hydroxyl group were the only two positions on 222 being appreciably deprotonated.  Use of derivatives of 
222 in which the pyrone hydroxyl group was blocked (i.e., 225 and 226) also did not facilitate desired 
carbocycle formation.  We concluded that not only was deprotonation extremely difficult at the desired 
site, but the conversion of pyrone 222, which bears some aromatic character, to the non-aromatic 
cyclohexanetrione 203 is a thermodynamically unfavorable process. 
 
 
Scheme 2.7. (a) Proposed and (b) unsuccessful synthesis of carbocycle 203 from pyrone 222.  
 
 
Electrocyclic Cascade Approach 
Due to the propensity of a linear polyketide to undergo O-cyclization to form a pyrone, we 
explored an alternative synthesis strategy that would mitigate heterocycle formation.  We surmised that an 
electrocyclic cascade reaction involving two equivalents of an alkynyl ether (227) and a disubstituted 
ketene (228) may be used to construct 229, which is a diether of carbocycle 203 (Scheme 2.8a).  In this 
reaction, a [2+2] cycloaddition of one equivalent of the alkynyl ether 227 with ketene 228 would produce 
cyclobutenone 230 (Scheme 2.8b).  Subsequent thermolysis would reveal vinylketene 231 via retro-4π 
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electrocyclization,576 which upon exposure to a second equivalent of alkynyl ether 227 would undergo a 
second [2+2] cycloaddition to form homologated cyclobutenone 232.  After another retro-4π 
electrocyclization to reveal a dienylketene 233, a final 6π electrocyclization would yield 229.  Analogous 
electrocyclic cascade reactions have been used to synthesize heavily substituted aryl rings,577 and in 
several instances even non-aromatic cyclohexadienones.578 
 
 
Scheme 2.8. (a) Proposed electrocyclic cascade and (b) mechanism for the synthesis of cyclohexadienone 229. 
 
 
                                                      
576 For reviews of electrocyclic opening of cyclobutenones, see: (a) Belluš, D.; Ernst, B. Angew. Chem. Int. Ed. 
Engl. 1988, 27, 797-827. (b) Moore, H. W.; Yerxa, B. R. Chemtracts Org. Chem. 1992, 5, 273-313.  
 
577 (a) Druey, J.; Jenny, E. F.; Schenker, K.; Woodward, R. B. Helv. Chim. Acta 1962, 45, 600-610. (b) Swenton, J. 
S.; Saurborn, E.; Srinivasan, R.; Sonntag, F. I. J. Am. Chem. Soc. 1968, 90, 2990-2991. (c) Neuse, E. W.; Green, B. 
R. Liebigs Ann. Chem. 1974, 1534-1535. (d) Mayr, H. Angew. Chem. Int. Ed. Engl. 1975, 14, 500-501. (e) 
Danheiser, R. L.; Gee, S. K. J. Org. Chem. 1984, 49,1672-1674. (f) Taing, M.; Moore, H. W. J. Org. Chem. 1996, 
61, 329-340. (g) Turnbull, P.; Heileman, M. J.; Moore, H. W. J. Org. Chem. 1996, 61, 2584-2585. (h) Xiong, Y.; 
Moore, H. W. J. Org. Chem. 1996, 61, 9168-9177. (i) Paquette, L. A. Eur. J. Org. Chem. 1998, 1709-1728. 
 
578 (a) Fishbein, P. L.; Moore, H. W. J. Org. Chem. 1985, 50, 3226-3228. (b) Dorsey, D. A.; King, S. M.; Moore, H. 
W. J. Org. Chem. 1986, 51, 2814-2816. 
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We first analyzed the reactivity of ketenes 206 and 208 with the known ethyl alkynyl ether 234, 
synthesized from the prenylation of ethoxyacetylene (Scheme 2.9).579 At temperatures below 100 ºC, no 
reaction occurred; however, above this threshold, oligimerization of 234 was observed.  At such 
temperatures, a retro-ene reaction may occur with 234,580 producing the very reactive monosubstituted 
ketene 235.   
 
 
Scheme 2.9. Attempted cycloaddition of alkynyl ether 234 with ketenes 206 and 208. 
 
 
In order to possibly circumvent this issue, we hypothesized that tert-butylcyanoketene581 (236) 
may react with alkynyl ether 234 at reduced temperatures due to the reduced steric environment 
surrounding the reactive ketene functionality (Scheme 2.10).582 Unlike acylketenes 206 and 208, 
cyanoketene 236 cannot be isolated neat; it is generated through the thermolysis of diazidobenzoquinone 
237 in toluene solution.583,584 After generating a solution of 236, addition of alkynyl ether 234 afforded 
not only the [2+2] cycloaddition product, cyclobutenone 238, but also azabicyclo[4.2.0]octantrienone 
                                                      
579 Gao, X.; Hall, D. G. J. Am. Chem. Soc. 2005, 127, 1628-1629. 
 
580 Liang, L.; Ramaseshan, M.; MaGee, D. I. Tetrahedron 1993, 49, 2159-2168. 
 
581 For examples of reactions involving 236, see: Al-Husaini, A. H.; Moore, H. W. J. Org. Chem. 1985, 50, 2595-
2597. 
 
582 For a review of cyanoketene chemistry, see: Moore, H. W.; Gheorghiu, M. D. Chem. Soc. Rev. 1981, 10, 289-
328. 
 
583 Weyler, W., Jr.; Duncan, W. G.; Liewen, M. B.; Moore, H. W. Org. Synth. 1976, 55, 32-38. 
 
584 We attempted to synthesize 236 from a 2-cyanoacetyl chloride (analogous to the synthesis of ketene 206); 
however, an allene was cleanly afforded, presumably through NEt3-promoted hetero-[2+2] cycloaddition of two 
equivalents of the ketene followed by decarboxylation of the resulting β-lactone.   
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239.  A possible mechanism for the formation of 239 involves the [4+2] cycloaddition of 236 with 234 to 
form 240, which may be depicted as a diploe or a diradical.  Coupling of this intermediate with a second 
equivalent of alkynyl ether 234 would afford 239 via 241.  An electrocyclic cascade that may involve an 
intermediate similar to 240 has been reported.585 Further, heating a solution of 238 and 234 did not yield 
239, demonstrating that 238 is not an intermediate in the synthesis of 239.  Subsequent optimization of 
this reaction for the synthesis of cyclobutenone 238 allowed us to access functional amounts of this 
intermediate for later electrocyclic cascade cyclization studies.586  
 
 
Scheme 2.10. (a) Thermolytic formation of 238 and 239, and (b) a possible mechanism for the formation of 239.a 
a Conditions: (a) PhMe, reflux; 234, rt to 120 ºC, 33% 238, 5% 239. 
 
We then explored the use of cyclobutenone 238 as an intermediate toward desired 
cyclohexadienone 229.  As indicated above, extended heating of 238 with alkynyl ether 234 did not yield 
further coupling products.  Attempted coupling of the more reactive lithium alkynoate 242, generated 
from successive lithium-bromine exchanges from α,α-dibromoester 243,587 only gave low yields of α-
pyrone 244 and linear ethyl ester 245, formed through the interception and opening of the cyclobutenone 
                                                      
585 Nguyen, N. V.; Chow, K.; Karlsson, J. O.; Doedens, R. J.; Moore, H. W. J. Org. Chem. 1986, 51, 419-420. 
 
586 See the experimental section of this chapter for details.   
 
587 (a) Shindo, M.; Sato, Y.; Shishido, K. Tetrahedron 1998, 54, 2411-2422. (b) Shindo, M.; Sato, Y.; Koretsune, R.; 
Yoshikawa, T.; Matsumoto, K.; Itoh, K.; Shishido, K. Chem. Pharm. Bull 2003, 51, 477-478.   
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by residual ethoxide from the formation of alkynoate 242 (Scheme 2.11).  Akin to the polyketide route 
results, pyrone formation prevails in the absence of oxygen blocking groups.  The ethanolysis product 245 
along with its double-bond isomer was also generated by heating 238 with ethanol. 
 
 
Scheme 2.11. The reaction of in situ derived lithium alkynoate 242 with cyclobutenone 238.a 
a Conditions: (a) t-BuLi, THF, –78 ºC to rt; 238, 8% 244, 12% 245. 
 
 
Owing to pyrone formation from the use of alkynoate 242 and the propensity of ethyl alkynyl 
ether 234 to undergo retro-ene cyclization, we then investigated the use of methyl alkynyl ether 246, an 
alkynyl ether incapable of retro-ene rearrangement.  It was synthesized from the base-mediated coupling 
of dichloroacetylene (generated in situ from trichloroethylene, 247), methanol, and prenyl bromide 
(Scheme 2.12a).588 However, when an excess of 246 was heated to 140 ºC with cyclobutenone 238, the 
only product isolated was phloroglucinol diether 248.  A plausible mechanism for the formation of this 
aromatic product is shown in Scheme 2.12b.  Coupling of 238 with 246 to afford the desired 
cyclohexadienone 249 may have occurred via the proposed electrocyclic cascade reaction—[2+2] 
cycloaddition of ring-opened vinylketene 250 with alkynyl ether 246, ensuing retro-4π electrocyclization 
of cyclobutenone 251 to dienylketene 252, and subsequent 6π electrocyclization to give 249—but under 
the reaction conditions, rapid loss of the tert-butyl group from 249 may have afforded 248.  This 
dissociation may operate via a concerted retro-ene cyclization process or an ionic retro-SN1-type reaction.  
                                                      
588 (a) Moyano, A.; Charbonnier, F.; Greene, A. E. J. Org. Chem. 1987, 52, 2919-2922. (b) Denmark, S. E.; Dixon, 
J. A. J. Org. Chem. 1998, 63, 6167-6177.   
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Miller and others have observed the elimination of sterically demanding alkyl groups from similar 
“blocked aromatic” cyclohexadienone systems.589 
 
 
Scheme 2.12. (a) Synthesis and (b) possible mechanism for the formation of 248 from the coupling of 246 and 238.a 
a Conditions: (a) MeOH, KH, THF; 247, –60 ºC to rt; BuLi, –78 to –10 ºC; prenyl bromide, HMPA, –78 ºC to rt, 53%; (b) 
xylenes, 140 ºC, 25%. 
 
 
We then explored potential methods of mitigating this terminal tert-butyl elimination step to 
isolate the desired cyclohexadienone 249 (Table 2.1).  As mentioned above, Miller has observed similar 
tert-butyl eliminations from cyclohexadienones, and these processes were mediated by either heat or 
acid.589a-c We repeated the reaction of alkynyl ether 246 with cyclobutenone 238 in the presence of amine 
base to determine if trace amounts of acid were promoting this elimination.  However, in the presence of 
                                                      
589 (a) Miller, B.; Margulies, H. J. Am. Chem. Soc. 1965, 87, 5106-5111. (b) Miller, B. J. Am. Chem. Soc. 1970, 92, 
6252-6259. (c) Miller, B. Acc. Chem. Res. 1975, 8, 245-256. (d) Nishinaga, A.; Shimizu, T.; Matsuura, T. 
Tetrahedron Lett. 1981, 22, 5293-5296. (e) Tashiro, M.; Itoh, T.; Yoshiya, H.; Fukata, G. Org. Prep. Proced. Int. 
1984, 16, 155-164. (f) Hewgill, F. R.; Stewart, J. M. J. Chem. Soc., Chem. Commun. 1984, 1419-1420. (g) Kende, 
A. S.; Hebeisen, P. Tetrahedron Lett. 1985, 26, 3769-3772. (h) Miller, B.; Baghdadchi, J. J. Chem. Soc., Chem. 
Commun. 1986, 511-512. (i) Miller, B.; Baghdadchi, J. J. Org. Chem. 1987, 52, 3390-3394. 
OMe
MeMe
246
MeOH +Cl
Cl
Cl a. KH; 247;
    prenyl–Br
247
EtO
OMe
Me
CN
t-Bu
238
b. 140 ºC
•
O
EtO
MeO
t-Bu
CN
246
250
Me
Me
Me
Me
238
retro-4π
electrocyclization
[2+2] 
cycloaddition
O
MeO
EtO t-Bu
CN
MeO OEt
•
Ot-Bu
CN
251
Me
Me
Me
Me
Me
Me
Me Me
O
OEtMeO
Me
Me
Me Me
t-Bu
CN
6π
electrocyclization
249 252
retro-4π
electrocyclization
OH
OEtMeO
Me
Me
Me Me
CN
248
t-Bu elimination
OH
OEtMeO
Me
Me
Me Me
CN
248
a.
b.
(53%) (25%)
+
143
 144 
N,N-diethylaniline (entry 1), not only was a greater proportion of 248 obtained but we also isolated ester 
253 (Figure 2.2), the result of opening of cyclobutenone 238 by phenol 248.  Use of the more basic 
Hünig’s base also gave both products with complete mass recovery (entry 2).  We did not observe any 
conversion with the use of microwave irradiation (entry 3).  Photolysis (entries 4-6) of a mixture of 238 
and 246 in the presence of benzophenone as a triplet sensitizer only gave 254, the [2+2] cycloaddition 
product of benzophenone and 246.590 Changing the reaction solvent from xylenes to heptane, with the 
goal of destabilizing tert-butyl cation formation, did not prevent the formation of 248 (entry 7).   
 
Table 2.1. Attempted formation of 249 from 246 and 238. 
 
Entry Conditions Results 
1 PhNEt2 (0.10 equiv), xylenes, 140 ºC 248 (20%), 253 (20%) 
2 i-Pr2NEt (0.20 equiv), xylenes, 140 ºC 248 (22%), 253 (78%) 
3 PhMe, µwave, 140 ºC, 4 h no reaction 
4 hv, PhH, rt, 1 d no reaction 
5 hv, acetone, rt, 1 d decomposition of 246 
6 benzophenone, hv, PhH, rt, 22 h  254 (28%) 
7 heptane, 140 ºC, 12 h 248, decomposition 
8 BHT (0.20 equiv), 140 ºC, PhMe, 12 h 255 (6%) 
9 BHT (0.20 equiv), i-Pr2NEt (0.20 equiv), PhMe, 140 ºC, 12 h 248 (13%), 255 (5%), 257 (42%) 
 
                                                      
590 For examples of photolytic cyclobutenone ring-opening, see: (a) Baldwin, J. E.; McDaniel, M. C. J. Am. Chem. 
Soc. 1968, 90, 6118-6124. (b) Toda, F.; Todo, E. Chem. Lett. 1974, 1279-1280. (c) Toda, F.; Todo, Y.; Todo, E. 
Bull. Chem. Soc. Jpn. 1976, 49, 2645-2646. (d) Danheiser, R. L.; Casebier, D. S.; Firooznia, F. J. Org. Chem. 1995, 
60, 8341-8350. 
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Figure 2.2. Products obtained from the reactions of 246 with 238. 
 
 
We also repeated the experimental protocol with the addition of BHT to investigate whether 
radical intermediates were involved (Table 2.1, entry 8); however, the only product isolated was 
transposed phloroglucinol diether 255.  This product may form via Diels–Alder [4+2] type cycloaddition 
between ring-opened vinyl ketene 250 to form cyclohexadienone 256 initially, which undergoes tert-butyl 
elimination (Scheme 2.13).  The isolation of 255 indicates that a retro-ene cyclization mechanism for this 
tert-butyl elimination is unlikely.591 Unsurprisingly, the combination of BHT and Hünig’s base additives 
gave a mixture of products, including 248, 255, and the ester adduct 257 (entry 9). 
 
 
Scheme 2.13. A possible mechanism for the formation of 255 from the reaction of 246 with 238 (Table 2.1, entry 5). 
 
 
                                                      
591 A retro-ene cyclization mechanism cannot be ruled out all together, since a [1,3]-transposition of the tert-butyl 
group may occur, placing the substituent at the α-position of the ketone.  Similar alkyl shifts have been observed by 
Miller.  For more information, see ref. 589. 
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Given the inability to isolate cyclohexadienone 249 from cyclobutenone 238, we investigated the 
chemistry of methyl alkynyl ether 246 with other ketenes (Scheme 2.14).  Heating a solution of 246 and 
ketoketene 206 afforded γ-pyrone 258.  A similar product, 259, was isolated in the reaction of 246 with 
carbethoxyketene 208 along with cyclobutenone 260.  This cyclobutenone may have formed via initial 
[2+2] cycloaddition of 246 and 208 followed by [1,3]-acyl shift.  We also explored the reactivity of 
ketenethioate 261,592 which was synthesized593 from Meldrum’s acid derivative 262594 via acid chloride 
263.  Heating a solution of this ketene with 246 produced α-pyrone 264. 
 
 
Scheme 2.14. Reactivity of alkynyl ether 246 with various ketenes.a 
a Conditions: (a) xylenes, 140 ºC, 4%; (b) PhMe, 110 ºC, 25% total yield (inseparable mixture of 259 and 260); (c) i-Pr2NEt, 
TMSCl, MeCN, 0 ºC; EtSH, 43 ºC; HCl, H2O; (d) PCl5, Et2O, reflux, 77% (2 steps); (e) NEt3, PhH, 39%; (f) PhMe, 110 ºC, 38%. 
 
                                                      
592 This is the first known (alkanethiol)acylketene to be made and is the first acylketene bearing a non-first row 
element acyl substituent.   
 
593 Magdziak, D.; Lalic, G.; Lee, H. M.; Fortner, K. C.; Aloise, A. D.; Shair, M. D. J. Am. Chem. Soc. 2005, 127, 
7284-7285. 
 
594 Huang, X.; Chan, C.-C.; Wu, Q.-L. Tetrahedron Lett. 1982, 23, 75-76. 
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Overall, these results indicated that under the conditions necessary to promote the desired 
electrocyclic cascade reaction, tert-butyl elimination to afford an aromatic product was unavoidable.  
Changes to the nature of the alkynyl ether, ketene coupling partner, solvent, and source of heat did not 
hinder this deleterious division of the desired product.  Another approach we pursued involved the use of 
an ynamine coupling partner instead of an alkynyl ether.595 We hypothesized that a more nucleophilic 
ynamine may allow the electrocyclic cascade reaction to proceed at a lower temperature and possibly 
allow for the isolation of our desired product.596 Indeed, stirring a solution of diethyl ynamine 265597 and 
cyclobutenone 238 at 40 ºC afforded a mixture of vinylcyclobutenone 266 and allenyl amide 267 
(Scheme 2.15a).  Both products may originate from 1,2-addition of the ynamine to the cyclobutenone 
carbonyl to form intermediate ketene-immonium ion 268, which after retro-4π electrocyclization may 
reveal enolate 269 (Scheme 2.15b).  C-Alkylation of the immonium ion by the enolate would afford 266 
directly, and O-alkylation would provide allenyl amide 267 via retro-4π electrocyclization of oxetene 270.   
 
                                                      
595 For reviews on the synthesis and reactivity of ynamines, see: (a) Ficini, J. Tetrahedron 1976, 12, 1449-1486. (b) 
Collard-Motte, J.; Janousek, Z. Top. Curr. Chem. 1986, 130, 89-131. (c) Zificsak, C. A.; Mulder, J. A.; Hsung, R. 
P.; Rameshkumar, C.; Wei, L.-L. Tetrahedron 2001, 57, 7575-7606. 
 
596 For an example of a reaction of an ynamine with a cyclobutenone, see: Ficini, J.; Falou, S.; d’Angelo, J. 
Tetrahedron Lett. 1977, 18, 1931-1934. 
 
597 (a) Ficini, J.; Barbara, C. Bull. Soc. Chim. Fr. 1965, 2787-2793. (b) Sauvêtre, R.; Normant, J. F. Tetrahedron 
Lett. 1982, 23, 4325-4328. 
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Scheme 2.15. (a) Synthesis and possible mechanisms for the formation of (b) of 266 and 267 from 265 and 238.a 
a Conditions: (a) PhMe, rt to 40 ºC, 12% 266, 68% 267. 
 
We then attempted to convert vinylcyclobutenone 266 to cyclohexadienone 271.  Given the 
similarity of 266 to intermediate 232 in Scheme 2.8b, we rationalized that a retro-4π electrocyclization 
followed by a 6π electrocyclization would afford 271.  However, under a variety of conditions, we were 
not able to isolate this desired product (Table 2.2).  While heating a benzene solution of 266 at 60 ºC did 
not result in any reaction (entry 1), heating at or above 90 ºC (entries 2-3) afforded aniline 272 as the sole 
product (Figure 2.3).  The formation of 272 from 266 is analogous to the formation of 255 from the 
reaction of 246 and 238, in which tert-butyl elimination rapidly occurred in the reaction medium.  Further 
heating, and the addition of BHT and Hünig’s base did not inhibit the formation of 272 (entries 4-6).  The 
only product from photolysis of 266 was double-bond isomer 273 (entries 7-8). 
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Table 2.2. Attempted formation of 271 from 266. 
 
Entry Conditions Results 
1 PhH, 60 ºC, 19 h no reaction 
2 PhH, 90 ºC, 14 h 272 is only product by NMR 
3 PhH, 140 ºC, 15 min 272 (48%), 266 (27% recovery) 
4 BHT, PhH, 90 ºC, 14 h 272 is only product by NMR 
5 i-Pr2NEt, PhH, 90 ºC, 14 h 272 is only product by NMR 
6 i-Pr2NEt, BHT, PhH, 90 ºC, 14 h 272 is only product by NMR 
7 hv, PhH, 4 h 273 (26%), 266 (32% recovery) 
8 hv, PhH, 12 h decomposition 
 
 
Figure 2.3. Products obtained from the reactions of 266. 
 
Given the propensity for tert-butyl elimination from putative cyclohexadienone intermediates, we 
also briefly investigated the use of tert-butyl(chloro)ketene (274) as a coupling partner in this 
electrocyclic cascade strategy (Scheme 2.16).  Replacement of the acyl or cyano group on the ketene with 
a chlorine atom may prevent undesireable elimination of the bulky alkyl group from a potential 
cyclohexadienone product.  Treating a solution of acyl chloride 275 with base provided in situ generation 
of 274,598 which was trapped with alkynyl ether 246 to form cyclobutenone 276.  However, further 
heating of this cyclobutenone with alkynyl ether 246 did not afford a desired coupling product; rather, 
rearranged cyclobutenone 277 was isolated, possibly the product of a [1,3]-chloride shift.   
                                                      
598 Brady, W. T.; Scherubel, G. A. J. Org. Chem. 1974, 39, 3790-3791. 
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Scheme 2.16. Formation and reactivity of cyclobutenone 276.a 
a Conditions: (a) NEt3, PhH, rt to reflux, 27%; (b) PhMe, 110 ºC, 49% (16% recovered 276). 
 
In summary, a variety of approaches to mitigate tert-butyl elimination were explored.  Varying 
the reaction parameters, including ketene coupling partners, heteroatom-functionalized alkynyl coupling 
partners, use of photolytic conditions, and use of reaction additives, failed to inhibit this process.  With 
the inability to isolate a stable cyclohexadienone bearing a quaternary center functionalized with a tert-
butyl substituent, we concluded that this electrocyclic cascade approach was inherently flawed, and we 
therefore sought to explore an alternative strategy for the construction of the bicyclo[3.3.1]nonane core of 
hyperforin.   
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Experimental Section 
General Procedures. All reactions were performed in oven-dried or flame-dried glassware under 
a positive pressure of argon unless otherwise noted.  Flash column chromatography was performed as 
described by Still et al.599 employing silica gel 60 (40-63 µm, Whatman).  Both preparatory and analytical 
thin-layer chromatography (TLC) were performed using 0.25 mm silica gel 60 F254 plates.  
Materials. Commercial reagents and solvents were used as received with the following 
exceptions.  Tetrahydrofuran, diethyl ether, dichloromethane, toluene, benzene, hexane, acetonitrile, and 
N,N-dimethylformamide were degassed with argon and passed through a solvent purification system 
(designed by J. C. Meyer of Glass Contour) utilizing alumina columns as described by Grubbs et al.600 
unless otherwise noted.  Triethylamine, diisopropylamine, pyridine, and chlorotrimethylsilane were 
distilled over calcium hydride.  Hexamethylphosphoramide was distilled over calcium hydride under 
reduced pressure.  Prenyl bromide was distilled under reduced pressure.  Lithium chloride was stored in a 
vacuum oven for at least 24 h before use.  Potassium hydride was washed five times with pentane and 
dried under reduced pressure directly prior to use.  The molarities of butyllithium and tert-butyllithium 
solutions were determined by titration with 1,10-phenanthroline as an indicator (average of three 
determinations).  THF solutions of lithium diisopropylamide were prepared by addition of a hexane 
solution of butyllithium (1 equiv) to a THF solution of the appropriate amine (1.1 equiv) cooled to –78 ºC 
and stirring the solution for 30 min at 0 ºC. 
Instrumentation.  1H NMR spectra were recorded with Varian INOVA-600 and Varian INOVA-
500 spectrometers, are reported in parts per million (δ), and are calibrated using residual non-deuterated 
solvent as an internal reference: CDCl3, δ 7.26 (CHCl3).  Data for 1H NMR spectra are reported as 
follows: chemical shift (multiplicity, coupling constants, integration).  Multiplicities are reported as 
follows: s = singlet; d = doublet; t = triplet; q = quartet; septet = septet; m = multiplet; br = broad, or 
                                                      
599 Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923-2925. 
 
600 Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518-
1520. 
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combinations thereof.  13C NMR spectra were recorded with a Varian INOVA-500 spectrometer, are 
reported in parts per million (δ), and are referenced from the central peak of the carbon resonance of the 
solvent: CDCl3, δ 77.23.  Infrared (IR) data were recorded on a Varian 1000 FT-IR using NaCl plates or 
on a Bruker Alpha FT-IR spectrometer outfitted with an Eco-ATR sampling module.  High-resolution 
mass spectra (HRMS) were recorded using electrospray ionization (ESI) mass spectroscopy on an Agilent 
6210 TOF LC/MS or a Bruker q-TOF Maxis Impact mass spectrometer.  Gas chromatography mass 
spectra (GCMS) were performed on a Shimadzu GC-2014 equipped with an AOC-20i auto-injector.  
Microwave irradiation was accomplished using a CEM Discover microwave reactor.  Photoirradiation 
was accomplished using a water-cooled, 5-inch 450-watt Hanovia UV immersion lamp.  No filter was 
used unless specifically indicated.     
Note: For clarity, intermediates that have are not explicitly mentioned in this chapter are 
numbered sequentially in the experimental section beginning with 278. 
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2,2,6-Trimethyl-5-(3-methylbut-2-en-1-yl)-4H-1,3-dioxin-4-one (213):   
A THF (350 mL) solution of 212569 (18.5 g, 69.0 mmol, 1 equiv) in a 3-neck, 1-L round-bottom flask was 
cooled to –30 ºC and treated dropwise with a THF solution of isopropylmagnesium chloride (2.0 M, 38 
mL, 76 mmol, 1.1 equiv) via equal-pressure dropping funnel.  After stirring at –30 ºC for 20 min, 
copper(I) bromide (990. mg, 6.90 mmol, 0.1 equiv) and lithium chloride (585 mg, 13.8 mmol, 0.2 equiv) 
were added, and prenyl bromide (12 mL, 100 mmol, 1.5 equiv) was added after 5 min.  After stirring at –
30 ºC for 2 h, the reaction was quenched with brine and extracted thrice with Et2O.  The organic extracts 
were combined, washed with brine, dried over MgSO4, filtered, and concentrated in vacuo to a green oil.  
Flash column chromatography (500 mL SiO2, 95:5 → 9:1 hexane:EtOAc) afforded 12.14 g (57.74 mmol, 
84% yield) of 213 as a pale yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 5.05 (t, J = 6.8 Hz, 1H), 2.94 (d, J = 6.8 Hz, 2H), 1.96 (s, 3H), 1.68 (m, 
6H), 1.63 (s, 6H). 
13C NMR (125 MHz; CDCl3) δ: 163.5, 162.4, 132.5, 121.8, 105.14, 104.94, 25.8, 25.3, 24.1, 18.0, 17.6. 
FTIR (thin film) νmax: 2994, 2916, 2859, 1716, 1643, 1389, 1347, 1268, 1235, 1204, 1148, 1054, 973, 
919, 835, 781, 732 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C12H18O3, 233.1144; found, 233.1148. 
TLC Rf = 0.43 (8:2 hexane:EtOAc). 
 
OO
O
MeMe
Me
i-PrMgCl, THF, –30 ºC, 20 min;
CuBr, LiCl, –30 ºC, 5 min;
prenyl bromide, –30 ºC, 2 h
(84%)
I
OO
O
MeMe
Me
MeMe212 213
153
 154 
 
2,2-Dimethyl-5-(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)-4H-1,3-dioxin-4-one (214): 
1,3-Dimethyl-3,4,5,6-tetrahydro-2-pyrimidinone (10.4 mL, 86.3 mmol, 1.5 equiv) was added to a freshly 
prepared THF solution of lithium diisopropylamide (0.69 M, 82.9 mL, 57.5 mmol, 1 equiv) in a 200-mL 
recovery flask cooled to 0 ºC.  After stirring for 20 min, 213 (12.10 g, 57.5 mmol, 1 equiv) was added, 
and the solution was stirred at 0 ºC for 20 min.  After cooling to –40 ºC, prenyl bromide (8.6 mL, 75 
mmol, 1.3 equiv) was added, and the reaction was allowed to slowly warm overnight.  After stirring for 
20 h at rt, the reaction was quenched by the addition of ice-cold 1 N HCl and extracted thrice with Et2O.  
The organic extracts were combined, washed with brine, dried over MgSO4, filtered, and concentrated in 
vacuo to a brown oil.  Flash column chromatography (500 mL SiO2, 9:1 hexane:EtOAc) afforded 7.30 g 
(26.2 mmol, 46% yield) of 214 as a pale yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 5.07 (t, J = 6.9 Hz, 1H), 5.04 (t, J = 6.1 Hz, 1H), 2.95 (d, J = 6.9 Hz, 2H), 
2.29-2.27 (m, 2H), 2.21 (m, 2H), 1.68 (s, 6H), 1.67 (s, 3H), 1.63 (s, 6H), 1.60 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 166.2, 162.7, 133.4, 132.2, 122.5, 122.3, 105.1, 104.9, 31.2, 25.88, 
25.85, 25.3, 25.0, 23.9, 18.04, 17.90. 
FTIR (thin film) νmax: 2967, 2915, 2859, 1720, 1637, 1444, 1371, 1268, 1204, 1130, 1047, 979, 845 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C17H26O3, 301.1784; found, 301.1774.  
TLC Rf = 0.33 (9:1 hexane:EtOAc).   
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tert-Butyl 7-methyl-2-(3-methylbut-2-en-1-yl)-3-oxooct-6-enoate (216): 
An acetone (500 mL) and DMF (30 mL) slurry of 215571 (20. g, 88 mmol, 1 equiv), prenyl bromide (11.2 
mL, 97.2 mmol, 1.1 equiv), and potassium carbonate (24.4 g, 177 mmol, 2 equiv) in a 3-neck 1-L round-
bottom flask outfitted with a reflux condenser was heated to reflux.  After refluxing for 21 h, the reaction 
was cooled to rt and concentrated in vacuo.  Short-path distillation (6 mmHg, 110-117 ºC) afforded 16.71 
g (56.8 mmol, 64%) of 216 as a colorless oil.   
1H NMR (600 MHz; CDCl3) δ: 5.04 (t, J = 7.2 Hz, 1H), 5.00 (t, J = 7.4 Hz, 1H), 3.33 (m, 1H), 2.55 (m, 
1H), 2.50-2.43 (m, 3H), 2.26-2.21 (m, 2H), 1.66 (s, 6H), 1.61 (s, 3H), 1.60 (s, 3H), 1.43 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 205.4, 169.0, 134.4, 132.9, 122.9, 120.4, 81.8, 60.3, 42.3, 28.1, 27.1, 
25.95, 25.87, 22.4, 18.00, 17.84. 
FTIR (thin film) νmax: 2971, 2916, 2859, 1735, 1712, 1450, 1368, 1249, 1144, 845 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C18H30O3, 295.2259; found, 295.2268.  
TLC Rf = 0.39 (9:1 hexane:EtOAc).  
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1-tert-Butyl 7-ethyl 6-(tert-butyl)-2,4-bis(3-methylbut-2-en-1-yl)-3,5-dioxoheptanedioate (210): 
216 (346 mg, 1.18 mmol, 1 equiv) was added to a THF (3 mL) slurry of sodium hydride (60% suspension 
in mineral oil, 46 mg, 1.23 mmol, 1.05 equiv) cooled to 0 ºC in a 10-mL recovery flask.  After stirring for 
10 min, a hexane solution of butyllithium (2.73 M, 0.65 mL, 1.76 mmol, 1.5 equiv) was added, and the 
yellow-orange slurry was stirred at 0 ºC.  After 10 min, 208566 (200 mg, 1.18 mmol, 1 equiv) was added, 
and the solution was allowed to warm to rt.  After 90 min, the reaction was quenched at rt with 2 N HCl, 
diluted with H2O, and extracted thrice with Et2O.  The organic extracts were combined, washed with 
brine, dried over MgSO4, filtered, and concentrated in vacuo to a yellow oil.  Flash column 
chromatography (100 mL SiO2, 95:5 → 9:1 hexane:EtOAc) afforded 299 mg (0.643 mmol, 55%) of 210 
as a yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 5.86-5.83 (m, ~0.5H), 5.08-4.92 (m, 2H), 4.25-4.09 (m, 2H), 4.00-3.90 
(m, ~1H), 3.57-3.44 (m, ~1H), 3.23-3.17 (m, ~1H), 3.11-3.07 (m, ~0.5H), 2.59-2.38 (m, 3H), 1.74-1.56 
(m, 12H), 1.46-1.41 (m, 9H), 1.30-1.24 (m, 3H), 1.12-1.04 (m, 9H) (mixture of tautomers and 
diastereomers). 
13C NMR (125 MHz; CDCl3) δ: 201.0, 200.1, 199.63, 199.50, 199.02, 198.82, 191.53, 191.51, 187.32, 
187.22, 169.4, 169.0, 168.36, 168.34, 168.20, 168.15, 167.96, 167.89, 134.74, 134.60, 134.56, 134.53, 
134.40, 134.21, 120.6, 120.41, 120.38, 120.24, 120.19, 120.14, 100.70, 100.69, 82.4, 82.1, 81.7, 67.6, 
67.2, 67.0, 66.8, 66.5, 65.7, 63.83, 63.79, 61.5, 61.29, 61.22, 60.9, 60.07, 60.05, 59.5, 56.56, 56.54, 35.2, 
35.02, 34.99, 34.82, 34.69, 34.51, 28.35, 28.31, 28.28, 28.25, 28.15, 28.06, 28.01, 27.97, 27.34, 27.23, 
27.19, 26.8, 25.87, 25.84, 25.78, 17.92, 17.88, 14.28, 14.25, 14.23 (mixture of tautomers and 
diastereomers). 
FTIR (thin film) νmax: 2969, 2933, 2873, 1730, 1598, 1448, 1368, 1246, 1143, 1043, 1025, 845 cm–1. 
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HRMS–ESI (m / z): [M+H]+ calculated for C27H44O6, 465.3207; found, 465.3211.  
TLC Rf = 0.61 (8:2 hexane:EtOAc).  
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S-tert-Butyl 7-methyl-3-oxooct-6-enethioate (278): 
A DME (16 mL) solution of 217572 (5.52 mL, 31.5 mmol, 1 equiv) was added dropwise to a DME (125 
mL) slurry of sodium hydride (60% suspension in mineral oil, 1.38 g, 34.6 mmol, 1.1 equiv) cooled to 0 
ºC in a 500-mL round-bottom flask.  After stirring for 5 min, the slurry was cooled to –30 ºC, and a 
hexane solution of butyllithium (2.60 M, 13.3 mL, 34.6 mmol, 1.1 equiv) was added slowly.  After 
stirring the bright orange slurry at –30 ºC for 10 min, prenyl bromide (4.0 mL, 34.6 mmol, 1.1 equiv) was 
added, and the yellow slurry was allowed to slowly warm to rt.  After stirring 90 min, the reaction was 
quenched with sat. aq. NH4Cl and extracted thrice with EtOAc.  The organic extracts were combined, 
washed with brine, dried over MgSO4, filtered, and concentrated in vacuo to a yellow oil.  Short-path 
distillation (6 mmHg, 100-105 ºC) afforded 4.66 g (19.2 mmol, 61% yield) of 278 as a pale yellow oil.  
1H NMR (500 MHz; CDCl3) δ: 5.32 (s, 1H, minor tautomer), 5.09-5.03 (m, 1H, both tautomers), 3.55 (s, 
2H, major tautomer), 2.55 (t, J = 7.4 Hz, 2H, both tautomers), 2.28-2.22 (m, 3H, both tautomers), 2.15-
2.12 (m, 1H, both tautomers), 1.69 (s, 3H, minor tautomer), 1.67 (s, 3H, major tautomer), 1.61 (s, 3H, 
both tautomers), 1.51 (s, 9H, minor tautomer), 1.47 (s, 9H, major tautomer). 
13C NMR (125 MHz; CDCl3) δ: 202.3, 196.4, 192.8, 176.1, 133.2, 122.65, 122.51, 99.8, 58.7, 49.2, 48.3, 
43.3, 35.3, 30.4, 29.8, 25.9, 25.1, 22.4, 17.91, 17.88 (mixture of tautomers). 
FTIR (thin film) νmax: 2965, 2924, 2862, 1723, 1674, 1614, 1455, 1364, 1178, 1160, 1080, 978, 863 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C13H22O2S, 243.1421; found, 243.1413.  
TLC Rf = 0.43 (9:1 hexane:EtOAc). 
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S-tert-Butyl 7-methyl-2-(3-methylbut-2-en-1-yl)-3-oxooct-6-enethioate (218): 
278 (5.76 g, 23.8 mmol, 1 equiv) was added to a DME (100 mL) slurry of sodium hydride (60% 
suspension in mineral oil, 950. mg, 30.9 mmol, 1.3 equiv) cooled to 0 ºC in a 200-mL recovery flask.  
After stirring for 5 min, prenyl bromide (3.6 mL, 31 mmol, 1.3 equiv) was added to the yellow solution, 
and the reaction was allowed to slowly warm to rt overnight.  After 12 h, the reaction was quenched with 
the addition of H2O and by pouring the resulting mixture onto ice-cold 1 N NaOH.  The mixture was then 
extracted thrice with CHCl3.  The organic extracts were combined, washed with H2O and brine, dried over 
MgSO4, filtered, and concentrated in vacuo.  The resulting colorless oil was retaken in 98:2 
hexane:EtOAc and passed through a short plug of SiO2, rinsing with 98:2 hexane:EtOAc.  Concentration 
of the filtrate in vacuo afforded 7.39 g (23.8 mmol, >99% yield) of 218 as a colorless oil.   
1H NMR (600 MHz; CDCl3) δ: 5.03 (t, J = 7.2 Hz, 1H), 4.98 (t, J = 7.3 Hz, 1H), 3.58 (t, J = 7.5 Hz, 1H), 
2.60-2.46 (m, 4H), 2.24 (q, J = 7.2 Hz, 2H), 1.66 (s, 6H), 1.61 (s, 6H), 1.45 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 204.1, 195.9, 134.8, 133.0, 122.8, 119.9, 68.4, 58.7, 49.0, 42.2, 29.8, 
28.0, 25.93, 25.87, 22.5, 17.99, 17.85. 
FTIR (thin film) νmax: 2965, 2922, 2859, 1723, 1672, 1454, 1364, 1162, 984, 926, 825 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C18H30O2S, 333.1858; found, 333.1859.  
TLC Rf = 0.65 (9:1 hexane:EtOAc).   
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Ethyl 2-(tert-butyl)-6-((tert-butylthio)carbonyl)-9-methyl-4-(3-methylbut-2-en-1-yl)-3,5-dioxodec-8-
enoate (211): 
A DME (1.1 mL) solution of 218 (663 mg, 2.14 mmol, 1 equiv) was added dropwise to a DME (8.5 mL) 
slurry of sodium hydride (60% suspension in mineral oil, 94 mg, 2.35 mmol, 1.1 equiv) cooled to 0 ºC in 
a 25-mL recovery flask.  After stirring the pink solution at 0 ºC for 5 min, it was cooled to –30 ºC, and a 
hexane solution of butyllithium (2.60 M, 0.90 mL, 2.4 mmol, 1.1 equiv) was added dropwise.  The 
resulting yellow-orange solution was stirred for 10 min at –30 ºC, and 208566 (400 mg, 2.35 mmol, 1.1 
equiv) was added dropwise.  The resulting yellow-orange solution was allowed to slowly warm to rt 
overnight.  After 16 h, the solution was quenched by pouring it onto sat. aq. NH4Cl, and the resulting 
mixture was extracted thrice with EtOAc.  The organic extracts were combined, washed with brine, dried 
over MgSO4, filtered, and concentrated in vacuo to an orange oil.  Flash column chromatography (100 
mL SiO2, 98:2 → 8:2 hexane:EtOAc) afforded 398 mg (0.828 mmol, 39% yield) of 211 as a yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 5.29 (m, ~0.5H), 5.08-4.81 (m, 2H), 4.22-3.88 (m, 2H), 3.72-3.31 (m, 
3H), 2.51-2.23 (m, ~3.5H), 1.65-1.33 (m, 12H), 1.23-1.11 (m, 3H), 1.05-0.93 (m, 9H) (mixture of 
tautomers and diastereomers). 
13C NMR (125 MHz; CDCl3) δ: 199.30, 199.27, 199.25, 199.05, 198.8, 198.37, 198.22, 198.02, 197.3, 
195.02, 194.94, 194.61, 194.55, 168.21, 168.09, 168.03, 167.6, 134.84, 134.80, 134.74, 134.70, 134.50, 
134.35, 122.3, 120.30, 120.19, 120.08, 119.96, 119.84, 119.73, 119.68, 118.3, 101.6, 77.2, 68.34, 68.21, 
68.13, 67.7, 67.34, 67.29, 67.21, 67.16, 67.01, 66.92, 66.80, 66.77, 66.74, 66.66, 66.55, 65.6, 61.48, 
61.31, 61.21, 61.16, 61.08, 60.96, 60.84, 60.75, 60.71, 60.4, 59.0, 56.75, 56.67, 53.5, 51.8, 49.27, 49.24, 
49.04, 48.97, 36.4, 35.4, 35.1, 34.74, 34.69, 34.56, 34.53, 34.39, 34.26, 33.7, 30.06, 30.04, 29.75, 29.69, 
29.66, 29.62, 29.3, 28.82, 28.64, 28.52, 28.34, 28.14, 28.10, 28.06, 28.03, 28.00, 27.65, 27.55, 27.47, 
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27.40, 27.14, 26.99, 26.4, 25.74, 25.69, 25.66, 24.6, 17.88, 17.84, 17.78, 17.76, 17.73, 17.67, 14.26, 
14.22, 14.18, 14.14 (mixture of tautomers and diastereomers). 
FTIR (thin film) νmax: 2963, 2914, 2872, 1725, 1671, 1455, 1365, 1302, 1221, 1144, 1043, 935 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C27H44O5S, 503.2802; found, 503.2807.  
TLC Rf = 0.51 (8:2 hexane:EtOAc). 
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Ethyl 2-(tert-butyl)-4-methyl-3-oxopentanoate (221): 
A THF (265 mL) solution of 208566 (18.0 g, 106 mmol, 1 equiv) in a 1-L recovery flask was cooled to 0 
ºC, and a THF solution of isopropylmagnesium chloride (2.0 M, 58 mL, 120 mmol, 1.1 equiv) was added 
slowly over 10 min.  After the addition was complete, the reaction was allowed to slowly warm to rt.  
After stirring for 3 h, the reaction was quenched via dropwise addition of H2O followed by sat. aq. NH4Cl 
and extracted thrice with EtOAc.  The organic extracts were combined, washed with sat. aq. NaHCO3 and 
brine, dried over MgSO4, and filtered through a short plug of SiO2, rinsing with EtOAc.  The filtrate was 
concentrated in vacuo to afford 23 g (110 mmol, >99% yield) of 221 as a colorless oil.   
1H NMR (600 MHz; CDCl3) δ: 4.15 (q, J = 7.1 Hz, 2H), 3.52 (s, 1H), 2.69 (7, J = 6.8 Hz, 1H), 1.24 (t, J 
= 7.1 Hz, 3H), 1.09 (d, J = 6.8 Hz, 3H), 1.08 (s, 9H), 1.04 (d, J = 6.8 Hz, 3H). 
13C NMR (125 MHz; CDCl3) δ: 209.1, 168.9, 65.8, 61.0, 42.6, 34.7, 28.4, 18.35, 18.18, 14.4. 
FTIR (thin film) νmax: 2964, 2909, 2874, 1736, 1714, 1466, 1366, 1303, 1223, 1206, 1142, 1021 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C12H22O3, 215.1651; found, 215.1642.  
TLC Rf = 0.42 (9:1 hexane:EtOAc). 
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2-(tert-Butyl)-4-methylpent-1-ene-1,3-dione (206): 
A MeOH (465 mL) solution of 221 (10.0 g, 46.7 mmol, 1 equiv) in a 1-L round-bottom flask was treated 
with an aqueous solution of sodium hydroxide (50% by weight, 93 mL).  The exothermic yellow solution 
was placed in a rt water bath and stirred for 12 h.  The reaction was then concentrated partially in vacuo, 
cooled to 0 ºC, and slowly acidified with concentrated HCl.  After warming the mixture to rt, it was 
extracted thrice with EtOAc.  The organic extracts were combined, washed with brine, dried over MgSO4, 
filtered, and concentrated in vacuo to a pale yellow oil.  The oil was taken up in Et2O (210 mL) in a 3-
neck 500-mL round-bottom flask outfitted with a reflux condenser.  Phosphorous(V) chloride (17.6 g, 
84.6 mmol, 2 equiv) was added, and the mixture was heated to reflux.  After stirring for 4 h at reflux, the 
reaction was cooled to rt and transferred via cannula to a Schlenk filter funnel and filtered under positive 
N2 pressure.  The yellow filtrate was distilled directly (6 mmHg, 62-64 ºC) to afford 7.03 g (34.3 mmol, 
73% yield over 2 steps) of 279 as a colorless oil.  A PhH (48 mL) solution of 279 (6.91 g, 33.8 mmol, 1 
equiv) in a 100-mL recovery flask was treated with triethylamine (9.4 mL, 68 mmol, 2 equiv), and the 
resulting yellow slurry was stored in the dark for 7 h.  The slurry was then passed through a Schlenk filter 
funnel under positive N2 pressure.  The filtrate was distilled directly (6 mmHg, 30-32 ºC) to afford 2.89 g 
(17.2 mmol, 51% yield) of 206 as a colorless oil. 
1H NMR (600 MHz; CDCl3) δ: 2.54 (septet, J = 6.7 Hz, 1H), 1.24 (s, 9H), 1.11 (d, J = 6.7 Hz, 5H). 
13C NMR (125 MHz; CDCl3) δ: 200.1, 197.1, 59.7, 41.5, 31.7, 29.5, 19.6. 
FTIR (thin film) νmax: 2966, 2908, 2874, 2097, 1668, 1459, 1384, 1365, 1248, 1193, 1157, 940 cm–1. 
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4-Hydroxy-3,5-bis(3-methylbut-2-en-1-yl)-6-(2,2,5-trimethyl-4-oxohexan-3-yl)-2H-pyran-2-one 
(222): 
A DME (0.6 mL) solution of 218 (336 mg, 1.08 mmol, 1 equiv) was added to a DME (5 mL) slurry of 
sodium hydride (60% suspension in mineral oil, 48 mg, 1.18 mmol, 1.1 equiv) cooled to 0 ºC in a 25-mL 
round-bottom flask.  After stirring the resulting pink solution at 0 ºC for 5 min, it was cooled to –30 ºC 
and a hexane solution of butyllithium (1.8 M, 0.65 mL, 1.2 mmol, 1.1 equiv) was added dropwise.  After 
stirring for 10 min at –30 ºC, 206 (200. mg, 1.18 mmol, 1.1 equiv) was added and the reaction was 
allowed to slowly warm to rt.  After stirring for 3.5 h, the reaction was quenched with sat. aq. NH4Cl and 
extracted thrice with EtOAc.  The organic extracts were combined, washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo.  Flash column chromatography (75 mL SiO2, 95:5 → 9:1 → 1:1 
hexane:EtOAc) afforded 218 mg (0.56 mmol, 52% yield) of 222 as a white flocculent solid.   
1H NMR (600 MHz; CDCl3) δ: 7.95 (br s, 1H), 5.22 (t, J = 7.3 Hz, 1H), 5.02 (t, J = 6.0 Hz, 1H), 3.57 (s, 
1H), 3.21 (d, J = 7.3 Hz, 2H), 3.17 (dd, J = 16.0, 5.6 Hz, 1H), 3.11 (dd, J = 16.0, 7.3 Hz, 1H), 2.68 
(septet, J = 6.8 Hz, 1H), 1.72 (s, 3H), 1.70 (s, 6H), 1.66 (s, 3H), 1.04 (s, 9H), 0.91 (d, J = 6.8 Hz, 3H), 
0.90 (d, J = 6.8 Hz, 3H). 
13C NMR (125 MHz; CDCl3) δ: 209.8, 164.9, 164.5, 156.0, 136.6, 133.3, 121.0, 120.4, 114.6, 103.0, 
61.1, 39.9, 35.6, 28.9, 25.92, 25.72, 24.0, 23.3, 19.6, 18.10, 18.08, 18.01. 
FTIR (thin film) νmax: 3252 (br), 2967, 2874, 1727, 1666, 1559, 1449, 1217 cm–1. 
HRMS–ESI (m / z): [M+K]+ calculated for C24H36O4, 427.2245; found, 427.2228. 
TLC Rf = 0.41 (7:3 hexane:EtOAc). 
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4-Methoxy-3,5-bis(3-methylbut-2-en-1-yl)-6-(2,2,5-trimethyl-4-oxohexan-3-yl)-2H-pyran-2-one 
(225): 
A THF (3 mL) solution of 222 (168 mg, 0.432 mmol, 1 equiv) in a 20-mL scintillation vial was treated 
with an Et2O solution of trimethylsilyldiazomethane (2.0 M, 0.43 mL, 0.87 mmol, 2 equiv).  After stirring 
the yellow solution at rt for 23 h, it was quenched with sat. aq. NH4Cl and extracted thrice with EtOAc.  
The organic extracts were combined, washed with brine, dried over Na2SO4, filtered, and concentrated in 
vacuo to a yellow oil.  Flash column chromatography (20 mL SiO2, 95:5 → 8:2 hexane:EtOAc) afforded 
162.3 mg (0.4032 mmol, 93% yield) of 225 as a pale yellow oil.   
1H NMR (600 MHz; CDCl3) δ 5.15 (t, J = 7.1 Hz, 1H), 5.10 (t, J = 6.8 Hz, 1H), 3.89 (s, 3H), 3.89 (s, 
1H), 3.51-3.47 (m, 1H), 3.10-3.06 (m, 2H), 3.02 (dd, J = 14.4, 7.1 Hz, 1H), 2.61 (7, J = 6.8 Hz, 1H), 1.78 
(s, 3H), 1.72 (s, 3H), 1.69 (s, 3H), 1.66 (s, 3H), 1.09 (s, 9H), 1.04 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 6.8 Hz, 
3H). 
13C NMR (125 MHz; CDCl3) δ: 210.2, 179.5, 162.5, 154.5, 132.3, 132.1, 126.3, 121.9, 121.6, 104.0, 
60.2, 56.1, 41.7, 36.4, 29.0, 25.95, 25.79, 24.2, 21.2, 18.8, 18.28, 18.18, 18.0. 
FTIR (thin film) νmax: 2962, 2913, 2872, 1723, 1652, 1618, 1592, 1462, 1401, 1324, 1266, 1178, 1124, 
1021, 974 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C25H38O4, 403.2846; found, 403.2843.  
TLC Rf = 0.55 (8:2 hexane:EtOAc). 
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3,5-bis(3-Methylbut-2-en-1-yl)-2-oxo-6-(2,2,5-trimethyl-4-oxohexan-3-yl)-2H-pyran-4-yl benzoate 
(226): 
A pyr (1 mL) solution of 222 (59.8 mg, 0.15 mmol, 1 equiv) in a 5-mL pear-shaped flask was treated with 
benzoyl chloride (16 µL, 0.17 mmol, 1.1 equiv).  After stirring the reaction for 9 h, it was poured onto sat. 
aq. NaHCO3 and extracted thrice with EtOAc.  The organic extracts were combined, washed with brine, 
dried over Na2SO4, filtered, and concentrated in vacuo to a brown oil.  Flash column chromatography (15 
mL SiO2, 95:5 hexane:EtOAc) afforded 36.9 mg (74.9 µmol, 50% yield) of 226 as a pale yellow oil. 
1H NMR (600 MHz; CDCl3) δ: 8.13-8.10 (m, 2H), 7.69-7.65 (m, 1H), 7.53 (td, J = 7.8, 3.8 Hz, 2H), 5.09 
(t, J = 7.0 Hz, 1H), 4.96 (t, J = 5.0 Hz, 1H), 3.66 (s, 1H), 3.20-2.96 (m, 4H), 2.76 (7, J = 6.8 Hz, 1H), 1.56 
(s, 3H), 1.55 (s, 3H), 1.47 (s, 3H), 1.42 (s, 3H), 1.12 (s, 9H), 1.02 (d, J = 6.8 Hz, 3H), 0.99 (d, J = 6.8 Hz, 
3H). 
13C NMR (125 MHz; CDCl3) δ: 209.5, 163.12, 163.04, 159.2, 134.5, 133.80, 133.70, 130.5, 128.9, 128.1, 
120.9, 119.4, 118.2, 116.0, 61.2, 40.3, 36.0, 32.9, 29.0, 25.81, 25.65, 25.2, 24.6, 19.7, 18.16, 18.02, 17.94. 
FTIR (thin film) νmax: 2967, 2931, 2872, 1743, 1723, 1565, 1452, 1375, 1258, 1229, 1176, 1059, 1022, 
706 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C31H40O5, 493.2949; found, 493.2957. 
TLC Rf = 0.66 (1:1 hexane:EtOAc). 
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A PhMe (7 mL) solution of 237582 (82 mg, 0.27 mmol, 1 equiv) in a 2-neck 25-mL round-bottom flask 
outfitted with a reflux condenser was refluxed for 90 min, whereupon the initially orange solution turned 
yellow.  After cooling to rt, 234579 (150. mg, 1.09 mmol, 4 equiv) was added, producing an orange 
solution.  After stirring for 8 h at rt, it was heated at 60 ºC for 12 h, and then at 120 ºC for 3 h.  The bright 
orange red solution was cooled to rt and concentrated in vacuo to an orange red oil.  Flash column 
chromatography (100 mL SiO2, 95:5 → 9:1 hexane:EtOAc) afforded 46 mg (0.18 mmol, 33% yield) of 
238 as an orange oil and 10 mg (0.025 mmol, 5% yield) of 239 as an orange oil.   
1-(tert-Butyl)-2-ethoxy-3-(3-methylbut-2-en-1-yl)-4-oxocyclobut-2-enecarbonitrile (238): 
1H NMR (600 MHz; CDCl3) δ: 5.08 (t, J = 7.0 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 2.85-2.83 (m, 2H), 1.68 
(s, 3H), 1.61 (s, 3H), 1.45 (t, J = 7.1 Hz, 3H), 1.09 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 179.6, 172.9, 134.4, 124.6, 119.3, 117.2, 70.0, 68.3, 34.6, 26.4, 25.7, 
22.0, 18.0, 15.2. 
FTIR (thin film) νmax: 2972, 2229, 1768, 1654, 1619, 1599, 1381, 1334 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C16H23NO2, 284.1621; found, 284.1611.  
TLC Rf = 0.39 (8:2 hexane:EtOAc). 
6-(tert-Butyl)-3,7-diethoxy-4,8-bis(3-methylbut-2-en-1-yl)-2-azabicyclo[4.2.0]octa-1,3,7-trien-5-one 
(239): 
1H NMR (500 MHz; CDCl3) δ: 5.23 (t, J = 7.1 Hz, 1H), 5.18 (t, J = 7.5 Hz, 1H), 4.53 (dq, J = 10.0, 7.1 
Hz, 1H), 4.46 (dq, J = 10.5, 7.1 Hz, 1H), 4.37 (m, 2H), 3.12 (dd, J = 14.0, 7.5 Hz, 1H), 3.03 (dd, J = 16.2, 
7.1 Hz, 1H), 2.94 (dd, J = 16.2, 7.0 Hz, 1H), 2.84 (dd, J = 14.0, 7.5 Hz, 1H), 1.71 (s, 6H), 1.66 (s, 3H), 
1.64 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H), 0.99 (s, 9H). 
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13C NMR (125 MHz; CDCl3) δ: 191.9, 180.8, 168.2, 162.7, 133.7, 130.6, 124.8, 123.3, 119.7, 110.6, 
69.8, 63.4, 36.8, 29.9, 28.5, 25.98, 25.82, 22.9, 22.5, 18.04, 18.02, 15.53, 15.50. 
FTIR (thin film) νmax: 2968, 2942, 1631, 1572, 1370, 1332, 1263 cm–1.  
HRMS–ESI (m / z): [M+H]+ calculated for C25H37NO3, 400.2846; found, 400.2860. 
TLC Rf = 0.30 (8:2 hexane:EtOAc). 
 
Optimized procedure for the synthesis of 238: 
An orange PhMe (180 mL) solution of 237582 (5.47 g, 18.1 mmol, 2.5 equiv) in a 3-neck 500-mL round-
bottom flask outfitted with a reflux condenser was heated to 102.5 ± 2.5 ºC for 90 min.  After cooling the 
reaction to rt, a PhMe (36 mL) solution of 234579 (1.00 g, 7.24 mmol, 1 equiv) was added.  The resulting 
deep red solution was heated to 102.5 ± 2.5 ºC for 90 min, cooled to rt, and concentrated in vacuo to a 
dark red oil.  Flash column chromatography (500 mL SiO2, 95:5 → 9:1 → 8:2 hexane:EtOAc) afforded 
1.70 g (6.50 mmol, 90% yield) of 238 as an orange oil. 
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Ethyl 2,2-dibromo-5-methylhex-4-enoate (243): 
A THF (5.5 mL) solution of 280601 (3.01 g, 19.3 mmol, 1 equiv) was added dropwise to a freshly prepared 
THF solution of lithium diisopropylamide (0.30 M, 66 mL, 20. mmol, 1.05 equiv) cooled to –78 ºC in a 
200-mL recovery flask.  After stirring for 25 min at –78 ºC, 1,2-dibromo-1,1,2,2-tetrafluoroethane (3.5 
mL, 29 mmol, 1.5 equiv) was added.  The resulting black-brown solution was stirred at –78 ºC for 30 min 
and subsequently quenched by pouring onto sat. aq. NaHCO3.  The mixture was extracted thrice with 
hexane.  The organic extracts were combined, washed with H2O and brine, dried over MgSO4, filtered, 
and concentrated in vacuo to a yellow oil.  Short-path distillation (6 mmHg, 56-58 ºC) afforded 2.25 g 
(9.57 mmol) of a mono-brominated intermediate.  A THF (2.8 mL) solution of this intermediate (2.22 g, 
9.44 mmol, 1 equiv) was added dropwise to a freshly prepared THF solution of lithium diisopropylamide 
(0.30 M, 34 mL, 9.9 mmol, 1.05 equiv) cooled to –78 ºC in a 100-mL recovery flask.  After stirring for 25 
min at –78 ºC, 1,2-dibromo-1,1,2,2-tetrafluoroethane (1.7 mL, 14.2 mmol, 1.5 equiv) was added.  The 
pale yellow solution was stirred at –78 ºC for 30 min and subsequently quenched by pouring onto sat. aq. 
NaHCO3.  The mixture was extracted thrice with hexane.  The organic extracts were combined, washed 
with H2O and brine, dried over MgSO4, filtered, and concentrated in vacuo to a brown oil.  Short-path 
distillation (6 mmHg, 80-85 ºC) afforded 1.74 g (5.54 mmol, 29% yield over 2 steps) of 243 as a colorless 
oil.   
1H NMR (600 MHz; CDCl3) δ: 5.24 (t, J = 7.0 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 3.31 (d, J = 7.0 Hz, 
2H), 1.75 (s, 3H), 1.68 (s, 3H), 1.35 (t, J = 7.1 Hz, 3H). 
13C NMR (125 MHz; CDCl3) δ: 166.4, 137.9, 118.7, 64.0, 60.5, 46.0, 26.2, 18.9, 14.0. 
FTIR (thin film) νmax: 2980, 2932, 2914, 1733, 1445, 1298, 1222, 1177, 1029, 1014, 859, 793, 628 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C9H14Br2O2, 336.9226; found, 336.9233.  
                                                      
601 Cermak, D. M.; Wiemer, D. F.; Lewis, K.; Hohl, R. J. Bioorg. Med. Chem. 2000, 8, 2729-2737. 
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TLC Rf = 0.53 (9:1 hexane:EtOAc). 
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A THF (1 mL) solution of 243 (96 mg, 0.31 mmol, 1 equiv) in a 10-mL recovery flask was cooled to –78 
ºC and treated with a pentane solution of tert-butyllithium (1.70 M, 0.72 mL, 12 mmol, 4 equiv) dropwise 
over 7 min.  The yellow solution was stirred at –78 ºC for 90 min, and then slowly warmed from 0 ºC to 
rt.  After 4 hours, 238 (80.0 mg, 0.306 mmol, 1 equiv) was added at rt.  After stirring at rt for 14 h, the 
reaction was quenched by pouring onto sat. aq. NH4Cl and extracted thrice with Et2O.  The organic 
extracts were combined, washed with H2O and brine, dried over Na2SO4, filtered, and concentrated in 
vacuo to a viscous orange-red oil.  Flash column chromatography (100 mL SiO2, 95:5 → 9:1 → 8:2 → 
1:1 hexane:EtOAc) afforded 9 mg (0.02 mmol, 8% yield) of 244 as a pale yellow oil and 10. mg (0.038 
mmol, 12% yield) of 245 as a pale yellow oil.  
2-(4-Ethoxy-3,5-bis(3-methylbut-2-en-1-yl)-2-oxo-2H-pyran-6-yl)-3,3-dimethylbutanenitrile (244): 
1H NMR (600 MHz; CDCl3) δ: 5.17 (t, J = 6.7 Hz, 1H), 4.98 (t, J = 6.5 Hz, 1H), 3.96 (dd, J = 7.0, 1.9 
Hz, 1H), 3.94 (dd, J = 7.0, 1.9 Hz, 1H), 3.63 (s, 1H), 3.17 (d, J = 6.7 Hz, 2H), 3.13 (dd, J = 16.3, 6.5 Hz, 
1H), 2.98 (dd, J = 16.3, 6.5 Hz, 1H), 1.73 (s, 9H), 1.70 (s, 3H), 1.39 (t, J = 7.0 Hz, 3H), 1.17 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 165.9, 163.8, 150.9, 134.0, 133.6, 121.1, 120.5, 117.2, 116.9, 116.4, 
70.7, 43.5, 36.3, 28.3, 25.91, 25.77, 24.6, 24.0, 18.27, 18.21, 15.8. 
FTIR (thin film) νmax: 2969, 2931, 2242, 1720, 1639, 1562, 1445, 1375, 1204, 1063, 1022 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C23H33NO3, 372.2533; found, 372.2524.  
TLC Rf = 0.24 (8:2 hexane:EtOAc). 
Z-Ethyl 4-cyano-3-ethoxy-5,5-dimethyl-2-(3-methylbut-2-en-1-yl)hex-3-enoate (245): 
1H NMR (600 MHz; CDCl3) δ: 5.09 (t, J = 7.5 Hz, 1H), 4.23 (dq, J = 10.8, 7.1 Hz, 1H), 4.18 (dq, J = 
10.8, 7.1 Hz, 1H), 4.03-3.92 (m, 2H), 3.76 (dq, J = 8.9, 7.0 Hz, 1H), 2.71 (dt, J = 14.3, 6.7 Hz, 1H), 2.44 
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(dt, J = 14.3, 8.9 Hz, 1H), 1.70 (s, 3H), 1.64 (s, 3H), 1.31 (t, J = 7.0 Hz, 3H), 1.28 (t, J = 7.1 Hz, 3H), 
1.23 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 171.2, 165.8, 134.9, 120.10, 119.99, 108.6, 65.8, 61.7, 49.6, 33.1, 29.9, 
27.6, 25.9, 18.0, 15.4, 14.3. 
FTIR (thin film) νmax: 2967, 2929, 2872, 2202, 1734, 1600, 1445, 1365, 1296, 1207, 1148, 1030 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C18H29NO3, 308.2220; found, 308.2218.  
TLC Rf = 0.36 (8:2 hexane:EtOAc). 
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1-Methoxy-5-methylhex-4-en-1-yne (246): 
A THF (120 mL) solution of methanol (2.5 mL, 61 mmol, 1 equiv) was added via cannula over 15 min to 
a THF (120 mL) slurry of freshly washed potassium hydride (4.91 g, 122 mmol, 2 equiv) in a 500-mL 
round-bottom flask.  After stirring at rt for 105 min, the reaction was cooled to –60 ºC, and a THF (70 
mL) solution of trichloroethylene (5.5 mL, 61 mmol, 1 equiv) was added, and the cooling bath was 
removed.  After stirring for 75 min, the reaction was cooled to –78 ºC, and a hexane solution of 
butyllithium (2.73 M, 54 mL, 150 mmol, 2.4 equiv) was added.  After slowly warming the reaction to –10 
ºC over 105 min, the reaction was cooled to –78 ºC, and a HMPA (14 mL) solution of prenyl bromide 
(7.1 mL, 61 mmol, 1 equiv) was added via cannula.  The cooling bath was then removed, and the reaction 
was stirred at rt for 4 h and was subsequently quenched with a small amount of sat. aq. NaHCO3, diluted 
with H2O, and extracted thrice with pentane.  The organic extracts were combined, washed with H2O and 
brine, dried over Na2SO4, filtered, and concentrated in vacuo to a dark brown oil.  Short-path distillation 
(6 mmHg, 54-70 ºC) afforded 4.04 g (32.5 mmol, 53% yield) of 246 as a pale yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 5.16 (t, J = 6.9 Hz, 1H), 3.81 (s, 3H), 2.80 (d, J = 6.9 Hz, 2H), 1.70 (s, 
3H), 1.61 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 132.9, 121.0, 90.7, 65.5, 35.5, 25.7, 17.8, 16.3. 
FTIR (thin film) νmax: 2965, 2927, 2857, 2281, 1449, 1376, 1241, 1172, 961, 841 cm–1. 
GCMS (m / z): [M]+ 124 (11%), 109 (90%), 69 (25%), 28 (100%).  
TLC Rf = 0.32 (99:1 hexane:EtOAc). 
OMe
MeMe
246MeOH + Cl
Cl
Cl KH, THF, rt, 105 min;247, –60 ºC to rt, 75 min;
BuLi, hexane, –78 to –10 ºC, 105 min;
prenyl bromide, HMPA, –78 ºC to rt, 4 h
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2-Ethoxy-6-hydroxy-4-methoxy-3,5-bis(3-methylbut-2-en-1-yl)benzonitrile (248): 
A xylenes (3 mL) solution of 238 (34.3 mg, 0.131 mmol, 1 equiv) and 246 (80. mg, 0.64 mmol, 5 equiv) 
was heated to 140 ºC in a 10-mL sealed tube.  After stirring at 140 ºC for 22 h, the reaction was cooled to 
rt and concentrated in vacuo to an orange oil. Flash column chromatography (100 mL SiO2, 95:5 → 9:1 
→ 8:2 hexane:EtOAc) followed by preparatory thin-layer chromatography (2 × 99:1 hexane:EtOAc) 
afforded 11 mg (0.033 mmol, 25% yield) of 248 as a white residue. 
1H NMR (600 MHz; CDCl3) δ: 6.08 (br s, 1H), 5.21 (t, J = 7.0 Hz, 1H), 5.10 (t, J = 6.7 Hz, 1H), 4.16 (q, 
J = 7.0 Hz, 2H), 3.71 (s, 3H), 3.38 (d, J = 7.0 Hz, 2H), 3.27 (d, J = 6.7 Hz, 2H), 1.83 (s, 3H), 1.77 (s, 3H), 
1.76 (s, 3H), 1.68 (s, 3H), 1.44 (t, J = 7.0 Hz, 3H). 
13C NMR (125 MHz; CDCl3) δ: 161.9, 159.5, 157.4, 136.7, 132.0, 123.2, 122.0, 121.2, 116.7, 114.9, 
92.0, 71.2, 62.0, 26.03, 25.90, 23.61, 23.49, 18.19, 18.13, 15.9. 
 
Key 1D nOe correlations. 
FTIR (thin film) νmax: 3363 (br), 2978, 2930, 2226, 1597, 1579, 1445, 1385, 1097 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C20H27NO3, 330.2064; found, 330.2055.  
TLC Rf = 0.75 (95:5 hexane:EtOAc). 
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E-2-Cyano-3-ethoxy-5-methoxy-4,6-bis(3-methylbut-2-en-1-yl)phenyl 4-cyano-3-ethoxy-5,5-
dimethyl-2-(3-methylbut-2-en-1-yl)hex-3-enoate (253): 
A xylenes (1 mL) solution of 238 (12 mg, 0.046 mmol), 246 (28.5 mg, 0.230 mmol, 5 equiv), and 
Hünig’s base (~1 mg, 0.01 mmol, 0.2 equiv) was sparged with N2 for 5 min in a 10-mL sealed tube and 
subsequently heated to 140 ºC.  After stirring for 8.5 h at 140 ºC, the reaction was cooled to rt and 
concentrated in vacuo.  Flash column chromatography (25 mL SiO2, 98:2 → 9:1 hexane:EtOAc) afforded 
3.4 mg (0.010 mmol, 22% yield) of 248 as a white residue and 10.5 mg (0.018 mmol, 78% yield) of 253 
as a colorless residue. 
1H NMR (600 MHz; CDCl3) δ: 5.14 (t, J = 7.3 Hz, 1H), 5.10 (t, J = 6.4 Hz, 1H), 5.02 (t, J = 5.8 Hz, 1H), 
4.27 (dd, J = 9.0, 6.0 Hz, 1H), 4.21-4.16 (m, 3H), 4.08-4.05 (m, 1H), 3.73 (s, 3H), 3.33 (d, J = 6.4 Hz, 
2H), 3.26 (d, J = 5.8 Hz, 2H), 2.82 (m, 1H), 2.66 (m, 1H), 1.76 (s, 3H), 1.74 (s, 3H), 1.72 (s, 3H), 1.71-
1.69 (s, 9H), 1.44 (t, J = 7.0 Hz, 3H), 1.36 (t, J = 6.9 Hz, 3H), 1.26 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 169.0, 164.2, 162.4, 160.0, 150.1, 135.6, 133.5, 132.6, 128.4, 125.5, 
122.4, 121.5, 119.7, 119.5, 114.3, 109.8, 79.4, 71.5, 67.1, 62.1, 49.8, 33.4, 29.9, 27.7, 25.95, 25.86, 25.80, 
24.1, 23.8, 18.28, 18.17, 18.11, 15.9, 15.3. 
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Key 1D nOe correlation. 
FTIR (thin film) νmax: 2961, 2923, 2854, 2229, 2203, 1769, 1599, 1440, 1385, 1099 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C36H50N2O5, 613.3612; found, 613.3611. 
TLC Rf = 0.48 (8:2 hexane:EtOAc). 
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4-(3-Methoxyprop-2-yn-1-yl)-3,3-dimethyl-2,2-diphenyloxetane (254): 
A PhH (3 mL) solution of 238 (40. mg, 0.15 mmol, 1 equiv), 246 (95 mg, 0.77 mmol, 5 equiv), and 
benzophenone (9 mg, 0.05 mmol, 0.3 equiv) in a 10-mL borosilicate test tube placed in a continuous flow 
H2O bath was irradiated with quartz-filtered light for 22 h.  The reaction was then concentrated in vacuo 
to an orange-yellow oil.  Flash column chromatography (30 mL SiO2, 95:5 hexane:EtOAc) afforded 4.3 
mg (0.014 mmol, 28% yield) of 254 as a white flocculent solid. 
1H NMR (600 MHz; CDCl3) δ: 7.58 (dd, J = 8.5, 1.2 Hz, 2H), 7.43 (dd, J = 8.4, 1.2 Hz, 2H), 7.33-7.27 
(m, 4H), 7.20-7.15 (m, 2H), 4.44 (dd, J = 9.2, 5.6 Hz, 1H), 3.79 (s, 3H), 2.51 (dd, J = 16.1, 5.6 Hz, 1H), 
2.40 (dd, J = 16.1, 9.2 Hz, 1H), 1.15 (s, 3H), 1.12 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 145.1, 144.2, 128.2, 127.9, 126.69, 126.54, 125.8, 125.2, 92.2, 91.3, 
84.2, 65.5, 46.0, 31.9, 26.6, 20.9, 20.5. 
FTIR (thin film) νmax: 3058, 3025, 2972, 2943, 2275, 1449, 1239, 995, 959, 709 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C21H22O2, 307.1693; found, 307.1697.  
TLC Rf = 0.51 (8:2 hexane:EtOAc). 
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2-Ethoxy-4-hydroxy-6-methoxy-3,5-bis(3-methylbut-2-en-1-yl)benzonitrile (255): 
A PhMe (3 mL) solution of 238 (40. mg, 0.15 mmol, 1 equiv), 246 (95 mg, 0.77 mmol, 5 equiv), and 2,6-
di-tert-butyl-4-methylphenol (7 mg, 0.03 mmol, 0.2 equiv) was heated to 140 ºC in a 10-mL sealed tube.  
After stirring at 140 ºC for 12 h, the reaction was cooled to rt and concentrated in vacuo to an orange oil.  
Flash column chromatography (30 mL SiO2, 95:5 hexane:EtOAc) followed by preparatory thin-layer 
chromatography (1 × 98:2 CH2Cl2:Et2O) afforded 3 mg (9 µmol, 6% yield) of 255 as a colorless residue. 
1H NMR (600 MHz; CDCl3) δ: 6.11 (s, 1H), 5.17-5.14 (m, 2H), 4.11 (q, J = 7.0 Hz, 2H), 3.94-3.92 (m, 
3H), 3.37-3.33 (m, 4H), 1.80 (s, 6H), 1.75 (s, 3H), 1.74 (s, 3H), 1.44 (t, J = 7.0 Hz, 3H). 
13C NMR (125 MHz; CDCl3) δ: 160.2, 159.3, 135.5, 135.1, 121.47, 121.42, 117.73, 117.59, 115.5, 93.4, 
71.5, 62.5, 26.0, 23.20, 23.03, 18.18, 18.15, 15.9. 
FTIR (thin film) νmax: 3396 (br), 2979, 2928, 2225, 1586, 1438, 1389, 1178, 1097 cm–1.  
HRMS–ESI (m / z): [M+Na]+ calculated for C20H27NO3, 352.1883; found, 352.1888. 
TLC Rf = 0.68 (95:5 CH2Cl2:Et2O). 
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E-4-cyano-3-ethoxy-5-methoxy-2,6-bis(3-methylbut-2-en-1-yl)phenyl 4-cyano-3-ethoxy-5,5-
dimethyl-2-(3-methylbut-2-en-1-yl)hex-3-enoate (257): 
A PhMe (3 mL) solution of 238 (40. mg, 0.15 mmol, 1 equiv), 246 (95 mg, 0.77 mmol, 5 equiv), 2,6-di-
tert-butyl-4-methylphenol (7 mg, 0.03 mmol, 0.2 equiv), and Hünig’s base (5 µL, 0.03 mmol, 0.2 equiv) 
was heated to 140 ºC in a 10-mL sealed tube.  After stirring for 10.5 h, the reaction was cooled to rt and 
concentrated in vacuo to a brown-red oil.  Flash column chromatography (25 mL SiO2, 95:5 
hexane:EtOAc) afforded 6.3 mg (0.019 mmol, 13% yield) of 248 as a colorless residue, 2.5 mg (7.6 µmol, 
5% yield) of 255 as a colorless residue, and 19.1 mg (0.032 mmol, 42% yield) of 257 as a colorless 
residue. 
1H NMR (600 MHz; CDCl3) δ: 5.24 (t, J = 6.4 Hz, 1H), 5.11 (t, J = 6.7 Hz, 1H), 5.05 (s, 1H), 5.00 (t, J = 
6.5 Hz, 1H), 4.27-4.22 (m, 1H), 4.22-4.17 (m, 2H), 4.15-4.11 (m, 1H), 3.74 (s, 3H), 3.33 (d, J = 6.6 Hz, 
2H), 3.30-3.19 (m, 4H), 1.76 (s, 3H), 1.71 (s, 6H), 1.68 (s, 3H), 1.67 (s, 6H), 1.44 (t, J = 5.7 Hz, 3H), 1.42 
(t, J = 5.8 Hz, 3H), 1.14 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 166.5, 162.3, 160.1, 150.4, 133.8, 132.9, 132.5, 128.1, 125.2, 122.5, 
121.77, 121.63, 118.9, 114.0, 98.4, 72.0, 71.5, 62.1, 43.7, 36.3, 29.9, 28.2, 26.9, 25.88, 25.86, 25.84, 
25.80, 24.04, 23.86, 18.26, 18.22, 18.19, 15.95, 15.81. 
FTIR (thin film) νmax: 2967, 2930, 2857, 2228, 1729, 1597, 1439, 1387, 1160, 1084, 1041, 1024, 988  
cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C36H50N2O5, 613.3623; found, 613.3612.  
TLC Rf = 0.50 (8:2 hexane:EtOAc). 
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3-(tert-Butyl)-2-isopropyl-6-methoxy-5-(3-methylbut-2-en-1-yl)-4H-pyran-4-one (258): 
A xylenes (4.8 mL) solution of 206 (41 mg, 0.24 mmol, 1 equiv) and 246 (150 mg, 1.2 mmol, 5 equiv) 
was heated to 140 ºC in a 50-mL sealed tube.  After stirring at 140 ºC for 7 h, the reaction was cooled to rt 
and concentrated in vacuo.  Flash column chromatography (30 mL SiO2, 95:5 → 9:1 → 8:2 
hexane:EtOAc) followed by preparatory thin-layer chromatography (2 × 9:1 hexane:EtOAc) afforded 2.5 
mg (8.5 µmol, 4% yield) of 258 as a colorless residue.   
1H NMR (600 MHz; CDCl3) δ: 5.19 (t, J = 6.7 Hz, 1H), 3.93 (s, 3H), 3.67 (septet, J = 6.7 Hz, 1H), 3.02 
(d, J = 6.7 Hz, 2H), 1.72 (s, 3H), 1.67 (s, 3H), 1.44 (s, 9H), 1.25 (d, J = 6.8 Hz, 6H). 
13C NMR (125 MHz; CDCl3) δ: 181.5, 162.7, 161.0, 131.9, 128.3, 122.4, 103.8, 55.2, 35.1, 31.7, 30.9, 
26.0, 21.12, 21.06, 18.0. 
 
Key 1D nOe correlation. 
FTIR (thin film) νmax: 2067, 2921, 1664, 1611, 1462, 1381, 1314, 1262, 1141 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C18H28O3, 315.1931; found, 315.1945. 
TLC Rf = 0.26 (8:2 hexane:EtOAc).   
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A PhMe (5.8 mL) solution of 208566 (50. mg, 0.29 mmol, 1 equiv) and 246 (182 mg, 1.47 mmol, 5 equiv) 
in a 10-mL sealed tube was heated to 110 ºC.  After stirring for 19.5 h at 110 ºC, the reaction was cooled 
to rt and concentrated in vacuo to a yellow oil.  Flash column chromatography (30 mL SiO2, 95:5 
hexane:EtOAc) afforded 22.0 mg of an inseparable mixture of 259 and 260 (1.3:1 ratio by 1H NMR 
spectroscopy; 0.069 mmol, 25% total yield) as a colorless oil. 
FTIR (thin film) νmax:  2967, 2954, 2930, 2916, 1719, 1679, 1624, 1608, 1381, 1350, 1263, 1239 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C17H26O4, 317.1723; found, 317.1714.  
TLC Rf = 0.43 (8:2 hexane:EtOAc). 
3-(tert-Butyl)-2-ethoxy-6-methoxy-5-(3-methylbut-2-en-1-yl)-4H-pyran-4-one (259):602 
1H NMR (600 MHz; CDCl3) δ: 4.99 (t, J = 7.6 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.89 (s, 3H), 2.90 (dd, J 
= 15.5, 7.6 Hz, 1H), 2.49 (dd, J = 15.5, 7.6 Hz, 1H), 1.69 (s, 3H), 1.63 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 
1.15 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 180.6, 174.4, 171.0, 136.2, 135.2, 117.7, 73.1, 61.7, 59.6, 31.4, 28.4, 
27.9, 26.1, 18.04, 14.4. 
Ethyl 3-(tert-butyl)-2-methoxy-1-(3-methylbut-2-en-1-yl)-4-oxocyclobut-2-enecarboxylate (260):602 
1H NMR (600 MHz; CDCl3) δ: 5.15 (t, J = 7.0 Hz, 1H), 4.25 (q, J = 7.1 Hz, 2H), 3.91 (s, 3H), 3.00 (d, J 
= 7.0 Hz, 2H), 1.69 (s, 3H), 1.65 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H), 1.36 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 182.4, 158.24, 158.17, 131.9, 122.3, 111.1, 104.0, 66.1, 55.9, 33.9, 30.5, 
25.9, 21.2, 17.97, 15.0. 
                                                      
602 NMR assignments of the mixture were elucidated using heteronuclear 2D-NMR techniques.   
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S-Ethyl 2-(chlorocarbonyl)-3,3-dimethylbutanethioate (263): 
A MeCN (4 mL) solution of 262594 (813 mg, 4.06 mmol, 1 equiv) in a 20-mL scintillation vial was cooled 
to 0 ºC.  Hünig’s base (777 µL, 4.47 mmol, 1.1 equiv) followed by chlorotrimethylsilane (567 µL, 4.47 
mmol, 1.1 equiv) were added dropwise over 10 min.  After stirring an additional 10 min at 0 ºC, 
ethanethiol (316 µL, 4.26 mmol, 1.05 equiv) was added.  The resulting white slurry was warmed to 43 ºC, 
whereupon a colorless solution formed.  After stirring at 43 ºC for 4.5 h, the solution was cooled to rt, 
quenched with 0.3 M HCl, and extracted thrice with Et2O.  The organic extracts were combined and 
extracted once with sat. aq. NaHCO3.  This aqueous extract was stirred vigorously while an aqueous 10% 
HCl solution was added dropwise until the pH of the solution was < 2.  This solution was extracted thrice 
with Et2O.  These organic extracts were combined, washed with brine, dried over MgSO4, filtered, and 
concentrated to a colorless oil, which solidified upon cooling.  An Et2O (12 mL) solution of this material 
and phosphorous(V) chloride (1.46 g, 6.99 mmol, 2 equiv) in a 2-neck 25-mL round-bottom flask 
outfitted with a reflux condenser was refluxed for 2.5 h.  After cooling the solution to rt, it was transferred 
via cannula to a Schlenk filter funnel and filtered under a positive pressure of N2 followed by one Et2O 
rinse.  The filtrate was concentrated under a stream of N2 and distilled directly.  Short-path distillation (6 
mmHg, 65-70 ºC) afforded 604 mg (2.71 mmol, 77% yield over 2 steps) of 263 as a colorless oil.   
1H NMR (600 MHz; CDCl3) δ: 3.98 (s, 1H), 2.97 (m, 2H), 1.29 (t, J = 7.4 Hz, 3H), 1.15 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 191.1, 167.1, 80.5, 36.8, 28.3, 24.9, 14.5. 
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S-Ethyl 3,3-dimethyl-2-oxomethylidenebutanethioate (261): 
A PhH (3.8 mL) solution of 263 (593 mg, 2.66 mmol, 1 equiv) in a 10-mL pear-shaped flask was treated 
with triethylamine (0.74 mL, 5.3 mmol, 2 equiv), immediately causing a white precipitate to form.  After 
allowing the flask to stand for 16 h at rt, the reaction was diluted with PhH and filtered through a Schlenk 
filter funnel under a positive pressure of N2.  The pale yellow precipitate was washed twice with PhH.  
The resulting pale yellow filtrate was concentrated in vacuo.  Short-path distillation (6 mmHg, 45-50 ºC) 
afforded 195 mg (1.05 mmol, 39% yield) of 261 as a colorless oil.   
1H NMR (500 MHz; CDCl3) δ: 2.96 (q, J = 7.4 Hz, 2H), 1.28 (t, J = 7.4 Hz, 3H), 1.26 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 189.5, 110.9, 62.9, 32.8, 29.8, 23.8, 15.4. 
FTIR (thin film) νmax: 2965, 2919, 2874, 2108, 1661, 1241, 1158, 864, 773 cm–1. 
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5-(tert-Butyl)-6-(ethylthio)-4-methoxy-3-(3-methylbut-2-en-1-yl)-2H-pyran-2-one (264): 
A PhMe (3.2 mL) solution of 261 (30. mg, 0.16 mmol, 1 equiv) and 246 (100 mg, 0.81 mmol, 5 equiv) 
was heated to 110 ºC in a 10-mL sealed tube.  After stirring at 110 ºC for 11 h, the reaction was cooled to 
rt and concentrated in vacuo.  Flash column chromatography (30 mL SiO2, 95:5 hexane:EtOAc) afforded 
19.0 mg (0.061 mmol, 38% yield) of 264 as a colorless residue.   
1H NMR (600 MHz; CDCl3) δ: 5.04 (t, J = 6.2 Hz, 1H), 3.65 (s, 3H), 3.07 (m, 4H), 1.71 (s, 3H), 1.70 (s, 
3H), 1.40 (s, 9H), 1.35 (t, J = 7.4 Hz, 3H). 
13C NMR (125 MHz; CDCl3) δ: 168.0, 163.9, 155.9, 133.3, 121.6, 120.0, 115.2, 62.3, 35.7, 30.4, 25.8, 
25.2, 18.3, 15.5. 
 
Key 1D nOe correlations. 
FTIR (thin film) νmax: 2964, 2930, 1717, 1597, 1509, 1343, 1118, 1008, 942 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C17H26O3S, 333.1495; found, 333.1497. 
TLC Rf = 0.30 (9:1 hexane:EtOAc).  
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A PhH (2 mL) solution of 238 (171 mg, 0.65 mmol, 1 equiv) and 265597 (100. mg, 0.65 mmol, 1 equiv) 
was stirred at rt in a sealed tube for 9.5 h.  The reaction was then heated to 40 ºC for 1 d.  The reaction 
was subsequently cooled to rt and concentrated in vacuo to a red oil.  Flash column chromatography (100 
mL SiO2, 95:5 → 9:1 → 8:2 hexane:EtOAc) afforded 32 mg (0.077 mmol, 12% yield) of 266 as a pale 
yellow oil and 183 mg (0.44 mmol, 68% yield) of 267 as a pale yellow oil.   
E-2-((3-Butyl-2-(diethylamino)-1-(3-methylbut-2-en-1-yl)-4-oxocyclobut-2-en-1-
yl)(ethoxy)methylene)-3,3-dimethylbutanenitrile (266): 
1H NMR (600 MHz; CDCl3) δ: 4.97 (t, J = 7.2 Hz, 1H), 4.58 (dq, J = 10.0, 7.1 Hz, 1H), 3.61-3.53 (m, 
2H), 3.28-3.21 (m, 3H), 2.64 (dd, J = 15.9, 7.2 Hz, 1H), 2.31 (dd, J = 15.9, 7.2 Hz, 1H), 2.19-2.10 (m, 
2H), 1.66 (s, 3H), 1.62 (s, 3H), 1.57 (m, 2H), 1.36 (m, J = 2.9 Hz, 2H), 1.32 (t, J = 7.1 Hz, 3H), 1.25 (s, 
9H), 1.22 (m, 6H), 0.90 (t, J = 7.4 Hz, 3H). 
13C NMR (125 MHz; CDCl3) δ: 180.8, 168.9, 165.0, 134.7, 118.64, 118.57, 117.9, 110.3, 72.0, 67.8, 
45.9, 42.6, 35.3, 31.1, 30.9, 27.4, 26.2, 23.7, 22.9, 18.4, 14.9, 14.1, 13.8, 12.7. 
 
Key 1D nOe correlations. 
HRMS–ESI (m / z): [M+Na]+ calculated for C26H42N2O2, 437.3139; found, 437.3150.  
FTIR (thin film) νmax: 2962, 2933, 2873, 2198, 1744, 1586, 1451 cm–1. 
TLC Rf = 0.51 (8:2 hexane:EtOAc). 
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E-2-Butyl-6-cyano-5-ethoxy-N,N-diethyl-7,7-dimethyl-4-(3-methylbut-2-en-1-yl)octa-2,3,5-
trienamide (267): 
1H NMR (500 MHz; CDCl3) δ: 5.14 (t, J = 7.3 Hz, 1H), 3.89-3.79 (m, 2H), 3.39-3.28 (m, 4H), 2.90 (dd, J 
= 16.1, 7.3 Hz, 1H), 2.81 (dd, J = 16.1, 7.3 Hz, 1H), 2.38-2.30 (m, 2H), 1.66 (s, 3H), 1.58 (s, 3H), 1.43-
1.38 (m, 2H), 1.36-1.28 (m, 2H), 1.22 (t, J = 7.1 Hz, 3H), 1.15 (s, 9H), 1.07 (t, J = 7.1 Hz, 6H), 0.85 (t, J 
= 7.2 Hz, 3H). 
13C NMR (125 MHz; CDCl3) δ: 200.4, 166.3, 163.7, 135.0, 119.46, 119.33, 104.7, 103.6, 100.9, 65.8, 
42.8 (br), 39.5 (br), 33.0, 30.8, 30.59, 30.47, 29.8, 25.8, 22.4, 17.9, 15.3, 14.6 (br), 13.9, 12.9 (br). 
 
Key 1D nOe correlations. 
FTIR (thin film) νmax: 2967, 2934, 2873, 2201, 1959, 1633, 1595, 1458, 1429, 1274, 1220, 739 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C26H42N2O2, 415.3319; found, 415.3321.  
TLC Rf = 0.31 (8:2 hexane:EtOAc). 
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3-Butyl-4-(diethylamino)-6-ethoxy-2-hydroxy-5-(3-methylbut-2-en-1-yl)benzonitrile (272): 
A PhH (1 mL) solution of 266 (6.0 mg, 14 µmol) was heated to 140 ºC for 15 min in a 10-mL sealed tube.  
The reaction was subsequently cooled to rt and concentrated in vacuo to an orange oil.  Preparatory thin-
layer chromatography (1 × 98:2 hexane:EtOAc) afforded 2.4 mg (6.7 µmol, 48% yield) of 272 as a pale 
yellow oil and 1.6 mg (3.9 µmol, 27% recovery) of 266 as a pale yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 5.39 (br s, 1H), 4.99 (t, J = 6.1 Hz, 1H), 4.12 (q, J = 7.0 Hz, 2H), 3.30 (d, 
J = 6.1 Hz, 2H), 3.06 (q, J = 7.1 Hz, 4H), 2.61-2.58 (m, 2H), 1.73 (s, 3H), 1.67 (s, 3H), 1.52-1.46 (m, 
3H), 1.44-1.40 (m, 5H), 1.02 (t, J = 7.1 Hz, 6H), 0.96 (t, J = 7.2 Hz, 3H). 
13C NMR (125 MHz; CDCl3) δ: 155.8, 155.5, 154.6, 131.0, 128.9, 126.2, 124.3, 115.5, 91.4, 70.8, 48.4, 
31.5, 26.7, 25.84, 25.73, 23.8, 18.3, 15.9, 14.8, 14.2. 
FTIR (thin film) νmax: 3323 (br), 2965, 2929, 2855, 2228, 1592, 1556, 1447, 1378, 1119 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C22H34N2O2, 381.2512; found, 381.2505.  
TLC Rf = 0.65 (95:5 hexane:EtOAc). 
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Z-2-((3-Butyl-2-(diethylamino)-1-(3-methylbut-2-en-1-yl)-4-oxocyclobut-2-en-1-
yl)(ethoxy)methylene)-3,3-dimethylbutanenitrile (273): 
A PhH (1 mL) solution of 266 (5.0 mg, 12 µmol) in a 12-mL quartz test tube was irradiated in a 
continuous flow rt H2O bath for 4 h.  The reaction was then concentrated in vacuo to an orange-yellow 
oil.  Preparatory thin-layer chromatography (1 × 95:5 hexane:EtOAc → 1 × 9:1 hexane:EtOAc) afforded 
1.3 mg (3.1 µmol, 26% yield) of 273 as a pale yellow residue and 1.6 mg (3.9 µmol, 32% recovery) of 
266 as a pale yellow residue.   
1H NMR (600 MHz; CDCl3) δ: 5.01 (t, J = 7.0 Hz, 1H), 4.24 (dq, J = 9.0, 7.0 Hz, 1H), 3.84 (dq, J = 9.0, 
7.0 Hz, 1H), 3.38 (m, 2H), 3.23-3.18 (m, 2H), 3.03 (dd, J = 15.6, 7.0 Hz, 1H), 2.44 (dd, J = 15.6, 7.0 Hz, 
1H), 2.16-2.05 (m, 2H), 1.67 (s, 3H), 1.61 (s, 3H), 1.52-1.45 (m, 2H), 1.42 (s, 9H), 1.37-1.32 (m, 2H), 
1.30-1.28 (m, 3H), 1.23-1.18 (m, 6H), 0.90 (t, J = 7.3 Hz, 3H). 
13C NMR (125 MHz; CDCl3) δ: 179.7, 171.4, 165.9, 134.8, 118.7, 115.9, 114.1, 110.2, 74.6, 73.5, 46.3, 
42.0, 33.5, 32.16, 32.12, 31.94, 26.1, 23.5, 22.9, 18.6, 16.0, 14.3, 14.1, 13.5. 
FTIR (thin film) νmax: 2959, 2926, 2854, 2207, 1736, 1591, 1459, 1377 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C26H42N2O2, 415.3319; found, 415.3307.  
TLC Rf = 0.37 (8:2 hexane:EtOAc). 
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4-(tert-Butyl)-4-chloro-3-methoxy-2-(3-methylbut-2-en-1-yl)cyclobut-2-enone (276): 
A PhH (5 mL) solution of 275 (500 mg, 2.96 mmol 1 equiv) was added dropwise via cannula to a PhH 
(20 mL) solution of triethylamine (412 µL, 2.96 mmol, 1 equiv) and 246 (771 mg, 6.21 mmol, 2.1 equiv) 
in a 50-mL recovery flask.  The resulting yellow solution was stirred at rt for 80 min.  A reflux condenser 
was then attached to the recovery flask, and the reaction was refluxed for 90 min.  The reaction was then 
cooled to rt and concentrated in vacuo to a red-orange oil.  This oil was taken up in 9:1 hexane:EtOAc 
and filtered to remove an off-white solid.  The filtrate was concentrated in vacuo to a red-orange oil.  
Flash column chromatography (100 mL SiO2, 95:5 → 9:1 hexane:EtOAc) afforded 209 mg (0.81 mmol, 
27% yield) of 276 as a pale yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 5.04 (t, J = 7.0 Hz, 1H), 4.09 (s, 3H), 2.86-2.78 (m, 2H), 1.61 (s, 3H), 
1.56 (s, 3H), 1.02 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 185.7, 178.7, 133.9, 124.2, 119.4, 89.9, 60.3, 36.6, 26.3, 25.5, 21.4, 17.8. 
FTIR (thin film) νmax: 2974, 1771, 1622, 1457, 1356, 1258, 991 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C14H21ClO2, 257.1303; found, 257.1314.  
TLC Rf = 0.18 (95:5 hexane:EtOAc). 
t-Bu
Cl
Cl
O
+
OMe
MeMe
246
MeO
OMe
Me
t-Bu
Cl275
276
NEt3, PhH, rt, 80 min;
reflux, 90 min
(27%)
189
 190 
 
2-(tert-Butyl)-4-chloro-3-methoxy-4-(3-methylbut-2-en-1-yl)cyclobut-2-enone (277): 
A PhMe (3 mL) solution of 276 (50. mg, 0.19 mmol, 1 equiv) and 246 (48 mg, 0.39 mmol, 2 equiv) was 
heated to 140 ºC in a 10-mL sealed tube.  After stirring at 140 ºC for 18.5 h, the reaction was cooled to rt 
and concentrated in vacuo to a yellow-orange oil.  Flash column chromatography (30 mL SiO2, 95:5 → 
9:1 hexane:EtOAc) afforded 24 mg (0.094 mmol, 49% yield) of 277 as a pale yellow oil along with 8 mg 
(0.03 mmol, 16% recovery) of 276 as a pale yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 4.99 (t, J = 7.5 Hz, 1H), 4.15 (s, 3H), 3.02 (dd, J = 15.5, 7.5 Hz, 1H), 
2.71 (dd, J = 15.5, 7.5 Hz, 1H), 1.69 (s, 3H), 1.64 (s, 3H), 1.14 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 183.2, 176.3, 137.1, 135.3, 117.4, 82.1, 59.2, 35.7, 31.3, 28.1, 26.0, 18.1. 
FTIR (thin film) νmax: 2967, 2870, 1769, 1624, 1480, 1459, 1356 cm–1.  
HRMS–ESI (m / z): [M+H]+ calculated for C14H21ClO2, 257.1303; found, 257.1302.  
TLC Rf = 0.44 (9:1 hexane:EtOAc). 
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Chapter 3  
Total Synthesis of Hyperforin
191
 192 
Synthesis Overview 
Given the inability of prior strategies to construct model systems resembling the core of 
hyperforin, we pursued an alternative strategy that addressed previously experienced shortcomings.  One 
particular difficulty we encountered was the cyclization to form the phloroglucinol-derived carbocycle 
component of the bicyclo[3.3.1]nonane core of hyperforin.  As previously elaborated, these cyclization 
strategies often afforded heterocyclic rings, such as pyrones.  Further, when such a carbocycle was 
constructed, a very favorable elimination of a tert-butyl group was observed, producing a very stable 
aromatic product.  Given the difficulties with pursuing an intermediate such as alkyl halide 200, which 
involves strategic cleavage of the C5–C6 bond of hyperforin (1), we elected to pursue an alternative 
strategy involving cleavage of the extremely hindered C1–C8 bond (Scheme 3.1).  At first glance, such an 
approach would not take advantage of latent symmetry elements that would potentially shorten the 
synthesis sequence, considering that the C5 position of 281 is stereogenic owing to differential 
substitution at C1 and at C3.  In addition, a nucleophilic displacement strategy would not be feasible, 
considering the hindered nature of the C8 position.603 
 
 
Scheme 3.1. Retrosynthetic disconnection of hyperforin at two key positions. 
 
                                                      
603 SN1-type cyclization to form the C1–C8 bond of PPAPs has been explored (see ref. 534).  When the C8 position 
contains differential substitution, as in the case of hyperforin, this cyclization mode produced a 1:1 mixture of 
diastereomers at the C8 position.   
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To reconcile these challenges, we developed a new synthesis strategy for hyperforin (Scheme 
3.2a).  In order to engender prostereogenicity at the key C5 position during a key cyclization event, the 
C1 isopropyl ketone and the C3 prenyl group were removed to afford intermediate 282.  These 
substituents may be installed late in the synthesis sequence via precendented bridgehead acylation and 
metalation-prenylation protocols, respectively.604 In addition, the C7 prenyl group was replaced with an 
alcohol functionality.  This functional group exchange in 282 facilitates a mechanistic development of a 
transform, whereby the C7 alcohol would form an epoxide with the C8 position.  The formation of the 
C1–C8 bond would now be reduced to a 6-endo-tet epoxide-opening cyclization reaction of 283, a 
reaction that has been utilized previously to form carbon-carbon bonds at hindered positions.605 
 
                                                      
604 For examples of PPAP total syntheses that employ these reactions at a late stage, see refs. 510 and 527. 
 
605 For examples of 6-endo-tet carbocyclization reactions that open epoxides at a tertiary position, see: (a) 
Armstrong, R. J.; Weiler, L. Can. J. Chem. 1986, 64, 584-596. (b) Pettersson, L.; Magnusson, G.; Frejd, T. Acta 
Chem. Scand. 1993, 47, 196-207. (c) Nakada, M.; Kojima, E.-i.; Iwata, Y. Tetrahedron Lett. 1998, 39, 313-316. (d) 
Beszant, S.; Giannini, E.; Zanoni, G.; Vidari, G. Tetrahedron: Asymmetry 2002, 13, 1245-1255. (e) Tong, R.; 
Valentine, J. C.; McDonald, F. E.; Cao, R.; Fang, X.; Hardcastle, K. I. J. Am. Chem. Soc. 2007, 129, 1050-1051. (f) 
Boone, M. A.; Tong, R.; McDonald, F. E.; Lense, S.; Cao, R.; Hardcastle, K. I. J. Am. Chem. Soc. 2010, 132, 5300-
5308. 
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Scheme 3.2. (a) Retrosynthesis of hyperforin involving C1–C8 bond cleavage and (b) transitition-state analysis of the key 
cyclization reaction. 
 
 
An analysis of this key cyclization event is depicted in Scheme 3.2b.  Owing to a plane of 
symmetry in the cyclohexadienone ring, the C5 position of 283 is prostereogenic.  During the key 
epoxide-opening cyclization involving this intermediate, two diastereotopic nucleophilic enol ethers, at 
C1 and at C3, may engage in bonding interaction with the epoxide when activated with a Lewis acid.  
Transition state 284 is favored to yield 282 over its diastereomeric transition state 285, which must adopt 
a boat-like conformation containing two severe eclipsing interactions in forming 286.  Additionally, due 
to geometric constraints of orbital overlap, a 6-(enolendo)-tet cyclization should be favored over a 5-
(enolendo)-tet cyclization.606 Ultimately, the combinations of these factors culminate in: (1) the 
construction of the bicyclo[3.3.1]nonane core of hyperforin; (2) the introduction of stereochemistry at the 
previously prostereogenic C5 position; (3) the creation of a stereogenic quaternary center at C8; and (4) 
the formation of a conformationally rigid tertiary stereogenic center at C1.  Additionally, given our 
                                                      
606 Baldwin, J. E.; Lusch, M. J. Tetrahedron 1982, 38, 2939-2947. 
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interests in creating a library of hyperforin analogs, alcohol 282 is also an ideal intermediate for 
diversification, in which a variety of groups may be appended at the C1, C3, and C7 positions.  
Dearomative Allylation Approach 
 Given the difficulties we encountered while attempting to synthesize cyclohexadienones, we 
chose a well-precedented approach to an intermediate very similar to key cyclization precursor 283.  A 
Sharpless epoxidation of geraniol607 (287) afforded (S,S)-2,3-epoxygeraniol (288) in 91% ee, which upon 
mesylation and Finkelstein bromination gave epoxygeranyl bromide 289 (Scheme 3.3).608 Large 
quantities of 289 (120-130 g per batch of material) were processed through this three-step protocol, which 
involved only a single distillation and no silica gel chromatography.  Regioselective lithiation of 
phloroglucinol triether 146528 followed by coupling with 289 afforded alkylation product 290.  After 
desilylation to reveal phenol 291, a Pd- and Ti-catalyzed dearomative allylation reaction, using a protocol 
developed for the total synthesis of (±)-garsubellin A by Danishefsky,527,529 produced cyclohexadienone 
292.  This allylation was highly regioselective, and only trace amounts of aromatic allylation products 
were observed.  
 
                                                      
607 Hanson, R. M.; Sharpless, K. B. J. Org. Chem. 1986, 51, 1922-1925. 
 
608 Gash, R. C.; MacCorquodale, F.; Walton, J. C. Tetrahedron 1989, 45, 5531-5538. 
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Scheme 3.3. Synthesis of cyclization precursor 292.a 
a Conditions: (a) Ti(Oi-Pr)4, L-(+)-DET, TBHP, 4Å MS, CH2Cl2, –30 to –10 ºC, 92%, 91% ee; (b) MsCl, NEt3, CH2Cl2, 0 ºC, 
97%; (c) LiBr, acetone, reflux, 94%; (d) BuLi, THF, 0 ºC to rt; 289, 0 ºC to rt, 81%; (e) TBAF, THF, 84%; (f) Pd(OAc)2, Ti(Oi-
Pr)4, allyl methyl carbonate, PPh3, PhH, 50 ºC, 46% (48% recovered 291). 
 
 
We then screened a variety of acids to promote the conversion of 292 to the desired cyclization 
product 293 (Table 3.1).  Unfortunately, both Lewis (entries 1-12) and Brønsted (entries 13-15) acids 
failed to produce even trace amounts of our desired product.  In many instances (entries 1, 3, 5, 6, 12, and 
14), we isolated ketone 294, the result of acid-mediated epoxide-ketone rearrangement (Figure 3.1).  In 
other cases (entries 2, 10, and 13), acid activation of the epoxide promoted elimination to form allylic 
alcohols and allylic silyl ethers, such as 295, 296, 297, and 298.609 Byproducts 299 and 300 originated 
from exogenous nucleophilic opening of the epoxide (entries 5 and 15).  The only cyclization product 
observed was cyclopentanol 301 (entry 7), the result of 5-exo-tet opening of the epoxide by the pendant 
homoprenyl sidechain in 292. 
                                                      
609 These byproducts were not rigorously characterized; we surmised the structure of these compounds via 
comparison to 292 as well as spectroscopic analysis of reaction mixtures.   
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Table 3.1. Attempted conversion of cyclohexadienone 292 to bicyclo[3.3.1]nonane 293. 
 
Entry  Acid  Conditions  Result  
1 TMSOTf  CH2Cl2, –78 to 0 ºC, 5 h  294, decomposition 
2 TMSOTf  DTBMP, CH2Cl2, –78 to 0 ºC, 1 d  295 and 296 are the only observed products 
3 BF3·Et2O CH2Cl2, –78 ºC to rt, 2 h  294 (43%) 
4 Et2AlCl  CH2Cl2, –78 ºC to rt, 3 d  no reaction  
5 EtAlCl2  CH2Cl2, –78 ºC to rt, 1 d  294 is the only observed product 
6 AlCl3  CH2Cl2, –78 ºC, 75 min  >99% conversion to 294 
7 TiCl4  CH2Cl2, –78 to 0 ºC, 4 h  301 is the only observed product 
8 SnCl4  CH2Cl2, –78 to –30 ºC, 5.5 h  299 is the only observed product 
9 MgBr2·Et2O CH2Cl2, –78 ºC to rt, 1 d  no reaction 
10 Sn(OTf)2  CH2Cl2, –78 ºC to rt, 1 d  297 and 298 are the only observed products 
11 Zn(OTf)2  CH2Cl2, –78 ºC to rt, 3 d  no reaction 
12 Sc(OTf)3  CH2Cl2, –78 ºC to rt, 3.5 h  >99% conversion to 294 
13 CSA CH2Cl2, –78 ºC to rt, 1 d  297 and 298 are the only observed products 
14 p-TsOH·H2O CH2Cl2, –78 ºC to rt, 1.5 h  294 is the only observed product 
15 HCl (pH 2) H2O, 0 ºC to rt, 1 d  300 is the only observed product 
 
 
 
Figure 3.1. Various byproducts formed during attempted conversion of 292 to 293. 
 
From these studies, we concluded that the cyclohexadienone did not bear sufficient nucleophilic 
character to engage the activated epoxide.  The byproducts obtained involved exogenous nucleophile 
delivery to the epoxide or even participation of the homoprenyl olefin in the formation of 301, whereas 
the cyclohexadienone portion of the molecule remained unchanged.  In order to increase the nucleophilic 
character of the enol ether functionality present in 292, we attemped to excise the carbonyl group.  While 
several attempts to form a hydrazone failed, hydride reduction of 292 afforded cyclohexadiene 302 
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(Scheme 3.4).  Gratifyingly, exposure of this compound to TMSOTf in the presence of DTBMP afforded 
cyclization product 303 as a single diastereomer in 85% yield.   
 
 
Scheme 3.4. Cascade cyclization of 302 to form 303.a 
a Conditions: (a) LAH, CH2Cl2, Et2O, 0 ºC, 44%; (b) TMSOTf, DTBMP, CH2Cl2, –78 ºC, 85%; (c) Pearlman’s catalyst, TBHP, 
Cs2CO3, O2, CH2Cl2, 0 to 4 ºC, 17%; (e) TMSOTf, CH2Cl2, –78 ºC, 52%. 
 
 
In this reaction, the stereochemistry of two key quaternary centers of hyperforin were established: 
at the previously prostereogenic C5 carbon, and at the C8 position.  In addition to the construction of the 
bicyclo[3.3.1]nonane framework, the formation of a cyclic methyl ketal bridging the C7 and C9 carbons 
was an unexpected outcome to this reaction, formed from the intramolecular interception of the C9 
oxocarbenium ion by the C7 oxygen atom in intermediate 304 (Scheme 3.4).  Nevertheless, the 
establishment of this cyclic ketal was fortuitous, safeguarding the C7 carbinol from oxidation during 
subsequent allylic oxidation to reestablish carbonyl functionality at the C2 position.  This allylic oxidation 
of 303 was accomplished using Pearlman’s catalyst and TBHP610 to furnish β-methoxyenone 305.  We 
also briefly screened several other Lewis acids for the conversion of 302 to 303; however, lower yields of 
303 were observed with BF3·Et2O and SnCl4.  Omission of DTBMP afforded ketone 306 as the only 
reaction product.  
 
                                                      
610 Yu, J.-Q.; Wu, H.-C.; Corey, E. J. Org. Lett. 2005, 7, 1415-1417. 
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Double Alkylation Approach 
Even though this route allowed us to access β-methoxyenone 305, we resolved to develop a more 
straightforward means of accessing advanced intermediates.  Over the three-step sequence beginning with 
cyclohexadienone 292 and ending with 305, a carbonyl was reduced and subsequently reintroduced.  Our 
solution involved direct, sequential coupling of a prenyl halide (307) and epoxygeranyl bromide (289) 
with 1,5-dimethoxy-1,4,-cyclohexadiene (308)611 to form cyclization precursor 309 (Scheme 3.5). 
Cyclohexadiene 308 may be synthesized from the Birch reduction of 1,3-dimethoxybenzene,612 and 
numerous examples of regioselective alkylations at the methylene proximal to the methoxy groups in 308 
have been reported.613  
 
 
Scheme 3.5. Retrosynthesis of cyclization precursor 309. 
 
For the synthesis of 309, we investigated both sequences of additions: (1) coupling of 308 with 
289 followed by alkylation with 307 and (2) coupling of 307 with 289 followed by alkylation with 289.  
Deprotonation of 308 was accomplished using t-BuLi, and subsequent trapping with bromide 289 
                                                      
611 We also briefly explored a route involving the Birch reduction of 1,3-dimethoxy-2-prenylbenzene; however, the 
conditions necessary for this reduction (i.e., Na, NH3, reflux, 12-18 h) also resulted in reduction of the prenyl olefin. 
 
612 Piers, E.; Grierson, J. R. J. Org. Chem. 1977, 42, 3755-3757.  
 
613 For examples of regioselective alkylation of 308, see: (a) Nelson, N. A.; Tamura, Y. Can. J. Chem. 1965, 43, 
1323-1328. (b) Harvey, R. G.; Pataki, J.; Lee, H. J. Org. Chem. 1986, 51, 1407-1412. (c) Pattenden, G.; Teague, S. 
J. Tetrahedron 1987, 43, 5637-5652. (d) Toth, J. E.; Hamann, P. R.; Fuchs, P. L. J. Org. Chem. 1988, 53, 4694-
4708. (e) Middleton, D. S.; Simpkins, N. S.; Begley, M. J.; Terrett, N. K. Tetrahedron 1990, 46, 545-564. (f) 
Laschat, S.; Narjes, F.; Overman, L. E. Tetrahedron 1994, 50, 347-358. (g) Mori, K.; Abe, K. Liebigs Ann. 1995, 
943-948. (h) Imamura, Y.; Takikawa, H.; Mori, K. Tetrahedron Lett. 2002, 43, 5743-5746. (i) Studer, A.; Amrein, 
S.; Schleth, F.; Schulte, T.; Walton, J. C. J. Am. Chem. Soc. 2003, 125, 5726-5733. (j) Hughes, C. C.; Trauner, D. 
Tetrahedron 2004, 60, 9675-9686.  
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afforded 310 as a single regioisomer (Scheme 3.6).  Unfortunately but not unexpectedly, deprotonation of 
this intermediate afforded bicyclo[5.1.0]octadiene 311, the product of internal trapping with concomitant 
opening of the epoxide functionality.   
 
 
Scheme 3.6. Deprotonation of 310 led to isolation of 311.a 
a Conditions: (a) t-BuLi, THF, –78 ºC; 289, –78 ºC to rt, 45%; (b) t-BuLi, THF, –78 to –30 ºC; prenyl bromide, –78 ºC to rt, 27% 
(29% recovered 310). 
 
 
Prenylation of cyclohexadiene 308 was surprisingly problematic.  Initially, alkylation of 
metalated 308 with prenyl bromide was rather unselective, providing both the desired coupling product 
312 as well as its regioisomer 313 in equal amounts (Scheme 3.7).  These regioisomers were separated by 
treatment with SiO2; exposure of unprocessed reaction mixtures facilitated the selective conversion of 313 
to the more-polar β-methoxyenones 314 and 315, while 312 remained unchanged.   
 
 
Scheme 3.7. Nonselective prenylation of cyclohexadiene 308.a 
a Conditions: (a) t-BuLi, THF, –78 ºC; HMPA, –78 ºC; prenyl bromide, –78 ºC to rt; H2O; SiO2, 44% 312. 
 
 
Even though from a practical standpoint, large quantities of 312 were readily available through 
this selective hydrolysis protocol, we resolved to improve the overall selectivity of this reaction (Table 
3.2).  In the absence of HMPA, selectivity improved marginally (entry 2).  While the addition of MgBr2 
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reversed selectivity, the addition of BaI2 improved selectivity for the formation of 313 (entries 4-5).  
Substituting t-BuLi for s-BuLi in the deprotonation step had no effect on regioselectivity (entry 5).  When 
prenyl chloride was used instead of prenyl bromide in otherwise identical conditions to entry 1, 
regioselectivity improved to 2:1 in favor of the desired regioisomer (entry 6).  Several additives were 
studied in the coupling 308 with prenyl chloride (entries 7-9): ZnCl2 afforded significant amounts of 3-
methoxycyclohex-2-enone, and while both CeCl3 and BaI2614 further improved regioselectivity, the 
former additive caused a decrease in conversion.  The method of preparing anhydrous BaI2 also had a 
significant effect on this alkylation. Anhydrous BaI2 made from drying commercially available 
BaI2·2H2O under vacuum615 afforded a 3:1 ratio of 312:313 with a 61% yield of 313 (entry 9).  Preparing 
BaI2 in situ from the reaction of barium metal with I2616 provided complete regiocontrol for the synthesis 
of 312, which was isolated in 91% yield (entry 10).   
                                                      
614 The effects of barium iodide on the regioselectivity of nucleophilic allylation has been studied: (a) Yanagisawa, 
A.; Yasue, A.; Yamamoto, H. Synlett 1993, 686-688. (b) Yanagisawa, A.; Habaue, S.; Yasue, K.; Yamamoto, H. J. 
Am. Chem. Soc. 1994, 116, 6130-6141. (c) Yanagisawa, A.; Yamada, Y.; Yamamoto, H. Synlett 1997, 1090-1092. 
(d) Van den Bossche, J.; Shin, J.; Thompson, D. H. J. Org. Chem. 2007, 72, 5005-5007. 
 
615 Yanagisawa, A.; Yasue, K.; Yamamoto, H. Org. Synth. 1997, 74, 178-186.  
 
616 Corey, E. J.; Lin, S.; Luo, G. Tetrahedron Lett. 1997, 38, 5771-5774. (b) Corey, E. J. Harvard University, 
Cambridge, MA. Personal communication, 2012. 
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Table 3.2. Prenylation of cyclohexadiene 308. 
 
Entry Metalation conditions Alkylation conditions 312:313 ratio 312 yield 
1a t-BuLi, THF, –78 ºC; HMPA prenyl–Br, –78 ºC to rt     1 : 1 44% 
2 t-BuLi, THF, –78 ºC prenyl–Br, –78 ºC to rt  1.3 : 1 37% 
3 t-BuLi, THF, –78 ºC; MgBr2 prenyl–Br, –78 ºC to rt     1 : 2.2 n.d. 
4 t-BuLi, THF, –78 ºC; BaI2 prenyl–Br, –78 ºC to rt     2 : 1 n.d. 
5 s-BuLi, THF, –78 ºC; TMEDA prenyl–Br, –78 ºC to rt     1 : 1 n.d. 
6 t-BuLi, THF, –78 ºC; HMPA  prenyl–Cl, –78 ºC to rt     2 : 1 n.d. 
7 t-BuLi, THF, –78 ºC; ZnCl2 prenyl–Cl, –78 ºC to rt              b n.d. 
8 t-BuLi, THF, –78 ºC; CeCl3  prenyl–Cl, –78 ºC to rt   2.5 : 1 c 
9 t-BuLi, THF, –78 ºC; BaI2,d  prenyl–Cl, –78 ºC to rt      3 : 1 61% 
10 t-BuLi, THF, –78 ºC; BaI2,e  prenyl–Cl, –78 to –30 ºC  >20 : 1 91% 
 
a The conditions presented in entry 1 are depicted in Scheme 3.7. 
b Afforded a 2:1 ratio of 312 to 3-methoxycyclohex-2-enone. 
c Low amount of conversion observed. 
d Anhydrous BaI2 prepared from drying BaI2·2H2O at 150 ºC at 6 mmHg pressure for 15 h. 
e Anhydrous BaI2 prepared from the reaction of Ba with I2. See experimental section for details. 
 
 
We then explored the alkylation of 312 with epoxygeranyl bromide 289 to form cyclization 
precursor 309.  Deuterium quench studies revealed that exposure to tert-butyllithium at –78 ºC did not 
lead to deprotonation of 312.  We therefore surveyed the use of several bases across a range of 
temperatures.  In general, a major byproduct during this coupling reaction was 1,3-dimethoxy-2-
prenylbenzene (316), an oxidation product of 312.  Low levels of deprotonation were observed with t-
BuLi at –45 ºC and –30 ºC, and increasing the stoichiometry of t-BuLi generally favored conversion to 
316.  Several additives, including HMPA, TMEDA, MgBr2, and BaI2 did not facilitate conversion to 309.  
The use of the lithium amide bases LDA and LiTMP did not lead to appreciable deprotonation, even 
when a solution of LDA and 312 was warmed to rt.  Similar results were observed with BuLi when 
warmed to –30 ºC.  Eventually, we discovered that optimal yields of 309 could be achieved through 
deprotonation of 312 with s-BuLi at –30 ºC followed by addition of 289 (Scheme 3.8).  If a solution of 
312 and s-BuLi was warmed above –30 ºC, significant amounts of 316 were produced. 
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Scheme 3.8. Synthesis of 309 from 312 and 289.a 
a Conditions: (a) s-BuLi, –78 to –30 ºC; 289, –78 ºC to rt, 51%. 
 
   
The subsequent cyclization of 309 afforded cyclic ketal 317 using conditions identical to the 
conversion of 302 to 303 (Scheme 3.9).  From a practical material throughput standpoint, we chose to 
replace DTBMP with 2,6-lutidine; no appreciable decline in yield was observed using the latter base, and 
it was a much easier reagent to obtain, implement, and separate from product with larger scale reactions.  
Using this new double alkylation strategy, we were able to access large quantities of 317 from 1,3-
dimethoxybenzene in 4 steps, a significant improvement from the prior approach involving dearomative 
allylation of 291.   
 
 
Scheme 3.9. Cyclization of 309 to 317.a 
a Conditions: (a) TMSOTf, DTBMP, CH2Cl2, –78 ºC, 90% or TMSOTf, 2,6-lutidine, CH2Cl2, –78 ºC, 79%. 
 
 
The next step in our synthesis sequence involved the allylic oxidation617 of 317 to β-
methoxyenone 318 (Table 3.3).  This was an exceptionally challenging transformation given the seven 
allylic sites present in 303 and the steric environment surrounding the desired oxidation site at the C2 
position.  Numerous allylic oxidation conditions were screened and can be classified into three distinct 
categories: (1) the combination of a high-valent metal species and TBHP (entries 1-22); (2) stoichiometric 
                                                      
617 For a recent review of allylic oxidations in total synthesis, see: Nakamura, A.; Nakada, M. Synthesis 2013, 45, 
1421-1451. 
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metal oxidants (entries 23-32); and (3) the combination of hypervalent iodide species and TBHP (entries 
33-65).  In many cases, we observed several byproducts, including transposed tert-butyl peroxide 319, 
enone 320, and ketone 321 (Figure 3.2).   
 
Table 3.3. Allylic oxidation of enol ether 317. 
 
Entry   Oxidants (equiv) Additives (equiv) Conditions Results 
1   Pd(OH)2/C (0.1), TBHP (5) K2CO3 (5) CH2Cl2, 4 ºC, 12 h 318 (15%) 
2   Pd(OH)2/C (0.1), TBHP (5), O2 Cs2CO3 (5) CH2Cl2, 4 ºC, 4 h 318 (16%), 320 (45%), 317 (37%) 
3   Pd(OH)2/C (0.2), TBHP (5) KOH (1.2) CH2Cl2, 4 ºC, 7 h 318 (24%), 319 (14%) 
4   Pd(OH)2/C (0.2), TBHP (5) K3PO4 (1.2) CH2Cl2, 4 ºC, 7 h low conversion to 319 
5   Pd(OH)2/C (0.2), TBHP (5) K2CO3 (5) CH2Cl2, 4 ºC, 20 h low conversion to 319 
6   Pd(OH)2/C (0.2), TBHP (5) Cs2CO3 (5) CH2Cl2/DMSO, 4 ºC, 20 h no reaction 
7   Pd(OH)2/C (1), TBHP (5) Cs2CO3 (5) CH2Cl2, 4 ºC, 3 h 318 (27%), 319 (2%), 320 (26%) 
8   Pd(OH)2/C (1), CHP (5) Cs2CO3 (5) CH2Cl2, 4 ºC, 3 h low conversion to 318 and 319 
9   Pd(OAc)2 (0.25), TBHP (5) K2CO3 (1) CH2Cl2, 4 ºC, 3 h no reaction 
10   Pd(OAc)2 (1), TBHP (excess) Cs2CO3 (1.2) MeCN, rt, 12 h 318 (5%) 
11   Pd/C (0.2), TBHP (5) Cs2CO3 (5) CH2Cl2, 4 ºC, 17 h mixture of 318 and 319 
12   NaOCl (excess), TBHP (5) none EtOAc, rt, 3 h selectively afforded 319 
13   Cr(CO)6 (0.05), TBHP (3) none PhH, 75 ºC, 17 h selectively afforded 320 
14   PDC (2), TBHP (2) none PhH, 0 ºC to rt, 5 h 318 (14%), 320 (37%) 
15   Mn(OAc)3 (0.1), TBHP (4) K2CO3 (0.5) EtOAc, rt, 3.5 h 318 (11%) 
16   FeCl2·4H2O (2), TBHP (3) none MeCN, rt, 10 min selectively afforded 321 
17   NiCl2·6H2O (0.5), TBHP (5) Cs2CO3 (5) CH2Cl2, 4 ºC, 17 h no reaction 
18   CuI (0.1), TBHP (10) none MeCN, 55 ºC, 16 h selectively afforded 319 
19   SeO2 (1), TBHP (4) none CH2Cl2, rt, 14 h decomposition 
20   RuCl3 (0.1), TBHP (10) none c-Hex, rt, 16 h low conversion to 318, 319, and 320 
21   Rh2(cap)4 (0.1), TBHP (5) K2CO3 (0.5) CH2Cl2, rt, 12h decomposition 
22   CAN (2), TBHP (5) none MeCN, rt, 10 min 321 (29%) 
23   DDQ (2) none wet acetone, rt, 9 h selectively afforded 321 
24   TEMPO (2.2), s-BuLi (1.1) none THF, –78 ºC to rt, 12 h no reaction 
25   PDC (20) none PhH, rt, 30 h very low conversion to 320 
26   CrO3·DMP (20) none CH2Cl2, 0 ºC, 5 h decomposition 
27   (PhSe)2 (2), PhIO2 (10) pyr (100), 4Å MS PhCl, 110 ºC, 14 h decomposition 
28   CAN (2) none MeCN/H2O, rt, 15 min mixture of 320 and 321 
29   CAN (2) NEt3 (5) MeCN/DMSO, rt, 3 d no reaction 
30   CAN (2), O2 none MeCN, rt, 10 min selectively afforded 321 
31   CAN (2), TEMPO (4) none MeCN, rt, 20 h decomposition 
32   CAN (2), pyridine N-oxide (3) none MeCN, rt, 1.5 h selectively afforded 320 
33   PhIO (3), TBHP (4) K2CO3 (0.5) pentOAc, 4 ºC, 20 h mixture of 318, 320, and 321 
34   PhIO (3), TBHP (4) Cs2CO3 (4) EtOAc, 4 ºC, 14 h mixture of 318, 320, and 321 
35   PhI(OAc)2 (3), TBHP (4) K2CO3 (0.5) EtOAc, 4 ºC, 3.5 h 318 (14%) 
36   PhI(OAc)2 (3), TBHP (4) K2CO3 (0.5) EtOAc, 4 ºC, 12 h 318 (11%) 
37   PhI(OAc)2 (3), TBHP (4) K2CO3 (0.5) pentOAc, 4 ºC, 10 h 318 (13%), 320 (25%) 
38   PhI(OAc)2 (3), TBHP (4) K2CO3 (0.5) PrCO2Bu, 4 ºC, 5 h 319 (17%) 
39   PhI(OAc)2 (3), TBHP (4), O2 K2CO3 (0.5) pentOAc, 4 ºC, 1 d mixture of 318, 320, and 321 
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Table 3.3 (continued). Allylic oxidation of enol ether 317. 
Entry   Oxidants (equiv) Additives (equiv) Conditions Results 
40   PhI(OAc)2 (3), TBHP (4) Cs2CO3 (4) EtOAc, –78 ºC, 4 h mixture of 318, 319, and 321 
41   PhI(OAc)2 (3), TBHP (4) none pentOAc, 4 ºC, 12 h mixture of 318 and 321 
42   PhI(TFA)2 (2), TBHP (1.5) Cs2CO3 (2) EtOAc, 4 ºC, 75 min 318 (10%), 319 (24%), 320 (28%) 
43   PhI(TFA)2 (3), TBHP (4) K2CO3 (0.5) pentOAc, 4 ºC, 75 min 318 (23%), 320 (37%) 
44   PhI(TFA)2 (3), TBHP (4) K2CO3 (0.5), 3Å MS pentOAc, 4 ºC, 2 d mixture of 318 and 320 
45   PhI(TFA)2 (3), TBHP (4) K3PO4 (4) EtOAc, 4 ºC, 45 min mixture of 318, 320, and 321 
46   PhI(TFA)2 (3), TBHP (4) Cs2CO3 (4) EtOAc, 4 ºC, 13 h 318 (21%), 320 (12%) 
47   PhI(TFA)2 (3), TBHP (4) Cs2CO3 (4) EtOAc, –30 ºC, 90 min 318 (19%), 320 (28%) 
48   PhI(TFA)2 (3), TBHP (4) Cs2CO3 (4) EtOAc, –78 ºC, 1 h 318 (17%), 319 (4%) 
49   PhI(TFA)2 (3), TBHP (4) Cs2CO3 (4) EtOAc, –78 ºC, 3.5 h 318 (23%), 319 (10%) 
50   PhI(TFA)2 (3), TBHP (4) Cs2CO3 (4) CH2Cl2, –78 ºC, 1 h 318 (16%) 
51   PhI(TFA)2 (3), TBHP (4) Cs2CO3 (4) MeCN, –40 ºC, 2 h mixture of 318, 319, 320, and 321 
52   PhI(TFA)2 (3), TBHP (4), O2 Cs2CO3 (4) EtOAc, –78 ºC, 1 h 318 (30%) 
53   PhI(TFA)2 (3), TBHP (4) Cs2CO3 (4) EtOAc, –78 ºC, 1 h 318 (16%) 
54   PhI(TFA)2 (3), TBHP (4) Cs2CO3 (4) EtOAc, –78 ºC, 2 h 318 (17%) 
55   PhI(TFA)2 (3), CHP (4) Cs2CO3 (4) EtOAc, –78 ºC, 1 h 318 (14%), 319 (5%), 320 (15%) 
56   PhI(TFA)2 (3), BzOOt-Bu (4) Cs2CO3 (4) EtOAc, –78 ºC to rt, 1 d no reaction 
57   PhI(TFA)2 (3), BPX (4) Cs2CO3 (4) EtOAc, –78 ºC, 90 min decomposition 
58   PhI(TFA)2 (5), TBHP (excess) Cs2CO3 (10) EtOAc, –78 ºC, 30 min 318 (17%), 320 (11%) 
59   322 (2) K2CO3 (4) PhH, rt, 3 d 319 (26%), 320 (5%) 
60   322 (2) Cs2CO3 (4) PhH, rt, 12 h mixture of 318 and 319 
61   322 (3), TBHP (4) Cs2CO3 (4) EtOAc, –78 ºC to rt, 1 d mixture of 318, 320, and 321 
62   322 (2), O2 K2CO3 (4) PhH, rt, 1 d 318 (9%) 
63   PhIO2 (3), TBHP (4) K2CO3 (4) EtOAc, 4 ºC, 12 h selectively afforded 319 
64   IBX (3) none DMSO, 110 ºC, 14 h mixture of 318, 320, and 321 
65   DMP (3) Cs2CO3 (4) CH2Cl2, rt, 2 d no reaction 
 
 
Figure 3.2. Byproducts from the allylic oxidation of 317 and the structure of peroxyiodoxolone 322. 
 
Given the early success with the allylic oxidation of 303 to afford 306, we first focused on the 
Pearlman’s catalyst-TBHP allylic oxidation system (Table 3.3, entries 1-8).610 Despite increases in 
catalyst stoichiometry, we typically observed a considerable conversion to enone 320 and variable 
conversion to peroxide 319.  Additionally, while changing the identity of the base mitigated has enone 
formation in similar systems,618 we did not observe significant changes in product distribution through the 
                                                      
618 (a) Yu, J.-Q.; Corey, E. J. Org. Lett. 2002, 4, 2727-2730. (b) Yu, J.-Q.; Corey, E. J. J. Am. Chem. Soc. 2003, 125, 
3232-3233. 
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use of K2CO3, KOH, K3PO4, or Cs2CO3.  Using different Pd catalysts had no positive effect on desired 
yield (entries 9-11).  A variety of other known allylic oxidation systems, involving the combination of 
TBHP and: NaOCl,619 Cr(CO)6,620 PDC,621 Mn(OAc)3,622 FeCl2·4H2O,623 NiCl2·6H2O,624 CuI,625 SeO2,626 
RuCl3,627 Rh2(cap)4,628 and CAN, also did not afford large proportions of 318 selectively (entries 12-22).  
When stoichiometric metal oxidants were used (entries 23-32), we did not observe any 318 but rather 
enone 320 and ketone 321 in cases where significant decomposition was not observed.  
In addition to the use of metal-based oxidants, we also investigated the use of hypervalent iodine 
reagents, both in the presence and in the absence of TBHP (Table 3.3, entries 33-65).  Prior studies by the 
Yeung group illustrated the effectiveness of PhI(OAc)2-TBHP for the allylic oxidation of a wide range of 
substrates.629 It is believed that exposure of iodosobenzene species 323 to TBHP generates [bis(tert-
butylperoxy)iodo]benzene (324, Scheme 3.10).630 This is predicted to be a particularly unstable 
                                                      
619 Kolympadi, M.; Liapis, M.; Ragoussis, V. Tetrahedron 2005, 61, 2003-2010.  
 
620 (a) Pearson, A. J.; Chen, Y.-S.; Hsu, S.-Y.; Ray, T. Tetrahedron Lett. 1984, 25, 1235-1238. (b) Pearson, A. J.; 
Chen, Y.-S.; Han, G. R.; Hsu, S.-Y.; Ray, T. J. Chem. Soc., Perkins Trans. 1 1985, 267-273. 
 
621 (a) Chidambaram, N.; Chandrasekaran, S. J. Org. Chem. 1987, 52, 5048-5051. (b) Schultz, A. G.; Taveras, A. G.; 
Harrington, R. E. Tetrahedron Lett. 1988, 29, 3907-3910. 
 
622 Shing, T. K. M.; Yeung, Y.-Y.; Su, P. L. Org. Lett. 2006, 8, 3149-3151.  
 
623 (a) Barton, D. H. R.; Le Gloahec, V. N. Tetrahedron 1998, 54, 15457-15468. (b) Nakanishi, M.; Bolm, C. Adv. 
Synth. Catal. 2007, 349, 861-864. 
 
624 Salavati-Niasari, M.; Babazadeh-Arani, H. J. Mol. Catal. A 2007, 274, 58-64. 
 
625 Salvador, J. A. R.; e Melo, M. L. S.; Campos Neves, A. S. Tetrahedron Lett. 1997, 38, 119-122.  
 
626 Mateos, A. F.; Barrueco, O. F.; González, R. R. Tetrahedron Lett. 1990, 31, 4343-4346. 
 
627 Miller, R. A.; Li, W.; Humphrey, G. R. Tetrahedron Lett. 1996, 37, 3429-3432. 
 
628 (a) Catino, A. J.; Forslund, R. E.; Doyle, M. P. J. Am. Chem. Soc. 2004, 126, 13622-13623. (b) Catino, A. J.; 
Nichols, J. M.; Choi, H.; Gottipamula, S.; Doyle, M. P. Org. Lett. 2005, 7, 5167-5170. (c) McLaughlin, E. C.; Choi, 
H.; Wang, K.; Chiou, G.; Doyle, M. P. J. Org. Chem. 2009, 74, 730-738. 
 
629 (a) Zhao, Y.; Yeung, Y.-Y. Org. Lett. 2010, 12, 2128-2131. (b) Zhao, Y.; Yim, W.-L.; Yan, C. K.; Yeung, Y.-Y. 
Org. Lett. 2011, 13, 4308-4311. (c) Zhao, Y.; Chew, X.; Leung, G. Y. C.; Yeung, Y.-Y. Tetrahedron Lett. 2012, 53, 
4766-4769.   
 
630 Milas, N. A.; Plesnicar, B. J. Am. Chem. Soc. 1968, 90, 4450-4453. 
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intermediate, which undergoes reductive elimination to afford PhI and di-tert-butyl tetroxide (325), which 
decomposes into a variety of tert-butyl polyoxide radicals (326), eventually leading to oxygen evolution, 
and to formation of t-BuOH and t-BuOOt-Bu.  These processes appear to be solvent dependent.   
 
 
Scheme 3.10. Reaction of a generic iodosobenzene species 323 with TBHP. 
 
The rate at which 324 forms and decomposes to PhI and 325 is affected by several factors, 
including solvent and temperature.  Exposure of PhI(TFA)2 to TBHP forms 324 at temperatures as low as 
–30 ºC using CH2Cl2; the use of more Lewis basic solvents EtOAc, acetone, THF, and MeCN led to lower 
conversion rates in subsequent allylic oxidations at that temperature.631 Solvent effects were also observed 
in the PhI(OAc)2-TBHP allylic oxidation system.629a Use of ester solvents containing large alkyl 
substituents led to higher yields.  This may be due to the solvent effects on the conversion of 323 to 324, 
with more sterically demanding Lewis basic solvents decreasing the rate of this reaction.   
Several mechanisms may be proposed for the allylic oxidation of 317.  One plausible mechanism 
involves three distinct stages: a radical abstraction; radical combination; and base-promoted elimination 
(Scheme 3.11).  First, the radical abstraction of a hydrogen atom at the C2 position forms allylic radical 
327.  This radical may be intercepted to form peroxide 328, which then may eliminate alkoxide anion via 
methine deprotonation632 at C2 to afford 318.  This mechanistic proposal may also explain the formation 
of several byproducts.  Interception of allylic radical 327 with a tert-buty peroxy radical may form 319.  
                                                      
631 (a) Catir, M.; Kilic, H. Synlett 2004, 2151-2154. (b) Catir, M.; Kilic, H. Synlett 2010, 1319-1322.  
 
632 For an early example of base-mediated cleavage of a dialkyl peroxide, see: Kornblum, N.; DeLaMare, H. E. J. 
Am. Chem. Soc. 1951, 73, 880-881. 
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In addition, E1cB-type expulsion of a peroxy anion from 328 may afford enoxonium 329, which upon 
demethylation would afford enone 320. 
 
 
Scheme 3.11. A plausible radical-based mechanism for the formation of 318 and other oxidation products from 317. 
 
In many allylic oxidation experiments, we isolated a significant amount of 319, and we 
investigated the possible conversion of this peroxide to the desired β-methoxyenone 318.  Exposure of 
peroxide 319 to a variety of basic, acidic, and reducing conditions did not afford more than trace amounts 
of 318.  Only upon exposure of 319 to FeCl2·4H2O633 in a Fenton-type reaction,634 appreciable (5-10% 
yield) amounts of β-methoxyenone 318 were produced.  The inability to convert 319 to 318 meant that 
this peroxide was a detrimental byproduct in this reaction process, and we sought to mitigate its formation 
to improve the yield of 318.  Since a peroxide would approach from outside the concavity of the bicyclic 
core of 327 to form the epimer shown in 328, subsequent C2 deprotonation would be exceedingly 
                                                      
633 For examples of the reaction of peroxides with Fe(II) salts, see: (a) O’Neill, P. M.; Searle, N. L.; Raynes, K. J.; 
Maggs, J. L.; Ward, S. A.; Storr, R. C.; Park, B. K.; Posner, G. H. Tetrahedron Lett. 1998, 39, 6065-6068. (b) Singh, 
C.; Gupta, N.; Tiwari, P. Tetrahedron Lett. 2005, 46, 4551-4554. (c) Opsenica, I.; Terzić, N.; Opsenica, D.; 
Angelovski, G.; Lehnig, M.; Eilbracht, P.; Tinant, B.; Juranić, Z.; Smith, K. S.; Yang, Y. S.; Diaz, D. S.; Smith, P. 
L.; Milhous, W. K.; Doković, D.; Šolaja, B. A. J. Med. Chem. 2006, 49, 3790-3799. 
 
634 For a review of the Fenton reaction, see: Koppenol, W. H. Free Radical Bio. Med. 1993, 15, 645-651.  
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difficult given the steric environment around this position.635 We hypothesized that if oxygen was present, 
it may intercept 327 and subsequently form a hydroperoxide (328, R = H), and this species may undergo 
more facile C2 deprotonation to form the desired β-methoxyenone 318. 
Taking all these factors into consideration and screening a variety of conditions involving 
iodine(III) reagents (Table 3.3, entries 33-58), we were obtained 318 in 30% yield (entry 52).  While the 
use of large ester solvents (i.e., amyl acetate and butyl butyrate) decreased the rate at which radical tert-
butyl polyoxides formed, their relatively high melting points prevented the cooling of the reaction 
mixtures to further decrease the rate of radical formation.  EtOAc was the solvent of choice, allowing 
reaction mixtures to be cooled to –78 ºC while preventing fast decomposition of TBHP and the 
hypervalent iodine reagent.  In addition, we found that PhI(TFA)2 was optimal relative to PhI(OAc)2 and 
PhIO, and the addition of a vigorous stream of oxygen into the reaction mixture caused a significant 
increase in product yield.  We also assessed the use of several iodine(V) reagents, such as 
peroxyiodoxolone 322,636 PhIO2, IBX, and DMP (entries 59-65); however, the use of these reagents did 
not afford the desired allylic oxidation product selectively.  Even though yields of the desired β-
methoxyenone 318 were not dramatically improved using the optimized PhI(TFA)2-TBHP-O2 system, the 
use of hypervalent iodine reagents were more conducive for large scale allylic oxidations of 317, 
necessary for processing large quantities of material for the total synthesis endeavor.  
With access to large amounts of β-methoxyenone 318, we developed a synthesis strategy that 
would allow us to quickly access hyperforin.  We hypothesized that hyperforin (1) may be accessed from 
cyclopropane 330 (Scheme 3.12a).  The cyclopropane present in 330 is activated by both the C1 and C9 
carbonyl groups,637 and nucleophilic addition of a prenylmetal species may occur selectively at the C7 
                                                      
635 The difficulty with C2 deprotonation of 328 may favor enone 320 formation via enoxonium 329. 
 
636 Ochiai, M.; Ito, T.; Takahashi, H.; Nakanishi, A.; Toyonari, M.; Sueda, T.; Goto, S.; Shiro, M. J. Am. Chem. Soc. 
1996, 118, 7716-7730.  
 
637 It should be noted that there is very little orbital overlap between the C9–O π* orbital and the C7–C9 σ orbital. 
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position and not at the C8 quaternary center.638 This addition would result in an intermediate C1 
bridgehead organometallic 331, which upon exposure to isobutyryl chloride may directly provide the 
methyl ether of hyperforin (60, Scheme 3.12b).  In one single operation, two of the three key remaining 
C–C bonds of hyperforin would be established: prenylation at the C7 position and acylation at the C1 
position (highlighted in Scheme 3.12b).  The remaining C3 prenyl group would be installed via a 
precedented tandem deprotonation-transmetalation-alkylation protocol of 318 to afford 332, the precursor 
to 330 via sequential bridgehead lithiation and intramolecular cyclization.510  
 
 
Scheme 3.12. (a) Retrosynthesis of hyperforin (1) from β-methoxyenone 318 via cyclopropane 330, and (b) a proposed tandem 
1,5-addition-bridgehead acylation of 330 to form O-methyl hyperforin (60). 
 
 
Prenylation at the C3 position of 318 was accomplished through the previously mentioned 
sequential LiTMP-mediated deprotonation, transmetalation with Li(2-Th)CuCN,511 and trapping with 
prenyl bromide510 to afford 333 (Scheme 3.13a).  A variety of Lewis and Brønsted acidic conditions were 
then screened for the hydrolysis of the cyclic ketal present in 333.  No reactivity was observed using 
                                                      
638 For examples of diacylcyclopropane 1,5-addition that is selective for the least hindered position, see: (a) 
Tanimori, S.; Kainuki, T.; Nakayama, M. Biosci. Biotech. Biochem. 1992, 56, 1807-1809. (b) Jiang, X.; Covey, D. 
F. J. Org. Chem. 2002, 67, 4893-4900. 
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aqueous HOAc, LiBF4, Sc(OTf)3, CuCl2·2H2O, or InCl3, or anhydrous conditions involving Ti(Oi-
Pr)4/MeOH or SmCl3/TMSCl.  Loss of the C3, C5, and C8 olefin functionality was observed when p-
TsOH·H2O, TFA, Amberlyst-15 acidic resin, or CAN was employed.  While no reactivity was observed 
with aqueous HCl, PPTS, or BF3·Et2O/TBAI at rt, decomposition was observed upon heating.  Several 
reagents led to selective cleavage of the C4 O-methyl ether, including HBr, BBr3, TMSI, and 
FeCl3·6H2O.  Selective cyclic ketal hydrolysis was ultimately accomplished using BrBMe2;639 exposure of 
333 to this reagent at –78 ºC led to hemiketal 334.  The conversion of 333 to 334 may proceed via 
coordination of the Lewis acidic reagent to the Lewis basic cyclic ketal oxygen to give intermediate 335, 
which may undergo ketal cleavage to form oxocarbenium ion 336 (Scheme 3.13b).  The displaced 
bromide anion may then intercept the oxocarbenium ion to form the unstable geminal bromoether 337, a 
species we observed spectroscopically but did not isolate.  Upon exposure of 337 to H2O upon reaction 
quench, the product hemiketal 334 is formed.  The reaction was chemoselective for cyclic ketal cleavage 
at –78 ºC; at higher temperatures, C4 O-methyl ether cleavage was also observed.  Hydrolysis of 334 was 
accomplished by refluxing in wet acetone with PPTS to afford 332.   
 
                                                      
639 (a) Guidon, Y.; Yoakim, C.; Morton, H. E. Tetrahedron Lett. 1983, 24, 2969-2972. (b) Guidon, Y.; Yoakim, C.; 
Morton, H. E. J. Org. Chem. 1984, 49, 3912-3920. (c) Guidon, Y.; Girard, Y.; Berthiaume, S.; Gorys, V.; Lemieux, 
R.; Yoakim, C. Can. J. Chem. 1990, 68, 897-902.   
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Scheme 3.13. (a) Prenylation and cyclic ketal hydrolysis of 318, and (b) a possible mechanism for the conversion of 333 to 334.a 
a Conditions: (a) LiTMP, THF, –78 ºC; Li(2-Th)CuCN, THF, –78 to –40 ºC; prenyl bromide, –78 to –40 ºC, 71%; (b) BrBMe2, 
CH2Cl2, –78 ºC; NEt3; NaHCO3, H2O, 89%; (c) PPTS, acetone/H2O, reflux, 92%. 
 
 
We then attempted to synthesize cyclopropane 330 from alcohol 332; however, we did not obtain 
this desired product (Scheme 3.14).  After conversion to triflate 338, exposure to LDA led to 
decomposition, including LDA-mediated hydride transfer to the C9 ketone.640 Treatment with NaOMe in 
MeOH, conditions known to promote bridgehead functionalization,641 led to quantitative conversion to 
methanopentalene 339, the product of methoxide addition to the C4 position followed by cyclization of 
the resulting C3 enolate to the C7 position.  Studies with mesylate 340 were also unsuccessful.  While 
                                                      
640 The reducing ability of LDA has been reported.  For several examples, see ref. 527 and: (a) Kowalski, C.; Creary, 
X.; Rollin, A. J.; Burke, M. C. J. Org. Chem. 1978, 43, 2601-2608. (b) Majewski, M. Tetrahedron Lett. 1988, 29, 
4057-4060.  For a review of lithium dialkylamide reduction, see: Majewski, M.; Gleave, D. M. J. Organomet. Chem. 
1994, 470, 1-16. 
 
641 Nickon, A.; Covey, D. F.; Huang, F.-C.; Kuo, Y.-N. J. Am. Chem. Soc. 1975, 97, 904-905. 
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treatment with LDA also resulted in decomposition, exposure to NaOMe/MeOH afforded rearranged 
cyclopropane 341.  This product may have formed via initial cleavage of the C1–C2 bond with 
concomitant C1–C7 bond formation from C2 hemiketal anion 342, followed by lactone formation upon 
aqueous workup.  
 
 
Scheme 3.14. Byproducts isolated from attempted bridgehead lithiations of 338 and 340.a 
a Conditions: (a) Tf2O, pyr, CH2Cl2, –43 to 0 ºC, 84%; (b) NaOMe, MeOH, 0 ºC to rt, >99%; (c) MsCl, NEt3, CH2Cl2, 0 ºC, 82%; 
(d) NaOMe, MeOH, 0 to 70 ºC, 15%. 
 
 
Since there is very poor overlap of the C9 ketone π orbital with the C1–H methine σ* orbital and 
that a major source of byproducts was hydride addition to the C9 ketone, we also explored the bridgehead 
lithiation chemistry of a series of intermediates bearing a C9 dimethyl ketal (Scheme 3.15).  By 
quenching the BrBMe2-mediated reaction of 333 with MeOH before introduction of H2O, dimethyl ketal 
343 was isolated instead of hemiketal 334.  Reactions of the triflate 344 derived from this intermediate 
were investigated; however, we did not observe desired cyclopropane formation.  Exposure of 344 to 
LDA afforded tricyclononane 345, which may have formed via deprotonation of the C3 prenyl methylene 
with subsequent C4–C7 bond formation, yielding intermediate 346.  After formation of extended enolate 
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347, quenching with H2O may afford 345.  Treatment of 344 with s-BuLi led to 348, the result of 1,2-
addition of s-Bu anion to the C2 ketone followed by displacement of the C7 triflate with the resulting 
alkoxide.  Reactions of mesylate 349 and pivalate 350 were also fruitless; when reactivity was observed, 
it was typically due to C3 prenyl methylene deprotonation.   
 
 
Scheme 3.15. Synthesis and reactivity of 343 derivatives.a 
a Conditions: (a) BrBMe2, CH2Cl2, –78 ºC; MeOH, NEt3, –78 ºC, 67%; (b) Tf2O, pyr, CH2Cl2, –40 to –10 ºC, 71%; (c) MsCl, 
pyr, CH2Cl2, 0 ºC to rt, 39%; (d) PivCl, pyr, DMAP, 0 ºC to rt, 82%; (e) LDA, THF, –78 to –20 ºC, 42% (10% recovered 344); 
(f) s-BuLi, THF, –78 ºC, 33%. 
 
 
Given the enhanced acidity of the bisallylic methylene attached to C3, we elected to pursue a 
synthesis strategy in which cyclopropation to form the C1–C7 bond would precede C3 prenylation.  
BrBMe2-mediated cyclic ketal hydrolysis of 318 afforded hemiketal 351, and subsequent hydrolysis 
afforded alcohol 282 (Scheme 3.16).  Triflation of 282 yielded 352.  Gratifyingly, exposure of this triflate 
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to LDA in the presence of TMSCl produced cyclopropane 353.  In this reaction, silylation of the C3 
position accompanied C1 bridgehead lithiation with subsequent C1–C7 bond formation, providing 353.  
An observed, unstable byproduct in this reaction was the result of LDA-mediated C9 ketone reduction, 
which was isolated in variable amounts.   
 
 
Scheme 3.16. Synthesis of cyclopropane 353.a 
a Conditions: (a) BrBMe2, CH2Cl2, –78 ºC; NEt3, –78 ºC; NaHCO3, H2O, –78 ºC to rt, 79%; (b) PPTS, H2O/acetone, reflux, 90%; 
(c) Tf2O, pyr, CH2Cl2, –43 to 5 ºC, 80%; (d) LDA, TMSCl, THF, –78 ºC, 49%.   
 
 
We then attempted 1,5-addition of a variety of nucleophiles to the activated cyclopropane present 
in 353; however, under all conditions screened, we did not isolate any desired products (354, Table 3.4).  
In general, we explored the use of organocuprates642 as nucleophiles, given past precedent of the use of 
these reagents for cyclopropane opening.643 We utilized the Lewis acids TMSCl and BF3·Et2O in an 
attempt to further activate the cyclopropane for nucleophilic attack.644,645 The 1,5-addition of 
                                                      
642 For reviews of organocuprate chemistry, see: (a) Posner, G. H. Org. React. 1975, 22, 253-400. (b) Lipshutz, B. 
H. Synlett 1990, 119-128. 
 
643 For examples of allylcuprate additions to activated cyclopropanes, see: (a) Corey, E. J.; Fuchs, P. L. J. Am. 
Chem. Soc. 1972, 94, 4014-4015. (b) Mioskowski, C.; Manna, S.; Falck, J. R. Tetrahedron Lett. 1983, 24, 5521-
5524. (c) Bertz, S. H.; Dabbagh, G.; Cook, J. M.; Honkan, V. J. Org. Chem. 1984, 49, 1739-1743. (d) Taber, D. F.; 
Kewson, K. R.; Raman, K.; Rheingold, A. L. Tetrahedron Lett. 1984, 25, 5283-5286. (e) He, M.; Tanimori, S.; 
Nakayama, M. Biosci. Biotech. Biochem. 1995, 59, 900-902. 
 
644 Lipshutz, B. H.; Dimock, S. H.; James, B. J. Am. Chem. Soc. 1993, 115, 9283-9284. 
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alkylcuprates to activated cyclopropanes may also be catalyzed by PBu3.646 Due to the inability of 
accessing prenyllithium from lithium insertion into a prenyl halide,647 several modes of prenyl cuprate 
formation were explored.  In entry 1, Rieke copper(0) was generated,648 but the reagent derived from Cu* 
and prenyl chloride did not react with the substrate.  The only product we observed in this reaction was 
355 (Figure 3.3),649 the result of nucleophilic opening of THF solvent.  No reactivity was observed with 
prenylcuprates derived from: (a) prenyl–MgBr and CuI650 (entries 2-3) and (b) prenyl–Li651 and CuI 
(entries 4-5).  The generation of prenylcuprate652 from prenyl–SnBu3,653 BuLi,654 and CuI afforded iodide 
356 and proteodesilylation product 357 (entries 6-7).655 Iodide 356 was the only product obtained in these 
                                                      
645 For a review of the use of Lewis acids in organocopper chemistry, see: Yamamoto, Y. Angew. Chem. Int. Ed. 
Engl. 1986, 25, 947-959. 
 
646 Kauffman, G. B.; Teter, L. A. Inorg. Synth. 1963, 7, 9-12. 
 
647 Rapid Wurtz coupling was observed upon attempted halogen-lithium exchange of allyl halides.  For more 
information, see: (a) Seyferth, D.; Weiner, M. A. J. Org. Chem. 1959, 24, 1395-1396. (b) Seyferth, D.; Weiner, M. 
A. J. Org. Chem. 1961, 26, 4797-4800.  
 
648 (a) Ebert, G. W.; Rieke, R. D. J. Org. Chem. 1984, 49, 5282-5283. (b) Wehmeyer, R. M.; Rieke, R. D. J. Org. 
Chem. 1987, 52, 5057-5059. (c) Rieke, R. D.; Wehmeyer, R. M.; Wu, T.-C.; Ebert, G. W. Tetrahedron 1989, 45, 
443-454. (d) Stack, D. E.; Dawson, B. T.; Rieke, R. D. J. Am. Chem. Soc. 1991, 113, 4672-2673. (e) Stack, D. E.; 
Dawson, B. T.; Rieke, R. D. J. Am. Chem. Soc. 1992, 114, 5110-5116. (f) Stack, D. E.; Klein, W. R.; Rieke, R. D. 
Tetrahedron Lett. 1993, 34, 3063-3066. 
 
649 (a) Sakane, S.; Maruoka, K.; Yamamoto, H. Tetrahedron 1986, 42, 2203-2209. (b) Korthals, K. A.; Wulff, W. D. 
J. Am. Chem. Soc. 2008, 130, 2898-2899.  
 
650 Lipshutz, B. H.; Hackmann, C. J. Org. Chem. 1994, 59, 7437-7444. 
 
651 Prenyllithium was generated from the reaction of phenyl prenyl ether with Li.  For more information, see: Eisch, 
J. J.; Jacobs, A. M. J. Org. Chem. 1963, 28, 2145-2146.  
 
652 (a) Lipshutz, B. H.; Crow, R.; Dimock, S. H.; Ellsworth, E. L.; Smith, R. A. J.; Behling, J. R. J. Am. Chem. Soc. 
1990, 112, 4063-4064. (b) Lipshutz, B. H.; Ellsworth, E. L.; Dimock, S. H.; Smith, R. A. J. J. Am. Chem. Soc. 1990, 
112, 4404-4410. 
 
653 For the synthesis of tributylprenylstannane, see: (a) Naruta, Y.; Nishigaichi, Y.; Maruyama, K. Org. Synth. 1993, 
71, 118-124. (b) Kiyokawa, K.; Yasuda, M.; Baba, A. Organometallics 2011, 30, 2039-2043. 
 
654 For the generation of allyllithium reagents from the reaction of allyltributylstannanes and BuLi, see: Desponds, 
O.; Schlosser, M. J. Organomet. Chem. 1991, 409, 93-101. 
 
655 357 and 358 were not rigorously characterized; we surmised the structure of these compounds via comparison to 
353 as well as spectroscopic analysis of reaction mixtures. 
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studies in which the cyclopropane ring of 353 was opened.  We also briefly explored the TMSOTf-
mediated addition of allyltrimethylsilane656 (entry 14), but the only product observed was 357.   
 
Table 3.4. Attempted formation of 354 from nucleophilic 1,5-additions to 353. 
 
Entry Reagent (equiv) Reagent formation Additives Solvent Temperature Result 
1 prenyl–Cu* (10) LiNap; CuCN, LiBr; prenyl–Cl TMSCl THF –78 to 0 ºC 355 is only product 
2 prenyl–Cu (2.2) prenyl–MgBr; CuI, LiCl TMSCl THF –78 to 40 ºC no reaction 
3 prenyl–Cu (10) prenyl–MgBr; CuI TMSCl THF –78 ºC to rt no reaction 
4 prenyl–Cu (5) prenyl–OPh, Li; CuI BF3·Et2O, PBu3 Et2O/THF –78 to 10 ºC no reaction 
5 prenyl–Cu (25) prenyl–OPh, Li; CuI BF3·Et2O, PBu3 Et2O/THF –78 ºC to rt no reaction 
6 prenyl–Cu (5) prenyl–SnBu3, BuLi; CuI, LiCl TMSCl THF –78 to 0 ºC no reaction 
7 prenyl–Cu (30) prenyl–SnBu3, BuLi; CuI, LiCl TMSCl THF –78 ºC to rt 356 (50%), 357 (50%) 
8 Bu2CuLi (5) BuLi, CuI none Et2O  –78 to 0 ºC decomposition 
9 Bu2CuLi (5) BuLi, CuI BF3·Et2O Et2O  –78 ºC 358 is only product 
10 Bu2CuLi (5) BuLi, CuI TMSCl Et2O  –78 ºC 358 is only product 
11 Bu2Cu(CN)Li2 (5) BuLi, CuCN BF3·Et2O Et2O  –78 ºC 358 is only product 
12 Bu2Cu(CN)Li2 (5) BuLi, CuCN TMSCl Et2O  –78 ºC 358 is only product 
13 Bu2Cu(CN)Li2 (5) BuLi, CuCN none THF –78 ºC to rt no reaction 
14 allyl–TMS -- TMSOTf CH2Cl2  –78 ºC to rt 357 is only product 
 
 
Figure 3.3. Byproducts obtained from the reaction of 353 with various nucleophiles. 
 
 
Owing to the variability of prenyl–metal formation,657 we also assessed the reactivity of butyl-
derived cuprate species for this cyclopropane-opening reaction (Table 3.4, entries 8-13).  The preparation 
                                                      
656 For examples of allyltrimethylsilane addition to activated cyclopropanes, see: (a) Ohno, M.; Matsuoka, S.; 
Eguchi, S. J. Org. Chem. 1986, 51, 4553-4558. (b) Bambal, R.; Kemmitt, R. D. W. J. Chem. Soc., Chem. Commun. 
1988, 734-735. (c) Monti, H.; Afshari, M.; Léandri, G. J. Organomet. Chem. 1995, 486, 69-78. (d) Sugita, Y.; 
Yamadoi, S.; Hosoya, H.; Yokoe, I. Chem. Pharm. Bull. 2001, 49, 657-658. (e) Gharpure, S. J.; Shukla, M. K.; 
Vijayasree, U. Org. Lett. 2009, 11, 5466-5469. 
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of these reagents was much more straightforward than the preparation of prenylcuprates.  Both Gilman658 
and Lipshutz-type659 higher order cuprates were examined.  In these cases, the only product we isolated 
was 358,655 the result of 1,2-addition to the C9 ketone (Figure 3.3).     
Given the propensity of nucleophilic 1,2-addition to the C9 ketone, we also synthesized and 
explored the chemistry of cyclopropane 359, in which the reactive ketone was masked as a dimethyl ketal.  
BrBMe2-mediated cyclic ketal opening of 318 followed by a methanol quench afforded alcohol 360 
(Scheme 3.17).  A variety of conditions were screened for the synthesis of 359 from the derived triflate 
361.660 Exposure of 361 to LDA and TMSCl only afforded vinylsilane 362.661 We rationalized that a 
smaller lithium amide base may promote bridgehead deprotonation, since the presence of the C9 dimethyl 
ketal significantly increased the steric environment surrounding the C1 methine.  Exposure of 362 to 
excess LiNEt2 provided the desired cyclopropane 359 along with sulfamate 363, the product of 
diethylamide displacement of trifluoromethide from 361.  To the best of our knowledge, this is the only 
known example of trifluoromethide displacement from an alkyl triflate to form a sulfamate.  Such a 
displacement is thermodynamically tenable, given the relative acidity of fluoroform (pKa ~ 25-28)662 
versus diethylamine (pKa ~ 31).663 Upon reexposure of 363 to LDA or LiNEt2, only trace amounts of 359 
were produced.  Interestingly, upon exposure of 361 to LiNEt2, rearranged cyclopropane 364 was 
                                                      
657 For an example of unexpected reactivity involving an allyl cuprate, see: Hutchinson, D. K.; Fuchs, P. L. 
Tetrahedron Lett. 1986, 27, 1429-1432. 
 
658 (a) Gilman, H.; Jones, R. G.; Woods, L. A. J. Org. Chem. 1952, 17, 1630-1634. (b) Whitesides, G. M.; Fischer, 
W. F., Jr.; Filippo, J. S., Jr.; Bashe, R. W.; House, H. O. J. Am. Chem. Soc. 1969, 91, 4871-4882. (c) Lipshutz, B. 
H.; Kozlowski, J. A.; Wilhelm, R. S. J. Org. Chem. 1983, 48, 546-550. 
 
659 (a) Lipshutz, B. H.; Kozlowski, J.; Wilhelm, R. S. J. Am. Chem. Soc. 1982, 104, 2305-2307. (b) Lipshutz, B. H.; 
Wilhelm, R. S.; Kozlowski, J. A.; Parker, D. J. Org. Chem. 1984, 49, 3928-3938. 
 
660 All intermediates bearing both a C9 dimethyl ketal and a C7 triflate were particularly unstable and were not fully 
characterized.   
 
661 Reexposure of this product to LDA did not afford cyclopropane 359. 
 
662 Klabunde, K. J.; Burton, D. J. J. Am. Chem. Soc. 1972, 94, 5985-5990. 
 
663 Ahlbrecht, H.; Schneider, G. Tetrahedron 1986, 42, 4729-4741. 
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isolated.664 This rearrangement product may arise from 1,2-alkyl shift of carbenoid intermediate 365.  
This reaction is remarkable given the contrasting reactivity of closely related triflate 362. 
 
 
Scheme 3.17. Synthesis of cyclopropane 359 and byproducts 363 and 364.a 
a Conditions: (a) BrBMe2, NEt3, CH2Cl2, –78 ºC; MeOH, NEt3; NaHCO3, H2O, 61%; (b) Tf2O, CH2Cl2, –40 to 0 ºC; (c) LDA, 
TMSCl, HMPA, THF, –78 to 0 ºC; (d) LiNEt2, THF, –78 to –10 ºC, 14% 359, 42% 363 (both yields from 360); (e) LiNEt2, THF, 
–78 ºC to rt, 44% (from 360). 
 
 
We then sought to improve the yield of 359 through the intermediacy of benzenesulfonate 366, 
since displacement of a phenyl anion would be highly unlikely.  Treatment of alcohol 360 with BsCl 
afforded 366 (Scheme 3.18).  Exposure of this sulfonate to LDA and TMSCl afforded vinylsilanes 367 
and 368, in which the sulfonate functionality directed lithiation and subsequent silylation upon the 
attached phenyl ring.  Exposure of both of these products to LiNEt2 afforded 359 in identical yield.  
Unfortunately, we were unable to successfully convert cyclopropane 359 to a desired ring-opened product 
                                                      
664 The structure of 364 was elucidated from the appearance of nOe correlations between the cyclopropyl methine to 
both ketal methyl groups, circumstances that would be highly unlikely in the desired cyclopropane. 
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369.  A variety of conditions were screened, similar to those found in Table 3.4.  Proteodesilylation at the 
C3 position and hydrolysis of the C9 ketal were the only products we isolated in this endeavor.   
 
 
Scheme 3.18. Synthesis of 359 via benzenesulfonate 366 and unsuccessful formation of 369 from 359.a 
a Conditions: (a) BsCl, pyr, CH2Cl2, –40 ºC to rt, 48% yield; (b) LDA, TMSCl, THF, –78 to 0 ºC, 29% 367, 41% 368; (c) LiNEt2, 
THF, –78 ºC to rt, 47% (from either 367 or 368).  
 
 
In summary, we did not observe desired 1,5-addition to both 353 and 359 despite screening a 
variety of nucleophiles under a litany of reaction conditions.  Iodide 356 was the only product isolated in 
which 1,5-addition occurred.  Given the ability of an iodide to act as a functional handle, we briefly 
explored the reactivity of this compound (Scheme 3.19).665 Attempted metal-iodine exchange of 356 
afforded cyclohexenedione 370.666 The formation of this ring-opened product is unsurprising considering 
the orbital overlap between the σ(C7–M) and the σ*(C1–C8) bonds of possible intermediate 371.  Keck 
allylation530 of 356 very cleanly afforded 372.  Upon radical formation at the C7 position, a facile 5-exo-
                                                      
665 Due to the paucity of iodide 356, the products of these reactions were not fully characterized; however, 
spectroscopic analysis provided sufficient evidence to support the structural assertions made herein. 
 
666 Micouin, L.; Knochel, P. Synlett 1997, 327-328.  
 
OR
OMeO
O
Me
Me
Me
Me
Me
Me
OMe b. LDA
    TMSCl
MeO
OMe
MeO
O OMe
Me
Me
TMS
S
O
O TMS
TMS
367 (29%)
+
360: R = H
366: R = Bs a. BsCl(48%)
Me
Me MeO
OMe
MeO
O OMe
Me
Me
TMS
S
O
O
TMS
Me
Me
368 (41%)
367 or 368
c. LiNEt2
(47%)
9
Me
OMe
MeO
O OMe
Me
Me
TMS
Me
Me
359
various
nucleophiles
R
OMeO
O
Me
Me
Me
Me
Me
Me
OMe
TMS
369
3
220
 221 
trig radical cyclization preceded intermolecular allylation.  Similar cyclization products were obtained 
from attempted Ni-catalyzed Fu–Negishi couplings of 356.667 
 
 
Scheme 3.19. Reactions of iodide 356.a 
a Conditions: (a) ZnBr2, i-PrMgCl, Et2O, THF, rt; 356; CuCN, LiCl, –78 ºC; prenyl bromide, –78 ºC to rt, 40%; (b) AIBN, 
allyltributylstannane, PhH, 80 ºC, >99%. 
 
 
Total Synthesis of Hyperforin 
Even though Keck coupling of 356 provided the undesired cyclization product 372, we were 
intrigued by the facility of this radical-based transformation.  We resolved to utilize a Keck allylation 
strategy for the installation of the C7 prenyl group, given the aforementioned result and the successful 
implementation of a Keck allylation strategy in the total synthesis of (±)-garsubellin A by Danishefsky.668 
In order to prevent cyclization prior to intermolecular allylation, masking the olefin present in the C8 side 
chain was required.  A similar strategy was utilized in the total synthesis of ent-hyperforin by Shibasaki, 
in which formal methanolysis provided a temporary means of veiling the C8 olefin.669 We rationalized 
                                                      
667 (a) Zhou, J. (S.); Fu, G. C. J. Am. Chem. Soc. 2003, 125, 14726-14727. (b) Zhou, J. (S.); Fu, G. C. J. Am. Chem. 
Soc. 2004, 126, 1340-1341. (c) Netherton, M. R.; Fu, G. C. Adv. Synth. Catal. 2004, 346, 1525-1532. (d) Strotman, 
N. A.; Sommer, S.; Fu, G. C. Angew. Chem. Int. Ed. 2007, 46, 3556-3558. (e) Saito, B.; Fu, G. C. J. Am. Chem. Soc. 
2007, 129, 9602-9603. (f) Lu, Z.; Fu, G. C. Angew. Chem. Int. Ed. 2010, 49, 6676-6678. 
668 See discussion on page 120 and ref. 527. 
 
669 Specifically, the strategy was implemented in the sequence starting with intermediate 115 and ending with 122.  
See the discussion starting on page 113 and ref. 512.  
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that a similar protecting group strategy would minimally affect existing methodology while providing a 
practical and prudent means of achieving a total synthesis of hyperforin.   
We began implementing this strategy by synthesizing methyl ether 373 from the 
methoxymercuration of epoxygeranyl bromide 289 (Scheme 3.20).  Coupling of 373 with cyclohexadiene 
312 afforded cyclization precursor 374, and exposure of this intermediate to TMSOTf provided the 
expected enol ether 375.  Subsequent allylic oxidation using our optimized PhI(TFA)2–TBHP–O2 system 
provided β-methoxyenone 376.  However, treatment with BrBMe2 not only hydrolyzed the cyclic ketal of 
376 but also displaced the tertiary methyl ether functionality to form bromide 377 as the only isolated 
product.  Decreasing the BrBMe2 stoichiometry afforded bromide 378, indicating that methyl ether 
cleavage preceded cyclic ketal hydrolysis.   
 
 
Scheme 3.20. Synthesis and reactivity of methyl ether 376.a 
a Conditions: (a) Hg(OAc)2, MeOH; NaOH, H2O, 0 ºC; NaBH4, 0 ºC; 88%, 4% recovered 289; (b) s-BuLi, THF, –78 to –30 ºC; 
289, –78 to 0 ºC, 67%; (c) TMSOTf, 2,6-lutidine, CH2Cl2, –78 ºC, 76%; (d) PhI(TFA)2, TBHP, Cs2CO3, O2, EtOAc, –78 to 0 ºC, 
29%; (e) BrBMe2 (5 equiv), NEt3, CH2Cl2, –78 ºC; NEt3; H2O, NaHCO3, 37%; (f) BrBMe2 (2 equiv), NEt3, CH2Cl2, –78 ºC; 
NEt3; H2O, NaHCO3, >90% conversion.   
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Since Lewis acid coordination was a likely cause of this unintended reactivity, we hypothesized 
that a more sterically encumbered ether would be less prone to cleavage during the ketal hydrolysis step.  
Accordingly, triethylsilyl ether 379 was synthesized in two steps from epoxygeranyl bromide 289:  (1) 
oxymercuration of 289, and (2) silylation of the resulting alcohol 380 (Scheme 3.21).  We attempted to 
append other, more sterically demanding silyl moieties to 380; however, intramolecular epoxide-opening 
cyclization preceded silylation.  Coupling of 379 with cyclohexadiene 312 yielded 381, which upon 
exposure to TMSOTf generated enol ether 382.  Allylic oxidation, using aforementioned conditions with 
minor modifications, afforded β-methoxyenone 383 in a significantly higher yield than previous, similar 
allylic oxidations.  Unfortunately, exposure of this compound to BrBMe2 at –78 ºC produced the tertiary 
bromide 377, previously observed in the reaction of 376.  Nevertheless, we discovered that if the reaction 
was cooled to below –90 ºC, silyl ether cleavage was avoided while negligibly affecting the cyclic ketal 
hydrolysis, and we obtained the desired hemiketal 384.670 LiTMP-mediated methanol extrusion from 384 
yielded 385. 
 
                                                      
670 Methyl ether cleavage was still observed in the reaction of 376 and BrBMe2 when performed below –90 ºC. 
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Scheme 3.21. Synthesis of triethylsilyl ether 385.a 
a Conditions: (a) Hg(OAc)2, acetone, H2O; NaOH, 0 ºC; NaBH4, 0 ºC, 91%; (b) TESCl, imid, DMF, 97%; (c) s-BuLi, THF, –78 
to –30 ºC; 379, –78 to –40 ºC, 85%; (d) TMSOTf, 2,6-lutidine, CH2Cl2, –78 ºC, 79%; (e) PhI(TFA)2, TBHP, Cs2CO3, 4Å MS, 
EtOAc, O2, –78 to 0 ºC, 44%; (f) BrBMe2, NEt3, CH2Cl2, –78 ºC; NEt3, NaHCO3, H2O, 48%; (g) BrBMe2, NEt3, CH2Cl2, –95 ºC; 
NEt3, NaHCO3, H2O, 57%; (h) LiTMP, THF, –78 to 0 ºC, 97%. 
 
 
Installation of the key C7 prenyl group was accomplished in three steps from 385 via a Keck 
allylation strategy.  A variety of radical initiating functional groups were screened in the radical allylation 
reaction step to afford 386, including phenyl thiocarbonate 387,671 pentafluorophenyl thiocarbonate 
388,672 methyl xanthate 389, and imidazole carbothioate 390 (Scheme 3.22).  In addition, we screened 
several methods of radical generation, including: (1) the use of AIBN, activated both thermally and 
photochemically; (2) photochemical radical generation (in the absence of a radical promotor); and (3) the 
combination of BEt3 and air.  A major byproduct in these studies was 391, the result of reductive 
deoxygenation.  Ultimately, we found that the activation of 388 with BEt3 and air afforded 386 in 
                                                      
671 387 was synthesized in one step from hemiketal 384 rather than from 385.  See experimental section for details. 
 
672 N-Hydroxysuccinimide (NHS) was utilized in the formation of 388 from 385.  For more information on the use 
of NHS in the synthesis of thiocarbonates, see: Barton, D. H. R.; Jaszberenyi, J. C. Tetrahedron Lett. 1989, 30, 
2619-2622. 
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consistently good yield.  Past studies have found that the pentafluorophenyl thiocarbonate radical 
precursor functionality has a relatively long half-life for radical generation;673 this prolonged half-life may 
prevent the formation of unintended byproducts and favor the selective formation of the intended 
allylation product.  Cross metathesis of 386 with 2-methyl-2-butene catalyzed by Hoveyda–Grubbs 
second-generation catalyst (117) yielded 392, a product containing the requisite C7 prenyl moiety.  
Exposure of 392 to LiTMP and TMSCl afforded vinylsilane 393. 
 
 
Scheme 3.22. Installation of the C7 prenyl moiety.a 
a Conditions: (a) BuLi, THF, –78 ºC; ClC(S)OPh, –78 ºC to rt, 60% (from 384); (b) ClC(S)OC6F5, NHS, pyr, PhMe, 80 ºC, 82%; 
(c) NaH, CS2, THF, 0 ºC; MeI, 0 ºC to rt, 79%; (d) 1,1’-thiocarbonyldiimidazole, DMAP, CH2Cl2, 40 ºC, 54%; (e) allyltributyl-
stannane, BEt3, air, PhH, 72% 386, 16% 391; (f) 117, 2-methyl-2-butene, CH2Cl2, 40 ºC, 86%; (g) LiTMP, TMSCl, THF, –78 to 
0 ºC, 90%. 
 
 
We then investigated the C1 bridgehead functionalization of 393.  This was an extremely 
challenging transformation, given the steric environment around the intended reaction center.  In addition, 
considering that we intended to functionalize the C1 position with an isopropyl ketone, this meant that an 
electrophile bearing an acidic α-proton needed to be employed.  In general, we focused our attention on 
                                                      
673 Barton, D. H. R.; Dorchak, J.; Jaszberenyi, J. C. Tetrahedron 1992, 48, 7435-7446.   
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several variables in screening this bridgehead functionalization reaction, including: (1) choice of base; (2) 
deprotonation time and temperature; (3) quenching temperature; (4) choice of electrophile; (5) various 
additives; and (6) reaction concentration.  Specifically, we screened various amide bases, including LDA, 
LiNEt2, LiTMP, and various other TMP-derived organometallics (e.g., TMP–MgX, TMP–ZnCl).674 In 
general, reduction of the C9 ketone was observed with LDA and LiNEt2, and non-lithium TMP 
organometallics failed to deprotonate the C1 methine.  MeCu(TMP)CNLi2675 was the only such base to 
react with 393, providing alcohol 394 as the result of methyl addition to the C9 ketone (Scheme 3.23).   
Appreciable deprotonation using LiTMP was not observed below –20 ºC in THF solution; however, 
prolonged exposure of 393 to LiTMP above –20 ºC caused significant decomposition.  Eventually, we 
discovered that optimal deprotonation of 393 with LiTMP was accomplished in 5 min at 0 ºC.  Likewise, 
quenching temperature was also an important parameter in LiTMP-mediated reactions owing to the 
instability of 393 and its coupling products at relatively elevated temperatures.  Significant increases in 
material recovery were observed when reactions were quenched at –20 ºC and lower. 
 
 
Scheme 3.23. Reaction of 393 with MeCu(TMP)CNLi2.a 
a Conditions: (a) MeCu(TMP)CNLi2, THF, –78 to 0 ºC; i-PrC(O)Cl, –78 ºC to rt, 49%, 15% recovered 393. 
 
 
                                                      
674 For examples of the use of TMP-derived organometallics in organic synthesis, see: (a) Krasovskiy, A.; 
Krasovskaya, V.; Knochel, P. Angew. Chem. Int. Ed. 2006, 45, 2958-2961. (b) Clososki, G. C.; Rohbogner, C. J.; 
Knochel, P. Angew. Chem. Int. Ed. 2007, 46, 7681-7684. (c) Wunderlich, S. H.; Knochel, P. Angew. Chem. Int. Ed. 
2007, 46, 7685-7688. (d) Bresser, T.; Mosrin, M.; Monzon, G.; Knochel, P. J. Org. Chem. 2010, 75, 4686-4695. 
 
675 Usui, S.; Hashimoto, Y.; Morey, J. V.; Wheatley, A. E. H.; Uchiyama, M. J. Am. Chem. Soc. 2007, 129, 15102-
15103. 
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We also examined the use of several electrophiles.  A reaction between the 393 and i-PrCHO was 
observed, but the product obtained in these reactions also contained C9 ketone reduction, possibly 
through internal hydride transfer.  Dimethyl ketene was an ideal coupling partner, having no acidic α-
proton, but we were not able to isolate any coupling products from reactions using this electrophile.  
Coupling reactions with I2 resulted in decomposition.  In the end, we observed our desired product 
through the use of either isobutyryl chloride or cyanide,520 the latter providing marginally improved yields 
on a consistent basis.  In addition, reaction concentration was an important factor for this reaction.   
Optimal yields were observed with concentrations above 0.05 M.  As a result of these findings, the 
optimized bridgehead acylation of 393 to afford 395 is depicted in Scheme 3.24.  This is a significant 
improvement over prior PPAP total syntheses involving C1 bridgehead acylation, which required multiple 
steps involving a bridgehead iodide to synthesize similar intermediates.510,527,531 
 
 
Scheme 3.24. Bridgehead acylation of 393.a 
a Conditions: (a) LiTMP, THF, –78 ºC, 10 min; 0 ºC, 5 min; i-PrC(O)CN, –78 to –30 ºC, 49%. 
 
 
It should be noted that we also briefly explored the bridgehead lithiation chemistry of 396 and 
397 (Figure 3.4).  Under a variety of conditions, C1 functionalization was not observed in reactions 
involving 396.  Unsurprisingly, we observed products arising from C3 bisallylic methylene deprotonation 
upon exposure of 397 to lithium amide bases.    
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Figure 3.4. Structures of 396 and 397. 
 
Having achieved bridgehead acylation, we investigated the desilylation and dehydration of 395.  
We hypothesized that under certain conditions, both tasks may be accomplished in a single step to afford 
398.  Heating 395 in the presence of strong acids, such as CSA and p-TsOH, caused slow decomposition 
of the starting material, and in the presence of weaker acids, desilylation was observed but not elimination 
of the resulting tertiary carbinol.  If microwave irradiation was utilized as the source of heat and using 
both p-TsOH and HOAc, we were able to access our desired product 398 (Scheme 3.25).  In addition to 
398, we also isolated variable amounts of double-bond isomer 399.  2-Methyl-2-butene was used as an 
additive to this reaction to prevent the isomerization of the other olefins present in 395.   
 
 
Scheme 3.25. Desilylation and dehydration of 395 to form 398, and the structure of double bond isomer 399.a 
a Conditions: (a) p-TsOH·H2O, HOAc, 2-methyl-2-butene, PhMe, µwave, 100 ºC, 65%. 
 
 
Total synthesis of hyperforin was accomplished in two steps from 398 (Scheme 3.26).  First, C3 
prenylation was accomplished using stepwise lithiation, transmetalation with Lipshutz’s cuprate,511 and 
prenyl bromide alkylation to afford hyperforin O-methyl ether (60).  This compound was 
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spectroscopically identical to 60 semisynthetically derived from hyperforin.309,676 Finally, demethylation 
under Krapcho conditions provided hyperforin (1).  The hyperforin obtained from this synthesis was 
spectroscopically indistinguishable from hyperforin that we isolated from SJW as well as published data 
on the natural product.677 
   
 
Scheme 3.26. Completion of the total synthesis of hyperforin.a 
a Conditions: (a) LDA, THF, –78 ºC; Li(2-Th)CuCN, –78 to –40 ºC; prenyl bromide, –78 to –30 ºC, 98%; (b) LiCl, DMSO, 120 
ºC, 55% 1, 14% 400, 23% 401. 
 
 
Two other rearranged products were isolated in this final deprotection step, 400 and 401.  A 
possible mechanism for the formation of these byproducts involves formal C-to-O acyl migration of 
hyperforin, which may be facilitated by cleavage of the C1–C2 bond to form an intermediate ketene 402 
(Scheme 3.27).  Chloromethane, a byproduct of the demethylation reaction, may react with 400 to form 
                                                      
676 See experimental section for more details. 
 
677 See experimental section for more details.  A detailed procedure for the isolation of hyperforin from St. John’s 
wort extract is also provided.   
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401.  A similar C-to-O migration has been observed previously by Plietker.678 Interestingly, the PPAP 
laxifloranone107 (403) and the chromenone-type acylphoroglucinol mahureone A679 (404) are analogously 
related despite being isolated from two disparate plant species.680 
 
 
Scheme 3.27. A possible mechanism for the formation of 400 and 401 from 1, and structures of laxifloranone and mahureone A. 
 
Overall, these efforts culminated in a total synthesis of the naturally occurring enantiomer of 
hyperforin.  The synthesis is 18 steps at its longest linear sequence, starting from geraniol (287).  Relative 
and absolute stereochemistry in the synthesis is established through a Sharpless epoxidation reaction.  The 
route is also considerably scalable; more than 40 mg of synthetic hyperforin were generated in a single 
batch.  By recognizing latent symmetry elements embedded in the hyperforin core, we quickly established 
                                                      
678 Möws, K.; Schürmann, M.; Preut, H.; Plietker, B. Acta Cryst. 2009, E65, o1751-o1751.   
 
679 Massiot, G.; Long, C.; David, B.; Serrano, M.-J.; Daubié, F.; Alby, F.; Ausseil, F.; Knibiehler, M.; Moretti, C.; 
Hoffman, J.-S.; Cazaux, C.; Lavaud, C. J. Nat. Prod. 2005, 68, 979-984. 
 
680 Mahureone A is a known inhibitor of DNA polymerase β.  For more information, see: Boudsocq, F.; Benaim, P.; 
Canitrot, Y.; Knibiehler, M.; Ausseil, F.; Capp, J. P.; Bieth, A.; Long, C.; David, B.; Shevelev, I.; Frierich-
Heinecken, E.; Hübscher, U.; Amalric, F.; Massiot, G.; Hoffmann, J. S.; Cazaux, C. Mol. Pharmacol. 2005, 67, 
1485-1492. 
Me
Me
O
OH
Me
Me
Me
Me
Ph
O
OH
O
O
Me Me O
MeMe
Me
Me
O
OH
Me
Me
Me
Me
O
PhO
HO
laxifloranone (403) mahureone A (404)
O OH
Me
O
Me
Me
Me
Me
O
Me
Me
Me
Me
1
Me Me
OH
Me
O–
Me
Me
Me
Me
O
Me
Me
Me
Me
402
•
O
Me Me
O–
MeMe
O
Me
Me
Me Me
Me
OH
Me
Me
Me
Me
H
H
•O
+
+
400 + 4011
2
230
 231 
the bicyclo[3.3.1]nonane core of hyperforin through a diastereoselective epoxide-opening cascade 
cyclization reaction.  In this key conversion of 381 to 382, the stereochemical identity of three key carbon 
centers were established including two quaternary centers.  Further, the practicality and modularity of this 
synthesis may be exploited to quickly access a library of hyperforin analogs.   
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Experimental Section 
General Procedures. All reactions were performed in oven-dried or flame-dried glassware under 
a positive pressure of argon unless otherwise noted.  Flash column chromatography was performed as 
described by Still et al.599 employing silica gel 60 (40-63 µm, Whatman).  Both preparatory and analytical 
thin-layer chromatography (TLC) were performed using 0.25 mm silica gel 60 F254 plates.  
Materials. Commercial reagents and solvents were used as received with the following 
exceptions.  Tetrahydrofuran, diethyl ether, dichloromethane, toluene, benzene, hexane, acetonitrile, and 
N,N-dimethylformamide were degassed with argon and passed through a solvent purification system 
(designed by J. C. Meyer of Glass Contour) utilizing alumina columns as described by Grubbs et al.600 
unless otherwise noted.  Diethylamine, triethylamine, diisopropylamine, pyridine, 2,2,6,6-
tetramethylpiperidine, dimethyl sulfoxide, and chlorotrimethylsilane were distilled over calcium hydride.  
Hexamethylphosphoramide was distilled over calcium hydride under reduced pressure.  Geraniol, 
titanium(IV) isopropoxide, prenyl chloride, prenyl bromide, allyltributylstannane, and trimethylsilyl 
trifluoromethanesulfonate were distilled under reduced pressure.  N-Hydroxysuccinimide was 
recrystallized using ethanol.  [bis(Trifluoroacetoxy)iodo]benzene was crystallized from the reaction of 
(diacetoxyiodo)benzene with trifluoroacetic acid and subsequently dried under reduced pressure (1 
mmHg).  Cesium carbonate was dried for at least 12 h at 150 ºC under reduced pressure (1 mmHg).  
Lithium bromide, lithium chloride, and molecular sieves were stored in a vacuum oven for at least 24 h.  
The molarities of butyllithium, sec-butyllithium, and tert-butyllithium solutions were determined by 
titration with 1,10-phenanthroline as an indicator (average of three determinations).  THF solutions of 
lithium diethylamide, lithium diisopropylamide, and lithium 2,2,6,6-tetramethylpiperidide were prepared 
by addition of a hexane solution of butyllithium (1 equiv) to a THF solution of the appropriate amine (1.1 
equiv) cooled to –78 ºC and stirring the solution for 30 min at 0 ºC.  PhH solutions of triethylborane were 
prepared by addition of neat triethylborane to PhH. 
Instrumentation.  1H NMR spectra were recorded with Varian INOVA-600, Varian INOVA-
500, and Varian Mercury 400 spectrometers, are reported in parts per million (δ), and are calibrated using 
232
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residual non-deuterated solvent as an internal reference: CDCl3, δ 7.26 (CHCl3); C6D6, δ 7.16 (C6D5H); 
CD3OD, δ 3.31 (CD2HOD).  Data for 1H NMR spectra are reported as follows: chemical shift 
(multiplicity, coupling constants, integration).  Multiplicities are reported as follows: s = singlet; d = 
doublet; t = triplet; q = quartet; septet = septet; m = multiplet; br = broad, or combinations thereof.  13C 
NMR spectra were recorded with a Varian INOVA-500 spectrometer, are reported in parts per million (δ), 
and are referenced from the central peak of the carbon resonance of the solvent: CDCl3, δ 77.23; C6D6, δ 
128.06; CD3OD, δ 49.00.  Infrared (IR) data were recorded on a Varian 1000 FT-IR using NaCl plates or 
on a Bruker Alpha FT-IR spectrometer outfitted with an Eco-ATR sampling module.  High-resolution 
mass spectra (HRMS) were recorded using electrospray ionization (ESI) mass spectroscopy on an Agilent 
6210 TOF LC/MS or a Bruker q-TOF Maxis Impact mass spectrometer.  Gas chromatography mass 
spectra (GCMS) were performed on a Shimadzu GC-2014 equipped with an AOC-20i auto-injector.  
Microwave irradiation was accomplished using a CEM Discover microwave reactor.  High-performance 
liquid chromatography was performed on a Agilent 1100 series HPLC.  Chiral high performance liquid 
chromatography (HPLC) was performed on an Agilent 1200 series HPLC. 
Note: For clarity, intermediates that have are not explicitly mentioned in this chapter are 
numbered sequentially in the experimental section beginning with 405. 
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((2S,3S)-3-Methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl)methanol (288):681 
A CH2Cl2682 solution of tert-butyl hydroperoxide683 (4.0 M, 410. mL, 1.64 mol, 1.5 equiv) was added via 
cannula over 1 h to a CH2Cl2 (850 mL) slurry of 4Å molecular sieves (30.43 g, powdered), L-(+)-diethyl 
tartrate (28.2 mL, 164 mmol, 0.15 equiv), and titanium(IV) isopropoxide (32.5 mL, 110. mmol, 0.1 equiv) 
in a 3-neck 5-L round-bottom flask cooled to an internal reaction temperature of –25 ºC.  The resulting 
yellow slurry was stirred at –25 ºC for 30 min and then cooled to an internal reaction temperature of –30 
ºC.  A CH2Cl2 (175 mL) solution of geraniol (287, 169.08 g, 1.0961 mol, 1 equiv) was added via cannula, 
followed by a CH2Cl2 (50 mL) rinse.  Throughout this addition, the internal reaction temperature of the 
reaction was maintained ≤ –20 ºC.  After stirring at –30 ºC for 75 min, the reaction was warmed to –10 ºC 
over 2 h.  The reaction was then quenched at –10 ºC with H2O (500 mL) followed by a 30 wt% H2O 
solution of NaOH saturated in NaCl (300 mL).  After stirring vigorously at rt for 45 min, the emulsion 
was diluted with MeOH (1.5 L) and brine (300 mL), and the layers were separated.  The aqueous layer 
was washed thrice with CH2Cl2.  The organic extracts were combined, washed with brine, dried over 
MgSO4, filtered, and concentrated in vacuo to an opaque yellow oil.  Short-path distillation (6 mmHg, 90-
93 ºC) afforded 171.05 g (1.0045 mol, 92% yield) of 288 as a pale yellow oil. 
1H NMR (600 MHz; CDCl3) δ: 5.08 (t, J = 7.1 Hz, 1H), 3.82 (ddd, J = 11.8, 6.9, 4.7 Hz, 1H), 3.68 (ddd, 
J = 11.7, 6.8, 4.6 Hz, 1H), 2.97 (dd, J = 6.6, 4.3 Hz, 1H), 2.12-2.04 (m, 2H), 1.70-1.65 (m, 5H), 1.61 (s, 
3H), 1.50-1.45 (m, 1H), 1.30 (s, 3H).  
13C NMR (125 MHz; CDCl3) δ: 132.3, 123.5, 63.2, 61.6, 61.4, 38.7, 25.9, 23.9, 17.8, 16.9.  
                                                      
681 This procedure was adapted from ref. 607. 
 
682 The CH2Cl2 used in this procedure was dried through storage over 3Å molecular sieves (pelleted) for at least 24 
h. 
    
683 See ref. 607 for preparation of a CH2Cl2 solution of tert-butyl hydroperoxide.   
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FTIR (thin film) νmax: 3420 (br), 2968, 2928, 2859, 1455, 1385, 1077, 1036, 865 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C10H18O2, 193.1199; found, 193.1200. 
  
€ 
[α]D
23 = –5.36º (c 3.04, CHCl3); [91% ee sample from literature:607   
€ 
[α]D
25  = –5.3º (c 3.0, CHCl3)]. 
TLC Rf = 0.45 (1:1 hexane:EtOAc). 
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Chiral HPLC Trace of 288 
 
Racemic sample: HPLC (ChiralPak AS-H, 9:1 isopropanol:hexane, 1 mL/min, 210 nm)  
 
 
 
Scalemic sample: HPLC (ChiralPak AS-H, 9:1 isopropanol:hexane, 1 mL/min, 210 nm)  
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((2S,3S)-3-Methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl)methyl methanesulfonate (405):684 
A CH2Cl2685 (1.2 L) solution of 288 (100.00 g, 587.37 mmol, 1 equiv) and triethylamine (123 mL, 881 
mmol, 1.5 equiv) in a 2-neck 2-L round-bottom flask outfitted with an equal pressure dropping funnel 
was cooled to an internal reaction temperature of –10 ºC, and methanesulfonyl chloride (59.5 mL, 763 
mmol, 1.3 equiv) was added dropwise via the equal pressure dropping funnel over 30 min, maintaining an 
internal reaction temperature ≤ 0 ºC.  After the addition was complete, the yellow slurry was stirred at 0 
ºC for 15 min, and then quenched at 0 ºC with H2O.  The layers were separated, and the aqueous layer 
was washed thrice with CH2Cl2.  The organic extracts were combined, washed sequentially with 2 N HCl, 
brine, and sat. aq. NaHCO3, dried over Na2SO4, filtered, and concentrated in vacuo.  The resulting yellow 
oil was dissolved in 95:5 hexane:EtOAc and passed through a plug of SiO2, rinsing with 95:5 
hexane:EtOAc.  Concentration of the filtrate in vacuo yielded 142.19 g (572.56 mmol, 97% yield) of 405 
as a yellow oil that was used without further purification.   
1H NMR (600 MHz; CDCl3) δ: 5.07 (t, J = 7.0 Hz, 1H), 4.42 (dd, J = 11.7, 4.1 Hz, 1H), 4.25 (dd, J = 
11.7, 7.1 Hz, 1H), 3.09-3.07 (m, 4H), 2.12-2.05 (m, 2H), 1.71-1.66 (m, 4H), 1.61 (s, 3H), 1.52-1.47 (m, 
1H), 1.33 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 132.6, 123.1, 68.9, 61.3, 59.3, 38.3, 38.0, 25.8, 23.7, 17.8, 17.0. 
FTIR (thin film) νmax: 2969, 2931, 2860, 1456, 1358, 1176, 981, 957, 833 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C11H20O4S, 249.1155; found, 249.1157. 
  
€ 
[α]D
23 = –13.9º (c 4.08, CHCl3). 
TLC Rf = 0.55 (1:1 hexane:EtOAc). 
                                                      
684 This procedure was adapted from ref. 608. 
 
685 The CH2Cl2 used in this procedure was dried through storage over 3Å molecular sieves (pelleted) for at least 24 
h. 
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(2S,3R)-3-(Bromomethyl)-2-methyl-2-(4-methylpent-3-en-1-yl)oxirane (289):686 
A Me2CO (1 L) slurry of 405 (141.96 g, 571.64 mmol, 1 equiv) and lithium bromide (99.29 g, 1.143 mol, 
2 equiv) was heated to reflux in a 2-L recovery flask outfitted with a reflux condenser.  After refluxing for 
90 min, the slurry was cooled to rt and filtered.  The yellow filtrate was concentrated in vacuo.  The 
resulting yellow oil was diluted with H2O and extracted thrice with 9:1 hexane:EtOAc.  The organic 
extracts were combined, washed sequentially with H2O, sat. aq. NaHCO3, and brine, dried over Na2SO4, 
filtered, and concentrated in vacuo.  The resulting pale yellow oil was dissolved in 9:1 hexane:EtOAc, 
and passed through a plug of SiO2, rinsing with 9:1 hexane:EtOAc.  Concentration of the filtrate in vacuo 
yielded 125.35 g (537.64 mmol, 94% yield) of 289 as a pale yellow oil that was used without further 
purification. 
1H NMR (600 MHz; CDCl3) δ: 5.10 (t, J = 7.1 Hz, 1H), 3.54 (dd, J = 10.4, 5.9 Hz, 1H), 3.24 (dd, J = 
10.4, 7.8 Hz, 1H), 3.08 (dd, J = 7.8, 5.9 Hz, 1H), 2.13-2.05 (m, 2H), 1.74-1.70 (m, 4H), 1.61 (s, 3H), 1.45 
(ddd, J = 13.7, 9.3, 7.1 Hz, 1H), 1.31 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 132.5, 123.4, 63.2, 61.7, 38.6, 29.9, 25.9, 24.0, 17.9, 16.3. 
FTIR (thin film) νmax: 2969, 2928, 2859, 1451, 1385, 1217, 1112, 1071, 890, 652 cm–1. 
PCI-GC/MS (m / z): [M+NH4]+ 250 (100%), 252 (97.7%). 
  
€ 
[α]D
23 = +22.6º (c 4.34, CHCl3). 
TLC Rf = 0.72 (1:1 hexane:EtOAc). 
                                                      
686 This procedure was adapted from ref. 608. 
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(3,5-Dimethoxy-4-(((2S,3S)-3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-
yl)methyl)phenoxy)triisopropylsilane (290): 
A THF (54 mL) solution of 146 (3.169 g, 10.8 mmol, 1 equiv) in a 200-mL recovery flask was cooled to 
0 ºC, and a hexane solution of butyllithium (2.60 M, 4.6 mL, 12 mmol, 1.1 equiv) was added dropwise 
over 5 min.  The cooling bath was then removed, and the resulting yellow solution was stirred at rt for 1 
h.  After cooling the reaction to 0 ºC and stirring at that temperature for 30 min, 289 (2.76 g, 11.8 mmol, 
1.1 equiv) was added dropwise.  The cooling bath was subsequently removed, and the resulting colorless 
solution was stirred at rt for 3 h.  The reaction was then quenched at rt with sat. aq. NH4Cl, diluted with 
H2O, and extracted thrice with EtOAc.  The organic extracts were combined, washed with brine, dried 
over Na2SO4, filtered, and concentrated in vacuo to a yellow oil.  Flash column chromatography (500 mL 
SiO2, 95:5 hexane:EtOAc) afforded 4.034 g (8.72 mmol, 81% yield) of 290 as a colorless oil.   
1H NMR (600 MHz; CDCl3) δ: 6.10 (s, 2H), 5.29 (s, 1H), 5.00 (t, J = 7.1 Hz, 1H), 3.75 (s, 6H), 2.98 (dd, 
J = 13.6, 4.4 Hz, 1H), 2.88 (dd, J = 7.6, 4.4 Hz, 1H), 2.68 (dd, J = 13.6, 7.6 Hz, 1H), 1.61 (m, 1H), 1.59 
(s, 3H), 1.54 (s, 3H), 1.37 (s, 3H), 1.34 (td, J = 6.8, 3.2 Hz, 1H), 1.26 (septet, J = 7.4 Hz, 3H), 1.12 (d, J = 
7.4 Hz, 18H). 
13C NMR (125 MHz; CDCl3) δ: 159.1, 156.2, 131.7, 124.0, 107.2, 96.4, 63.5, 61.7, 55.7, 39.2, 25.8, 24.1, 
22.5, 18.2, 17.7, 16.9, 12.9. 
FTIR (thin film) νmax: 2961, 2945, 2868, 1606, 1593, 1496, 1463, 1414, 1200, 1158, 1134, 1021, 883, 
686  cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C27H46O4Si, 485.3058; found, 485.3064. 
TLC Rf = 0.55 (8:2 hexane:EtOAc). 
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3,5-Dimethoxy-4-(((2S,3S)-3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl)methyl)phenol (291): 
A THF (30 mL) solution of 290 (3.97 g, 8.58 mmol, 1 equiv) in a 100-mL recovery flask was treated with 
a THF solution of tetrabutylammonium fluoride (1.0 M, 9.0 mL, 9.0 mmol, 1.05 equiv).  After stirring at 
rt for 1 h, the reaction was quenched at rt with sat. aq. NH4Cl, extracted once with hexane, and extracted 
twice with EtOAc.  The organic extracts were combined, washed with brine, dried over Na2SO4, filtered, 
and concentrated in vacuo to a pale yellow oil.  Flash column chromatography (400 mL SiO2, 7:3 → 1:1 
hexane:EtOAc) afforded 2.200 g (7.18 mmol, 84% yield) of 291 as a colorless oil.   
1H NMR (500 MHz; CDCl3) δ: 6.06 (s, 2H), 5.11 (s, 1H), 4.99 (t, J = 7.1 Hz, 1H), 3.76 (s, 6H), 2.97 (dd, 
J = 13.5, 4.6 Hz, 1H), 2.91 (dd, J = 7.3, 4.6 Hz, 1H), 2.69 (dd, J = 13.5, 7.3 Hz, 1H), 2.07-1.95 (m, 2H), 
1.63 (m, J = 5.2 Hz, 1H), 1.59 (s, 3H), 1.54 (s, 3H), 1.38 (s, 3H), 1.37-1.33 (m, 1H). 
13C NMR (125 MHz; CDCl3) δ: 159.3, 156.4, 131.9, 123.8, 106.0, 92.1, 64.1, 62.6, 55.7, 39.1, 25.8, 24.1, 
22.3, 17.7, 16.9. 
FTIR (thin film) νmax:  3368 (br), 2936, 2840, 1618, 1603, 1475, 1431, 1206, 1134, 999 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C18H26O4, 307.1904; found, 307.1909.  
TLC Rf = 0.50 (1:1 hexane:EtOAc). 
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4-Allyl-3,5-dimethoxy-4-(((2S,3S)-3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-
yl)methyl)cyclohexa-2,5-dienone (292): 
A PhH (36 mL) solution of 291 (2.189 g, 7.14 mmol, 1 equiv), triphenylphosphine (150. mg, 0.572 mmol, 
0.08 equiv), and palladium(II) acetate (32 mg, 0.14 mmol, 0.02 equiv) in a 100-mL recovery flask was 
treated sequentially with allyl methyl carbonate (2.0 mL, 18 mmol, 2.5 equiv) and titanium(IV) 
isopropoxide (423 µL, 1.43 mmol, 0.2 equiv).  The resulting dark red solution was heated to 50 ºC and 
stirred at that temperature for 2 h.  The resulting orange-red solution was subsequently cooled to rt and 
quenched with sat. aq. NH4Cl.  After stirring at rt for 5 min, 1 N HCl was added, and the mixture was 
extracted thrice with EtOAc.  The organic extracts were combined, washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo to a orange slurry.  Flash column chromatography (250 mL SiO2, 7:3 
→ 6:4 → 1:1 hexane:EtOAc) afforded 1.148 g (3.31 mmol, 46% yield) of 292 as a pale yellow oil and 
1.060 g (3.46 mmol, 48% recovery) of 291 as a pale yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 5.59 (s, 1H), 5.58 (s, 1H), 5.39 (ddt, J = 17.1, 10.0, 7.2 Hz, 1H), 5.00-
4.92 (m, 3H), 3.73 (s, 3H), 3.70 (s, 3H), 2.61-2.54 (m, 2H), 2.40 (t, J = 5.9 Hz, 1H), 2.14 (dd, J = 13.9, 
5.9 Hz, 1H), 2.04 (dd, J = 13.9, 5.9 Hz, 1H), 1.98-1.88 (m, 2H), 1.64 (s, 3H), 1.56 (s, 3H), 1.50 (ddd, J = 
13.7, 9.7, 6.3 Hz, 1H), 1.27 (ddd, J = 13.7, 10.0, 6.5 Hz, 1H), 1.17 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 188.0, 173.1, 172.6, 132.2, 131.9, 123.6, 118.4, 103.55, 103.45, 60.7, 
59.3, 56.2, 56.0, 49.7, 41.7, 38.9, 35.7, 25.8, 23.9, 17.8, 16.7. 
FTIR (thin film) νmax: 2928 (br), 1654, 1627, 1592, 1384, 1233, 1206, 1144 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C21H30O4, 369.2036; found, 369.2043. 
TLC Rf = 0.20 (1:1 hexane:EtOAc). 
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4-Allyl-4-(3,7-dimethyl-2-oxooct-6-en-1-yl)-3,5-dimethoxycyclohexa-2,5-dienone (294): 
A CH2Cl2 (1 mL) solution of 292 (3.3 mg, 9.5 µmol, 1 equiv) in a 10-mL pear-shaped flask was cooled to 
–78 ºC, and 1 drop of boron trifluoride ethyl etherate was added.  After stirring the reaction for 10 min at 
–78 ºC, it was placed in a 0 ºC bath.  After stirring the reaction at 0 ºC for 2 h, it was quenched at 0 ºC 
with brine, diluted with sat. aq. NH4Cl, and extracted five times with EtOAc.  The organic extracts were 
combined, dried over Na2SO4, filtered, and concentrated in vacuo to a yellow residue.  Flash column 
chromatography (4 mL SiO2, 2:8 hexane:EtOAc) afforded 1.4 mg (4.0 µmol, 43% yield) of 294 as a 
colorless residue.   
1H NMR (500 MHz; CDCl3) δ: 5.55 (s, 2H), 5.48-5.40 (m, 1H), 5.04 (t, J = 6.4 Hz, 1H), 4.96 (dd, J = 
10.3, 1.3 Hz, 1H), 4.94 (dd, J = 17.2, 1.3 Hz, 1H), 3.67 (s, 6H), 3.07 (d, J = 16.8 Hz, 1H), 3.03 (d, J = 
16.8 Hz, 1H), 2.45 (d, J = 7.5 Hz, 2H), 2.41 (q, J = 6.9 Hz, 1H), 1.89 (q, J = 7.5 Hz, 2H), 1.68 (s, 3H), 
1.66-1.60 (m, 1H), 1.58 (s, 3H), 1.30-1.24 (m, 1H), 1.00 (d, J = 6.9 Hz, 3H). 
13C NMR (125 MHz; CDCl3) δ: 210.5, 188.4, 172.71, 172.62, 132.5, 131.5, 123.9, 118.8, 102.90, 102.86, 
56.08, 56.06, 48.3, 46.3, 45.9, 43.2, 32.9, 25.93, 25.76, 17.9, 16.2. 
FTIR (thin film) νmax: 2965, 2922, 2853, 1715, 1654, 1622, 1446, 1388, 1234, 1205, 1147, 851 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C21H30O4, 369.2036; found, 369.2036.  
TLC Rf = 0.44 (EtOAc). 
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(2S,3S)-3-((1-Allyl-2,6-dimethoxycyclohexa-2,5-dien-1-yl)methyl)-2-methyl-2-(4-methylpent-3-en-1-
yl)oxirane (302): 
A CH2Cl2 (0.5 mL) solution of 292 (106 mg, 0.31 mmol, 1 equiv) was transferred via cannula to a CH2Cl2 
(0.5 mL) slurry of lithium aluminum hydride (23 mg, 0.61 mmol, 2 equiv) in a 10-mL pear-shaped flask 
cooled to –78 ºC, followed by a CH2Cl2 (0.5 mL) rinse.  After stirring for 30 min at –78 ºC, Et2O (0.5 mL) 
was added, and the reaction was placed in a 0 ºC bath.  After stirring at 0 ºC for 75 min, the reaction was 
quenched sequentially at 0 ºC with H2O (23 µL), 15% (w/v) NaOH (23 µL), and H2O (69 µL).  The 
mixture was warmed to rt, diluted with H2O, and extracted four times with EtOAc.  The organic extracts 
were combined, washed with H2O and brine, dried over Na2SO4, filtered, and concentrated in vacuo to a 
brown residue.  Flash column chromatography (30 mL SiO2, 95:5 hexane:EtOAc) afforded 45 mg (0.14 
mmol, 44% yield) of 302 as a colorless residue.   
1H NMR (600 MHz; CDCl3) δ: 5.57 (ddt, J = 17.1, 10.1, 7.1 Hz, 1H), 5.05 (t, J = 7.1 Hz, 1H), 4.94-4.88 
(m, 2H), 4.80 (t, J = 3.5 Hz, 1H), 4.76 (t, J = 3.5 Hz, 1H), 3.54 (s, 3H), 3.49 (s, 3H), 2.78 (q, J = 3.5 Hz, 
2H), 2.64 (dd, J = 8.0, 4.0 Hz, 1H), 2.39 (qd, J = 12.7, 7.2 Hz, 2H), 2.03 (dd, J = 13.7, 4.0 Hz, 1H), 1.97 
(q, J = 7.9 Hz, 2H), 1.76 (dd, J = 13.7, 8.0 Hz, 1H), 1.67 (s, 3H), 1.58 (s, 3H), 1.57-1.54 (m, 1H), 1.29 (dt, 
J = 13.5, 8.4 Hz, 1H), 1.18 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 153.80, 153.73, 135.3, 131.8, 124.2, 116.1, 93.23, 93.17, 61.25, 61.09, 
54.6, 54.2, 46.2, 40.2, 39.4, 34.2, 25.8, 24.2, 24.0, 17.8, 16.8. 
FTIR (thin film) νmax: 2932, 2831, 1694, 1659, 1451, 1381, 1223, 1206, 1139, 908 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C21H32O3, 333.2424; found, 333.2425.  
TLC Rf = 0.78 (1:1 hexane:EtOAc). 
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(2S,3S,3aR,7R,7aS)-7-Allyl-6,7a-dimethoxy-3-methyl-3-(4-methylpent-3-en-1-yl)-2,3,3a,4,7,7a-
hexahydro-2,7-methanobenzofuran (303): 
A CH2Cl2 (6 mL) solution of 302 (100. mg, 0.301 mmol, 1 equiv) and 2,6-di-tert-butyl-4-methylpyridine 
(124 mg, 0.602 mmol, 2 equiv) in a 20-mL scintillation vial was cooled to –78 ºC, and trimethylsilyl 
trifluoromethanesulfonate (65 µL, 0.36 mmol, 1.2 equiv) was added dropwise.  After stirring the bright 
yellow solution at –78 ºC for 30 min, it was quenched at –78 ºC with sat. aq. NaHCO3 and extracted four 
times with EtOAc.  The organic extracts were combined, washed with brine, dried over Na2SO4, filtered, 
and concentrated in vacuo to a pale yellow oil.  Flash column chromatography (50 mL SiO2, 99:1 
hexane:EtOAc) afforded 85 mg (0.26 mmol, 85% yield) of 303 as a colorless oil.   
1H NMR (600 MHz; CDCl3) δ: 6.02 (ddt, J = 17.2, 10.1, 7.1 Hz, 1H), 5.04 (t, J = 7.1 Hz, 1H), 5.01-4.95 
(m, 2H), 4.54 (dd, J = 5.7, 2.1 Hz, 1H), 3.75 (d, J = 5.3 Hz, 1H), 3.48 (s, 3H), 3.47 (s, 3H), 2.42 (dd, J = 
14.1, 7.1 Hz, 1H), 2.29 (dd, J = 14.1, 7.1 Hz, 1H), 2.19 (ddd, J = 18.1, 6.7, 2.2 Hz, 1H), 2.07-2.02 (m, 
2H), 2.01-1.93 (m, 1H), 1.86 (dd, J = 12.5, 5.3 Hz, 1H), 1.81 (d, J = 12.5 Hz, 1H), 1.72-1.65 (m, 4H), 
1.58 (s, 3H), 1.47-1.42 (m, 1H), 1.25-1.20 (m, 1H), 1.14 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 158.1, 138.3, 131.7, 124.9, 115.8, 112.5, 90.8, 79.1, 54.6, 51.3, 46.3, 
44.4, 42.0, 38.88, 38.73, 33.6, 28.1, 25.9, 22.9, 20.1, 17.8. 
 
Key 1D nOe correlation.  
FTIR (thin film) νmax: 2966, 2930, 1671, 1578, 1460, 1439, 1376, 1304, 1215, 1168, 1136, 1062, 1001, 
906 cm–1. 
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HRMS–ESI (m / z): [M+Na]+ calculated for C21H32O3, 355.2244; found, 355.2245.  
TLC Rf = 0.53 (9:1 hexane:EtOAc). 
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(2S,3S,3aS,7R,7aS)-7-Allyl-6,7a-dimethoxy-3-methyl-3-(4-methylpent-3-en-1-yl)-3,3a,7,7a-
tetrahydro-2,7-methanobenzofuran-4(2H)-one (305): 
A CH2Cl2 (1.7 mL) slurry of 303 (55 mg, 0.17 mmol, 1 equiv) and cesium carbonate (292 mg, 0.83 mmol, 
5 equiv) in a 10-mL pear-shaped flask was cooled to 0 ºC open to air, and Pearlman’s catalyst (4.4 mg, 
0.0082 mmol based on Pd, 0.05 equiv) and a decane solution of tert-butyl hydroperoxide (5.5 M, 150 µL, 
0.83 mmol, 5 equiv) were added in sequence.  The flask was sealed, purged with O2 via O2 balloon, and 
stirred at 4 ºC for 13 h.  The slurry was subsequently diluted with CH2Cl2 and filtered through a short plug 
of SiO2, rinsing with CH2Cl2 followed by EtOAc.  The filtrate was concentrated in vacuo to a colorless 
oil.  Flash column chromatography (20 mL SiO2, 8:2 hexane:EtOAc) afforded 10.4 mg (0.030 mmol, 17% 
yield) of 305 as a colorless residue.   
1H NMR (600 MHz; CDCl3) δ: 5.98 (m, 1H), 5.35 (s, 1H), 5.06-5.01 (m, 2H), 4.99 (t, J = 7.1 Hz, 1H), 
3.91 (d, J = 5.5 Hz, 1H), 3.71 (s, 3H), 3.48 (s, 3H), 2.69 (s, 1H), 2.53 (dd, J = 14.2, 6.7 Hz, 1H), 2.39 (dd, 
J = 14.2, 7.9 Hz, 1H), 2.06 (d, J = 13.1 Hz, 1H), 2.04-1.98 (m, 2H), 1.73-1.67 (m, 1H), 1.64 (s, 3H), 1.55 
(s, 3H), 1.43-1.36 (m, 1H), 1.34-1.28 (m, 1H), 1.25 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 197.8, 180.7, 136.8, 132.1, 124.2, 117.3, 115.2, 100.9, 81.0, 56.9, 56.5, 
52.1, 48.3, 48.1, 38.3, 38.0, 34.1, 27.9, 25.9, 22.8, 17.8. 
FTIR (thin film) νmax: 2964, 2923, 2850, 1652, 1604, 1459, 1373, 1228, 1046, 1001 cm–1.  
HRMS–ESI (m / z): [M+Na]+ calculated for C21H30O4, 369.2036; found, 369.2034. 
TLC Rf = 0.46 (6:4 hexane:EtOAc).  
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(2S,3aR,7R,7aS,8S)-3a-Allyl-7a-methoxy-8-methyl-8-(4-methylpent-3-en-1-yl)hexahydro-2,7-
methanobenzofuran-4(2H)-one (306): 
A CH2Cl2 (1 mL) solution of 302 (2.6 mg, 7.8 µmol, 1 equiv) in a 10-mL pear-shaped flask was cooled to 
–78 ºC, and trimethylsilyl trifluoromethanesulfonate (2 µL, 10 µmol, 1.5 equiv) was added.  After stirring 
the resulting yellow solution at –78 ºC for 10 min, it was quenched at –78 ºC with sat. aq. NaHCO3, 
diluted with H2O, and extracted thrice with EtOAc.  The organic extracts were combined, washed with 
brine, dried over Na2SO4, filtered, and concentrated in vacuo to a white residue. Flash column 
chromatography (4 mL SiO2, 9:1 hexane:EtOAc) afforded 1.3 mg (4.1 µmol, 52% yield) of 306 as a white 
residue.   
1H NMR (600 MHz; CDCl3) δ: 5.87 (dddd, J = 17.1, 10.2, 8.9, 5.7 Hz, 1H), 5.07 (t, J = 7.2 Hz, 1H), 
5.05-4.99 (m, 2H), 3.92 (d, J = 5.6 Hz, 1H), 3.46 (s, 3H), 2.58 (dd, J = 14.0, 5.7 Hz, 1H), 2.52 (ddd, J = 
15.1, 10.9, 7.6 Hz, 1H), 2.38 (ddd, J = 15.1, 7.4, 4.1 Hz, 1H), 2.16-2.10 (m, 2H), 2.10-2.04 (m, 1H), 2.01 
(dd, J = 13.7, 5.6 Hz, 1H), 1.95 (d, J = 13.7 Hz, 1H), 1.92-1.87 (m, 1H), 1.86-1.76 (m, 2H), 1.68 (s, 3H), 
1.59 (s, 3H), 1.49 (m, 1H), 1.42 (ddd, J = 13.7, 11.9, 4.9 Hz, 1H), 1.20 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 212.9, 136.4, 132.3, 124.3, 117.7, 116.4, 79.1, 58.4, 52.2, 45.9, 41.6, 
36.3, 36.0, 35.1, 33.8, 28.1, 25.9, 23.3, 19.0, 17.9. 
 
Key 1D nOe correlations. 
FTIR (thin film) νmax: 2972, 2924, 1702, 1467, 1439, 1328, 1312, 1219, 1180, 1148, 995, 908 cm–1. 
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HRMS–ESI (m / z): [M+H]+ calculated for C20H30O3, 319.2268; found, 319.2263.  
TLC Rf = 0.47 (8:2 hexane:EtOAc). 
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(2S,3S)-3-((2,6-Dimethoxycyclohexa-2,5-dien-1-yl)methyl)-2-methyl-2-(4-methylpent-3-en-1-
yl)oxirane (310): 
A THF (6 mL) solution of 308 (250. mg, 1.78 mmol, 1 equiv) in a 25-mL recovery flask was cooled to –
78 ºC, and a pentane solution of tert-butyllithium (1.70 M, 2.2 mL, 3.8 mmol, 2.1 equiv) was added 
dropwise.  After stirring the dark yellow solution at –78 ºC for 1 h, 289 (873 mg, 3.75 mmol, 2.1 equiv) 
was added dropwise.  The resulting colorless solution was allowed to slowly warm to rt.  After stirring for 
7 h, the resulting yellow solution was quenched at rt with H2O and extracted thrice with EtOAc.  The 
organic extracts were combined, washed with brine, dried over Na2SO4, filtered, and concentrated in 
vacuo to a yellow oil.  Flash column chromatography (150 mL SiO2, 99:1 → 98:2 → 95:5 → 9:1 → 8:2 
hexane:EtOAc) afforded 234 mg (0.80 mmol, 45% yield) of 310 as a colorless oil.  
1H NMR (600 MHz; CDCl3) δ: 5.07 (t, J = 7.4 Hz, 1H), 4.73 (t, J = 3.6 Hz, 1H), 4.71 (t, J = 3.6 Hz, 1H), 
3.56 (s, 3H), 3.54 (s, 3H), 3.01 (quintet, J = 5.3 Hz, 1H), 2.87-2.76 (m, 2H), 2.72 (dd, J = 8.1, 4.4 Hz, 
1H), 2.12 (dt, J = 14.0, 4.9 Hz, 1H), 2.01 (q, J = 7.4 Hz, 2H), 1.81 (ddd, J = 14.0, 8.1, 4.6 Hz, 1H), 1.67 
(s, 3H), 1.59 (s, 3H), 1.58-1.53 (m, 1H), 1.39-1.33 (m, 1H), 1.19 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 154.2, 131.9, 124.2, 91.77, 91.73, 77.2, 61.3, 61.1, 54.6, 54.3, 39.22, 
39.14, 29.3, 25.9, 24.7, 23.9, 17.8, 16.7. 
FTIR (thin film) νmax: 2963, 2931, 2856, 1693, 1596, 1474, 1383, 1258, 1204, 1146, 1120, 774 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C18H28O3, 315.1931; found, 315.1927.  
TLC Rf = 0.53 (8:2 hexane:EtOAc). 
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(S)-2-((S)-4,8-Dimethoxyspiro[2.5]octa-4,7-dien-1-yl)-6-methylhept-5-en-2-ol (311): 
A THF (0.8 mL) solution of 310 (50. mg, 0.17 mmol, 1 equiv) in a 10-mL pear-shaped flask was cooled 
to –78 ºC, and a pentane solution of tert-butyllithium (1.70 M, 111 µL, 0.19 mmol, 1.1 equiv) was added 
dropwise.  The reaction was allowed to slowly warm to –30 ºC over 1 h.  The reaction was subsequently 
cooled to –78 ºC, and prenyl bromide (40. µL, 0.34 mmol, 2 equiv) was added.  After warming the 
reaction to rt over 2.5 h, it was quenched at rt with H2O and extracted thrice with EtOAc.  The organic 
extracts were combined, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to a 
pale yellow oil.  Flash column chromatography (30 mL SiO2, 98:2 → 95:5 hexane:EtOAc) afforded 13.6 
mg (47 µmol, 27% yield) of 311 as a colorless oil as well as 14.4 mg (49 µmol, 29% recovery) of 310 as a 
colorless oil.   
1H NMR (600 MHz; CDCl3) δ: 5.14 (t, J = 7.1 Hz, 1H), 4.96 (t, J = 3.8 Hz, 1H), 4.64 (t, J = 3.6 Hz, 1H), 
3.98 (s, 1H), 3.58 (s, 3H), 3.47 (s, 3H), 3.00 (dt, J = 21.2, 2.9 Hz, 1H), 2.93 (dt, J = 21.2, 4.6 Hz, 1H), 
2.21-2.11 (m, 2H), 1.68 (s, 3H), 1.62 (s, 3H), 1.55 (t, J = 8.5 Hz, 2H), 1.49-1.45 (m, 2H), 1.39-1.35 (m, 
1H), 1.17 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 154.0, 152.1, 131.3, 125.3, 95.9, 90.2, 69.7, 54.84, 54.69, 45.1, 35.7, 
28.4, 25.93, 25.90, 24.0, 22.7, 17.9, 11.4. 
FTIR (thin film) νmax: 3506, 2964, 2928, 2833, 1683, 1651, 1595, 1464, 1446, 1394, 1375, 1228,  1206, 
1135, 1105, 1042, 979, 770 cm–1.  
HRMS–ESI (m / z): [M+Na]+ calculated for C18H28O3, 315.1931; found, 315.1920.  
FTIR (thin film) νmax: 0.43 (8:2 hexane:EtOAc). 
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1,5-Dimethoxy-6-(3-methylbut-2-en-1-yl)cyclohexa-1,4-diene (312): 
Preparation of barium iodide.  Using a hand drill hammer, a chisel,687 and a lead brick positioned on the 
laboratory floor, mineral oil-coated barium rod was portioned into approximately 25 mm segments.  Each 
segment was flattened using the hammer to yield a barium pancake no thicker than 3 mm.  A well-
sharpened pair of metal cutting snips was used to cut each pancake into 1 mm × 2 mm × 10 mm slivers, 
which were washed with hexane.  A 2-neck 2-L round-bottom flask outfitted with a reflux condenser was 
charged with barium slivers (63.7 g, 464 mmol, 1.3 equiv) and THF (500 mL).  The flask was placed in a 
rt H2O bath, and iodine (99.6 g, 392 mmol, 1.1 equiv) was added in four portions over 20 min with 
vigorous stirring.  After subsequently stirring vigorously for 4 d at reflux, a white-gray slurry of barium 
iodide was produced.  
A THF (800 mL) solution of 308 (50.0 g, 357 mmol, 1 equiv) in a 2-neck 3-L round-bottom flask 
outfitted with an equal pressure dropping funnel was cooled using a –78 ºC dry ice/acetone bath.  The 
dropping funnel was charged with a pentane solution of tert-butyllithium (1.56 M, 250. mL, 392 mmol, 
1.1 equiv), and this solution was added in portions over 1 h, maintaining an internal reaction temperature 
≤ –65 ºC.  The resulting yellow slurry was stirred for an additional 45 min at –78 ºC.  The THF slurry of 
barium iodide (preparation described above) was poured into this solution under a heavy stream of Ar, 
and the resulting yellow-green slurry was stirred at –78 ºC for 45 min.688 A THF (50 mL) solution of 
prenyl chloride (44.2 mL, 392 mmol, 1.1 equiv) was added via cannula over 10 min, maintaining an 
internal reaction temperature ≤ –60 ºC, and the yellow-green slurry was allowed to slowly warm to –30 
ºC over 45 min.  The resulting green-gray slurry was then quenched at –30 ºC with H2O.  After warming 
                                                      
687 If a hand drill hammer and chisel are unavailable, a standard claw hammer and an appropriately-shaped shelving 
bracket may be employed in this step.  
 
688 Directly following the barium iodide addition, the internal reaction temperature rose to –30 ºC but returned to –
70 ºC within 10 min. 
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to room temperature, the mixture was diluted with hexane and extracted thrice with 9:1 hexane:EtOAc.  
The organic extracts were combined, sequentially washed twice with H2O and once with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo to a pale yellow oil.  Short-path distillation (6 mmHg, 76-82 
ºC) afforded 67.46 g (323.9 mmol, 91% yield) of 312 as a colorless oil.  
1H NMR (600 MHz; CDCl3) δ: 4.99 (t, J = 7.4 Hz, 1H), 4.68 (dd, J = 4.6, 3.0 Hz, 2H), 3.53 (s, 6H), 
2.94–2.91 (m, 1H), 2.78 (ddt, J = 20.7, 6.0, 3.0 Hz, 1H), 2.72 (dq, J = 20.7, 4.6 Hz, 1H), 2.41 (dd, J = 7.4, 
4.7 Hz, 2H), 1.64 (s, 3H), 1.55 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 154.5, 132.8, 120.6, 91.9, 54.4, 41.3, 28.5, 26.1, 24.7, 17.8. 
FTIR (thin film) νmax: 2995, 2933, 2910, 2825, 1695, 1663, 1446, 1394, 1230, 1206, 1148, 1048, 965, 
775 cm–1.  
HRMS–ESI (m / z): [M+Na]+ calculated for C13H20O2, 231.1356; found, 231.1350. 
TLC Rf = 0.77 (9:1 hexane:EtOAc).  
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(2S,3S)-3-((2,6-Dimethoxy-1-(3-methylbut-2-en-1-yl)cyclohexa-2,5-dien-1-yl)methyl)-2-methyl-2-(4-
methylpent-3-en-1-yl)oxirane (309): 
A THF (140 mL) solution of 312 (5.68 g, 27.3 mmol, 1 equiv) in a 500-mL recovery flask was cooled to 
–78 ºC, and a c-Hex solution of sec-butyllithium (1.43 M, 28.6 mL, 40.9 mmol, 1.5 equiv) was added 
portionwise over 10 min.  After stirring the bright orange solution at –78 ºC for 1 h, it was warmed to –30 
ºC over 90 min and maintained at –30 ºC for an additional 30 min.  The dark red solution was then cooled 
to –78 ºC, and a THF (25 mL) solution of 289 (9.54 g, 40.9 mmol, 1.5 equiv) was added over 2 min.  The 
resulting bright yellow solution was allowed to slowly warm to rt.  After stirring for 3 h, the reaction was 
quenched at rt with H2O and extracted thrice with EtOAc.  The organic extracts were combined, washed 
with H2O and brine, dried over Na2SO4, filtered, and concentrated in vacuo to a yellow oil.  Flash column 
chromatography (300 mL SiO2, 98:2 → 95:5 hexane:EtOAc) afforded 4.97 (13.8 mmol, 51% yield) of 
309 as a pale yellow oil.  
1H NMR (600 MHz; CDCl3) δ: 5.05 (t, J = 6.7 Hz, 1H), 4.90 (t, J = 7.1 Hz, 1H), 4.76 (t, J = 3.5 Hz, 1H), 
4.72 (t, J = 3.5 Hz, 1H), 3.51 (s, 3H), 3.47 (s, 3H), 2.75 (m, 2H), 2.63 (dd, J = 8.1, 3.9 Hz, 1H), 2.35-2.28 
(m, 2H), 2.04 (dd, J = 13.7, 3.9 Hz, 1H), 1.97 (q, J = 7.9 Hz, 2H), 1.76 (dd, J = 13.7, 8.1 Hz, 1H), 1.66 (s, 
3H), 1.62 (s, 3H), 1.58-1.56 (m, 4H), 1.54 (s, 3H), 1.27 (dt, J = 13.6, 8.3 Hz, 1H), 1.18 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 13-C NMR (126 MHz; CDCl3): δ 154.11, 154.05, 132.5, 131.8, 124.2, 
120.7, 93.02, 92.92, 61.4, 61.1, 54.5, 54.1, 46.2, 39.5, 34.6, 34.1, 26.1, 25.9, 24.3, 24.1, 17.85, 17.79, 
16.8. 
FTIR (thin film) νmax: 2965, 2924, 2855, 2930, 1693, 1658, 1450, 1380, 1205, 1151, 1122, 1075, 973, 
778, 688 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C23H36O3, 383.2557; found, 383.2554.  
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TLC Rf = 0.54 (8:2 hexane:EtOAc). 
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(2S,3S,3aR,7R,7aS)-6,7a-Dimethoxy-3-methyl-7-(3-methylbut-2-en-1-yl)-3-(4-methylpent-3-en-1-yl)-
2,3,3a,4,7,7a-hexahydro-2,7-methanobenzofuran (317): 
Method A, using 2,6-di-tert-butyl-4-methylpyridine: 
A CH2Cl2 (100 mL) solution of 309 (1.88 g, 5.21 mmol, 1 equiv) and 2,6-di-tert-butyl-4-methylpyridine 
(2.14 g, 10.4 mmol, 2 equiv) in a 250-mL round-bottom flask was cooled to –78 ºC, and trimethylsilyl 
trifluoromethanesulfonate (1.13 mL, 6.26 mmol, 1.2 equiv) was added.  After stirring the golden yellow 
solution at –78 ºC for 45 min, it was quenched at –78 ºC with sat. aq. NaHCO3.  After warming the 
mixture to rt, it was diluted with H2O and brine, and extracted thrice with EtOAc.  The organic extracts 
were combined, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to a yellow oil.  
Flash column chromatography (400 mL SiO2, 99:1 → 95:5 hexane:EtOAc) afforded 1.70 g (4.72 mmol, 
90% yield) of 317 as a colorless oil.   
Method B, using 2,6-lutidine: 
A CH2Cl2 (50 mL) solution of 309 (3.62 g, 10.0 mmol, 1 equiv) and 2,6-lutidine (2.4 mL, 30. mmol, 3 
equiv) in a 200-mL round-bottom flask was cooled to –78 ºC, and trimethylsilyl 
trifluoromethanesulfonate (3.6 mL, 20. mmol, 2 equiv) was added.  After stirring the golden yellow 
solution at –78 ºC for 45 min, it was quenched at –78 ºC with sat. aq. NaHCO3, warmed to rt, and 
extracted thrice with EtOAc.  The organic extracts were combined, washed sequentially with 2 N HCl, 
H2O, and brine, dried over Na2SO4, filtered, and concentrated in vacuo to a pale orange oil.  Flash column 
chromatography (250 mL SiO2, 1:1 → 1:3 hexane:CH2Cl2) afforded 2.84 g (7.88 mmol, 79% yield) of 
317 as a colorless oil. 
1H NMR (600 MHz; CDCl3) δ: 5.34 (t, J = 7.1 Hz, 1H), 5.03 (t, J = 7.1 Hz, 1H), 4.52 (dd, J = 5.6, 2.2 
Hz, 1H), 3.74 (d, J = 5.1 Hz, 1H), 3.48 (s, 3H), 3.46 (s, 3H), 2.36 (dd, J = 14.8, 6.8 Hz, 1H), 2.22-2.17 
TMSOTf, DTBMP
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(m, 2H), 2.05-2.01 (m, 2H), 1.98-1.96 (m, 1H), 1.82 (d, J = 12.4 Hz, 1H), 1.78 (dd, J = 12.4, 5.1 Hz, 1H), 
1.70 (s, 3H), 1.69-1.65 (m, 4H), 1.61 (s, 3H), 1.58 (s, 3H), 1.45 (td, J = 13.1, 4.7 Hz, 1H), 1.22 (td, J = 
13.1, 4.6 Hz, 1H), 1.14 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 13-C NMR (126 MHz; CDCl3): δ 158.5, 131.6, 131.1, 124.9, 123.6, 
112.7, 90.6, 78.9, 54.6, 51.4, 46.5, 44.4, 42.0, 39.4, 33.6, 32.8, 28.2, 26.4, 25.9, 22.9, 20.1, 17.99, 17.85. 
FTIR (thin film) νmax: 2965, 2931, 1670, 1451, 1374, 1214, 1165, 1126, 1079, 1003, 945, 839, 804 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C23H36O3, 361.2737; found, 361.2730.  
TLC Rf = 0.50 (9:1 hexane:EtOAc). 
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(2S,3S,3aS,7R,7aS)-6,7a-Dimethoxy-3-methyl-7-(3-methylbut-2-en-1-yl)-3-(4-methylpent-3-en-1-yl)-
3,3a,7,7a-tetrahydro-2,7-methanobenzofuran-4(2H)-one (318): 
An EtOAc (30 mL) slurry of 317 (3.30 g, 9.15 mmol, 1 equiv), cesium carbonate (12.9 g, 36.6 mmol, 4 
equiv), and a nonane solution of tert-butyl hydroperoxide (5.5 M, 6.7 mL, 27 mmol, 4 equiv) in a 3-neck 
200-mL round-bottom flask was sparged for 10 min with O2 and subsequently cooled to –78 ºC with 
vigorous O2 bubbling.  An EtOAc (25 mL) solution of [bis(trifluoroacetoxy)iodo]benzene (11.8 g, 27.5 
mmol, 3 equiv) was added dropwise over 8 min, followed by an EtOAc (5 mL) rinse.  After stirring the 
resulting yellow slurry at –78 ºC for 1 h, it was quenched at –78 ºC with sat. aq. Na2S2O3 and warmed to 
rt with vigorous stirring over 45 min.  The mixture was then extracted thrice with EtOAc.  The organic 
extracts were combined, sequentially washed with H2O and brine, dried over Na2SO4, filtered, and 
concentrated in vacuo to a yellow oil.  Flash column chromatography (250 mL SiO2, 98:2 CH2Cl2:Et2O) 
afforded 1.01 g (2.69 mmol, 30% yield) of 318 as a pale yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 5.34 (s, 1H), 5.29 (t, J = 6.4 Hz, 1H), 4.98 (t, J = 7.1 Hz, 1H), 3.89 (d, J = 
5.8 Hz, 1H), 3.70 (s, 3H), 3.47 (s, 3H), 2.68 (s, 1H), 2.42 (dd, J = 14.9, 6.3 Hz, 1H), 2.35 (dd, J = 14.9, 
8.0 Hz, 1H), 2.06 (d, J = 13.0 Hz, 1H), 2.03-1.97 (m, 1H), 1.93 (dd, J = 13.0, 5.8 Hz, 1H), 1.74-1.67 (m, 
1H), 1.70 (s, 3H), 1.64 (s, 3H), 1.62 (s, 3H), 1.55 (s, 3H), 1.38 (ddd, J = 14.0, 12.1, 4.8 Hz, 1H), 1.34-
1.29 (m, 1H), 1.27 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 197.9, 181.2, 132.9, 132.0, 124.2, 122.1, 115.4, 100.8, 80.8, 56.8, 56.4, 
52.2, 48.6, 48.1, 38.8, 34.2, 32.2, 27.9, 26.3, 25.8, 22.8, 17.97, 17.84. 
FTIR (thin film) νmax: 2970, 2927, 1651, 1604, 1452, 1374, 1228, 1071, 1003 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C23H34O4, 375.2530; found, 375.2528.  
TLC Rf = 0.25 (7:3 hexane:EtOAc). 
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(2S,3aR,6R,7S,7aS,8S)-6-(tert-Butylperoxy)-7a-methoxy-8-methyl-3a-(3-methylbut-2-en-1-yl)-8-(4-
methylpent-3-en-1-yl)hexahydro-2,7-methanobenzofuran-4(2H)-one (319): 
A PhH (2 mL) solution of 317 (21.4 mg, 59 µmol, 1 equiv) in a 2-dram scintillation vial was treated with 
322689 (40. mg, 0.12 mmol, 2 equiv) and potassium carbonate (33 mg, 0.24 mmol, 4 equiv).  After stirring 
the reaction at rt for 3 d, it was diluted with 1:1 hexane:EtOAc and filtered through a short plug of SiO2, 
rinsing with 1:1 hexane:EtOAc.  The filtrate was concentrated in vacuo to a white residue.  Flash column 
chromatography (25 mL SiO2, 992:8 CH2Cl2:Et2O) afforded 7 mg (20 µmol, 26% yield) of 319 as a 
colorless oil and 1 mg (3 µmol, 5% yield) of 320 as a colorless residue.   
1H NMR (600 MHz; CDCl3) δ: 5.39 (t, J = 7.2 Hz, 1H), 5.02 (t, J = 6.9 Hz, 1H), 4.73 (d, J = 5.3 Hz, 1H), 
4.46 (dd, J = 5.3, 1.1 Hz, 1H), 3.75 (d, J = 5.3 Hz, 1H), 3.56 (s, 3H), 3.53 (s, 3H), 2.46 (s, 1H), 2.37 (dd, J 
= 14.7, 6.9 Hz, 1H), 2.28 (dd, J = 14.7, 7.3 Hz, 1H), 2.04-1.93 (m, 1H), 1.82 (dd, J = 12.6, 5.3 Hz, 1H), 
1.77 (d, J = 12.6 Hz, 1H), 1.69 (s, 3H), 1.68 (m, 1H), 1.67 (s, 3H), 1.60 (s, 3H), 1.57 (s, 3H), 1.36 (td, J = 
12.8, 4.9 Hz, 1H), 1.29-1.26 (m, 1H), 1.25 (s, 9H), 1.21 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 164.9, 131.84, 131.68, 124.6, 123.4, 112.3, 89.0, 80.1, 79.1, 77.4, 55.0, 
52.2, 47.0, 44.14, 43.95, 38.3, 34.0, 32.1, 27.9, 26.9, 26.4, 25.9, 23.0, 17.99, 17.89. 
 
Key 1D nOe correlation.  
                                                      
689 322 was prepared as described in ref. 636. 
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FTIR (thin film) νmax: 2970, 2925, 2869, 1657, 1450, 1374, 1363, 1225, 1196, 1169, 1069, 1005, 990, 
880 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C27H44O5, 449.3262; found, 449.3248.  
TLC Rf = 0.25 (7:3 hexane:EtOAc). 
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(2S,3aR,7R,7aS,8S)-7a-Methoxy-8-methyl-3a-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-
3,3a,7,7a-tetrahydro-2,7-methanobenzofuran-4(2H)-one (320): 
A PhH (1 mL) solution of 317 (17.6 mg, 49 µmol, 1 equiv) in a 10-mL pear-shaped flask was cooled to 0 
ºC, and an aqueous solution of tert-butyl hydroperoxide (70% by weight, 14 µL, 98 µmol, 2 equiv) and 
pyridinium dichromate (37 mg, 98 µmol, 2 equiv) were added in sequence.  The reaction was allowed to 
slowly warm to rt over 5 h, whereupon it was passed through a short plug of SiO2, rinsing with EtOAc.  
The filtrate was concentrated in vacuo to an orange oil.  Flash column chromatography (30 mL SiO2, 9:1 
→ 8:2 hexane:EtOAc) afforded 6.2 mg (18 µmol, 37% yield) of 320 as a pale yellow residue and 2.5 mg 
(6.7 µmol, 14% yield) of 318 as a pale yellow residue. 
1H NMR (600 MHz; CDCl3) δ: 6.74 (dd, J = 10.2, 7.0 Hz, 1H), 6.06 (d, J = 10.2 Hz, 1H), 5.37 (t, J = 7.2 
Hz, 1H), 5.01 (t, J = 7.2 Hz, 1H), 3.88 (d, J = 6.0 Hz, 1H), 3.47 (s, 3H), 2.59 (d, J = 7.0 Hz, 1H), 2.46 (dd, 
J = 14.7, 6.2 Hz, 1H), 2.34 (dd, J = 14.7, 8.2 Hz, 1H), 1.98 (d, J = 13.6 Hz, 1H), 1.95-1.92 (m, 1H), 1.89 
(dd, J = 13.6, 6.0 Hz, 1H), 1.84-1.77 (m, 1H), 1.71 (s, 3H), 1.66 (s, 3H), 1.63 (s, 3H), 1.57 (s, 3H), 1.44-
1.39 (m, 1H), 1.31-1.23 (m, 4H). 
13C NMR (125 MHz; CDCl3) δ: 201.5, 146.4, 132.9, 132.3, 129.2, 124.0, 122.3, 116.2, 80.8, 55.5, 52.5, 
48.5, 46.1, 35.6, 34.8, 30.5, 27.0, 26.3, 25.9, 23.4, 18.00, 17.87. 
FTIR (thin film) νmax: 2966, 2925, 2870, 1728, 1673, 1449, 1375, 1220, 1005, 833 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C22H32O3, 367.2244; found, 367.2238.  
TLC Rf = 0.38 (8:2 hexane:EtOAc).   
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(2S,3aR,7R,7aS,8S)-7a-Methoxy-8-methyl-3a-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-
yl)hexahydro-2,7-methanobenzofuran-4(2H)-one (321): 
A MeCN (0.4 mL) solution of 317 (14.0 mg, 39 µmol, 1 equiv) and a nonane solution of tert-butyl 
hydroperoxide (5.5 M, 35 µL, 0.19 mmol, 5 equiv) in a 2-dram scintillation vial was treated with ceric 
ammonium nitrate (43 mg, 78 µmol, 2 equiv).  After stirring the reaction for 10 min at rt, it was quenched 
with sat. aq. NaHCO3, diluted with H2O, and extracted thrice with EtOAc.  The organic extracts were 
combined, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to a colorless oil.  
Flash column chromatography (25 mL SiO2, 95:5 → 9:1 hexane:EtOAc) afforded 3.9 mg (11 µmol, 29% 
yield) of 321 as a white flocculent solid.   
1H NMR (600 MHz; CDCl3) δ: 5.16 (t, J = 7.3 Hz, 1H), 5.06 (t, J = 7.1 Hz, 1H), 3.91 (d, J = 5.7 Hz, 1H), 
3.46 (s, 3H), 2.52 (ddd, J = 14.8, 11.0, 7.6 Hz, 1H), 2.43-2.35 (m, 2H), 2.20 (dd, J = 14.5, 9.2 Hz, 1H), 
2.12-2.04 (m, 2H), 1.97 (d, J = 13.7 Hz, 1H), 1.92-1.86 (m, 2H), 1.85-1.75 (m, 2H), 1.69 (s, 3H), 1.68 (s, 
3H), 1.61 (s, 3H), 1.60 (s, 3H), 1.49 (td, J = 12.8, 5.1 Hz, 1H), 1.41 (td, J = 12.8, 4.8 Hz, 1H), 1.20 (s, 
3H). 
13C NMR (125 MHz; CDCl3) δ: 213.2, 133.8, 132.2, 124.3, 121.5, 116.7, 79.0, 59.1, 52.2, 46.0, 41.5, 
36.1, 35.5, 33.8, 29.9, 28.2, 26.3, 25.9, 23.3, 19.1, 18.06, 17.90. 
FTIR (thin film) νmax: 2966, 2929, 2859, 1707, 1449, 1375, 1325, 1227, 1150, 1103, 999 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C22H34O3, 369.2400; found, 369.2412.  
TLC Rf = 0.65 (7:3 hexane:EtOAc). 
OMe
OMe
MeO
Me
Me
Me
Me
317
OMe
O
MeO
Me
Me
Me
Me
321
CAN, TBHP
MeCN, nonane
10 min, rt
(29%)
261
 262 
 
(2S,3S,3aS,7R,7aS)-6,7a-Dimethoxy-3-methyl-5,7-bis(3-methylbut-2-en-1-yl)-3-(4-methylpent-3-en-
1-yl)-3,3a,7,7a-tetrahydro-2,7-methanobenzofuran-4(2H)-one (333): 
A THF (19 mL) solution of 318 (697 mg, 1.86 mmol, 1 equiv) in a 100-mL recovery flask was cooled to 
–78 ºC, and a freshly prepared THF solution of lithium 2,2,6,6-tetramethylpiperidide (0.53 M, 7.0 mL, 3.7 
mmol, 2 equiv) was added.  After stirring the resulting yellow-orange solution at –78 ºC for 20 min, a 
THF solution of lithium (2-thienyl)cyanocopper(I) (0.22 M, 17 mL, 3.7 mmol, 2 equiv) was added slowly 
over 10 min.  The resulting brown slurry was allowed to slowly warm to –40 ºC over 20 min.  After 
stirring the brown slurry at –40 ºC for an additional 30 min, it was cooled to –78 ºC, and prenyl bromide 
(1.1 mL, 9.3 mmol, 5 equiv) was added.  The reaction was allowed to slowly warm to –40 ºC over 45 
min, maintained at that temperature for 15 min, and subsequently quenched at –40 ºC with sat. aq. NH4Cl.  
The mixture was warmed to rt and extracted thrice with EtOAc.  The organic extracts were combined, 
sequentially washed with H2O and brine, dried over Na2SO4, filtered, and concentrated in vacuo to a 
brown oil.  Flash column chromatography (200 mL SiO2, 95:5 hexane:EtOAc) afforded 586 mg (1.32 
mmol, 71% yield) of 333 as a pale yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 5.30 (t, J = 6.9 Hz, 1H), 4.99 (t, J = 6.7 Hz, 1H), 4.97 (t, J = 7.1 Hz, 1H), 
3.87 (d, J = 5.7 Hz, 1H), 3.81 (s, 3H), 3.45 (s, 3H), 3.03-3.01 (m, 2H), 2.72 (s, 1H), 2.47 (dd, J = 15.2, 6.9 
Hz, 1H), 2.31 (dd, J = 15.2, 6.9 Hz, 1H), 2.14 (d, J = 12.7 Hz, 1H), 1.99-1.95 (m, 1H), 1.92 (dd, J = 12.7, 
5.7 Hz, 1H), 1.74-1.70 (m, 4H), 1.68 (s, 3H), 1.65 (s, 9H), 1.55 (s, 3H), 1.33-1.28 (m, 2H), 1.26 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 198.6, 176.3, 132.2, 131.88, 131.80, 124.2, 122.8, 122.34, 122.28, 114.6, 
81.0, 61.0, 56.7, 52.1, 49.3, 48.4, 39.3, 34.3, 32.8, 27.9, 26.3, 25.84, 25.81, 22.75, 22.65, 18.10, 18.04, 
17.8. 
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FTIR (thin film) νmax: 2968, 2925, 1655, 1617, 1449, 1375, 1345, 1331, 1233, 1074, 1009, 941, 829 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C28H42O4, 443.3156; found, 443.3150.  
TLC Rf = 0.65 (7:3 hexane:EtOAc). 
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(1S,5R,7S,8S,9S)-7,9-Dihydroxy-4,9-dimethoxy-8-methyl-3,5-bis(3-methylbut-2-en-1-yl)-8-(4-
methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-en-2-one (334): 
A CH2Cl2 (5 mL) solution of 333 (91 mg, 0.21 mmol, 1 equiv) in a 10-mL recovery flask was cooled to –
78 ºC, and a CH2Cl2 solution of bromodimethylborane (2.65 M, 0.78 mL, 2.1 mmol, 10 equiv) was added 
dropwise.  The resulting yellow solution was stirred at –78 ºC for 20 min and sequentially quenched at –
78 ºC with NEt3 (2 mL) and sat. aq. NaHCO3.  The mixture was warmed to rt and extracted thrice with 
EtOAc.  The organic extracts were combined, sequentially washed with H2O, sat. aq. NH4Cl, and brine, 
dried over Na2SO4, filtered, and concentrated in vacuo to a viscous yellow oil.  Flash column 
chromatography (50 mL SiO2, 9:1 → 8:2 hexane:EtOAc) afforded 85 mg (0.18 mmol, 89% yield) of 334 
as a pale yellow oil. 
1H NMR (600 MHz; C6D6) δ: 5.56 (d, J = 11.5 Hz, 1H), 5.36 (t, J = 7.3 Hz, 1H), 5.29 (t, J = 6.6 Hz, 1H), 
3.72 (s, 1H), 3.68 (dd, J = 11.9, 5.3 Hz, 1H), 3.54 (s, 3H), 3.35 (dd, J = 15.2, 6.4 Hz, 1H), 3.19-3.15 (m, 
2H), 3.07 (s, 3H), 2.93 (dd, J = 14.1, 11.5 Hz, 1H), 2.91-2.84 (m, 1H), 2.27 (d, J = 14.1 Hz, 1H), 2.11-
2.06 (m, 1H), 2.01 (dd, J = 12.8, 11.9 Hz, 1H), 1.85 (d, J = 0.6 Hz, 3H), 1.73 (s, 3H), 1.73-1.69 (m, 1H), 
1.65-1.60 (m, 7H), 1.57 (s, 3H), 1.43 (s, 3H), 1.28 (td, J = 12.7, 4.4 Hz, 1H), 1.13 (s, 3H). 
13C NMR (125 MHz; C6D6) δ: 197.4, 171.2, 136.5, 131.9, 131.2, 125.8, 124.5, 123.44, 123.31, 100.3, 
73.5, 61.9, 57.6, 52.5, 48.2, 41.0, 39.8, 37.5, 30.9, 26.1, 25.84, 25.80, 23.8, 22.3, 18.08, 17.97, 17.7, 17.4. 
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Key 1D nOe correlations. 
FTIR (thin film) νmax: 3464 (br), 2969, 2928, 2859, 1665, 1615, 1450, 1376, 1329, 1235, 1087, 1040, 
986, 928, 907, 858, 737 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C28H44O5, 461.3262; found, 461.3254.  
TLC Rf = 0.40 (7:3 hexane:EtOAc).  
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(1S,5R,7S,8S)-7-Hydroxy-4-methoxy-8-methyl-3,5-bis(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-
1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione (332): 
A 4:1 acetone:H2O (10 mL) solution of 334 (84.8 mg, 0.184 mmol, 1 equiv) in a 25-mL recovery flask 
was treated with pyridinium para-toluenesulfonate (231 mg, 0.920 mmol, 5 equiv).  The flask was 
outfitted with a reflux condenser, and the reaction was heated to reflux.  After refluxing for 11 h, the 
reaction was cooled to rt, diluted with H2O, and extracted thrice with 1:1 hexane:EtOAc.  The organic 
extracts were combined, sequentially washed with sat. aq. NaHCO3 and brine, dried over Na2SO4, 
filtered, and concentrated in vacuo to a colorless oil.  Flash column chromatography (35 mL SiO2, 8:2 
hexane:EtOAc) afforded 72.8 mg (0.17 mmol, 92% yield) of 332 as a colorless oil. 
1H NMR (600 MHz; C6D6) δ: 5.37 (t, J = 6.9 Hz, 1H), 5.27 (t, J = 7.2 Hz, 1H), 5.19 (t, J = 6.5 Hz, 1H), 
3.63 (dd, J = 11.1, 5.1 Hz, 1H), 3.52 (s, 1H), 3.40 (s, 3H), 3.18 (dd, J = 15.4, 6.4 Hz, 1H), 3.10 (dd, J = 
15.4, 6.7 Hz, 1H), 2.67-2.57 (m, 2H), 2.44 (dd, J = 14.5, 7.3 Hz, 1H), 1.92-1.87 (m, 2H), 1.75 (s, 3H), 
1.69 (s, 3H), 1.66 (s, 3H), 1.64-1.60 (m, 5H), 1.58 (s, 6H), 1.39 (td, J = 12.9, 4.8 Hz, 2H), 0.84 (s, 3H), 
0.64 (br s, 1H). 
13C NMR (125 MHz; C6D6) δ: 204.5, 193.6, 173.6, 133.5, 132.3, 131.6, 126.1, 125.1, 123.0, 120.6, 72.1, 
69.8, 61.7, 57.8, 46.3, 39.8, 38.4, 30.7, 26.00, 25.98, 25.7, 23.7, 22.1, 18.14, 18.01, 17.90, 15.7. 
FTIR (thin film) νmax: 3488 (br), 2968, 2922, 2856, 1736, 1656, 1649, 1593, 1447, 1376, 1341, 1236, 
1059 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C27H40O4, 451.2819; found, 451.2830.  
TLC Rf = 0.36 (7:3 hexane:EtOAc). 
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(1S,2S,3S,5R)-6-Methoxy-2-methyl-5,7-bis(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-yl)-8,9-
dioxobicyclo[3.3.1]non-6-en-3-yl trifluoromethanesulfonate (338): 
A CH2Cl2 (3 mL) solution of 332 (33.5 mg, 78.2 mmol, 1 equiv) in a 10-mL test tube was cooled to –43 
ºC, and pyridine (44 µL, 0.54 mmol, 7 equiv) and trifluoromethanesulfonic anhydride (76 µL, 0.45 mmol, 
6 equiv) were added sequentially.  The resulting white slurry was allowed to slowly warm to 0 ºC over 
100 min.  The reaction was subsequently quenched at 0 ºC with sat. aq. NaHCO3 and extracted thrice with 
EtOAc.  The organic extracts were combined, washed with H2O and brine, dried over Na2SO4, filtered, 
and concentrated in vacuo to an orange oil.  Flash column chromatography (40 mL SiO2, 9:1 
hexane:EtOAc) afforded 36.8 mg (65.6 µmol, 84% yield) of 338 as a colorless oil.   
1H NMR (600 MHz; C6D6) δ: 5.22 (t, J = 6.9 Hz, 1H), 5.16-5.10 (m, 3H), 3.49 (s, 1H), 3.41 (s, 3H), 3.17 
(dd, J = 15.3, 7.1 Hz, 1H), 2.97 (dd, J = 15.3, 6.5 Hz, 1H), 2.59-2.49 (m, 2H), 2.35 (dd, J = 13.1, 5.4 Hz, 
1H), 2.29 (dd, J = 14.5, 7.5 Hz, 1H), 1.84 (dd, J = 13.1, 11.8 Hz, 1H), 1.80-1.73 (m, 1H), 1.72 (s, 3H), 
1.64-1.62 (m, 4H), 1.61 (s, 3H), 1.60 (s, 3H), 1.58 (s, 3H), 1.57 (s, 3H), 1.49 (td, J = 12.9, 4.6 Hz, 1H), 
0.75 (s, 3H). 
13C NMR (125 MHz; C6D6) δ: 201.6, 191.8, 172.2, 134.5, 133.7, 132.6, 126.7, 123.7, 121.7, 119.5, 90.9, 
69.4, 62.1, 57.4, 45.6, 37.8, 37.0, 30.3, 25.92, 25.86, 25.6, 23.5, 21.6, 18.13, 17.96, 17.87, 16.3. 
19F NMR (470 MHz; C6D6) δ: –75.54 (s, 3F). 
FTIR (thin film) νmax: 2972, 2916, 2860, 1741, 1661, 1597, 1414, 1244, 1210, 1146, 918 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C28H39F3O6S, 583.2312; found, 583.2293.  
TLC Rf = 0.50 (9:1 hexane:EtOAc). 
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(2R,3R,3aR,5S,6aR)-6,6-Dimethoxy-3-methyl-5,6a-bis(3-methylbut-2-en-1-yl)-3-(4-methylpent-3-en-
1-yl)hexahydro-2,5-methanopentalene-1,7(2H)-dione (339): 
A MeOH (0.25 mL) solution of 338 (12 mg, 21 µmol) in a 10-mL test tube was cooled to 0 ºC, and a 
MeOH solution of sodium methoxide (0.5 M, 1 mL) was slowly added.  The reaction was allowed to 
slowly warm to rt.  After stirring for 20 h, the reaction was quenched at rt with sat. aq. NaHCO3 and 
extracted thrice with 1:1 hexane:EtOAc.  The organic extracts were combined, washed with H2O and 
brine, dried over Na2SO4, filtered, and concentrated in vacuo to afford 9.1 mg (21 µmol, >99% yield) of 
339 as a white flocculent solid.   
1H NMR (600 MHz; C6D6) δ: 5.72 (t, J = 7.0 Hz, 1H), 5.45 (t, J = 7.9 Hz, 1H), 5.03 (t, J = 6.9 Hz, 1H), 
3.20 (d, J = 2.0 Hz, 1H), 3.12 (s, 3H), 3.04 (s, 3H), 2.81-2.76 (m, 2H), 2.71 (dd, J = 14.8, 7.7 Hz, 1H), 
2.39 (dd, J = 14.6, 7.9 Hz, 1H), 2.17 (dd, J = 12.4, 5.8 Hz, 1H), 2.10 (dd, J = 5.8, 1.9 Hz, 1H), 1.92 (d, J = 
12.4 Hz, 1H), 1.87 (dt, J = 15.7, 7.5 Hz, 1H), 1.71 (s, 3H), 1.69 (s, 3H), 1.66 (s, 3H), 1.64 (s, 3H), 1.63-
1.61 (m, 4H), 1.52 (s, 3H), 1.18 (t, J = 8.5 Hz, 2H), 0.77 (s, 3H). 
13C NMR (125 MHz; C6D6) δ: 203.7, 202.5, 133.6, 132.1, 131.6, 124.5, 122.3, 121.8, 107.7, 75.5, 66.24, 
66.07, 51.9, 51.2, 47.0, 44.8, 38.9, 35.0, 27.0, 26.6, 26.07, 26.02, 25.8, 22.2, 19.3, 18.10, 18.01, 17.7. 
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Key 1D nOe correlations. 
FTIR (thin film) νmax: 2968, 2926, 2856, 1754, 1706, 1443, 1375, 1308, 1195, 1171, 1141, 1097, 1072, 
1046, 858 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C28H42O4, 443.3156; found, 443.3148.  
TLC Rf = 0.41 (9:1 hexane:EtOAc). 
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(1S,2S,3S,5R)-6-Methoxy-2-methyl-5,7-bis(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-yl)-8,9-
dioxobicyclo[3.3.1]non-6-en-3-yl methanesulfonate (340): 
A CH2Cl2 (3 mL) solution of 332 (38.7 mg, 90.3 µmol, 1 equiv) in a 10-mL test tube was cooled to 0 ºC, 
and triethylamine (65 µL, 0.47 mmol, 5.2 equiv) and methanesulfonyl chloride (30 µL, 0.39 mmol, 4.3 
equiv) were added sequentially.  After stirring the reaction at 0 ºC for 10 min, it was quenched with sat. 
aq. NaHCO3 and extracted thrice with EtOAc.  The organic extracts were combined, washed with H2O 
and brine, dried over Na2SO4, filtered, and concentrated in vacuo to a colorless residue.  Flash column 
chromatography (40 mL SiO2, 9:1 hexane:EtOAc) afforded 37.5 mg (74.0 µmol, 82% yield) of 340 as a 
colorless oil. 
1H NMR (600 MHz; C6D6) δ: 5.31 (t, J = 6.9 Hz, 1H), 5.24-5.19 (m, 2H), 4.92 (dd, J = 11.6, 5.3 Hz, 1H), 
3.54 (s, 1H), 3.54 (s, 3H), 3.16 (dd, J = 15.4, 6.9 Hz, 1H), 3.10 (dd, J = 15.4, 6.5 Hz, 1H), 2.64-2.59 (m, 
2H), 2.55 (dd, J = 13.3, 5.3 Hz, 1H), 2.38 (dd, J = 14.5, 7.5 Hz, 1H), 2.07 (s, 3H), 1.92 (dd, J = 13.3, 11.6 
Hz, 1H), 1.85 (tt, J = 12.6, 6.2 Hz, 1H), 1.75 (s, 3H), 1.66 (s, 3H), 1.63 (s, 3H), 1.62 (s, 3H), 1.59 (s, 3H), 
1.59-1.56 (m, 4H), 1.52 (td, J = 12.8, 4.9 Hz, 1H), 0.87 (s, 3H). 
13C NMR (125 MHz; C6D6) δ: 202.9, 192.6, 173.3, 134.1, 133.2, 132.2, 127.0, 124.4, 122.2, 119.9, 81.5, 
69.8, 62.2, 57.6, 45.7, 38.2, 37.73, 37.69, 30.3, 25.99, 25.95, 25.75, 23.6, 21.8, 18.15, 18.00, 17.94, 16.5. 
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Key 1D nOe correlations. 
FTIR (thin film) νmax: 2968, 2918, 2857, 1738, 1658, 1597, 1449, 1360, 1342, 1236, 1178, 1061, 945, 
862 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C28H42O6S, 507.2775; found, 507.2781.  
TLC Rf = 0.50 (7:3 hexane:EtOAc). 
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(4aR,5aS,6S,6aR,6bR)-6b-Hydroxy-4-methoxy-6-methyl-3,4a-bis(3-methylbut-2-en-1-yl)-6-(4-
methylpent-3-en-1-yl)-4a,5,5a,6,6a,6b-hexahydro-2H-cyclopropa[4,5]cyclopenta[1,2-b]pyran-2-one 
(341): 
A MeOH solution of sodium methoxide (0.5 M, 1 mL) was slowly added to a 10-mL test tube cooled to 0 
ºC containing 340 (5.5 mg, 11 µmol).  The reaction was allowed to slowly warm to rt.  After 18 h, the test 
tube was sealed and heated to 70 ºC.  After stirring the reaction at 70 ºC for 9 h, it was cooled to rt, 
quenched with sat. aq. NaHCO3, and extracted thrice with 1:1 hexane:EtOAc.  The organic extracts were 
combined, sequentially washed with H2O and brine, dried over Na2SO4, filtered, and concentrated in 
vacuo to a pale yellow residue.  Preparatory thin-layer chromatography (1 × 8:2 hexane:EtOAc) afforded 
0.7 mg (1.6 µmol, 15% yield) of 341 as a colorless residue.   
1H NMR (600 MHz; C6D6) δ: 5.46 (t, J = 6.4 Hz, 1H), 5.39 (t, J = 6.4 Hz, 1H), 5.06 (t, J = 7.0 Hz, 1H), 
3.47 (s, 3H), 3.37 (dd, J = 15.5, 6.5 Hz, 1H), 3.23 (dd, J = 15.5, 5.9 Hz, 1H), 3.13-3.13 (br s, 1H), 2.48 
(dd, J = 14.5, 7.7 Hz, 1H), 2.44 (dd, J = 14.7, 5.6 Hz, 1H), 2.29 (dd, J = 14.7, 7.7 Hz, 1H), 1.99 (dt, J = 
11.4, 5.6 Hz, 2H), 1.65 (s, 3H), 1.63 (s, 3H), 1.63 (s, 3H), 1.58 (d, J = 8.0 Hz, 1H), 1.54 (s, 3H), 1.52 (s, 
3H), 1.49 (dd, J = 14.5, 4.7 Hz, 1H), 1.45 (s, 3H), 1.27 (s, 3H), 1.13 (td, J = 7.8, 4.8 Hz, 1H), 0.99-0.96 
(m, 2H). 
13C NMR (125 MHz; C6D6) δ: 170.3, 165.1, 133.6, 132.2, 131.2, 124.9, 123.2, 120.2, 115.0, 108.0, 65.0, 
61.6, 42.7, 41.8, 33.4, 31.9, 30.7, 28.1, 25.84, 25.81, 25.77, 25.6, 25.3, 18.1, 17.88, 17.71, 14.1. 
FTIR (thin film) νmax: 3308 (br), 2964, 2920, 2854, 1677, 1631, 1452, 1376, 1342, 1224, 1190, 1093, 
1005 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C27H40O4, 429.2999; found, 429.2991.  
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TLC Rf = 0.61 (8:2 hexane:EtOAc).   
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(1S,5R,7S,8S)-7-Hydroxy-4,9,9-trimethoxy-8-methyl-3,5-bis(3-methylbut-2-en-1-yl)-8-(4-
methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-en-2-one (343): 
A CH2Cl2 (12 mL) solution of 333 (210 mg, 0.47 mmol, 1 equiv) in a 25-mL recovery flask was cooled to 
–78 ºC, and a CH2Cl2 solution of bromodimethylborane (2.65 M, 1.8 mL, 4.7 mmol, 10 equiv) was added.  
The resulting yellow solution was stirred at –78 ºC for 10 min and sequentially quenched at –78 ºC with 
1:1 NEt3:MeOH (10 mL) and sat. aq. NaHCO3.  The mixture was warmed to rt and extracted thrice with 
EtOAc.  The organic extracts were combined, washed with H2O and brine, dried over Na2SO4, filtered, 
and concentrated in vacuo to a brown oil.  Flash column chromatography (100 mL SiO2, 9:1 
hexane:EtOAc) afforded 149 mg (0.31 mmol, 67% yield) of 343 as a pale yellow oil.   
1H NMR (600 MHz; C6D6) δ: 5.27 (t, J = 7.1 Hz, 1H), 4.94 (t, J = 7.2 Hz, 1H), 4.90 (t, J = 6.5 Hz, 1H), 
3.76 (s, 3H), 3.47 (ddd, J = 11.9, 6.5, 5.4 Hz, 1H), 3.23 (s, 3H), 3.10 (s, 3H), 3.02 (dd, J = 15.3, 6.5 Hz, 
1H), 2.89 (dd, J = 15.3, 6.5 Hz, 1H), 2.82 (s, 1H), 2.57 (dd, J = 15.4, 7.6 Hz, 1H), 2.26-2.21 (m, 2H), 
1.82-1.74 (m, 2H), 1.68 (dd, J = 13.2, 5.4 Hz, 1H), 1.61 (s, 3H), 1.57 (s, 3H), 1.55 (s, 6H), 1.54 (s, 3H), 
1.52 (s, 3H), 1.30 (td, J = 12.8, 4.7 Hz, 1H), 1.17-1.13 (m, 1H), 1.00 (s, 3H), 0.87 (td, J = 12.8, 4.6 Hz, 
1H). 
13C NMR (125 MHz; CDCl3) δ: 198.7, 174.5, 132.3, 131.8, 131.4, 125.1, 123.6, 122.51, 122.39, 103.1, 
74.0, 62.3, 59.2, 53.7, 51.1, 50.5, 40.5, 39.8, 36.1, 30.7, 26.2, 25.93, 25.86, 23.4, 21.8, 18.2, 17.95, 17.89. 
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Key 1D nOe correlations.  
FTIR (thin film) νmax: 3468 (br), 2965, 2925, 2857, 1683, 1613, 1451, 1376, 1336, 1225, 1153, 1100, 
1065 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C29H46O5, 475.3418; found, 475.3406.  
TLC Rf = 0.47 (8:2 hexane:EtOAc). 
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(1S,2S,3S,5R)-6,9,9-Trimethoxy-2-methyl-5,7-bis(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-
yl)-8-oxobicyclo[3.3.1]non-6-en-3-yl trifluoromethanesulfonate (344): 
A CH2Cl2 (2 mL) solution of 343 (42 mg, 88 µmol, 1 equiv) and pyridine (43 µL, 0.53 mmol, 6 equiv) in 
a 10-mL recovery flask was cooled to –40 ºC, and trifluoromethanesulfonic anhydride (74 µL, 0.44 
mmol, 5 equiv) was added.  After allowing the reaction to slowly warm from –40 ºC to –10 ºC over 75 
min, it was quenched at –10 ºC with sat. aq. NaHCO3 and extracted thrice with EtOAc.  The organic 
extracts were combined, washed sequentially with H2O, sat. aq. NH4Cl, and brine, dried over Na2SO4, 
filtered, and concentrated in vacuo to a brown residue.  Flash column chromatography (30 mL SiO2, 95:5 
hexane:EtOAc) afforded 37 mg (63 µmol, 71% yield) of 344 as a colorless oil.   
1H NMR (600 MHz; C6D6) δ: 5.56 (t, J = 6.9 Hz, 1H), 5.27-5.22 (m, 2H), 5.19 (dd, J = 12.0, 5.3 Hz, 1H), 
3.58 (s, 3H), 3.33 (dd, J = 14.9, 7.4 Hz, 1H), 3.09 (s, 1H), 3.02 (dd, J = 14.9, 6.4 Hz, 1H), 2.95 (s, 3H), 
2.91 (s, 3H), 2.80-2.78 (m, 1H), 2.63 (dd, J = 15.7, 7.2 Hz, 1H), 2.37-2.30 (m, 2H), 2.18 (dd, J = 12.9, 5.3 
Hz, 1H), 1.99 (tt, J = 12.5, 6.1 Hz, 1H), 1.80 (s, 3H), 1.70 (s, 3H), 1.68-1.64 (m, 10H), 1.57 (s, 3H), 1.37 
(td, J = 12.9, 4.3 Hz, 1H), 1.19 (s, 3H). 
13C NMR (125 MHz; C6D6) δ: 196.2, 172.5, 133.3, 132.0, 131.6, 128.4, 124.5, 122.37, 122.18, 102.5, 
94.7, 62.1, 59.7, 54.3, 50.46, 50.42, 40.3, 39.8, 34.1, 31.3, 25.98, 25.94, 25.7, 23.5, 21.7, 19.3, 18.03, 
17.90, 17.82. 
19F NMR (470 MHz; C6D6) δ: –75.71 (s, 3F). 
FTIR (thin film) νmax: 2973, 2917, 2859, 1739, 1659, 1596, 1413, 1243, 1207, 1145, 915, 881, 626 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C30H45F3O7S, 607.2911; found, 607.2892.  
TLC Rf = 0.61 (8:2 hexane:EtOAc). 
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(1R,2S,5S,6R,7R,Z)-2,9,9-Trimethoxy-6-methyl-1-(3-methylbut-2-en-1-yl)-3-(3-methylbut-3-en-1-
ylidene)-6-(4-methylpent-3-en-1-yl)tricyclo[3.3.1.02,7]nonan-4-one (345): 
A THF (1.2 mL) solution of 344 (7.0 mg, 12 mmol, 1 equiv) in a 10-mL pear-shaped flask was cooled to 
–78 ºC, and a freshly prepared THF solution of lithium diisopropylamide (0.088 M, 0.52 mL, 46 µmol, 4 
equiv) was added.  After stirring the reaction at –78 ºC for 1 h, it was allowed to slowly warm to –20 ºC 
over 1 h.  The reaction was quenched at –20 ºC with sat. aq. NaHCO3 and extracted thrice with EtOAc.  
The organic extracts were combined, washed with brine, dried over Na2SO4, filtered, and concentrated in 
vacuo to a yellow residue. Preparatory thin-layer chromatography (2 × 9:1 hexane:EtOAc) afforded 2.3 
mg (5.0 µmol, 42% yield) of 345 as a colorless residue and 0.1 mg (0.2 µmol, 10% recovery) of 345 as a 
colorless residue.  
1H NMR (600 MHz; C6D6) δ: 6.19 (t, J = 7.9 Hz, 1H), 5.59 (t, J = 7.4 Hz, 1H), 5.15 (t, J = 7.4 Hz, 1H), 
4.85 (s, 1H), 4.81 (s, 1H), 3.78 (dd, J = 15.6, 8.2 Hz, 1H), 3.69 (dd, J = 15.6, 7.4 Hz, 1H), 3.18 (s, 3H), 
3.06 (s, 3H), 3.00 (s, 3H), 2.87 (s, 1H), 2.73 (dd, J = 16.0, 8.5 Hz, 1H), 2.49 (dd, J = 16.0, 6.4 Hz, 1H), 
2.38 (dd, J = 10.1, 7.7 Hz, 1H), 2.32 (dtd, J = 19.2, 6.8, 5.4 Hz, 1H), 2.18 (d, J = 7.7 Hz, 1H), 2.01 (tt, J = 
12.8, 6.2 Hz, 1H), 1.90 (d, J = 10.1 Hz, 1H), 1.77 (s, 3H), 1.71 (s, 3H), 1.65 (s, 3H), 1.63 (s, 3H), 1.62 (s, 
4H), 1.43 (td, J = 13.1, 4.4 Hz, 1H), 1.26 (s, 3H), 1.09 (ddd, J = 13.1, 12.4, 4.5 Hz, 1H). 
13C NMR (125 MHz; C6D6) δ: 196.9, 144.5, 138.4, 131.9, 131.4, 130.8, 125.1, 123.4, 111.2, 103.9, 87.4, 
62.2, 57.6, 52.5, 49.8, 48.1, 44.6, 41.3, 37.1, 36.0, 27.8, 26.3, 25.9, 25.3, 22.8, 22.1, 21.4, 18.0, 17.7. 
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Key 1D nOe correlations. 
FTIR (thin film) νmax: 2965, 2933, 2857, 1708, 1625, 1440, 1376, 1354, 1204, 1123, 1079, 1057, 888  
cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C29H44O4, 479.3132; found, 479.3133.  
TLC Rf = 0.49 (9:1 hexane:EtOAc). 
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(2R,3S,3aS,5R,7aR)-7a-(sec-Butyl)-6-methoxy-3-methyl-5,7-bis(3-methylbut-2-en-1-yl)-3-(4-
methylpent-3-en-1-yl)-3,3a,5,7a-tetrahydro-2,5-methanobenzofuran-4(2H)-one (348): 
A THF (1 mL) solution of 344 (15 mg, 25 µmol, 1 equiv) in a 10-mL pear-shaped flask was cooled to –78 
ºC, and a c-Hex solution of sec-butyllithium (1.43 M, 69 µL, 99 µmol, 4 equiv) was added dropwise.  
After stirring the resulting yellow-green solution at –78 ºC for 30 min, it was quenched at –78 ºC with sat. 
aq. NaHCO3 and extracted thrice with EtOAc.  The organic extracts were combined, washed with brine, 
dried over Na2SO4, filtered, and concentrated in vacuo to a white residue.  Preparatory thin-layer 
chromatography (1 × 1:1 CH2Cl2:hexane) afforded 3.9 mg (8.3 µmol, 33% yield) of 348 as a white 
residue.   
1H NMR (600 MHz; C6D6) δ: 5.73-5.67 (m, 1H), 5.65-5.62 (m, 1H), 5.14 (t, J = 6.5 Hz, 1H), 3.85 (d, J = 
16.0 Hz, 1H), 3.38 (s, 3H), 3.32-3.25 (m, 1H), 2.88-2.78 (m, 2H), 2.56-2.43 (m, 1H), 2.02-1.83 (m, 5H), 
1.68 (s, 6H), 1.65 (s, 3H), 1.62 (s, 3H), 1.61 (s, 3H), 1.60 (s, 3H), 1.56 (s, 3H), 1.55 (s, 3H), 1.45-1.36 (m, 
3H), 1.35 (d, J = 7.3 Hz, 3H, diastereomer A), 0.98 (d, J = 7.1 Hz, 1H, diastereomer B), 0.92 (t, J = 7.4 
Hz, 3H diastereomer A), 0.87 (s, 3H), 0.85 (d, J = 7.5 Hz, 3H, diastereomer B). 
13C NMR (125 MHz; C6D6) δ: 206.40, 206.36, 161.2, 161.0, 134.2, 133.4, 133.11, 133.09, 131.6, 131.3, 
130.05, 130.02, 125.63, 125.53, 124.6, 121.1, 89.8, 89.36, 89.35, 84.97, 84.81, 61.7, 61.18, 61.14, 54.79, 
54.74, 51.78, 51.75, 44.9, 44.6, 38.62, 38.50, 34.99, 34.91, 28.2, 27.39, 27.30, 26.05, 25.89, 25.85, 25.79, 
25.75, 25.4, 23.8, 22.96, 22.89, 18.02, 17.99, 17.80, 17.77, 17.44, 17.43, 17.36, 14.9, 14.7, 13.99, 13.98, 
13.2 (mixture of two diastereomers). 
FTIR (thin film) νmax: 2966, 2929, 2874, 1724, 1634, 1451, 1376, 1231, 1124, 1042, 970 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C31H48O3, 469.3676; found, 469.3677.  
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TLC Rf = 0.55 (1:1 hexane:EtOAc). 
280
 281 
 
(1S,2S,3S,5R)-6,9,9-Trimethoxy-2-methyl-5,7-bis(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-
yl)-8-oxobicyclo[3.3.1]non-6-en-3-yl methanesulfonate (349): 
A CH2Cl2 (2 mL) solution of 343 (30. mg, 63 µmol, 1 equiv) and pyridine (31 µL, 0.38 mmol, 6 equiv) in 
a 10-mL pear-shaped flask was cooled to 0 ºC, and methanesulfonyl chloride (25 µL, 0.32 mmol, 5 equiv) 
was added.  The reaction was allowed to slowly warm to rt.  After 1 d, the reaction was quenched at rt 
with sat. aq. NaHCO3 and extracted thrice with EtOAc.  The organic extracts were combined, washed 
with brine, dried over Na2SO4, filtered, and concentrated in vacuo to a pale yellow oil.  Flash column 
chromatography (30 mL SiO2, 9:1 hexane:EtOAc) afforded 13.7 mg (25 µmol, 39% yield) of 349 as a 
pale yellow oil.  
1H NMR (600 MHz; C6D6) δ: 5.65 (t, J = 6.8 Hz, 1H), 5.36 (t, J = 6.8 Hz, 1H), 5.30 (t, J = 7.2 Hz, 1H), 
4.93 (dd, J = 11.5, 5.8 Hz, 1H), 3.74 (s, 3H), 3.35 (dd, J = 15.0, 7.2 Hz, 1H), 3.14-3.11 (m, 2H), 3.03 (s, 
3H), 2.97 (s, 3H), 2.91-2.83 (m, 1H), 2.70 (dd, J = 15.8, 6.9 Hz, 1H), 2.44 (dd, J = 15.8, 6.6 Hz, 1H), 
2.37-2.29 (m, 2H), 2.18 (s, 3H), 2.11-2.05 (m, 1H), 1.83 (s, 3H), 1.71 (s, 3H), 1.70 (s, 3H), 1.70-1.63 (m, 
7H), 1.59 (s, 3H), 1.40 (td, J = 13.0, 4.2 Hz, 1H), 1.29 (s, 3H). 
13C NMR (125 MHz; C6D6) δ: 196.9, 173.5, 132.7, 131.7, 130.9, 125.1, 124.7, 122.85, 122.67, 103.0, 
84.5, 62.4, 59.7, 54.1, 50.41, 50.34, 40.8, 39.6, 37.9, 34.7, 31.5, 26.07, 26.03, 25.85, 23.6, 21.9, 19.5, 
18.08, 17.98, 17.84. 
FTIR (thin film) νmax: 2968, 2925, 2858, 1668, 1615, 1450, 1358, 1336, 1226, 1177, 1065, 933, 862 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C30H48O7S, 575.3013; found, 575.3017.  
TLC Rf = 0.39 (8:2 hexane:EtOAc). 
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(1S,2S,3S,5R)-6,9,9-Trimethoxy-2-methyl-5,7-bis(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-
yl)-8-oxobicyclo[3.3.1]non-6-en-3-yl pivalate (350): 
A CH2Cl2 (2 mL) solution of 343 (30. mg, 63 µmol, 1 equiv), pyridine (31 µL, 0.38 mmol, 6 equiv), and 
4-(dimethylamino)pyridine (46 mg, 0.38 mmol, 6 equiv) in a 10-mL pear-shaped flask was cooled to 0 
ºC, and pivaloyl chloride (39 µL, 0.32 mmol, 5 equiv) was added.  The resulting colorless solution was 
allowed to slowly warm to rt.  After stirring for 4.5 h, the reaction was quenched at rt with sat. aq. 
NaHCO3 and extracted thrice with EtOAc.  The organic extracts were combined, washed with brine, dried 
over Na2SO4, filtered, and concentrated in vacuo to an oily white residue.  Flash column chromatography 
(25 mL SiO2, 95:5 hexane:EtOAc) afforded 29 mg (52 µmol, 82% yield) of 350 as a colorless oil. 
1H NMR (600 MHz; C6D6) δ: 5.70 (t, J = 6.7 Hz, 1H), 5.40 (t, J = 6.6 Hz, 1H), 5.33 (t, J = 7.3 Hz, 1H), 
5.18 (dd, J = 11.4, 5.5 Hz, 1H), 3.87 (s, 3H), 3.36 (dd, J = 15.2, 6.8 Hz, 1H), 3.17 (s, 2H), 3.09 (s, 3H), 
3.04 (s, 3H), 2.75 (dd, J = 15.9, 6.8 Hz, 1H), 2.52 (dd, J = 15.9, 6.6 Hz, 1H), 2.14-2.05 (m, 3H), 1.82 (s, 
3H), 1.70 (s, 3H), 1.69 (s, 3H), 1.65 (s, 3H), 1.61 (s, 6H), 1.55 (td, J = 13.1, 4.4 Hz, 1H), 1.45-1.36 (m, 
4H), 1.11 (s, 9H). 
13C NMR (125 MHz; C6D6) δ: 197.3, 177.6, 174.4, 132.4, 131.5, 130.4, 125.4, 124.6, 123.3, 122.9, 103.5, 
76.3, 62.5, 59.9, 53.9, 50.44, 50.35, 41.1, 39.17, 39.05, 32.9, 31.7, 27.2, 26.10, 26.01, 25.8, 23.8, 22.1, 
20.2, 18.1, 17.89, 17.84. 
FTIR (thin film) νmax: 2971, 2928, 2877, 1726, 1666, 1615, 1460, 1376, 1335, 1283, 1160, 1063 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C34H54O6, 581.3813; found, 581.3812.  
TLC Rf = 0.66 (8:2 hexane:EtOAc). 
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(1S,5R,7S,8S,9S)-7,9-Dihydroxy-4,9-dimethoxy-8-methyl-5-(3-methylbut-2-en-1-yl)-8-(4-
methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-en-2-one (351): 
A CH2Cl2 (3 mL) solution of 318 (99 mg, 0.26 mmol, 1 equiv) and triethylamine (22 µL, 0.16 mmol, 0.6 
equiv) in a 25-mL recovery flask was cooled to –78 ºC, and a CH2Cl2 solution of bromodimethylborane 
(1.54 M, 1.0 mL, 1.6 mmol, 6 equiv)690 was added slowly.  After stirring the reaction at –78 ºC for 15 
min, it was sequentially quenched at –78 ºC with NEt3 (1 mL) and sat. aq. NaHCO3.  After warming the 
mixture to rt, it was extracted thrice with EtOAc.  The organic extracts were combined, washed with H2O 
and brine, dried over Na2SO4, filtered, and concentrated in vacuo to a yellow-orange oil.  Flash column 
chromatography (30 mL SiO2, 8:2 → 7:3 hexane:EtOAc) afforded 81 mg (0.21 mmol, 79% yield) of 351 
as a flocculent white solid.   
1H NMR (600 MHz; CDCl3) δ: 5.48 (s, 1H), 5.26 (d, J = 11.5 Hz, 1H), 5.05 (t, J = 7.2 Hz, 1H), 3.75 (s, 
3H), 3.62 (dd, J = 12.1, 5.3 Hz, 1H), 3.57 (s, 1H), 3.26 (s, 3H), 2.88-2.83 (m, 2H), 2.36 (tt, J = 12.7, 6.2 
Hz, 1H), 2.25 (d, J = 14.3 Hz, 1H), 1.96 (t, J = 12.1 Hz, 1H), 1.90 (ddd, J = 19.4, 13.1, 6.7 Hz, 1H), 1.73 
(s, 3H), 1.71-1.67 (m, 4H), 1.65 (s, 6H), 1.46 (td, J = 12.9, 4.7 Hz, 1H), 1.31-1.22 (br s, 1H), 1.12 (s, 3H), 
1.06 (td, J = 12.9, 4.4 Hz, 1H). 
13C NMR (125 MHz; CDCl3) δ: 198.2, 176.1, 137.4, 131.4, 125.0, 122.1, 104.1, 100.6, 73.2, 57.6, 56.6, 
51.1, 48.6, 40.5, 39.2, 37.0, 30.0, 26.3, 25.9, 21.9, 18.01, 17.89, 17.0. 
FTIR (thin film) νmax:  3460 (br), 2969, 2928, 2859, 1648, 1602, 1451, 1375, 1221, 1084, 908, 731 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C23H36O5, 393.2636; found, 393.2632.  
TLC Rf = 0.50 (1:1 hexane:EtOAc). 
                                                      
690 A CH2Cl2 solution of bromodimethylborane was prepared as described in ref. 639b. 
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(1S,5R,7S,8S)-7-Hydroxy-4-methoxy-8-methyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-
yl)bicyclo[3.3.1]non-3-ene-2,9-dione (282): 
A 4:1 acetone:H2O (4 mL) solution of 351 and pyridinium para-toluenesulfonate (208 mg, 0.83 mmol, 5 
equiv) in a 10-mL recovery flask outfitted with a reflux condenser was heated to reflux.  After stirring at 
reflux for 15.5 h, the reaction was cooled to rt, diluted with H2O, and extracted thrice with 1:1 
hexane:EtOAc.  The organic extracts were combined, sequentially washed with H2O and brine, dried over 
Na2SO4, filtered, and concentrated in vacuo to a pale yellow oil.  Flash column chromatography (20 mL 
SiO2, 7:3 hexane:EtOAc) afforded 54 mg (0.15 mmol, 90% yield) of 282 as a white flocculent solid.   
1H NMR (600 MHz; CDCl3) δ: 5.68 (s, 1H), 5.09 (t, J = 7.2 Hz, 1H), 4.98 (t, J = 7.0 Hz, 1H), 3.83-3.81 
(m, 1H), 3.75 (s, 3H), 3.19 (s, 1H), 2.50 (dd, J = 14.6, 6.4 Hz, 1H), 2.40 (dd, J = 14.6, 7.6 Hz, 1H), 2.35 
(tt, J = 12.6, 6.8 Hz, 1H), 2.12 (dd, J = 13.3, 5.4 Hz, 1H), 1.92 (tt, J = 12.6, 6.5 Hz, 1H), 1.76 (dd, J = 
13.3, 11.6 Hz, 1H), 1.67 (s, 3H), 1.66 (s, 3H), 1.65 (s, 3H), 1.65 (s, 3H), 1.56 (td, J = 12.9, 4.8 Hz, 1H), 
1.32 (td, J = 12.8, 4.7 Hz, 1H), 0.91 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 205.2, 193.1, 177.5, 134.6, 132.2, 124.3, 119.0, 106.1, 72.1, 69.2, 57.1, 
56.1, 45.9, 39.4, 38.1, 29.5, 26.1, 25.9, 21.8, 18.1, 17.9, 15.7. 
FTIR (thin film) νmax: 3433 (br), 2969, 2915, 2858, 1735, 1649, 1589, 1448, 1352, 1228, 1193, 1052, 
1034, 843, 732 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C22H32O4, 361.2373; found, 361.2378.  
TLC Rf = 0.41 (1:1 hexane:EtOAc). 
OH
OMeO
O
Me
Me
Me
Me
Me
PPTS, acetone/H2O
reflux, 15.5 h
(90%)
OH
OMeO
O
Me
Me
Me
Me
Me
Me
OH
351 282
284
 285 
 
(1S,2S,3S,5R)-6-Methoxy-2-methyl-5-(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-yl)-8,9-
dioxobicyclo[3.3.1]non-6-en-3-yl trifluoromethanesulfonate (352): 
A CH2Cl2 (20 mL) solution of 282 (253 mg, 0.702 mmol, 1 equiv) and pyridine (341 µL, 4.21 mmol, 6 
equiv) in a 50-mL recovery flask was cooled to –43 ºC, and trifluoromethanesulfonic anhydride (0.59 mL, 
3.5 mmol, 5 equiv) was added.  The resulting yellow slurry was allowed to slowly warm to 5 ºC over 2 h, 
whereupon it was quenched with sat. aq. NaHCO3 and extracted thrice with EtOAc.  The organic extracts 
were combined, washed with H2O and brine, dried over Na2SO4, filtered, and concentrated in vacuo to a 
yellow oil.  The oil was retaken in 8:2 hexane:EtOAc and passed through a plug of SiO2, rinsing with 8:2 
hexane:EtOAc.  The filtrate was concentrated in vacuo to afford 277 mg (0.562 mmol, 80% yield) of 352 
as a yellow-orange oil. 
1H NMR (600 MHz; C6D6) δ: 5.32 (s, 1H), 5.19-5.15 (m, 2H), 5.07 (dd, J = 11.6, 5.5 Hz, 1H), 3.41 (s, 
1H), 2.66 (s, 3H), 2.64-2.57 (m, 1H), 2.45 (dd, J = 14.4, 6.6 Hz, 1H), 2.30-2.25 (m, 2H), 1.85 (dd, J = 
12.9, 11.9 Hz, 1H), 1.81-1.76 (m, 1H), 1.74 (s, 3H), 1.65 (t, J = 8.4 Hz, 2H), 1.62 (s, 3H), 1.55 (s, 3H), 
1.54 (s, 3H), 0.75 (s, 3H). 
13C NMR (125 MHz; C6D6) δ: 201.6, 189.9, 175.4, 134.9, 132.6, 123.6, 118.8, 106.3, 90.6, 68.8, 56.4, 
55.3, 45.3, 37.8, 36.6, 29.5, 25.86, 25.80, 21.7, 17.91, 17.82, 16.3. 
19F NMR (470 MHz; C6D6) δ: –75.61 (s, 3F). 
FTIR (thin film) νmax: 2969, 2925, 2858, 1738, 1654, 1636, 1592, 1434, 1214, 1138, 922, 820, 602 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C23H31F3O6S, 493.1866; found, 493.1865.  
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(1S,2S,3R,5R)-6-Methoxy-2-methyl-5-(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-yl)-7-
(trimethylsilyl)tricyclo[3.3.1.01,3]non-6-ene-8,9-dione (353): 
A THF (12 mL) solution of 352 (277 mg, 0.562 mmol, 1 equiv) in a 25-mL recovery flask was cooled to 
–78 ºC, and chlorotrimethylsilane (3.6 mL, 28 mmol, 50 equiv) and a THF solution of lithium 
diisopropylamide (0.50 M, 5.6 mL, 2.8 mmol, 5 equiv) were added sequentially.  After stirring the 
resulting orange solution at –78 ºC for 45 min, it was quenched at –78 ºC with sat. aq. NaHCO3.  The 
mixture was warmed to rt and extracted thrice with EtOAc.  The organic extracts were combined, 
sequentially washed with H2O and brine, dried over Na2SO4, filtered, and concentrated in vacuo to a 
yellow oil.  Flash column chromatography (75 mL SiO2, 95:5 hexane:EtOAc) afforded 114 mg (0.27 
mmol, 49% yield) of 353 as a pale yellow oil.   
1H NMR (600 MHz; C6D6) δ: 5.42 (t, J = 7.4 Hz, 1H), 5.29 (t, J = 7.1 Hz, 1H), 3.23 (s, 3H), 2.60 (dd, J = 
15.1, 6.4 Hz, 1H), 2.51-2.47 (m, 2H), 2.19 (tt, J = 12.5, 6.2 Hz, 1H), 1.87 (ddd, J = 13.0, 12.5, 5.2 Hz, 
1H), 1.80 (ddd, J = 13.5, 11.2, 6.2 Hz, 1H), 1.75 (dd, J = 14.0, 5.4 Hz, 1H), 1.69-1.67 (m, 4H), 1.66 (s, 
3H), 1.62 (s, 3H), 1.55 (s, 3H), 1.08 (s, 3H), 0.99 (dd, J = 7.9, 5.4 Hz, 1H), 0.36 (s, 9H). 
13C NMR (125 MHz; C6D6) δ: 200.3, 194.8, 184.3, 134.5, 131.64, 131.63, 124.7, 119.6, 74.2, 61.9, 56.9, 
48.1, 38.8, 37.7, 27.8, 26.29, 26.18, 25.905, 25.898 18.00, 17.85, 16.4, 0.8. 
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Key 1D nOe correlations. 
FTIR (thin film) νmax: 2968, 2918, 2860, 1762, 1664, 1523, 1451, 1438, 1386, 1233, 1201, 1157, 1042, 
962, 845, 761, 691 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C25H38O3Si, 415.2663; found, 415.2650.  
TLC Rf = 0.64 (9:1 hexane:EtOAc). 
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(1S,5R,7S,8S)-7-Iodo-4-methoxy-8-methyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-
yl)bicyclo[3.3.1]non-3-ene-2,9-dione (357): 
A mixture of copper(I) iodide (20. mg, 0.10 mmol, 30.7 equiv) and lithium chloride (5.3 mg, 0.12 mmol, 
36.7 equiv) in a 10-mL recovery flask was subjected to three cycles of heat gun drying under vacuum and 
purging with Ar.  The mixture was subsequently taken up in THF (0.5 mL) and stirred at rt for 3 min.  
Meanwhile, a THF (1 mL) solution of tributylprenylstannane (37 mg, 0.10 mmol, 30.4 equiv) in a 10-mL 
pear-shaped flask was cooled to –78 ºC, and a hexane solution of butyllithium (1.56 M, 63 µL, 99 µmol, 
29.2 equiv) was added.  After stirring the resulting bright yellow solution at –78 ºC for 15 min, it was 
transferred via dry ice-cooled cannula to the copper(I) iodide-lithium chloride solution cooled to –78 ºC.  
After stirring the resulting brown-red solution at –78 ºC for 10 min, chlorotrimethylsilane (22 µL, 0.17 
mmol, 51.0 equiv), a THF (0.25 mL) solution of 353 (1.4 mg, 3.4 µmol, 1 equiv), and a THF (0.25 mL) 
rinse of the flask that contained 353 were added in quick succession.  The reaction was then allowed to 
slowly warm to 0 ºC over 90 min and was stirred at 0 ºC for 2 h, at which point the reaction turned black.   
After stirring for an additional 1 h at 0 ºC, the resulting colorless solution was quenched at 0 ºC with sat. 
aq. NH4Cl and extracted thrice with EtOAc.  The organic extracts were combined, sequentially washed 
with H2O and brine, dried over Na2SO4, filtered, and concentrated in vacuo to a pale yellow residue.  
Preparatory thin-layer chromatography (1 × 8:2 hexane:EtOAc) afforded 0.8 mg (2 µmol, 50% yield) of 
357 as a colorless residue.   
1H NMR (600 MHz; CDCl3) δ: 5.76 (s, 1H), 5.08 (t, J = 7.1 Hz, 1H), 4.97 (t, J = 6.9 Hz, 1H), 4.35 (dd, J 
= 12.8, 5.0 Hz, 1H), 3.77 (s, 3H), 3.39 (s, 1H), 2.52-2.46 (m, 2H), 2.44-2.36 (m, 3H), 1.89 (tt, J = 12.4, 
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6.0 Hz, 1H), 1.68 (s, 3H), 1.68 (s, 3H), 1.65 (s, 6H), 1.60 (td, J = 12.9, 4.3 Hz, 1H), 1.55 (s, 3H), 1.28 (td, 
J = 12.9, 4.3 Hz, 1H), 1.05 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 203.7, 192.6, 176.1, 134.9, 132.4, 123.7, 118.7, 106.6, 67.7, 59.5, 57.2, 
46.8, 45.1, 41.9, 37.1, 29.2, 26.15, 25.95, 21.9, 21.0, 18.2, 17.9. 
FTIR (thin film) νmax: 2962, 2919, 2853, 1736, 1655, 1595, 1453, 1368, 1223, 1191 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C22H31IO3, 493.1210; found, 493.1193.  
TLC Rf = 0.41 (8:2 hexane:EtOAc). 
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(1S,5R,7S,8S)-7-Hydroxy-4,9,9-trimethoxy-8-methyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-
en-1-yl)bicyclo[3.3.1]non-3-en-2-one (360): 
A CH2Cl2 (6 mL) solution of 318 (456 mg, 1.22 mmol, 1 equiv) and triethylamine (102 µL, 0.731 mmol, 
0.6 equiv) in a 20-mL scintillation vial was cooled to –78 ºC, and a CH2Cl2 solution of 
bromodimethylborane (1.26 M, 5.8 mL, 7.3 mmol, 6 equiv)691 was added slowly.  The resulting orange-
red solution was stirred at –78 ºC for 45 min and subsequently quenched at –78 ºC through the addition of 
1:1 MeOH:NEt3 (8 mL).  The reaction was then poured onto sat. aq. NaHCO3 and extracted thrice with 
EtOAc.  The organic extracts were combined, sequentially washed with 2 N HCl, sat. aq. NaHCO3, and 
brine, dried over Na2SO4, filtered, and concentrated in vacuo to a yellow oil.  Flash column 
chromatography (150 mL SiO2, 8:2 hexane:EtOAc) afforded 303 mg (0.745 mmol, 61% yield) of 360 as a 
flocculent yellow solid.     
1H NMR (600 MHz; CDCl3) δ: 5.40 (s, 1H), 5.34 (t, J = 7.2 Hz, 1H), 5.04 (t, J = 7.2 Hz, 1H), 3.67 (s, 
3H), 3.57-3.54 (m, 1H), 3.35 (s, 3H), 3.23 (s, 3H), 2.89 (s, 1H), 2.68 (dd, J = 15.3, 8.0 Hz, 1H), 2.39-2.33 
(m, 2H), 1.92-1.88 (m, 1H), 1.84 (dd, J = 13.1, 12.1 Hz, 1H), 1.72 (dd, J = 13.1, 5.2 Hz, 1H), 1.68 (s, 
3H), 1.64 (s, 6H), 1.61 (s, 3H), 1.45 (td, J = 12.9, 4.8 Hz, 1H), 1.37 (m, 1H), 1.11 (s, 3H), 1.04 (td, J = 
12.9, 4.5 Hz, 1H). 
13C NMR (125 MHz; CDCl3) δ: 198.1, 179.0, 131.9, 131.4, 125.1, 122.1, 103.9, 103.0, 73.5, 59.0, 56.5, 
52.4, 51.2, 50.6, 40.6, 39.5, 36.8, 35.9, 30.4, 26.2, 25.9, 21.9, 18.1, 17.9. 
FTIR (thin film) νmax: 3455 (br), 2967, 2925, 2859, 1654, 1600, 1454, 1374, 1350, 1224, 1060 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C24H38O5, 429.2611; found, 429.2609.  
TLC Rf = 0.49 (1:1 hexane:EtOAc). 
                                                      
691 A CH2Cl2 solution of bromodimethylborane was prepared as described in ref. 639b. 
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A CH2Cl2 (3 mL) solution of 360 (56.8 mg, 0.140 mmol, 1 equiv) and pyridine (68 µL, 0.84 mmol, 6 
equiv) in a 10-mL recovery flask was cooled to –40 ºC, and trifluoromethanesulfonic anhydride (118 µL, 
0.699 mmol, 5 equiv) was added.  The resulting yellow slurry was allowed to slowly warm to 0 ºC over 
90 min, whereupon it was quenched at 0 ºC with sat. aq. NaHCO3 and extracted thrice with 8:2 
hexane:EtOAc.  The organic extracts were combined, washed with brine, dried over Na2SO4, filtered, and 
concentrated to an orange-brown oil.  A portion of this oil (30. mg, 56 µmol, 1 equiv) was dissolved in 
THF (1 mL) in a 10-mL test tube, cooled to –78 ºC, and treated sequentially with chlorotrimethylsilane 
(353 µL, 2.7 mmol, 50 equiv), a freshly prepared THF solution of lithium diisopropylamide (0.50 M, 0.56 
mL, 0.28 mmol, 5 equiv), and hexamethylphosphoramide (53 µL, 0.31 mmol, 5.5 equiv).  The orange 
slurry was stirred at –78 ºC for 1 h and was then allowed to warm to 0 ºC over 4 h.  The reaction was then 
quenched at 0 ºC with sat. aq. NaHCO3 and extracted thrice with 8:2 hexane:EtOAc.  The organic extracts 
were combined, sequentially washed five times with H2O and once with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo to an orange oil.  This oil was dissolved in THF (1 mL) in a 10-mL 
test tube, cooled to –78 ºC, and treated with a freshly prepared THF solution of lithium diethylamide 
(0.50 M, 1.1 mL, 0.56 mmol, 10 equiv).  The brown-orange solution was stirred at –78 ºC for 45 min and 
subsequently allowed to slowly warm to –10 ºC over 45 min.  The resulting red solution was then 
quenched at –10 ºC with sat. aq. NaHCO3 and extracted thrice with EtOAc.  The organic extracts were 
combined, sequentially washed with H2O and brine, dried over Na2SO4, filtered, and concentrated in 
vacuo to a brown oil.  Preparatory thin-layer chromatography (1 × 9:1 hexane:EtOAc containing 1% 
NEt3) afforded 3.5 mg (7.6 µmol, 14% yield from 360) of 359 as a colorless oil and 14.5 mg (23.6 µmol, 
42% yield from 360) of 363 as a pale yellow oil.   
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(1S,2R,3S,5R)-6,9,9-Trimethoxy-2-methyl-5-(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-yl)-7-
(trimethylsilyl)tricyclo[3.3.1.01,3]non-6-en-8-one (359): 
1H NMR (600 MHz; C6D6) δ: 5.54 (t, J = 7.1 Hz, 1H), 5.47 (t, J = 7.2 Hz, 1H), 3.37 (s, 3H), 2.99 (s, 3H), 
2.97 (s, 3H), 2.77-2.71 (m, 2H), 2.42 (dd, J = 15.0, 7.0 Hz, 1H), 2.41-2.34 (m, 1H), 2.06 (dd, J = 13.3, 6.6 
Hz, 1H), 1.84 (td, J = 12.3, 5.2 Hz, 1H), 1.74 (s, 3H), 1.73-1.68 (m, 4H), 1.68 (m, 4H), 1.62 (s, 3H), 1.54 
(s, 3H), 0.84 (t, J = 7.0 Hz, 1H), 0.48 (s, 9H). 
13C NMR (125 MHz; C6D6) δ: 199.0, 184.4, 131.2, 131.0, 129.3, 125.6, 123.2, 110.1, 74.2, 64.1, 53.6, 
52.3, 51.1, 50.6, 41.8, 38.1, 31.7, 28.3, 26.7, 26.00, 25.95, 17.89, 17.87, 16.5, 1.0. 
FTIR (thin film) νmax: 2965, 2924, 2854, 1669, 1577, 1453, 1340, 1207, 1145, 1080 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C27H44O4Si, 483.2901; found, 483.2908.  
TLC Rf = 0.68 (8:2 hexane:EtOAc). 
(1S,2S,3S,5R)-6,9,9-Trimethoxy-2-methyl-5-(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-yl)-8-
oxo-7-(trimethylsilyl)bicyclo[3.3.1]non-6-en-3-yl diethylsulfamate (363): 
1H NMR (500 MHz; C6D6) δ: 5.66 (t, J = 6.8 Hz, 1H), 5.40 (t, J = 7.2 Hz, 1H), 4.82 (dd, J = 12.0, 5.2 Hz, 
1H), 3.79 (s, 3H), 3.08-2.94 (m, 12H), 2.74 (dd, J = 15.8, 7.0 Hz, 1H), 2.55-2.51 (m, 2H), 2.42 (t, J = 12.6 
Hz, 1H), 2.15 (tt, J = 12.3, 6.0 Hz, 1H), 1.91 (td, J = 13.2, 4.4 Hz, 1H), 1.83 (s, 3H), 1.70 (s, 3H), 1.68 (s, 
3H), 1.59-1.51 (m, 4H), 1.34 (s, 3H), 0.85 (t, J = 7.1 Hz, 6H), 0.42 (s, 9H). 
13C NMR (125 MHz; C6D6) δ: 201.1, 187.2, 131.6, 131.1, 128.6, 125.2, 122.7, 103.3, 84.3, 65.0, 60.10, 
60.07, 55.0, 50.4, 42.7, 41.0, 39.9, 34.0, 31.4, 26.08, 25.99, 22.1, 20.6, 19.7, 17.97, 17.87, 14.2, 13.3, 1.0. 
FTIR (thin film) νmax: 2971, 2937, 1660, 1600, 1458, 1358, 1345, 1222, 1206, 1165, 1102, 1061, 929, 
830 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C31H55NO7SSi, 636.3361; found, 636.3371.  
TLC Rf = 0.55 (8:2 hexane:EtOAc). 
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(1R,2S,3R,5R)-4,4,6-Trimethoxy-2-methyl-5-(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-
yl)tricyclo[3.3.1.01,3]non-6-en-8-one (364): 
A CH2Cl2 (3 mL) solution of 360 (56.8 mg, 0.140 mmol, 1 equiv) and pyridine (68 µL, 0.84 mmol, 6 
equiv) in a 10-mL recovery flask was cooled to –40 ºC, and trifluoromethanesulfonic anhydride (118 µL, 
0.699 mmol, 5 equiv) was added.  The resulting yellow slurry was allowed to slowly warm to 0 ºC over 
90 min whereupon it was quenched at 0 ºC with sat. aq. NaHCO3 and extracted thrice with 8:2 
hexane:EtOAc.  The organic extracts were combined, washed with brine, dried over Na2SO4, filtered, and 
concentrated to an orange-brown oil.  A portion of this oil (23 mg, 43 µmol, 1 equiv) was dissolved in 
THF (1 mL) in a 10-mL test tube, cooled to –78 ºC, and treated with a freshly prepared THF solution of 
lithium diisopropylamide (0.50 M, 0.85 mL, 0.43 mmol, 10 equiv).  The resulting brown-orange solution 
was stirred at –78 ºC for 45 min and then allowed to slowly warm to rt.  After stirring the resulting dark 
red solution for 16.5 h, it was quenched at rt with sat. aq. NaHCO3 and extracted thrice with EtOAc.  The 
organic extracts were combined, washed with brine, dried over Na2SO4, filtered, and concentrated in 
vacuo to a brown oil.  Preparatory thin-layer chromatography (1 × 8:2 hexane:EtOAc) afforded 7.4 mg 
(19 µmol, 44% yield from 360) of 364 as a pale yellow oil. 
1H NMR (600 MHz; C6D6) δ: 5.33 (s, 1H), 5.31 (t, J = 7.2 Hz, 1H), 5.11 (t, J = 7.4 Hz, 1H), 3.24 (s, 3H), 
3.05 (s, 3H), 3.03 (s, 3H), 2.84 (dd, J = 14.6, 7.2 Hz, 1H), 2.80 (dd, J = 14.6, 9.0 Hz, 1H), 2.60-2.52 (m, 
1H), 2.24-2.18 (m, 1H), 2.00 (d, J = 12.8 Hz, 1H), 1.95-1.86 (m, 2H), 1.78 (d, J = 12.8 Hz, 1H), 1.67 (s, 
3H), 1.66 (s, 3H), 1.63 (s, 3H), 1.56 (s, 3H), 1.29 (s, 3H), 1.16 (d, J = 0.9 Hz, 1H). 
13C NMR (125 MHz; C6D6) δ: 13-C NMR (126 MHz; Benzene): δ 195.9, 179.9, 132.5, 131.2, 125.1, 
121.8, 111.6, 105.4, 72.2, 55.7, 50.9, 50.0, 48.6, 44.5, 43.8, 39.3, 38.5, 28.6, 26.2, 25.97, 25.91, 18.0, 
17.8, 14.7. 
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Key 1D nOe correlations. 
FTIR (thin film) νmax: 2965, 2926, 2857, 1675, 1575, 1440, 1339, 1225, 1173, 1141, 1063, 997, 834 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C24H36O4, 411.2506; found, 411.2512.  
TLC Rf = 0.34 (8:2 hexane:EtOAc).  
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(1S,2S,3S,5R)-6,9,9-Trimethoxy-2-methyl-5-(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-yl)-8-
oxobicyclo[3.3.1]non-6-en-3-yl benzenesulfonate (366): 
A CH2Cl2 (1 mL) solution of 360 (16.1 mg, 39.6 µmol, 1 equiv) and pyridine (19 µL, 0.24 mmol, 6 equiv) 
in a 10-mL recovery flask was cooled to –40 ºC, and benzenesulfonyl chloride (25 µL, 0.20 mmol, 5 
equiv) was added.  The resulting yellow solution was allowed to slowly warm to rt.  After stirring for 1 d, 
the reaction was quenched at rt with sat. aq. NaHCO3 and extracted thrice with EtOAc.  The organic 
extracts were combined, sequentially washed with H2O and brine, dried over Na2SO4, filtered, and 
concentrated in vacuo to a pale yellow oil.  Flash column chromatography (30 mL SiO2, 96:4 
PhH:EtOAc) afforded 10.5 mg (19.2 µmol, 48% yield) of 366 as a colorless oil.   
1H NMR (600 MHz; C6D6) δ: 7.79 (d, J = 7.9 Hz, 2H), 6.92 (t, J = 7.5 Hz, 1H), 6.84 (t, J = 7.7 Hz, 2H), 
5.44 (t, J = 6.9 Hz, 1H), 5.37 (s, 1H), 5.16 (t, J = 7.2 Hz, 1H), 4.84 (dd, J = 12.0, 5.3 Hz, 1H), 3.05 (s, 
1H), 2.97 (s, 3H), 2.96 (s, 3H), 2.92 (s, 3H), 2.87-2.79 (m, 1H), 2.64 (dd, J = 15.6, 7.6 Hz, 1H), 2.32 (dd, 
J = 15.6, 6.3 Hz, 1H), 2.19 (dd, J = 14.5, 10.6 Hz, 1H), 2.01-1.93 (m, 2H), 1.79 (s, 3H), 1.66 (s, 6H), 
1.50-1.46 (m, 4H), 1.32-1.24 (m, 4H). 
13C NMR (125 MHz; C6D6) δ: 195.4, 177.3, 138.3, 133.1, 131.29, 131.14, 129.0, 125.2, 122.5, 103.68, 
103.56, 85.7, 59.3, 55.9, 52.6, 50.7, 50.4, 40.8, 39.4, 33.9, 30.8, 26.10, 25.97, 21.9, 19.4, 17.9, 17.7. 
FTIR (thin film) νmax: 2965, 2925, 2857, 1655, 1599, 1448, 1363, 1223, 1186, 1097, 1186, 1097, 1050, 
940, 853, 723, 689, 590 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C30H42O7S, 547.2724; found, 547.2718.  
TLC Rf = 0.30 (95:5 PhH:EtOAc). 
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(2S,3R)-3-(Bromomethyl)-2-(4-methoxy-4-methylpentyl)-2-methyloxirane (373): 
A MeOH (110 mL) solution of mercury(II) acetate (10.3 g, 32.2 mmol, 1.5 equiv) in a 250-mL round-
bottom flask was treated with 289 (5.00 g, 21.4 mmol, 1 equiv).  After stirring the resulting white slurry 
at rt for 15 min, it was cooled to 0 ºC and was treated with an aqueous solution of NaOH (3 M, 35 mL).  
After stirring the resulting bright orange slurry at 0 ºC for 2 min, and a basic, aqueous solution of NaBH4 
(0.5 M NaBH4 in 3 M NaOH aqueous solution, 35 mL) was added.  The resulting gray slurry was stirred 
at 0 ºC for 15 min, diluted with H2O, and extracted thrice with 8:2 hexane:EtOAc.  The organic extracts 
were combined, sequentially washed thrice with H2O and once with brine, dried over Na2SO4, filtered, 
and concentrated in vacuo to a colorless oil.  Flash column chromatography (250 mL SiO2, 9:1 → 8:2 
hexane:EtOAc) afforded 4.98 g (18.8 mmol, 88% yield) of 373 as a colorless oil as well as 187 mg (0.802 
mmol, 3.7% recovery) of 289 as a colorless oil.   
1H NMR (600 MHz; CDCl3) δ: 3.53 (dd, J = 10.4, 5.9 Hz, 1H), 3.24 (dd, J = 10.4, 7.7 Hz, 1H), 3.16 (s, 
3H), 3.08 (dd, J = 7.7, 5.9 Hz, 1H), 1.67-1.62 (m, 1H), 1.48-1.40 (m, 5H), 1.30 (s, 3H), 1.13 (s, 6H). 
13C NMR (125 MHz; CDCl3) δ: 74.6, 63.3, 61.6, 49.4, 39.9, 38.8, 30.0, 25.1, 19.6, 16.3. 
FTIR (thin film) νmax: 2971, 2948, 2915, 2826, 1465, 1432, 1382, 1364, 1253, 1221, 1205, 1148, 1083, 
891, 652 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C11H21BrO2, 287.0617; found, 287.0621.  
TLC Rf = 0.18 (9:1 hexane:EtOAc). 
Me Me Me
O
BrMeO
Me Me
O
BrMe
Hg(OAc)2
MeOH, rt, 15 min;
NaOH, 0 ºC, 2 min;
NaBH4, NaOH, H2O
0 ºC, 10 min
(88%, 4% recovered 289)
289 373
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(2S,3S)-3-((2,6-Dimethoxy-1-(3-methylbut-2-en-1-yl)cyclohexa-2,5-dien-1-yl)methyl)-2-(4-methoxy-
4-methylpentyl)-2-methyloxirane (374): 
A THF (100 mL) solution of 312 (4.35 g, 20.9 mmol, 1 equiv) in a 250-mL round-bottom flask was 
cooled to –78 ºC, and a c-Hex solution of sec-butyllithium (1.21 M, 21.6 mL, 26.1 mmol, 1.25 equiv) was 
added slowly over 5 min.  The resulting yellow slurry was allowed to slowly warm from –78 ºC to –30 ºC 
over 40 min and then stirred at –30 ºC for 15 min.  The resulting red-orange slurry was cooled to –78 ºC, 
and a THF (20 mL) solution of 373 (4.98 g, 18.8 mmol, 0.9 equiv) was added followed by two THF (10 
mL each) rinses.  The resulting cream-colored slurry was allowed to slowly warm to 0 ºC.  After stirring 
for 3.5 h, the reaction was quenched at 0 ºC with H2O and extracted thrice with EtOAc.  The organic 
extracts were combined, sequentially washed with H2O and brine, dried over Na2SO4, filtered, and 
concentrated in vacuo to a yellow oil.  Flash column chromatography (400 mL SiO2, 9:1 → 8:2 
hexane:EtOAc) afforded 4.95 g (12.6 mmol, 67% yield) of 374 as a colorless oil.   
1H NMR (600 MHz; CDCl3) δ: 4.89 (t, J = 7.3 Hz, 1H), 4.76 (t, J = 3.6 Hz, 1H), 4.72 (t, J = 3.6 Hz, 1H), 
3.51 (s, 3H), 3.46 (s, 3H), 3.15 (s, 3H), 2.75 (t, J = 3.6 Hz, 2H), 2.61 (dd, J = 8.0, 3.9 Hz, 1H), 2.34-2.27 
(m, 2H), 2.03 (dd, J = 13.7, 3.9 Hz, 1H), 1.76 (dd, J = 13.7, 8.0 Hz, 1H), 1.62 (s, 3H), 1.54 (s, 3H), 1.54-
1.49 (m, 1H), 1.42-1.37 (m, 2H), 1.35-1.30 (m, 2H), 1.27-1.22 (m, 1H), 1.17 (s, 3H), 1.12 (s, 6H). 
13C NMR (125 MHz; CDCl3) δ: 154.09, 154.02, 132.5, 120.7, 93.05, 92.94, 74.7, 61.47, 61.27, 54.5, 
54.1, 49.3, 46.2, 40.11, 39.91, 34.6, 34.1, 26.1, 25.23, 25.17, 24.2, 19.8, 17.9, 16.8. 
FTIR (thin film) νmax: 2972, 2912, 2828, 1695, 1659, 1453, 1381, 1364, 1223, 1206, 1151, 1124, 1084, 
1033, 973, 952, 849, 779, 689 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C24H40O4, 393.2999; found, 393.3000.  
TLC Rf = 0.37 (8:2 hexane:EtOAc). 
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s-BuLi, c-Hex, THF
–78 to –30 ºC, 40 min;
–30 ºC, 15 min;
373, THF, –78 to 0 ºC, 3.5 h
(67%)
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(2S,3S,3aR,7R,7aS)-6,7a-Dimethoxy-3-(4-methoxy-4-methylpentyl)-3-methyl-7-(3-methylbut-2-en-1-
yl)-2,3,3a,4,7,7a-hexahydro-2,7-methanobenzofuran (375): 
A THF (63 mL) solution of 374 (4.91 g, 12.5 mmol, 1 equiv) and 2,6-lutidine (3.0 mL, 38 mmol, 3 equiv) 
in a 200-mL round-bottom flask was cooled to –78 ºC, and trimethylsilyl trifluoromethanesulfonate (4.5 
mL, 25 mmol, 2 equiv) was added.  The resulting golden yellow solution was stirred at –78 ºC for 45 min 
and subsequently quenched at –78 ºC with sat. aq. NaHCO3.  The mixture was warmed to rt and extracted 
thrice with CH2Cl2.  The organic extracts were combined, sequentially washed with 1 N HCl, H2O, and 
brine, dried over Na2SO4, filtered, and concentrated in vacuo to a pale yellow oil.  Flash column 
chromatography (300 mL SiO2, 95:5 → 9:1 hexane:EtOAc) afforded 3.74 g (9.52 mmol, 76% yield) of 
375 as a pale yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 5.33 (t, J = 7.1 Hz, 1H), 4.51 (dd, J = 5.5, 2.1 Hz, 1H), 3.74 (d, J = 4.6 
Hz, 1H), 3.47 (s, 3H), 3.45 (s, 3H), 3.15 (s, 3H), 2.34 (dd, J = 14.7, 6.8 Hz, 1H), 2.21 (dd, J = 6.8, 1.8 Hz, 
1H), 2.18 (dd, J = 6.7, 2.3 Hz, 1H), 2.03 (m, 1H), 2.02-1.99 (m, 1H), 1.77 (dd, J = 12.0, 4.6 Hz, 1H), 1.75 
(d, J = 12.0 Hz, 1H), 1.69 (s, 3H), 1.60 (s, 3H), 1.42-1.28 (m, 4H), 1.18 (td, J = 12.6, 3.0 Hz, 1H), 1.12 (s, 
3H), 1.11 (s, 3H), 1.11 (s, 3H), 1.03-0.95 (m, 1H). 
13C NMR (125 MHz; CDCl3) δ: 158.6, 131.2, 123.6, 112.6, 90.5, 79.0, 74.6, 54.6, 51.4, 49.3, 46.5, 44.5, 
41.9, 41.2, 39.3, 34.0, 32.8, 28.2, 26.4, 25.23, 25.15, 20.1, 18.5, 18.0. 
 
Key 1D nOe correlations. 
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FTIR (thin film) νmax: 2968, 2839, 1670, 1451, 1374, 1363, 1208, 1166, 1078, 1006, 843, 805, 785 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C24H40O4, 415.2819; found, 415.2832.  
TLC Rf = 0.49 (8:2 hexane:EtOAc). 
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(2S,3S,3aS,7R,7aS)-6,7a-Dimethoxy-3-(4-methoxy-4-methylpentyl)-3-methyl-7-(3-methylbut-2-en-1-
yl)-3,3a,7,7a-tetrahydro-2,7-methanobenzofuran-4(2H)-one (376): 
An EtOAc692 (30 mL) slurry of cesium carbonate (12.76 g, 36.2 mmol, 4 equiv), 375 (3.55 g, 9.04 mmol, 
1 equiv), and a nonane solution of tert-butyl hydroperoxide (5.5 M, 6.6 mL, 36 mmol, 4 equiv) in a 3-
neck 300-mL round-bottom flask was cooled to –78 ºC with rapid O2 bubbling, and an EtOAc (25 mL) 
solution of [bis(trifluoroacetoxy)iodo]benzene (11.67 g, 27.1 mmol, 3 equiv) was added dropwise over 30 
min followed by an EtOAc (5 mL) rinse.  After stirring the reaction at –78 ºC for 2 h, it was allowed to 
slowly warm to 0 ºC.  Afte stirring the pink slurry for 2.25 h, O2 bubbling was suspended, and the 
reaction was quenched at 0 ºC with sat. aq. Na2S2O3.  The resulting yellow slurry was stirred vigorously at 
rt for 45 min and then extracted thrice with EtOAc.  The organic extracts were combined, sequentially 
washed with H2O and brine, dried over Na2SO4, filtered, and concentrated in vacuo to a yellow oil.  Flash 
column chromatography (300 mL SiO2, 7:3 hexane:EtOAc) afforded 1.069 g (2.629 mmol, 29% yield) of 
376 as a pale yellow oil.  
1H NMR (600 MHz; CDCl3) δ: 5.33 (s, 1H), 5.29 (t, J = 7.2 Hz, 1H), 3.90 (d, J = 5.7 Hz, 1H), 3.70 (s, 
3H), 3.46 (s, 3H), 3.12 (s, 3H), 2.67 (s, 1H), 2.41 (dd, J = 14.9, 6.1 Hz, 1H), 2.34 (dd, J = 14.9, 8.0 Hz, 
1H), 2.00 (d, J = 13.0 Hz, 1H), 1.93 (dd, J = 13.0, 5.7 Hz, 1H), 1.69 (s, 3H), 1.62 (s, 3H), 1.39-1.29 (m, 
4H), 1.26 (s, 3H), 1.23-1.11 (m, 2H), 1.09 (s, 6H). 
13C NMR (125 MHz; CDCl3) δ: 198.0, 181.3, 133.0, 122.1, 115.4, 100.8, 80.7, 74.5, 56.8, 56.4, 52.2, 
49.3, 48.6, 48.1, 40.9, 38.8, 34.6, 32.1, 28.0, 26.3, 25.3, 25.0, 18.2, 17.9. 
FTIR (thin film) νmax: 2969, 2943, 2873, 1720, 1649, 1602, 1453, 1372, 1227, 1070, 1003, 681 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C24H38O5, 429.2611; found, 429.2614.  
TLC Rf = 0.18 (1:1 hexane:EtOAc). 
                                                      
692 The EtOAc used in this procedure was sparged with O2 for 30 min directly prior to use. 
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5-((2S,3R)-3-(Bromomethyl)-2-methyloxiran-2-yl)-2-methylpentan-2-ol (380): 
A 1:1 THF/H2O (1 L) slurry of mercury(II) acetate (255.52 g, 801.82 mmol, 1.5 equiv) in a 2-L recovery 
flask was treated with 289 (124.63 g, 534.55 mmol, 1 equiv), and the resulting yellow solution was stirred 
at rt for 10 min.  The solution was then cooled using a 0 ºC ice bath, and an aqueous solution of NaOH (3 
M, 900 mL) was added.  The resulting bright yellow-orange slurry was stirred at 0 ºC for 2 min, and a 
basic, aqueous solution of NaBH4 (0.5 M NaBH4 in 3 M NaOH aqueous solution, 900 mL) was added, 
immediately producing a gray slurry.  After stirring an additional 10 min at 0 ºC, the slurry was extracted 
thrice with EtOAc.  The organic extracts were combined, sequentially washed thrice with H2O and once 
with brine, dried over Na2SO4, filtered, and concentrated in vacuo.  The resulting yellow oil was dissolved 
in 1:1 hexane:EtOAc and passed through a plug of SiO2, rinsing with 1:1 hexane:EtOAc.  Concentration 
of the filtrate in vacuo yielded 122.21 g (486.58 mmol, 91% yield) of 380 as a pale yellow oil that was 
used without further purification.   
1H NMR (600 MHz; CDCl3) δ: 3.53 (dd, J = 10.4, 5.9 Hz, 1H), 3.24 (dd, J = 10.4, 7.8 Hz, 1H), 3.07 (dd, 
J = 7.7, 6.0 Hz, 1H), 1.67-1.63 (m, 1H), 1.51-1.44 (m, 5H), 1.43-1.39 (m, 1H), 1.31-1.29 (s, 3H), 1.20 (s, 
6H). 
13C NMR (125 MHz; CDCl3) δ: 71.0, 63.3, 61.5, 43.6, 38.7, 29.9, 29.51, 29.42, 20.0, 16.2. 
FTIR (thin film) νmax: 3458 (br), 2971, 2947, 2872, 1471, 1386, 1222, 1153, 1073, 891 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C10H19BrO2, 273.0461; found, 273.0457. 
  
€ 
[α]D
23 = +23.1º (c 1.83, CHCl3). 
TLC Rf = 0.32 (1:1 hexane:EtOAc). 
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((5-((2S,3R)-3-(Bromomethyl)-2-methyloxiran-2-yl)-2-methylpentan-2-yl)oxy)triethylsilane (379): 
A DMF (1 L) solution of 380 (121.84 g, 485.11 mmol, 1 equiv) and imidazole (132.10 g, 1.940 mol, 4 
equiv) in a 2-L recovery flask was placed in a rt H2O bath and treated with chlorotriethylsilane (163 mL, 
0.970 mol, 2 equiv).  After stirring the resulting yellow solution at rt for 105 min, the flask was cooled 
using a 0 ºC ice bath and slowly quenched with sat. aq. NaHCO3.  After effervescence ceased, the mixture 
was extracted thrice with 9:1 hexane:EtOAc.  The organic extracts were combined, sequentially washed 
thrice with H2O and once with brine, dried over Na2SO4, filtered, and concentrated in vacuo.  The 
resulting colorless oil was dissolved in 95:5 hexane:EtOAc and passed through a plug of SiO2, rinsing 
with 95:5 hexane:EtOAc. Concentration of the filtrate in vacuo yielded 171.69 g (469.84 mmol, 97% 
yield) of 379 as a colorless oil that was used without further purification.  
1H NMR (600 MHz; CDCl3) δ: 3.55 (dd, J = 10.4, 5.9 Hz, 1H), 3.25 (dd, J = 10.4, 7.9 Hz, 1H), 3.07 (dd, 
J = 7.8, 5.9 Hz, 1H), 1.66 (ddd, J = 13.2, 9.3, 5.3 Hz, 1H), 1.52-1.37 (m, 5H), 1.30 (s, 3H), 1.20 (s, 6H), 
0.94 (t, J = 7.9 Hz, 9H), 0.56 (q, J = 7.9 Hz, 6H). 
13C NMR (125 MHz; CDCl3) δ: 73.3, 63.4, 61.6, 45.0, 38.9, 30.11, 30.02, 20.2, 16.2, 7.3, 7.0. 
FTIR (thin film) νmax: 2953, 2912, 2876, 1462, 1383, 1364, 1233, 1155, 1042, 1017, 743, 724 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C16H33BrO2Si, 387.1325; found, 387.1326. 
  
€ 
[α]D
23 = +16.8º (c 6.20, CHCl3). 
TLC Rf = 0.83 (1:1 hexane:EtOAc). 
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((5-((2S,3S)-3-((2,6-Dimethoxy-1-(3-methylbut-2-en-1-yl)cyclohexa-2,5-dien-1-yl)methyl)-2-
methyloxiran-2-yl)-2-methylpentan-2-yl)oxy)triethylsilane (381): 
A THF (1 L) solution of 312 (46.52 g, 223.3 mmol, 1 equiv) in a 2-neck 3-L round-bottom flask outfitted 
with an equal pressure dropping funnel was cooled using a –78 ºC dry ice/acetone bath, and a c-Hex 
solution of sec-butyllithium (1.56 M, 170. mL, 235 mmol, 1.05 equiv) was added dropwise over 30 min 
via the equal pressure dropping funnel, maintaining an internal reaction temperature ≤ –65 ºC.  The 
resulting yellow-orange slurry was allowed to slowly warm to –30 ºC over 90 min, and the resulting deep 
red slurry was stirred at –30 ºC for 15 min.  The reaction was then cooled using a –78 ºC dry ice/acetone 
bath, and a THF (200 mL) solution of 379 (73.45 g, 201.0 mmol, 0.9 equiv) was added dropwise via 
cannula, followed by two THF (50 mL each) rinses, maintaining an internal reaction temperature ≤ –65 
ºC throughout the addition.  The resulting pale yellow solution was allowed to slowly warm to –40 ºC 
over 1 h and quenched at –40 ºC with sat. aq. NaHCO3, which produced a small amount of effervescence.  
The mixture was warmed to rt and extracted thrice with 1:1 hexane:EtOAc.  The organic extracts were 
combined, sequentially washed sequentially with H2O and brine, dried over Na2SO4, filtered, and 
concentrated in vacuo to a pale yellow oil.  Flash column chromatography (1 L SiO2, 98:2 hexane:EtOAc) 
afforded 83.99 g (170.4 mmol, 85% yield) of 381 as a colorless oil. 
1H NMR (600 MHz; CDCl3) δ: 4.90 (t, J = 7.3 Hz, 1H), 4.77 (t, J = 3.5 Hz, 1H), 4.72 (t, J = 3.6 Hz, 1H), 
3.52 (s, 3H), 3.47 (s, 3H), 2.76 (t, J = 3.6 Hz, 2H), 2.62 (dd, J = 8.0, 4.0 Hz, 1H), 2.31 (qd, J = 10.8, 7.6 
Hz, 2H), 2.03 (dd, J = 13.7, 3.9 Hz, 1H), 1.77 (dd, J = 13.7, 7.9 Hz, 1H), 1.63 (s, 3H), 1.55 (s, 3H), 1.53-
1.48 (m, 1H), 1.41-1.31 (m, 4H), 1.28-1.21 (m, 1H), 1.18 (s, 3H), 1.17 (s, 6H), 0.94 (t, J = 7.9 Hz, 9H), 
0.55 (q, J = 7.9 Hz, 6H). 
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13C NMR (125 MHz; CDCl3) δ: 154.09, 154.04, 132.5, 120.7, 93.02, 92.90, 73.5, 61.45, 61.32, 54.5, 
54.1, 46.2, 45.4, 39.9, 34.6, 34.2, 30.2, 30.0, 26.1, 24.3, 20.2, 17.9, 16.8, 7.3, 7.0. 
FTIR (thin film) νmax: 2953, 2913, 2831, 1695, 1660, 1458, 1382, 1224, 1206, 1152, 1124, 1041, 778, 
742, 723 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C29H52O4Si, 493.3708; found, 493.3708. 
  
€ 
[α]D
23 = +22.1º (c 0.58, CHCl3). 
TLC Rf = 0.27 (95:5 hexane:EtOAc). 
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((5-((3S,3aR,7R,7aS)-6,7a-Dimethoxy-3-methyl-7-(3-methylbut-2-en-1-yl)-2,3,3a,4,7,7a-hexahydro-
2,7-methanobenzofuran-3-yl)-2-methylpentan-2-yl)oxy)triethylsilane (382): 
A CH2Cl2 (30 mL) solution of 381 (2.73 g, 5.54 mmol, 1 equiv) in a 100-mL recovery flask was cooled 
using a –78 ºC dry ice/acetone bath, and 2,6-lutidine (1.3 mL, 17 mmol, 3 equiv) and trimethylsilyl 
trifluoromethanesulfonate (2.46 g, 11.1 mmol, 2 equiv) were added sequentially.  The resulting yellow 
solution was stirred at –78 ºC for 45 min and subsequently quenched at –78 ºC with sat. aq. NaHCO3.  
After warming the mixture to rt, it was extracted thrice with EtOAc.  The organic extracts were combined, 
sequentially washed with 2 N HCl, H2O, sat. aq. NaHCO3, and brine, dried over Na2SO4, filtered, and 
concentrated in vacuo to a colorless oil.  Flash column chromatography (200 mL SiO2, 99:1 → 98:2 
hexane:EtOAc) afforded 2.15 g (4.35 mmol, 79% yield of 382 as a pale yellow oil. 
1H NMR (600 MHz; CDCl3) δ: 5.33 (t, J = 7.1 Hz, 1H), 4.51 (dd, J = 5.5, 2.0 Hz, 1H), 3.72 (t, J = 2.7 
Hz, 1H), 3.47 (s, 3H), 3.45 (s, 3H), 2.34 (dd, J = 14.7, 6.8 Hz, 1H), 2.21-2.16 (m, 1H), 2.21-2.16 (m, 1H), 
2.04-2.00 (m, 1H), 2.04-2.00 (m, 1H), 1.76 (d, J = 2.7 Hz, 1H), 1.69 (s, 3H), 1.61 (s, 3H), 1.37 (m, 1H), 
1.35-1.34 (m, 1H), 1.34-1.31 (m, 1H), 1.31-1.29 (m, 1H), 1.19 (m, 1H), 1.16 (s, 3H), 1.16 (s, 3H), 1.12 (s, 
3H), 1.08-1.02 (m, 1H), 0.93 (t, J = 7.9 Hz, 9H), 0.54 (q, J = 7.9 Hz, 6H). 
13C NMR (125 MHz; CDCl3) δ: 158.6, 131.1, 123.6, 112.6, 90.5, 79.0, 73.4, 54.5, 51.4, 46.49, 46.34, 
44.5, 41.9, 39.3, 34.0, 32.7, 30.2, 30.0, 28.2, 26.3, 20.1, 18.9, 17.9, 7.3, 7.0.  
FTIR (thin film) νmax: 2960, 2876, 2839, 1669, 1456, 1375, 1240, 1166, 1007, 853, 803, 743, 722 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C29H52O4Si, 493.3708; found, 493.3716. 
  
€ 
[α]D
22 = +17.6º (c 2.76, CHCl3). 
TLC Rf = 0.50 (9:1 hexane:EtOAc). 
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(3S,3aS,7R,7aS)-6,7a-Dimethoxy-3-methyl-3-(4-methyl-4-((triethylsilyl)oxy)pentyl)-7-(3-methylbut-
2-en-1-yl)-3,3a,7,7a-tetrahydro-2,7-methanobenzofuran-4(2H)-one (383): 
An EtOAc693 (500 mL) slurry of [bis(trifluoroacetoxy)iodo]benzene (133.9 g, 311.4 mmol, 3 equiv), 
cesium carbonate (146.5 g, 415.3 mmol, 4 equiv), 4Å molecular sieves (8.0 g, powdered), and 382 (51.16 
g, 103.8 mmol, 1 equiv) in an open 2-L recovery flask was cooled using a –78 ºC dry ice/acetone bath 
with vigorous O2 bubbling through the slurry via three foreshortened glass pipettes.  An EtOAc (200 mL, 
sparged for 1 h with O2 directly prior to the reaction) dilution of a nonane solution of tert-butyl 
hydroperoxide (5.5 M, 38 mmol, 210 mmol, 2 equiv) was added via cannula over 20 min.  The resulting 
yellow slurry was allowed to slowly warm to –15 ºC over 2.5 h, at which point O2 bubbling was 
suspended.  The reaction was then quenched at –15 ºC with sat. aq. Na2S2O3.  After warming the slurry to 
rt, the layers were separated.  The aqueous layer was extracted thrice with EtOAc.  The organic extracts 
were combined, sequentially washed twice with H2O and once with brine, dried over Na2SO4, filtered, 
and concentrated in vacuo to a red oil.  Flash column chromatography (850 mL SiO2, 9:1 → 8:2 
hexane:EtOAc) afforded 22.92 g (45.23 mmol, 44% yield) of 383 as a viscous yellow syrup. 
1H NMR (500 MHz; CDCl3) δ: 5.28 (s, 1H), 5.24 (t, J = 7.1 Hz, 1H), 3.82 (d, J = 5.7 Hz, 1H), 3.64 (s, 
3H), 3.40 (s, 3H), 2.61 (s, 1H), 2.36 (dd, J = 14.8, 6.2 Hz, 1H), 2.28 (dd, J = 14.8, 8.1 Hz, 1H), 1.95 (d, J 
= 13.0 Hz, 1H), 1.86 (dd, J = 13.0, 5.7 Hz, 1H), 1.63 (s, 3H), 1.56 (s, 3H), 1.26 (m, 1H), 1.24 (m, 1H), 
1.21 (m, 1H), 1.20 (m, 1H), 1.19 (s, 3H), 1.09 (s, 6H), 1.04-0.96 (m, 1H), 0.85 (t, J = 7.9 Hz, 9H), 0.47 
(q, J = 7.9 Hz, 6H). 
13C NMR (125 MHz; CDCl3) δ: 197.8, 181.1, 132.6, 122.0, 115.2, 100.6, 80.6, 73.1, 56.7, 56.2, 52.0, 
48.4, 48.0, 45.7, 38.7, 34.5, 32.0, 30.1, 29.7, 27.8, 26.1, 18.5, 17.8, 7.1, 6.8. 
FTIR (thin film) νmax: 2966, 2913, 2875, 1653, 1606, 1457, 1373, 1229, 1172, 1006, 725 cm–1. 
                                                      
693 The EtOAc used in this procedure was sparged with O2 for 1 h directly prior to use. 
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HRMS–ESI (m / z): [M+Na]+ calculated for C29H50O5Si, 529.3320; found, 529.3304. 
  
€ 
[α]D
23 = +30.6º (c 3.22, CHCl3). 
TLC Rf = 0.50 (7:3 hexane:EtOAc). 
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(1S,5R,7S,8S,9S)-7,9-Dihydroxy-4,9-dimethoxy-8-methyl-8-(4-methyl-4-((triethylsilyl)oxy)pentyl)-5-
(3-methylbut-2-en-1-yl)bicyclo[3.3.1]non-3-en-2-one (384): 
A CH2Cl2 (20 mL) solution of 383 (794 mg, 1.57 mmol, 1 equiv) and triethylamine (131 µL, 0.940 mmol, 
6 equiv) in a 25-mL recovery flask was cooled using a –95 ºC ethanol/liquid nitrogen bath, and a CH2Cl2 
solution of bromodimethylborane694 (1.59 M, 5.9 mL, 0.94 mmol, 6 equiv) was added slowly over 5 min, 
maintaining a bath temperature below –90 ºC.  The resulting bright yellow solution was stirred at –95 ºC 
for an additional 10 min and sequentially quenched at –95 ºC with 6 mL NEt3 and sat. aq. NaHCO3.  After 
warming the mixture to rt, it was extracted thrice with EtOAc.  The organic extracts were combined, 
sequentially washed with 2 N HCl, H2O, sat. aq. NaHCO3, and brine, dried over Na2SO4, filtered, and 
concentrated in vacuo to a yellow-orange oil.  Flash column chromatography (150 mL SiO2, 8:2  → 7:3 
hexane:EtOAc) afforded 471 mg (0.897 mmol, 57% yield) of 384 as a white flocculent solid.   
1H NMR (600 MHz; CDCl3) δ: 5.48 (s, 1H), 5.26 (d, J = 9.0 Hz, 1H), 5.05 (t, J = 7.1 Hz, 1H), 3.74 (s, 
3H), 3.63-3.59 (m, 1H), 3.57 (s, 1H), 3.26 (s, 3H), 2.87-2.83 (m, 2H), 2.36 (tt, J = 12.5, 6.2 Hz, 1H), 2.25 
(d, J = 14.0 Hz, 1H), 2.01-1.93 (m, 2H), 1.92-1.86 (m, 1H), 1.73 (s, 3H), 1.68 (s, 3H), 1.65 (s, 6H), 1.46 
(td, J = 13.0, 4.8 Hz, 1H), 1.32 (d, J = 5.9 Hz, 1H), 1.11 (s, 3H), 1.05 (td, J = 12.9, 4.4 Hz, 1H). 
13C NMR (125 MHz; CDCl3) δ: 198.2, 176.1, 137.4, 131.4, 125.0, 122.1, 104.1, 100.6, 73.2, 57.6, 56.6, 
51.1, 48.5, 40.5, 39.2, 36.9, 30.0, 26.2, 25.9, 21.9, 18.00, 17.88, 17.0. 
FTIR (thin film) νmax: 3465(br), 2954, 2913, 2876, 1659, 1645, 1606, 1456, 1365, 1225, 1173, 1087, 
1044, 1016, 742, 725 cm–1.  
HRMS–ESI (m / z): [M+H]+ calculated for C23H36O5, 393.2636; found, 393.2632. 
  
€ 
[α]D
23 = –24º (c 0.70, CHCl3). 
                                                      
694 A CH2Cl2 solution of bromodimethylborane was prepared as described in ref. 639b. 
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TLC Rf = 0.50 (1:1 hexane:EtOAc). 
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(1S,5R,7S,8S)-7-Hydroxy-4-methoxy-8-methyl-8-(4-methyl-4-((triethylsilyl)oxy)pentyl)-5-(3-
methylbut-2-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione (385): 
A THF (8 mL) solution of 384 (419.9 mg, 0.8001 mmol, 1 equiv) in a 50-mL recovery flask was cooled 
using a –78 ºC dry ice/acetone bath, and a freshly prepared THF solution of lithium 2,2,6,6-
tetramethylpiperidide (0.50 M, 4.0 mL, 2.0 mmol, 2.5 equiv) was added.  The resulting orange solution 
was allowed to warm to 0 ºC over 50 min.  The reaction was then quenched at 0 ºC with sat. aq. NaHCO3 
at 0 ºC.  The mixture was warmed to rt and extracted thrice with EtOAc.  The organic extracts were 
combined, sequentially washed with H2O and brine, dried over Na2SO4, filtered, and concentrated in 
vacuo to an orange oil.  Flash column chromatography (100 mL SiO2, 7:3 hexane:EtOAc) afforded 381.6 
mg (0.7744 mmol, 97% yield) of 385 as a viscous yellow oil. 
1H NMR (600 MHz; CDCl3) δ: 5.63 (s, 1H), 4.95 (t, J = 7.0 Hz, 1H), 3.78 (d, J = 7.8 Hz, 1H), 3.73 (s, 
3H), 3.15 (s, 1H), 2.47 (dd, J = 14.5, 6.4 Hz, 1H), 2.37 (dd, J = 14.5, 7.6 Hz, 1H), 2.09 (dd, J = 13.4, 5.4 
Hz, 1H), 1.88 (s, 1H), 1.73 (dd, J = 13.3, 11.6 Hz, 1H), 1.65 (m, 7H), 1.52 (td, J = 12.6, 3.5 Hz, 1H), 1.39 
(td, J = 12.5, 4.1 Hz, 1H), 1.34-1.27 (m, 2H), 1.23 (m, 4H), 1.18 (s, 3H), 0.92 (t, J = 7.9 Hz, 9H), 0.86 (s, 
3H), 0.54 (q, J = 7.8 Hz, 6H). 
13C NMR (125 MHz; CDCl3) δ: 205.4, 193.1, 177.4, 134.4, 119.0, 105.9, 73.6, 72.0, 69.2, 57.0, 56.0, 
46.2, 45.6, 39.4, 38.4, 30.6, 29.50, 29.48, 26.1, 18.1, 17.9, 15.7, 7.3, 6.9. 
FTIR (thin film) νmax: 3458(br), 2953, 2876, 1740, 1733, 1661, 1594, 1454, 1364, 1231, 1038, 842, 743, 
724 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C28H48O5Si, 515.3163; found, 515.3170. 
  
€ 
[α]D
23 = +32.1º (c 2.30, CHCl3). 
TLC Rf = 0.56 (1:1 hexane:EtOAc). 
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O-((1S,2S,3S,5R)-6-Methoxy-2-methyl-2-(4-methyl-4-((triethylsilyl)oxy)pentyl)-5-(3-methylbut-2-
en-1-yl)-8,9-dioxobicyclo[3.3.1]non-6-en-3-yl) O-phenyl carbonothioate (387): 
A THF solution of 384 (71 mg, 0.14 mmol, 1 equiv) in a 10-mL recovery flask was cooled to –78 ºC, and 
a hexane solution of butyllithium (2.02 M, 141 µL, 0.28 mmol, 2.1 equiv) was added dropwise over 5 
min.  After stirring the reaction at –78 ºC for 20 min, O-phenyl chlorothionoformate (39 µL, 0.28 mmol, 
2.1 equiv) was added in one portion.  The resulting yellow solution was allowed to slowly warm to rt.  
After stirring for 90 min, the reaction was quenched at rt with sat. aq. NaHCO3 and extracted thrice with 
EtOAc.  The organic extracts were combined, sequentially washed with H2O and brine, dried over 
Na2SO4, filtered, and concentrated in vacuo to an orange oil.  Flash column chromatography (50 mL SiO2, 
95:5 hexane:EtOAc) afforded 51 mg (81 µmol, 60% yield) of 387 as a yellow oil.   
1H NMR (600 MHz; CDCl3) δ: 7.41 (dd, J = 8.4, 7.5 Hz, 2H), 7.30 (t, J = 7.5 Hz, 1H), 7.08-7.06 (m, 2H), 
5.74 (s, 1H), 5.53 (dd, J = 11.5, 5.4 Hz, 1H), 4.99 (t, J = 7.0 Hz, 1H), 3.80 (s, 3H), 3.25 (s, 1H), 2.56-2.53 
(m, 2H), 2.44 (dd, J = 14.6, 7.4 Hz, 1H), 1.86 (dd, J = 12.9, 11.7 Hz, 1H), 1.69-1.65 (m, 7H), 1.58-1.56 
(m, 1H), 1.47-1.41 (m, 2H), 1.37 (m, 2H), 1.23 (s, 3H), 1.23 (s, 3H), 1.03 (s, 3H), 0.95 (t, J = 7.9 Hz, 9H), 
0.58 (q, J = 7.9 Hz, 6H). 
13C NMR (125 MHz; CDCl3) δ: 204.2, 194.6, 192.2, 177.0, 153.4, 134.9, 129.8, 126.9, 122.0, 118.7, 
106.3, 84.6, 73.6, 69.8, 57.4, 55.7, 45.66, 45.60, 38.1, 34.3, 30.5, 29.7, 29.4, 26.2, 18.2, 17.8, 17.5, 7.4, 
7.0. 
FTIR (thin film) νmax:  2958, 2911, 2874, 1739, 1659, 1594, 1490, 1275, 1206, 1034, 1017, 743 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C35H52O7SSi, 651.3152; found, 651.3130.  
TLC Rf = 0.57 (7:3 hexane:EtOAc). 
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O-((1S,2S,3S,5R)-6-Methoxy-2-methyl-2-(4-methyl-4-((triethylsilyl)oxy)pentyl)-5-(3-methylbut-2-
en-1-yl)-8,9-dioxobicyclo[3.3.1]non-6-en-3-yl) O-(perfluorophenyl) carbonothioate (388): 
A PhMe (100 mL) solution of 385 (5.40 g, 11.0 mmol, 1 equiv), N-hydroxysuccinimide (1.26 g, 11.0 
mmol, 1 equiv), and pyridine (4.4 mL, 55 mmol, 5 equiv) in a 200-mL recovery flask was treated with 
pentafluorophenyl chlorothionoformate  (8.8 mL, 55 mmol, 5 equiv), and the resulting yellow-orange 
slurry was stirred at 80 ºC for 2 h.  After cooling the resulting orange slurry to rt, it was diluted with 
EtOAc and sequentially washed twice with H2O and once with brine, dried over Na2SO4, filtered, and 
concentrated in vacuo to a black oil.  Flash column chromatography (700 mL SiO2, 98:2 → 9:1 
hexane:EtOAc) afforded 6.47 g (9.00 mmol, 82% yield) of 388 as viscous brown-orange syrup.   
1H NMR (600 MHz; CDCl3) δ: 5.74 (s, 1H), 5.45 (dd, J = 11.6, 5.4 Hz, 1H), 4.98 (t, J = 6.9 Hz, 1H), 
3.80 (s, 3H), 3.27 (s, 1H), 2.55 (dd, J = 14.5, 6.3 Hz, 1H), 2.50 (dd, J = 13.0, 5.4 Hz, 1H), 2.45 (dd, J = 
14.5, 7.5 Hz, 1H), 1.92 (t, J = 12.3 Hz, 1H), 1.69-1.68 (m, 7H), 1.42-1.29 (m, 5H), 1.21 (s, 6H), 1.07 (s, 
3H), 0.94 (t, J = 7.9 Hz, 9H), 0.57 (q, J = 8.0 Hz, 6H). 
13C NMR (125 MHz; CDCl3) δ: 203.7, 191.8, 176.8, 135.1, 118.4, 106.3, 87.2, 73.5, 69.6, 57.4, 55.6, 
45.64, 45.45, 38.0, 34.0, 30.4, 29.7, 29.3, 26.1, 18.2, 17.7, 17.4, 7.3, 7.0.  
19F NMR (282 MHz; CDCl3) δ: –152.71 (d, J = 18.1 Hz, 2F), –156.71 (t, J = 21.9 Hz, 1F), –162.21 (t, J = 
19.8 Hz, 2F). 
FTIR (thin film) νmax: 2960, 2914, 2876, 1742, 1668, 1599, 1523, 1456, 1380, 1312, 1222, 1158, 1043, 
966, 845, 743, 725 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C34H47F5O6SSi, 741.2675; found, 741.2667. 
  
€ 
[α]D
23 = +5.16º (c 2.28, CHCl3). 
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TLC Rf = 0.69 (7:3 hexane:EtOAc). 
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O-((1S,2S,3S,5R)-6-Methoxy-2-methyl-2-(4-methyl-4-((triethylsilyl)oxy)pentyl)-5-(3-methylbut-2-
en-1-yl)-8,9-dioxobicyclo[3.3.1]non-6-en-3-yl) S-methyl carbonodithioate (389): 
A THF (2 mL) solution of 385 (18.0 mg, 36.5 µmol, 1 equiv) and carbon disulfide (22 µL, 0.37 mmol, 10 
equiv) in a 10-mL recovery flask was cooled to 0 ºC, and sodium hydride (60% suspension in mineral oil, 
15 mg, 0.37 mmol, 10 equiv) was added.  After stirring the resulting white slurry at 0 ºC for 30 min, 
iodomethane (23 µL, 0.37 mmol, 10 equiv) was added.  The resulting yellow slurry was allowed to slowly 
warm to rt.  After stirring for 15.5 h, the reaction was quenched at rt with sat. aq. NaHCO3 and extracted 
thrice with EtOAc.  The organic extracts were combined, sequentially washed with H2O and brine, dried 
over Na2SO4, filtered, and concentrated in vacuo to a yellow oil.  Flash column chromatography (20 mL 
SiO2, 98:2 → 95:5 → 9:1 hexane:EtOAc) afforded 16.8 mg (28.8 µmol, 79% yield) of 389 as a colorless 
oil.   
1H NMR (600 MHz; CDCl3) δ: 5.88 (dd, J = 11.6, 5.4 Hz, 1H), 5.73 (s, 1H), 4.97 (t, J = 7.0 Hz, 1H), 
3.80 (s, 3H), 3.23 (s, 1H), 2.55-2.50 (m, 4H), 2.48 (dd, J = 13.0, 5.4 Hz, 1H), 2.40 (dd, J = 14.6, 7.3 Hz, 
1H), 1.76 (dd, J = 13.0, 11.6 Hz, 1H), 1.62-1.60 (m, 7H), 1.40-1.22 (m, 5H), 1.19 (s, 6H), 1.07 (s, 3H), 
0.94 (t, J = 7.9 Hz, 9H), 0.56 (q, J = 7.9 Hz, 6H). 
13C NMR (125 MHz; CDCl3) δ: 215.8, 204.3, 192.2, 177.1, 134.8, 118.7, 106.2, 83.2, 73.5, 70.1, 57.3, 
55.7, 45.8, 45.5, 38.3, 34.5, 30.5, 29.7, 29.3, 26.1, 19.2, 18.2, 17.86, 17.74, 7.4, 7.0 
FTIR (thin film) νmax: 2956, 2911, 2874, 1739, 1658, 1595, 1458, 1353, 1231, 1208, 1050, 742, 724 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C30H50O5S2Si, 605.2761; found, 605.2737.  
TLC Rf = 0.28 (9:1 hexane:EtOAc). 
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O-((1S,2S,3S,5R)-6-Methoxy-2-methyl-2-(4-methyl-4-((triethylsilyl)oxy)pentyl)-5-(3-methylbut-2-
en-1-yl)-8,9-dioxobicyclo[3.3.1]non-6-en-3-yl) 1H-imidazole-1-carbothioate (390): 
A CH2Cl2 (1 mL) solution of 385 (19.2 mg, 39.0 µmol, 1 equiv), 1,1′-thiocarbonyldiimidazole (69 mg, 
0.390 mmol, 10 equiv), and 4-(dimethylamino)pyridine (5 mg, 40 µmol, 1 equiv) in a 10-mL test tube 
was sealed and heated to 40 ºC.  After stirring the brown-orange solution at 40 ºC for 30 h, it was cooled 
to rt, and quenched with a few drops of MeOH.  The mixture was diluted with sat. aq. NaHCO3 and 
extracted thrice with EtOAc.  The organic extracts were combined, sequentially washed with H2O and 
brine, dried over Na2SO4, filtered, and concentrated in vacuo to an orange oil.  Flash column 
chromatography (25 mL SiO2, 8:2 → 7:3 hexane:EtOAc) afforded 12.8 mg (21.2 µmol, 54% yield) of 390 
as a colorless oil. 
1H NMR (600 MHz; CDCl3) δ: 8.28 (s, 1H), 7.55 (s, 1H), 7.05 (s, 1H), 5.80-5.75 (m, 2H), 4.99 (t, J = 7.0 
Hz, 1H), 3.85 (s, 3H), 3.29 (s, 1H), 2.56-2.51 (m, 2H), 2.44 (dd, J = 14.6, 7.5 Hz, 1H), 1.85 (t, J = 12.3 
Hz, 1H), 1.71-1.64 (m, 7H), 1.40-1.23 (m, 5H), 1.17 (s, 3H), 1.17 (s, 3H), 1.13 (s, 3H), 0.91 (t, J = 7.9 
Hz, 9H), 0.53 (q, J = 7.9 Hz, 6H). 
13C NMR (125 MHz; CDCl3) δ: 203.7, 191.8, 183.4, 176.9, 137.0, 135.2, 131.4, 118.4, 117.9, 106.3, 
83.8, 73.4, 69.6, 57.5, 55.6, 45.6, 45.4, 38.4, 34.2, 30.5, 29.6, 29.3, 26.2, 18.18, 18.04, 17.8, 7.4, 7.0. 
FTIR (thin film) νmax: 2957, 2913, 2874, 1740, 1656, 1595, 1460, 1390, 1332, 1285, 1221, 1108, 1042, 
986, 742, 724 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C32H50N2O5SSi, 625.3102; found, 625.3082. 
TLC Rf = 0.58 (1:1 hexane:EtOAc). 
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388 (6.46 g, 8.99 mmol, 1 equiv) was taken up in PhH (10 mL) and allyltributylstannane (30 mL) in a 
200-mL recovery flask open to air, and a PhH solution of triethylborane (5.0 M, 0.90 mL, 4.5 mmol, 0.5 
equiv) was added.  The resulting golden yellow solution was stirred vigorously open to air for 30 min, 
and a PhH solution of triethylborane (5.0 M, 0.90 mL, 4.5 mmol, 0.5 equiv) was added.  After stirring an 
additional 40 min, the solution was concentrated partially in vacuo and purified using flash column 
chromatography (700 mL SiO2, 98:2 → 95:5 hexane:EtOAc) to afford 3.35 g (6.48 mmol, 72% yield) of 
386 as a colorless oil and 701 mg (1.47 mmol, 16% yield) of 391 as a pale yellow oil. 
(1S,5R,7S,8R)-7-Allyl-4-methoxy-8-methyl-8-(4-methyl-4-((triethylsilyl)oxy)pentyl)-5-(3-methylbut-
2-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione (386): 
1H NMR (600 MHz; CDCl3) δ: 5.69 (s, 1H), 5.65 (dddd, J = 16.8, 10.3, 8.5, 5.5 Hz, 1H), 5.01 (dd, J = 
4.9, 0.8 Hz, 1H), 4.99 (dd, J = 11.7, 0.8 Hz, 1H), 4.96 (t, J = 7.0 Hz, 1H), 3.73 (s, 3H), 3.13 (s, 1H), 2.46 
(dd, J = 14.4, 5.9 Hz, 1H), 2.36 (dd, J = 14.7, 7.8 Hz, 1H), 2.34-2.30 (m, 1H), 1.97 (dd, J = 13.9, 4.6 Hz, 
1H), 1.77-1.69 (m, 2H), 1.67-1.64 (m, 4H), 1.63 (s, 3H), 1.48-1.38 (m, 3H), 1.34-1.32 (m, 1H), 1.27 (m, 
1H), 1.24-1.22 (m, 4H), 1.21 (s, 3H), 0.94 (t, J = 7.9 Hz, 9H), 0.81 (s, 3H), 0.57 (q, J = 7.8 Hz, 6H). 
13C NMR (125 MHz; CDCl3) δ: 207.2, 193.9, 177.5, 137.2, 133.9, 119.5, 116.8, 106.5, 73.7, 70.8, 56.98, 
56.95, 46.2, 45.7, 39.8, 39.29, 39.16, 33.9, 30.6, 29.8, 29.6, 26.1, 18.13, 18.06, 17.90, 7.4, 7.0. 
FTIR (thin film) νmax: 2961, 2917, 2876, 1733, 1657, 1599, 1460, 1365, 1227, 1171, 1042, 1017, 743, 
724 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C31H52O4Si, 539.3527; found, 539.3521. 
  
€ 
[α]D
23 = +23.5º (c 0.54, CHCl3). 
TLC Rf = 0.45 (8:2 hexane:EtOAc). 
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(1S,5S,8R)-4-Methoxy-8-methyl-8-(4-methyl-4-((triethylsilyl)oxy)pentyl)-5-(3-methylbut-2-en-1-
yl)bicyclo[3.3.1]non-3-ene-2,9-dione (391): 
1H NMR (500 MHz; CDCl3) δ: 5.72 (s, 1H), 4.96 (t, J = 7.0 Hz, 1H), 3.74 (s, 3H), 2.97 (s, 1H), 2.50 (dd, 
J = 14.5, 6.0 Hz, 1H), 2.38 (dd, J = 14.5, 7.8 Hz, 1H), 1.84-1.80 (m, 1H), 1.77 (dd, J = 13.7, 4.2 Hz, 1H), 
1.69-1.67 (m, 1H), 1.65 (s, 3H), 1.63 (s, 3H), 1.52-1.27 (m, 7H), 1.25-1.20 (m, 3H), 1.18 (s, 6H), 0.92 (t, 
J = 7.9 Hz, 9H), 0.54 (q, J = 7.9 Hz, 6H). 
13C NMR (125 MHz; CDCl3) δ: 207.1, 194.1, 177.1, 133.9, 128.5, 119.5, 106.4, 73.6, 72.3, 56.9, 45.6, 
43.5, 42.3, 33.4, 31.8, 30.5, 29.80, 29.76, 26.1, 22.0, 18.16, 18.12, 7.3, 7.0. 
FTIR (thin film) νmax: 2954, 2911, 2875, 1733, 1655, 1597, 1458, 1365, 1224, 1044, 1015, 743, 724 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C28H48O4Si, 499.3214; found, 499.3204.  
TLC Rf = 0.38 (8:2 hexane:EtOAc). 
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(1S,5R,7S,8R)-4-Methoxy-8-methyl-8-(4-methyl-4-((triethylsilyl)oxy)pentyl)-5,7-bis(3-methylbut-2-
en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione (392): 
A CH2Cl2 (0.5 mL) and 2-methyl-2-butene (0.5 mL) solution of 386 (18.4 mg, 35.6 µmol, 1 equiv) and 
Hoveyda–Grubbs 2nd generation catalyst 117 (3.3 mg, 5.3 µmol, 0.15 equiv) in a sealed 10-mL test tube 
was stirred at 40 ºC for 2 h.  The olive-black solution was subsequently cooled to rt and concentrated in 
vacuo.  Flash column chromatography (50 mL SiO2, 95:5 hexane:EtOAc) afforded 16.7 mg (30.6 µmol, 
86% yield) of 392 as a colorless oil. 
1H NMR (600 MHz; CDCl3) δ: 5.69 (s, 1H), 4.98-4.94 (m, 2H), 3.73 (s, 3H), 3.12 (s, 1H), 2.45 (dd, J = 
14.2, 6.0 Hz, 1H), 2.36 (dd, J = 14.6, 7.7 Hz, 1H), 2.14-2.11 (m, 1H), 1.93 (dd, J = 14.0, 4.1 Hz, 1H), 
1.69 (s, 3H), 1.67-1.65 (m, 4H), 1.63 (s, 3H), 1.58-1.54 (m, 4H), 1.50-1.45 (m, 2H), 1.44-1.38 (m, 3H), 
1.34-1.30 (m, 2H), 1.22 (s, 3H), 1.21 (s, 3H), 0.94 (t, J = 7.9 Hz, 9H), 0.82 (s, 3H), 0.57 (q, J = 7.8 Hz, 
6H). 
13C NMR (125 MHz; CDCl3) δ: 207.4, 194.0, 177.5, 133.8, 133.3, 122.9, 119.7, 106.5, 73.7, 70.9, 57.1, 
56.9, 46.4, 45.7, 40.9, 39.5, 39.2, 30.6, 29.9, 29.6, 27.9, 26.10, 26.05, 18.16, 18.13, 18.06, 17.92, 7.4, 7.0. 
FTIR (thin film) νmax: 2964, 2914, 2876, 1733, 1659, 1656, 1600, 1453, 1368, 1227, 1045, 1017, 723  
cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C33H56O4Si, 567.3840; found, 567.3831. 
  
€ 
[α]D
22 = +27.2º (c 3.61, CHCl3). 
TLC Rf = 0.49 (9:1 hexane:EtOAc). 
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(1R,5R,7S,8R)-4-Methoxy-8-methyl-8-(4-methyl-4-((triethylsilyl)oxy)pentyl)-5,7-bis(3-methylbut-2-
en-1-yl)-3-(trimethylsilyl)bicyclo[3.3.1]non-3-ene-2,9-dione (393): 
A THF (1 mL) solution of 392 (22.9 mg, 42.0 µmol, 1 equiv) in a 10-mL test tube was cooled to –78 ºC, 
and chlorotrimethylsilane (53 µL, 420 µmol, 10 equiv) and a freshly prepared THF solution of lithium 
2,2,6,6-tetramethylpiperidide (0.50 M, 420 µL, 210 µmol, 5 equiv) were added sequentially.  After 
allowing the resulting golden yellow solution to slowly warm to 0 ºC over 1 h, it was quenched at 0 ºC 
with sat. aq. NaHCO3.  The mixture was then extracted thrice with EtOAc.  The organic extracts were 
combined, sequentially washed with H2O and brine, dried over Na2SO4, filtered, and concentrated in 
vacuo to a yellow oil.  Flash column chromatography (20 mL SiO2, 98:2 hexane:EtOAc) afforded 23.4 
mg (37.9 µmol, 90% yield) of 393 as a viscous yellow syrup.   
1H NMR (600 MHz; CDCl3) δ: 5.02-4.97 (m, 2H), 3.83 (s, 3H), 3.11 (s, 1H), 2.51 (dd, J = 14.4, 6.3 Hz, 
1H), 2.37 (dd, J = 14.5, 7.5 Hz, 1H), 2.15-2.11 (m, 1H), 1.99 (dd, J = 14.0, 3.7 Hz, 1H), 1.69 (s, 3H), 
1.68-1.63 (m, 9H), 1.57 (s, 3H), 1.48 (td, J = 12.7, 3.9 Hz, 1H), 1.46-1.37 (m, 2H), 1.30 (td, J = 12.2, 4.1 
Hz, 1H), 1.26-1.24 (m, 1H), 1.21 (s, 3H), 1.21 (s, 3H), 1.14 (td, J = 12.6, 4.2 Hz, 1H), 0.94 (t, J = 7.9 Hz, 
9H), 0.80 (s, 3H), 0.57 (q, J = 8.1 Hz, 6H), 0.23 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 207.9, 198.6, 185.7, 133.70, 133.59, 127.7, 122.8, 120.0, 73.7, 72.6, 
64.1, 59.7, 46.7, 45.7, 41.8, 39.29, 39.27, 30.6, 30.0, 29.7, 27.6, 26.02, 25.97, 18.21, 18.14, 17.88, 17.83, 
7.4, 7.0, 0.8. 
FTIR (thin film) νmax: 2962, 2914, 2876, 1729, 1652, 1556, 1461, 1440, 1382, 1247, 1216, 1045, 845, 
743, 724 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C36H64O4Si2, 617.4416; found, 617.4395.   
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[α]D
23 = +29.8º (c 1.24, CHCl3). 
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TLC Rf = 0.40 (95:5 hexane:EtOAc). 
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(1R,5S,7S,8R,9S)-9-Hydroxy-4-methoxy-8,9-dimethyl-8-(4-methyl-4-((triethylsilyl)oxy)pentyl)-5,7-
bis(3-methylbut-2-en-1-yl)-3-(trimethylsilyl)bicyclo[3.3.1]non-3-en-2-one (394): 
A THF (0.5 mL) solution of 393 (7.4 mg, 12 µmol, 1 equiv) in a 10-mL test tube was cooled to –78 ºC, 
and a freshly prepared THF solution of dilithium (cyano-κC)methyl(2,2,6,6-tetramethyl-1-
piperidinyl)copper695 (0.17 M, 353 µL, 60. µmol, 5 equiv) was added dropwise.  The resulting pale yellow 
solution was stirred at –78 ºC for 10 min and at 0 ºC for 15 min.  The resulting yellow solution was 
subsequently cooled to –78 ºC, and a THF solution of isobutyryl chloride (1.0 M, 60. µL, 60. µmol, 5 
equiv) was added.  The reaction was stirred at –78 ºC for 30 min and then allowed to slowly warm to rt.  
After stirring an additional 2.5 h, the reaction was quenched at rt with sat. aq. NH4Cl and extracted thrice 
with EtOAc.  The organic extracts were combined, sequentially washed with H2O, sat. aq. NaHCO3, and 
brine, dried over Na2SO4, filtered, and concentrated in vacuo to a yellow residue.  Preparatory thin-layer 
chromatography (1 × 95:5 hexane:EtOAc) afforded 3.7 mg (5.8 µmol, 49% yield) of 394 as a white 
flocculent solid and 1.1 mg (1.8 µmol, 15% recovery) of 393 as a pale yellow residue. 
1H NMR (600 MHz; CDCl3) δ: 5.40 (t, J = 6.8 Hz, 1H), 5.05 (t, J = 7.3 Hz, 1H), 3.73 (s, 3H), 2.43-2.41 
(m, 2H), 2.27 (s, 1H), 2.14 (dd, J = 13.2, 5.4 Hz, 1H), 2.02 (t, J = 13.2 Hz, 1H), 1.80-1.75 (m, 1H), 1.74-
1.72 (m, 4H), 1.67-1.63 (m, 7H), 1.61 (s, 3H), 1.50-1.36 (m, 4H), 1.34-1.24 (m, 5H), 1.23 (s, 3H), 1.21 (s, 
3H), 1.20 (s, 3H), 1.06 (s, 3H), 0.94 (t, J = 7.9 Hz, 9H), 0.56 (q, J = 7.9 Hz, 6H), 0.22 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 205.2, 187.1, 133.3, 132.8, 125.8, 124.1, 122.0, 100.3, 75.9, 74.0, 66.7, 
63.7, 52.6, 46.1, 42.9, 41.9, 38.0, 31.02, 30.83, 30.66, 29.4, 28.5, 27.3, 26.4, 26.0, 22.1, 18.2, 17.8, 7.4, 
7.0, 0.9. 
                                                      
695 For the preparation of a THF solution of dilithium (cyano-κC)methyl(2,2,6,6-tetramethyl-1-piperidinyl)copper, 
see ref. 675.  
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FTIR (thin film) νmax:  3503 (br), 2957, 2913, 1651, 1564, 1459, 1380, 1244, 1050, 843, 742, 723 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C37H68O4Si2, 633.4729; found, 633.4726.  
TLC Rf = 0.18 (95:5 hexane:EtOAc). 
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(1S,5R,7S,8R)-1-Isobutyryl-4-methoxy-8-methyl-8-(4-methyl-4-((triethylsilyl)oxy)pentyl)-5,7-bis(3-
methylbut-2-en-1-yl)-3-(trimethylsilyl)bicyclo[3.3.1]non-3-ene-2,9-dione (395): 
A THF (200 µL) solution of 393 (15.9 mg, 25.8 µmol, 1 equiv) in a 10-mL pear-shaped flask was cooled 
to –78 ºC, and a freshly prepared THF solution of lithium 2,2,6,6-tetramethylpiperidide (0.50 M, 155 µL, 
77.3 µmol, 3 equiv) was added dropwise.  The resulting yellow solution was stirred at –78 ºC for 10 min 
and at 0 ºC for 5 min.  The resulting orange solution was then cooled to –78 ºC, and isobutyryl cyanide696 
(12.5 mg, 129 µmol, 5 equiv) was added.  The resulting yellow solution was slowly warmed to –30 ºC 
over 35 min and subsequently quenched with sat. aq. NaHCO3.  The mixture was warmed to rt and 
extracted thrice with EtOAc.  The organic extracts were combined, sequentially washed with H2O and 
brine, dried over Na2SO4, filtered, and concentrated in vacuo to a yellow residue.  Preparatory thin-layer 
chromatography (3 × 98:2 hexane:EtOAc) afforded 8.6 mg (13 µmol, 49% yield) of 395 as a colorless 
residue. 
1H NMR (600 MHz; CDCl3) δ: 4.98 (m, 1H), 4.97 (m, 1H), 3.91-3.88 (s, 3H), 2.55 (dd, J = 14.5, 6.2 Hz, 
1H), 2.41 (dd, J = 14.4, 7.6 Hz, 1H), 2.08 (d, J = 13.5 Hz, 1H), 1.97 (septet, J = 6.5 Hz, 1H), 1.92-1.89 
(m, 1H), 1.89-1.85 (m, 1H), 1.78-1.70 (m, 1H), 1.68 (s, 3H), 1.66 (s, 3H), 1.66 (s, 3H), 1.60-1.59 (m, 1H), 
1.57-1.56 (s, 3H), 1.50-1.45 (m, 1H), 1.45-1.42 (m, 1H), 1.38-1.35 (m, 1H), 1.34-1.33 (m, 1H), 1.33-1.30 
(m, 1H), 1.29-1.25 (m, 1H), 1.17 (s, 3H), 1.16 (s, 3H), 1.13 (d, J = 6.5 Hz, 3H), 1.02 (d, J = 6.5 Hz, 3H), 
0.98 (s, 3H), 0.92 (t, J = 7.9 Hz, 9H), 0.54 (q, J = 8.0 Hz, 6H), 0.26 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 209.4, 197.6, 187.3, 134.4, 133.7, 128.3, 122.9, 119.4, 85.2, 73.6, 64.8, 
59.6, 49.5, 46.1, 44.4, 43.0, 38.4, 37.4, 30.4, 30.0, 27.3, 26.13, 25.96, 21.7, 21.1, 20.7, 18.28, 18.12, 13.8, 
7.4, 7.0, 0.7. 
                                                      
696 For the preparation of isobutyryl cyanide, see ref. 520. 
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FTIR (thin film) νmax: 2965, 2914, 2876, 1730, 1637, 1565, 1561, 1456, 1379, 1315, 1249, 1220, 1156, 
1049, 845, 743, 724 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C40H70O5Si2, 709.4654; found, 709.4626.  
  
€ 
[α]D
22 = –42.9º (c 0.46, CH2Cl2). 
TLC Rf = 0.47 (95:5 hexane:EtOAc). 
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(2S,3S,3aS,7R,7aS)-6,7a-Dimethoxy-3-methyl-3-(4-methyl-4-((triethylsilyl)oxy)pentyl)-7-(3-
methylbut-2-en-1-yl)-5-(trimethylsilyl)-3,3a,7,7a-tetrahydro-2,7-methanobenzofuran-4(2H)-one 
(396): 
A THF (3 mL) solution of 383 (147 mg, 0.290 mmol, 1 equiv) in a 10-mL test tube was cooled to –78 ºC, 
and chlorotrimethylsilane (184 µL, 1.45 mmol, 5 equiv) and a freshly prepared THF solution of lithium 
2,2,6,6-tetramethylpiperidide (0.50 M, 1.7 mL, 0.87, 3 equiv) were added sequentially.  The resulting 
bright yellow solution was stirred at –78 ºC for 10 min and then allowed to slowly warm to –35 ºC over 
25 min.  The reaction was subsequently quenched at –35 ºC with sat. aq. NaHCO3 and extracted thrice 
with EtOAc.  The organic extracts were combined, sequentially washed with H2O and brine, dried over 
Na2SO4, filtered, and concentrated in vacuo to a yellow oil.  Flash column chromatography (50 mL SiO2, 
95:5 hexane:EtOAc) afforded 114 mg (0.197 mmol, 68% yield) of 396 as a colorless oil. 
1H NMR (600 MHz; CDCl3) δ: 5.27 (t, J = 6.9 Hz, 1H), 3.85 (d, J = 5.6 Hz, 1H), 3.72 (s, 3H), 3.43 (s, 
3H), 2.62 (s, 1H), 2.51 (dd, J = 15.3, 6.9 Hz, 1H), 2.28 (dd, J = 15.3, 6.9 Hz, 1H), 2.12 (d, J = 12.6 Hz, 
1H), 1.90 (dd, J = 12.6, 5.6 Hz, 1H), 1.69 (s, 3H), 1.62 (s, 3H), 1.40-1.23 (m, 4H), 1.25-1.17 (m, 5H), 
1.16 (s, 3H), 1.14 (s, 3H), 0.90 (t, J = 7.8 Hz, 9H), 0.52 (q, J = 7.8 Hz, 6H), 0.19 (s, 9H). 
13C NMR (125 MHz; CDCl3) δ: 202.7, 187.3, 132.1, 122.2, 121.6, 115.2, 80.7, 73.3, 61.2, 57.5, 52.2, 
49.1, 48.1, 46.0, 39.4, 35.1, 32.7, 30.6, 29.6, 28.0, 26.2, 18.7, 18.0, 7.3, 7.0, 1.1. 
FTIR (thin film) νmax: 2953, 2910, 2875, 1646, 1571, 1458, 1311, 1244, 1224, 1070, 1045, 1011, 843, 
723 cm–1. 
HRMS–ESI (m / z): [M+K]+ calculated for C32H58O5Si2, 617.3454; found, 617.3437.  
TLC Rf = 0.67 (8:2 hexane:EtOAc). 
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(1S,5R,7S,8R)-4-Methoxy-8-methyl-8-(4-methyl-4-((triethylsilyl)oxy)pentyl)-3,5,7-tris(3-methylbut-
2-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione (397): 
A THF (0.5 mL) solution of 392 (7.2 mg, 13 µmol, 1 equiv) in a 10-mL test tube was cooled to –78 ºC, 
and a freshly prepared THF solution of lithium 2,2,6,6-tetramethylpiperidide (0.50 M, 53 µL, 26 µmol, 2 
equiv) was added dropwise.  After stirring the resulting bright yellow solution at –78 ºC for 20 min, a 
THF solution of lithium (2-thienyl)cyanocopper(I)511 (0.10 M, 264 µL, 26.4 mmol, 2 equiv) was added.  
The resulting brown slurry was allowed to slowly warm to –40 ºC over 20 min and subsequently stirred at 
–40 ºC for 30 min.  The resulting pale yellow solution was cooled to –78 ºC, and prenyl bromide (7.6 µL, 
66 µmol, 5 equiv) was added.  The reaction was allowed to slowly warm to 0 ºC over 2 h, and was then 
quenched at 0 ºC with sat. aq. NH4Cl and extracted thrice with EtOAc.  The organic extracts were 
combined, sequentially washed with H2O, sat. aq. NaHCO3, and brine, dried over Na2SO4, filtered, and 
concentrated in vacuo to a brown oil.  Flash column chromatography (20 mL SiO2, 98:2 hexane:EtOAc) 
afforded 7.0 mg (11 µmol, 86% yield) of 397 as a colorless oil.   
1H NMR (600 MHz; CDCl3) δ: 5.03-4.99 (m, 2H), 4.97 (t, J = 7.4 Hz, 1H), 3.88 (s, 3H), 3.17 (s, 1H), 
3.11 (d, J = 6.3 Hz, 2H), 2.47 (dd, J = 14.7, 6.0 Hz, 1H), 2.34 (dd, J = 14.7, 7.1 Hz, 1H), 2.15-2.10 (m, 
1H), 1.98 (dd, J = 14.0, 3.9 Hz, 1H), 1.71-1.68 (m, 4H), 1.67 (s, 6H), 1.66-1.65 (m, 4H), 1.65 (s, 3H), 
1.57 (s, 3H), 1.47 (td, J = 12.7, 4.1 Hz, 1H), 1.43-1.36 (m, 3H), 1.36-1.28 (m, 2H), 1.22 (s, 3H), 1.21 (s, 
3H), 1.11 (td, J = 12.7, 4.0 Hz, 1H), 0.94 (t, J = 7.8 Hz, 9H), 0.80 (s, 3H), 0.57 (q, J = 7.8 Hz, 6H). 
13C NMR (125 MHz; CDCl3) δ: 207.5, 195.0, 174.3, 133.51, 133.37, 132.6, 126.9, 122.9, 122.5, 120.2, 
73.7, 71.3, 62.3, 58.8, 46.7, 45.8, 41.3, 39.27, 39.07, 30.7, 30.3, 29.5, 27.7, 26.05, 26.00, 25.84, 23.5, 
18.23, 18.19, 18.12, 17.99, 17.82, 7.4, 7.0. 
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FTIR (thin film) νmax: 2963, 2914, 2875, 1732, 1655, 1601, 1452, 1382, 1340, 1233, 1170, 1043, 1016, 
743, 723 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C38H64O4Si, 635.4466; found, 635.4449.  
TLC Rf = 0.45 (9:1 hexane:EtOAc). 
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(1R,5R,7S,8R)-1-Isobutyryl-4-methoxy-8-methyl-5,7-bis(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-
en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione (398): 
A PhMe (0.5 mL) solution of 395 (2.2 mg, 3.2 µmol, 1 equiv) in a 7-mL microwave vial was treated with 
2-methyl-2-butene (100 µL), HOAc (50 µL), and a HOAc solution of para-toluenesulfonic acid 
monohydrate (1.0 M, 6.4 µL, 6.4 µmol, 2 equiv).  The vial was sealed and irradiated in a microwave 
reactor (200 watt power) to 100 ºC and held at that temperature for 15 min.  The resulting yellow solution 
was cooled to rt, quenched with sat. aq. NaHCO3, and extracted thrice with EtOAc.  The organic extracts 
were combined, sequentially washed with H2O and brine, dried over Na2SO4, filtered, and concentrated in 
vacuo to a yellow residue.  Preparatory thin-layer chromatography (3 × 1:1 hexane:CH2Cl2) afforded 1.0 
mg (2.1 µmol, 65% yield) of 398 as a colorless residue. 
1H NMR (600 MHz; CDCl3) δ: 5.89 (s, 1H), 5.04 (t, J = 6.8 Hz, 1H), 4.98 (t, J = 6.8 Hz, 1H), 4.93 (t, J = 
6.3 Hz, 1H), 3.80 (s, 3H), 2.49 (dd, J = 14.8, 6.5 Hz, 1H), 2.42 (dd, J = 14.7, 7.6 Hz, 1H), 2.15-2.07 (m, 
3H), 1.95-1.82 (m, 3H), 1.78-1.73 (m, 1H), 1.69 (s, 3H), 1.72-1.64 (m, 1H), 1.663 (s, 3H), 1.661 (s, 3H), 
1.64 (s, 3H), 1.59 (s, 3H), 1.56 (s, 3H), 1.46-1.40 (m, 2H), 1.13 (d, J = 6.5 Hz, 3H), 1.05 (d, J = 6.5 Hz, 
3H), 1.00 (s, 3H). 
13C NMR (125 MHz; CDCl3) δ: 209.5, 207.1, 193.0, 177.4, 134.4, 133.5, 131.3, 124.9, 122.6, 119.3, 
107.0, 84.4, 57.30, 57.12, 49.1, 43.2, 42.7, 39.4, 36.8, 29.7, 27.5, 26.18, 26.08, 25.91, 25.2, 21.7, 20.7, 
18.21, 18.19, 17.9, 13.8. 
FTIR (thin film) νmax: 2967, 2926, 2855, 1728, 1722, 1645, 1601, 1456, 1376, 1227 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C31H46O4, 483.3468; found, 483.3469. 
  
€ 
[α]D
22 = +37.0º (c 0.13, CHCl3). 
TLC Rf = 0.26 (9:1 hexane:EtOAc). 
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(1R,5R,7S,8R)-1-Isobutyryl-4-methoxy-8-methyl-5,7-bis(3-methylbut-2-en-1-yl)-8-(4-methylpent-4-
en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione (399): 
A PhMe (3 mL) solution of 395 (58.0 mg, 84.4 µmol, 1 equiv) in a 7-mL microwave vial was treated with 
2-methyl-2-butene (100 µL), HOAc (100 µL), magnesium sulfate (51 mg, 0.42 mmol, 5 equiv), and a 
HOAc solution of para-toluenesulfonic acid monohydrate (1.0 M, 60. µL, 60. µmol, 0.7 equiv).  The vial 
was sealed and irradiated in a microwave reactor (200 watt power) to 100 ºC and held at that temperature 
for 15 min.  The resulting yellow slurry was cooled to rt, quenched with sat. aq. NaHCO3, and extracted 
thrice with EtOAc.  The organic extracts were combined, sequentially washed with H2O and brine, dried 
over Na2SO4, filtered, and concentrated in vacuo to a yellow oil.  The oil was split into two samples and 
purified using preparatory high-performance liquid chromatography with a 30 mm × 250 mm Agilent 
Prep-SIL 10 µm column (injection volume: 500 µL each, hexane; detection at 254 nm; 23 ºC ± 2 ºC 
column temperature; 40 mL/min flow rate; gradient elution from 100:0 → 60:40 hexane:CH2Cl2 over 45 
min).  The fractions eluting at 34-37 min were collected and concentrated in vacuo to afford 6.2 mg (13 
µmol, 15% yield) of 399 as a colorless oil.  The fractions eluting at 28-33 min were collected and 
concentrated in vacuo to afford 19.3 mg (39.8 µmol, 47% yield) of 398 as a colorless oil. 
1H NMR (600 MHz; CDCl3) δ: 5.89 (s, 1H), 4.98 (t, J = 6.9 Hz, 1H), 4.93 (t, J = 6.8 Hz, 1H), 4.71-4.59 
(m, 2H), 3.80 (s, 3H), 2.48 (dd, J = 14.5, 6.0 Hz, 1H), 2.42 (dd, J = 14.5, 7.8 Hz, 1H), 2.11 (septet, J = 6.5 
Hz, 1H), 2.06 (dd, J = 13.9, 5.3 Hz, 1H), 1.96-1.83 (m, 4H), 1.76-1.72 (m, 1H), 1.70 (s, 3H), 1.69 (s, 3H), 
1.66 (s, 6H), 1.59-1.55 (m, 5H), 1.45-1.34 (m, 3H), 1.12 (d, J = 6.5 Hz, 3H), 1.05 (d, J = 6.5 Hz, 3H), 
0.99 (s, 3H). 
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13C NMR (125 MHz; CDCl3) δ: 209.6, 207.1, 193.0, 177.4, 146.3, 134.4, 133.5, 122.7, 119.3, 110.0, 
107.0, 84.4, 57.32, 57.12, 49.1, 43.3, 42.7, 39.4, 38.8, 36.8, 29.7, 27.5, 26.19, 26.10, 24.5, 22.7, 21.7, 
20.7, 18.22, 18.17, 13.8. 
FTIR (thin film) νmax: 2968, 2927, 2872, 1729, 1645, 1601, 1449, 1374, 1231 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C31H46O4, 505.3288; found, 505.3278.  
TLC Rf = 0.26 (9:1 hexane:EtOAc). 
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(1R,5R,7S,8R)-1-Isobutyryl-4-methoxy-8-methyl-3,5,7-tris(3-methylbut-2-en-1-yl)-8-(4-methylpent-
3-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione (60, hyperforin O-methyl ether):309 
A THF (5 mL) solution of 398 (107.4 mg, 222.5 µmol, 1 equiv) in a 50-mL pear-shaped flask was cooled 
using a –78 ºC dry ice/acetone bath, and a freshly prepared THF solution of lithium diisopropylamide 
(0.50 M, 1.3 mL, 670 µmol, 3 equiv) was added dropwise.  After stirring the resulting yellow solution at –
78 ºC for 20 min, a freshly prepared THF solution of 2-thienyl(cyano)copper lithium511 (0.10 M, 6.7 mL, 
0.67 mmol, 3 equiv) was added dropwise.  The resulting light brown solution was stirred at –78 ºC for 5 
min and at –40 ºC for 30 min.  The solution was then cooled using a –78 ºC dry ice/acetone bath, and 
prenyl bromide (437 µL, 3.34 mmol, 15 equiv) was added dropwise.  After slowly warming the golden 
yellow solution to –30 ºC over 90 min, it was quenched at –30 ºC with sat. aq. NH4Cl, warmed to rt, and 
extracted thrice with EtOAc.  The organic extracts were combined, sequentially washed with H2O, sat. aq. 
NaHCO3, and brine, dried over Na2SO4, filtered, and concentrated in vacuo to a yellow oil.  Flash column 
chromatography (75 mL SiO2, 98:2 hexane:EtOAc) afforded 120.6 mg (219.0 µmol, 98% yield) of 60 as 
a colorless oil. 
1H NMR (500 MHz; CDCl3) δ: 5.07-5.02 (m, 2H), 4.99 (t, J = 6.7 Hz, 1H), 4.95 (t, J = 7.1 Hz, 1H), 3.92 
(s, 3H), 3.18 (d, J = 6.5 Hz, 2H), 2.50 (dd, J = 14.7, 6.0 Hz, 1H), 2.41 (dd, J = 14.7, 7.4 Hz, 1H), 2.11-
2.06 (m, 2H), 1.99 (septet, J = 6.5 Hz, 1H), 1.92-1.84 (m, 3H), 1.77-1.70 (m, 1H), 1.69-1.66 (m, 15H), 
1.64 (s, 3H), 1.63-1.62 (m, 1H), 1.59 (s, 3H), 1.56 (s, 3H), 1.44-1.41 (m, 1H), 1.39-1.37 (m, 1H), 1.11 (d, 
J = 6.5 Hz, 3H), 1.02 (d, J = 6.5 Hz, 3H), 0.99 (s, 3H). 
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13C NMR (125 MHz; CDCl3) δ: 209.3, 207.3, 194.1, 174.1, 134.0, 133.5, 133.2, 131.2, 127.6, 125.0, 
122.7, 121.9, 119.9, 84.3, 62.6, 58.9, 49.4, 43.4, 42.8, 39.1, 36.7, 30.3, 27.3, 26.10, 26.01, 25.88, 25.80, 
25.1, 23.6, 21.5, 20.6, 18.27, 18.14, 18.12, 17.9, 13.8. 
FTIR (thin film) νmax: 2968, 2927, 2874, 1730, 1725, 1645, 1601, 1447, 1377, 1338, 1236, 1100, 1079, 
1060 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C36H54O4, 551.4095; found, 551.4102. 
  
€ 
[α]D
22 = +49.6º (c 0.33, CHCl3). 
TLC Rf = 0.52 (9:1 hexane:EtOAc). 
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Table 3.5. NMR data comparison of synthetic 60 with 60 derived from natural hyperforin (ref. 309). 
1H NMR (500 MHz, CDCl3)  13C NMR (125 MHz, CDCl3) 
Hyperforin-derived Synthetic  Hyperforin-derived Syntheticb 
5.05 (t, J = 7.0, 1H)  209.1 209.1 
5.03 (t, J = 7.0, 1H) 
5.07-5.02 (m, 2H) 
 207.1 207.1 
4.99 (t, J = 7.0, 1H) 4.99 (t, J = 6.7, 1H)  193.9 193.9 
4.94 (t, J = 7.1, 1H) 4.95 (t, J = 7.1, 1H)  173.9 173.9 
3.91 (s, 3H) 3.92 (s, 3H)  133.8 133.7 
3.17 (d, J = 6.5, 1H)a 3.18 (d, J = 6.5, 2H)  133.3 133.3 
2.49 (dd, J = 15.0, 6.0, 1H) 2.50 (dd, J = 14.7, 6.0, 1H)  132.9 132.9 
2.40 (dd, J = 15.0, 7.5, 1H) 2.41 (dd, J = 14.7, 7.4, 1H)  131.0 131.0 
2.10 (m, 1H)  127.4 127.4 
2.07 (m, 1H) 
2.11-2.06 (m, 2H) 
 124.7 124.8 
a 1.99 (septet, J = 6.5, 1H)  122.5 122.5 
1.87 (m, 1H)  121.7 121.7 
1.85 (m, 1H) 
1.92-1.84 (m, 3H) 
 119.7 119.7 
1.73 (m, 1H) 1.77-1.70 (m, 1H)  84.1 84.1 
1.67 (s, 3H)  a 62.3 
1.67 (s, 3H)  58.6 58.6 
1.67 (s, 3H)  49.2 49.1 
1.67 (s, 3H)  43.2 43.2 
1.63 (s, 3H) 
1.69-1.66 (m, 15H) 
 42.6 42.6 
1.63 (s, 3H) 1.64 (s, 3H)  38.8 38.8 
a 1.63-1.62 (m, 1H)  36.5 36.5 
1.58 (s, 3H) 1.59 (s, 3H)  30.1 30.1 
1.55 (s, 3H) 1.56 (s, 3H)  27.1 27.1 
a 1.44-1.41 (m, 1H)  25.9 25.9 
1.39 (m, 1H) 1.39-1.37 (m, 1H)  25.8 25.8 
1.10 (d, J = 6.5, 3H) 1.11 (d, J = 6.5, 3H)  25.7 25.7 
1.01 (d, J = 6.5, 3H) 1.02 (d, J = 6.5, 3H)  25.6 25.6 
0.98 (s, 3H) 0.99 (s, 3H)  24.9 24.9 
   23.4 23.4 
   21.3 21.3 
   20.4 20.4 
   18.0 18.0 
   17.9 17.91 
   17.9 17.89 
   17.6 17.6 
   13.6 13.6 
 
 
a Several NMR signals for 60 are not reported in ref. 309.  In particular, there are only 50 protons reported for 60, which contains 
54 protons.  Also, the shift of the O-methyl group is not reported in the 13C NMR data.   
b For the purpose of this analysis, the CDCl3 signal in the 13C NMR of synthetic 60 was re-referenced to 77.00 ppm to match the 
reported chemical shift reference in ref. 309. 
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Note: All manipulations for the following procedure were conducted in the dark.  Solvents used during 
the workup procedure were sparged for at least 15 min with N2 prior to use.    
A DMSO (3 mL) slurry of 60 (74.9 mg, 136 µmol, 1 equiv) and lithium chloride (58 mg, 1.4 mmol, 10 
equiv) in a 15-mL round-bottom flask was heated to 120 ºC.  After stirring the pale yellow solution for 30 
min at 120 ºC, it was cooled to rt, diluted with H2O, and extracted thrice with 1:1 hexane:EtOAc.  The 
organic extracts were combined, sequentially washed thrice with H2O and once with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo to afford a yellow oil.  Flash column chromatography (30 mL 
SiO2, 95:5 hexane:EtOAc) afforded 40.0 mg (74.5 µmol, 55% yield) of 1 as a colorless oil, 10.8 mg (19.6 
µmol, 14% yield) of 400 as a colorless oil, and 12.5 mg (23.3 µmol, 23% yield) of 401 as a colorless oil. 
Hyperforin (1):  
1H NMR (500 MHz; CD3OD) δ: 5.12 (t, J = 7.0 Hz, 1H), 5.04-4.95 (m, 3H), 3.12 (dd, J = 14.6, 7.2 Hz, 
1H), 3.07 (dd, J = 14.7, 7.1 Hz, 1H), 2.49 (dd, J = 14.4, 6.9 Hz, 1H), 2.40 (dd, J = 14.6, 6.8 Hz, 1H), 2.14 
(septet, J = 6.5 Hz, 1H), 2.10-2.02 (m, 1H), 2.02-1.87 (m, 3H), 1.78-1.72 (m, 3H), 1.71 (s, 3H), 1.68 (s, 
6H), 1.66 (s, 3H), 1.66-1.63 (m, 1H), 1.64 (s, 3H), 1.63 (s, 3H), 1.59 (s, 3H), 1.58 (s, 3H), 1.37 (dd, J = 
13.3, 12.2 Hz, 1H), 1.09 (d, J = 6.5 Hz, 3H), 1.04 (d, J = 6.5 Hz, 3H), 0.97 (s, 3H). 
13C NMR (125 MHz; CD3OD) δ: 211.7, 208.8, 134.6, 134.2, 133.5, 131.8, 126.1, 123.8, 122.6, 122.1, 
120.9, 82.6, 60.7, 49.5, 43.05, 43.02, 40.8, 37.9, 30.7, 28.6, 26.16, 26.06, 25.99, 25.92, 25.4, 22.5, 22.0, 
21.2, 18.27, 18.16, 18.11, 17.86, 15.3. 
FTIR (thin film) νmax: 3326 (br), 2969, 2925, 2876, 1725, 1601, 1447, 1377, 1232, 838 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C35H52O4, 537.3938; found, 537.3937. 
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€ 
[α]D
23 = +39.5º (c 3.02, EtOH); [natural sample from literature:1   
€ 
[α]D
18  = +41º (c 5, EtOH)]. 
TLC Rf = 0.26 (9:1 hexane:EtOAc). 
(3S,4aS,6S,7R)-8-Isobutyryl-3,7-dimethyl-3,4a,6-tris(3-methylbut-2-en-1-yl)-7-(4-methylpent-3-en-
1-yl)-4a,5,6,7-tetrahydro-2H-chromene-2,4(3H)-dione (400): 
1H NMR (500 MHz; CDCl3) δ: 5.09 (t, J = 6.1 Hz, 1H), 5.01-4.96 (m, 2H), 4.93 (t, J = 6.4 Hz, 1H), 2.71 
(septet, J = 6.9 Hz, 1H), 2.64 (dd, J = 13.7, 8.1 Hz, 1H), 2.57 (dd, J = 13.7, 7.1 Hz, 1H), 2.46 (dd, J = 
13.5, 2.7 Hz, 1H), 2.25 (dd, J = 14.5, 7.0 Hz, 1H), 2.06 (dd, J = 13.8, 4.9 Hz, 1H), 1.84-1.76 (m, 5H), 
1.74-1.69 (m, 4H), 1.69-1.63 (m, 4H), 1.62 (s, 3H), 1.62 (s, 3H), 1.60 (s, 3H), 1.59 (s, 3H), 1.52 (s, 3H), 
1.52-1.49 (m, 1H), 1.47 (s, 3H), 1.37 (t, J = 13.3 Hz, 1H), 1.31-1.25 (m, 1H), 1.21 (d, J = 6.9 Hz, 3H), 
1.15 (d, J = 6.9 Hz, 3H), 1.14 (s, 3H), 1.11-1.07 (m, 1H). 
13C NMR (125 MHz; CDCl3) δ: 209.0, 205.2, 169.8, 144.5, 137.2, 136.25, 136.11, 133.4, 132.0, 124.0, 
122.5, 119.3, 117.1, 56.8, 52.3, 42.6, 40.9, 37.51, 37.37, 34.3, 31.5, 27.27, 27.15, 26.24, 26.14, 26.10, 
25.9, 25.2, 23.2, 22.8, 18.7, 18.31, 18.28, 18.25, 17.8, 17.5. 
FTIR (thin film) νmax: 2971, 2930, 2875, 1778, 1724, 1699, 1665, 1451, 1377, 1255, 1237, 1136, 1094, 
1056, 844 cm–1. 
HRMS–ESI (m / z): [M+H]+ calculated for C36H54O4, 551.4096; found, 551.4095.  
TLC Rf = 0.66 (9:1 hexane:EtOAc). 
 (4aR,6S,7R)-4-Hydroxy-8-isobutyryl-7-methyl-3,4a,6-tris(3-methylbut-2-en-1-yl)-7-(4-methylpent-
3-en-1-yl)-4a,5,6,7-tetrahydro-2H-chromen-2-one (401): 
1H NMR (500 MHz; CDCl3) δ: 5.11-4.98 (m, 3H), 4.93 (t, J = 6.5 Hz, 1H), 3.35-3.33 (m, ~0.7H), 3.22 
(dd, J = 8.3, 5.8 Hz, ~0.3H), 2.77-2.56 (m, 3H), 2.52-2.42 (m, 1H), 2.25 (dd, J = 14.2, 6.3 Hz, ~0.3H), 
2.17-2.02 (m, 2H), 1.91 (dd, J = 14.5, 8.2 Hz, ~0.7H), 1.88-1.80 (m, 1H), 1.76 (s, ~1H), 1.75 (s, ~2H), 
1.72 (s, 3H), 1.69 (s, 3H), 1.66 (s, 3H), 1.63-1.62 (m, 4H), 1.62-1.61 (m, 4H), 1.60 (s, 3H), 1.60-1.44 (m, 
7H), 1.44-1.25 (m, 3H), 1.23 (s, 3H), 1.15-1.11 (m, 3H) (mixture of tautomers and diastereomers). 
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13C NMR (125 MHz; CDCl3) δ: 208.9, 202.3, 201.7, 167.2, 166.2, 145.3, 144.9, 137.75, 137.65, 137.4, 
136.9, 135.3, 133.50, 133.40, 132.00, 131.94, 124.03, 123.93, 122.49, 122.37, 119.7, 118.0, 116.97, 
116.88, 55.2, 54.6, 53.1, 52.6, 42.78, 42.64, 41.1, 37.9, 37.63, 37.46, 37.32, 34.1, 32.7, 29.6, 28.1, 27.34, 
27.31, 27.27, 26.24, 26.09, 26.07, 26.04, 25.90, 23.41, 23.21, 23.06, 22.97, 22.85, 18.95, 18.76, 18.35, 
18.28, 18.24, 18.22, 18.10, 17.86, 17.83, 17.81, 17.63 (mixture of tautomers and diastereomers). 
FTIR (thin film) νmax: 2969, 2916, 2875, 1781, 1728, 1697, 1665, 1447, 1377, 1254, 1223, 1142, 1102, 
1050 cm–1. 
HRMS–ESI (m / z): [M+Na]+ calculated for C35H52O4, 559.3758; found, 559.3756. 
TLC Rf = 0.51 (9:1 hexane:EtOAc). 
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Figure 3.5. 1H NMR spectra comparison of natural and synthetic hyperforin (1). 
ppm0.5 0.51.01.01.51.52.02.02.52.53.03.03.53.54.04.04.54.55.05.05.55.56.0
 isolated 1 
 synthetic 1 
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NMR Data Comparison of Synthetic and Natural Hyperforin (1). 
 
On the following pages, the 1H and 13C NMR data for synthetic 1 are compared to published data for 
natural 1 as well as synthetic ent-1.  All NMR data have been acquired using CD3OD solvent.  NMR 
spectrometer frequencies are noted.   
The references from which NMR data for natural 1 are presented include: 
Reference A: Erdelmeier, C. A. J. Pharmacopsychiatry 1998, 31 (Supplement 1), 2-6. 
Reference B: Adam, P. A.; Arigoni, D.; Bacher, A.; Eisenreich, W. J. Med. Chem. 2002, 45, 4786-4793. 
Reference C: Cui, Y.; Ang, C. Y. W.; Beger, R. D.; Heinze, T. M.; Hu, L.; Leakey, J. Drug Metab. 
Dispos. 2004, 32, 28-34. 
Reference D: Lee, J.-y.; Duke, R. K.; Tran, V. H.; Hook, J. M.; Duke, C. C. Phytochemistry 2006, 67, 
2550-2560. 
Reference E: Cao, X.; Wang, Q.; Li, Y.; Bai, G.; Ren, H.; Xu, C.; Ito, Y. J. Chromatogr. B 2011, 879, 
480-488. 
The reference from which NMR data for ent-1 are presented: 
Reference F: Shimizu, Y.; Shi, S.-L.; Usuda, H.; Kanai, M.; Shibasaki, M. Tetrahedron 2010, 66, 6569-
6584. 
 
The positional numbering scheme used for these tables is shown below. 
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As previously noted,462 small deviations in the NMR data from the different references may be attributed 
to not only different chemical shift references but also to the concentration of 1 and to the water content 
in the NMR sample, which influence the keto-enol tautomerization at the hyperforin C2–C4 position.  In 
the 1H NMR analysis of 1, we observed concentration- and water-dependent changes in the lineshape of 
the C26 proton signals and in the chemical shifts of the C11, C12, and C13 proton signals.  We also 
observed broadening of the C1 and C5 signals and an absence of the C2 and C4 signals in the 13C NMR 
spectrum of 1. 
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Table 3.7. 13C NMR data comparison of synthetic and natural hyperforin (1). 
  Ref. A Ref. B Ref. C Ref. D Ref. E Ref. F This work 
Position 50 MHz 125 MHz 150 MHz 150 MHz 150 MHz 125 MHz 125 MHz 
1 82.6 (br) 82 (br) 82.7 82.74 82.42 -- 82.6 (br) 
2 185.3 (br) -- 212.9 -- 209.64 -- -- 
3 122.1 122.12 121.3 122.1 120.25 121.90 122.1 
4 181.2 (br) -- 182.2 -- 181.59 -- -- 
5 60.8 (br) 60 (br) 61.2 -- 58.27 -- 60.7 (br) 
6 40.8 40.82 40.7 40.8 40.27 41.68 40.8 
7 43.0 42.95 43.3 43.1 42.57 43.94 43.02 
8 49.5 49.10 49.5 49.54 47.81 -- 49.5 
9 208.8 208.85 210.0 208.82 208.35 -- 208.8 
10 211.7 211.78 212.9 211.7 209.64 -- 211.7 
11 43.0 43.00 42.8 43.0 41.57 43.68 43.05 
12 22.0 21.98 21.0 21.99 20.44 22.86 22.0 
13 21.2 21.16 19.8 20.85 19.36 22.01 21.2 
14 15.3 15.31 15.2 15.3 15.8 16.13 15.3 
15 37.9 37.92 38.0 37.88 37.68 38.81 37.9 
16 25.4 25.42 28.8 28.62 27.66 26.33 25.4 
17 126.1 126.04 123.7 120.85 122.31 122.82 126.0 
18 131.8 131.84 133.9 134.69 133.36 -- 131.8 
19 25.9 25.87 25.9 25.90 24.88 26.74 25.92 
20 18.1 18.09 17.9 17.84 17.92 18.94 18.11 
21 28.6 28.62 25.6 25.43 24.0 29.52 28.6 
22 123.8 123.77 126.3 126.05 126.61 126.98 123.8 
23 134.2 134.25 131.6 131.81 131.61 135.04 134.2 
24 26.0 25.97 26.0 25.98 24.90 26.83 25.99 
25 18.2 18.15 18.1 18.1 18.01 19.01 18.16 
26 22.5 22.50 22.8 22.50 22.40 23.43 22.5 
27 122.6 122.53 124.1 122.54 122.71 124.73 122.6 
28 133.5 133.60 132.5 133.58 133.19 132.63 133.5 
29 26.1 26.05 26.1 26.16 24.99 26.90 26.06 
30 17.9 17.84 18.2 18.15 18.10 18.70 17.86 
31 30.7 30.69 30.8 30.70 30.03 31.59 30.7 
32 120.9 120.86 121.5 123.74 121.21 123.66 120.9 
33 134.7 134.71 134.1 134.25 132.93 135.44 134.6 
34 26.2 26.15 26.0 26.05 25.01 27.02 26.16 
35 18.3 18.25 18.2 18.25 18.14 19.10 18.27 
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Isolation of hyperforin (1) from St. John’s Wort extract:697 
Supercritical CO2 extract of St. John’s wort was obtained from Flavex Naturextrakte GmbH as a generous 
gift or was purchased from “From Nature with Love.” The brown resinous extract (1.468 g) was 
dissolved in MeOH (150 mL, saturated in heptane) and heptane (50 mL, saturated in MeOH) with the aid 
of sonication.  The layers were separated, and the heptane fraction was extracted twice with MeOH (75 
mL each, saturated in heptane).  The MeOH extracts were combined, washed twice with heptane (50 mL, 
saturated in MeOH), and concentrated in vacuo to a brown-yellow syrup.  Flash column chromatography 
(500 mL SiO2, 98:2 → 95:5 → 9:1 hexane:EtOAc) afforded 572 mg (1.07 mmol, 38% yield by weight of 
initial extract) of 1 as a pale yellow syrup.   
 
                                                      
697 This procedure was adapted from ref. 44. 
O OH
Me
O
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In the table below, all known 260 PPAPs are listed.  The PPAPs are presented in alphabetical 
order, except for certain instances (e.g., epimers, ethers).   Along with the name and structure of each 
PPAP, the plant species and geographical location from which that PPAP has been isolated is listed.  In 
cases where a PPAP has been isolated from multiple species, the species from which the PPAP was 
initially isolated is listed in boldface text.  In addition, references to spectroscopic data (i.e., NMR, UV, 
IR) and relevant crystal structure refinements are provided.  Optical rotation data is also listed.  Unless 
indicated by an explicit reference to an absolute configuration determination, an arbitrary enantiomer is 
depicted for each PPAP.  For certain PPAPs, multiple names have been given, mostly due to simultaneous 
discovery of the PPAP by several groups.  All alternative names are provided in italicized text below 
name that was provided by the initial published report.  If a PPAP has been isolated in both enantiomeric 
forms, the name of its corresponding enantiomeric PPAP is also found below its name. All references 
herein are found at the end of this appendix. 
 
 
acuminophenone A 
(1) 
 
Rheedia acuminata (La Paz, Bolivia)1 
 
(NMR, UV, IR)1 [α]D = +208º (CHCl3)1 
adhyperfirin  
(2) 
 
Hypericum empetrifolium (northern Jordan)2 
H. perforatum  
 Germany3 
 Epirus, Greece4  
 Cemernik Mountain, southern Serbia5 
H. reflexum (Halle-Wittenberg, Germany)3  
H. triquetrifolium (Al-Mafraq, Jordan)6 
 
1H NMR4 
O
O
OH
O
OH
OH
O
O OH
O
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 adhyperforin  
(3) 
 
Hypericum calycinum (Bonn, Germany)7 
H. elodes (Umbrian-Marchean Apennines, Italy)8 
H. maculatum (Prakovce, Slovakia)9 
H. perfoliatum (El Feidja, northwestern Tunisia)10 
H. perforatum 
 Mt. Taylor, Canberra, Australia11  
 Alpirsbach, Black Forest, Germany12  
 Epirus, Greece4 
 Italy13  
 Cemernik Mountain, southern Serbia5  
 Nová Ľubovňa, Slovakia14 
 El Feidja, northwestern Tunisia10 
H. ericoides (El Feidja, northwestern Tunisia)10  
 
1H NMR4,12 (13C NMR, UV, IR)12 
androforin A  
(4) 
 
Hypericum androsaemum (Yunnan, China)15 
 
(NMR, UV, IR)15 [α]D = –59.3º (MeOH)15 
aristophenone  
18,19-dihydroxy-
clusianone 
(5) 
 
Clusia torresii (Turrialba, Cartago, Costa Rica)16 
Garcinia aristata (Havana, Cuba)17 
G. multiflora (Diaoluo Mountain, Hainan, China)18  
G. xanthochymus (Homestead, Florida, USA)19 
propolis (Manaus, Brazil)20 
 
(NMR, UV, IR)17 [α]D = +58º (CHCl3)17 
chamone I  
(6) 
 
Clusia grandiflora (Canaima, Venezuela)21 
 
O-Me ether (NMR, IR)21 
chamone II  
(7) 
 
Clusia grandiflora (Canaima, Venezuela)21 
 
(NMR, IR)21 
O
O OH
O
O
O
O
O
O OH
O
O
OH
OH
O
O OH
O
O
O
O
O
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chamuangone 
cowanone 
ent-guttiferone Q 
(8) 
 
Garcinia cowa  
 Hat-Yai, Songkhla, Thailand22 
 Nong Khai, Thailand23 
 
(NMR, UV, IR)22,23 [α]D = +5.3º (CHCl3)23 
clusianone  
(9) 
 
Clusia burchellii (Campinas, São Paulo, Brazil)24 
C. congestiflora (Fresno, Colombia)25 
C. fluminensis 
 Campinas, São Paulo, Brazil24 
 Viçosa, São Paulo, Brazil26 
C. lanceolata (Campinas, São Paulo, Brazil)24 
C. pana-panari (Campinas, São Paulo, Brazil)24 
C. paralicola (Campinas, São Paulo, Brazil)24 
C. pernambucensis (Campinas, São Paulo, Brazil)24 
C. sandiensis (Machu Pichu, Peru)27 
C. spiritu-sanctensis (Campinas, São Paulo, Brazil)24,28 
C. weddelliana (Campinas, São Paulo, Brazil)24 
C. torresii (Turrialba, Cartago, Costa Rica)16 
Garcinia assigu (Central Province, Papua New 
Guinea)29 
G. brevipedicellata (Cameroon)30 
G. preussii (Cameroon)30 
Hypericum hypericoides (St. Andrew, Jamaica)31 
H. sampsonii (Jinhua, Zhejiang, China)32 
propolis (Campinas, São Paulo, Brazil)24 
 
NMR26,27,16 (UV, IR)27,16 [α]D = +60º,27 +58.3º16 (CHCl3) 
O-Me ether (NMR, IR, UV)28 [α]D = +60.7º (CHCl3)28 
structural revision;16 crystal structure;25 
O-Me ether crystal structure28 
7-epi-clusianone  
(10) 
 
Calophyllum thorelii (central Vietnam)33 
Clusia torresii (Turrialba, Cartago, Costa Rica)16 
Garcinia brasiliensis (Viçosa, Minas Gerais, 
Brazil)34,35,36 
G. brevipedicellata (Cameroon)30 
G. preussii (Cameroon)30 
Hypericum hypericoides (St. Andrew, Jamaica)31 
H. sampsonii (Hunan, China)37 
H. scabrum (Chimgan, Uzbekistan)38 
H. elegans (Balgarevo, Kavarna, Bulgaria)39 
Rheedia brasiliensis (Viçosa, Minas Gerais, Brazil)40 
R. edulis (Broward County, Florida, USA)41 
R. gardneriana (Viçosa, Minas Gerais, Brazil)42,43 
propolis (Manaus, Brazil)20 
 
NMR16,34,44 IR16,44 UV16,41,44 
[α]D = +60º,34,44 +62.3º,16 +66º (CHCl3)45  
+15.6º (MeOH)41 
structural revision;16 crystal structure;37,42,45  
absolute configuration45 
O OH
O
O
O OH
O
O
OHO
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18-hydroxyclusianone 
(11) 
 
Hypericum hypericoides (St. Andrew, Jamaica)31 
 
(NMR, UV, IR)31 
18-hydroxy-7-epi-
clusianone  
(12) 
 
Hypericum hypericoides (St. Andrew, Jamaica)31 
 
(NMR, UV, IR)31 [α]D = +64º (CHCl3)31 
coccinone B  
(13) 
 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
 
(NMR, UV, IR)46 [α]D = –55º (CHCl3)46 
7-epi-coccinone B 
(14) 
 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
(NMR, UV, IR)47 [α]D = –50º (CHCl3)47 
coccinone C  
(15) 
 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
 
(NMR, UV, IR)46 [α]D = –60º (CHCl3)46 
O OH
O
O
OH
O OH
O
O
OH
O
O
O
O
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O
O
O
O
OH
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OH
O
O
O
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coccinone D  
(16) 
 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
 
(NMR, UV, IR)46 [α]D = –76º (CHCl3)46 
coccinone E 
(17) 
 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
 
(NMR, UV, IR)46 [α]D = –70º (CHCl3)46 
coccinone F  
(18) 
 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
 
(NMR, UV, IR)46 [α]D = –32º (CHCl3)46 
coccinone G  
(19) 
 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
 
(NMR, UV, IR)46 [α]D = –16º (CHCl3)46 
coccinone H  
(20) 
 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
 
(NMR, UV, IR)46 [α]D = +2º (CHCl3)46 
crystal structure46 
cycloxanthochymol 
(21) 
 
Garcinia livingstonei (Homestead, Florida, USA)48 
G. nujiangensis (Nujiang, Yunnan, China)49 
G. pyrifera (Sungai Petani, Kedah, Malaysia)50 
G. subelliptica (Okinawa, Japan)51 
G. xanthochymus (Homestead, Florida, USA)19 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
 
(UV, IR)46 [α]D = +112º (CHCl3)46 
characterized as mixture with 153 (NMR, UV, IR)50,51  
[α]D = +142º (CHCl3)50 [α]D = +158º (MeOH)51 
O
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ent-cycloxanthchymol 
(22) 
 
Garcinia nujiangensis (Nujiang, Yunnan, China)49 
G. subelliptica (northern mountains, Taiwan)52 
 
(NMR, UV, IR)52 [α]D = –80.9º (MeOH)52 
dorstenpictanone  
(23) 
 
Dorstenia picta (Moraceae; Nkolbibanda, Cameroon)53 
 
(NMR, IR)53 
enervosanone  
(24) 
 
Calophyllum enervosum (Bukitinggi, West Sumatra, 
Indonesia)54,55 
 
(NMR, UV, IR)54 [α]D = +10º (MeOH)54 
eugeniaphenone  
(25) 
 
Garcinia eugeniaefolia (Riau Islands, Indonesia)56 
 
(NMR, IR);56 crystal structure56 
furoadhyperforin 
(26) 
 
Hypericum perforatum 
 Mt. Taylor, Canberra, Australia11 
 Mt. Orzen, southeast Serbia57,58 
 
1H NMR11,57 13C NMR11 
furoadhyperforin 
isomer A  
(27) 
 
Hypericum perforatum (Tokushima, Japan)59 
 
(NMR, IR)59 [α]D = +33.8 (CHCl3)59 
O
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furoadhyperforin 
isomer B  
(28) 
 
Hypericum perforatum (Tokushima, Japan)59 
 
(NMR, IR)59 [α]D = +13.8 (CHCl3)59 
furohyperforin  
(29) 
 
Hypericum henryi (Lünchun, Yunnan, China)60 
Hypericum perforatum 
 Mt. Taylor, Canberra, Australia11  
 Chile61 
 China62 
 Italy13 
 Tokushima, Japan59 
 Mt. Orzen, southeast Serbia57,58,63 
 
NMR11,58,61,62 (UV, IR)58,61 
[α]D = +68º,58 +62.4º61 (CHCl3) [α]D = +81.9º (MeOH)61 
33-deoxy-33-
hydroperoxy-
furohyperforin  
(30) 
 
Hypericum perforatum 
 Chile64 
 Tokushima, Japan59 
 
(NMR, UV, CD)64 [α]D = +75.0º (CHCl3)64 
furohyperforin A 
(31) 
 
Hypericum perforatum (Mt. Orzen, southeast Serbia)58,63 
 
(NMR, UV, IR)63  
deoxyfurohyperforin 
A  
(32) 
 
Hypericum perforatum (Mt. Orzen, southeast Serbia)58 
 
(NMR, UV, IR)58 [α]D = +42 (CH2Cl2)58 
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furohyperforin  
isomer 1  
(33) 
 
Hypericum perforatum 
 Mt. Taylor, Canberra, Australia11 
 Tokushima, Japan59 
 
NMR11,59 [α]D = +49.7 (CHCl3)59 
27-epi-furohyperforin 
isomer 1  
(34) 
 
Hypericum perforatum (Tokushima, Japan)59 
 
NMR59 [α]D = +14.5 (CHCl3)59 
furohyperforin  
isomer 2  
(35) 
 
Hypericum perforatum 
 Mt. Taylor, Canberra, Australia11 
 Tokushima, Japan59 
 
NMR11 
garcicowin A  
(36) 
 
Garcinia cowa (Yunnan, China)65 
 
(NMR, UV, IR)65 [α]D = –219.0º (CHCl3)65 
garcicowin B  
(37) 
 
Garcinia cowa (Yunnan, China)65,66 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. yunnanensis (Dehong, Yunnan, China)66 
 
(NMR, UV, IR)65 [α]D = –16.0º (CHCl3)65 
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garcicowin C  
(38) 
 
Garcinia cowa (Yunnan, China)65,66 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. oblongifolia (Bobai, Guangxi, China)66 
G. paucinervis (Xishuangbanna, Yunnan, China)67 
G. xanthochymus (Xishuangbanna, Yunnan, China)66 
 
(NMR, UV, IR)65 [α]D = –72.1º (CHCl3)65 
garcicowin D  
(39) 
 
Garcinia cowa (Yunnan, China)65,66 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. multiflora (Wanning, China)66 
G. oblongifolia (Bobai, Guangxi, China)66 
G. paucinervis (Xishuangbanna, Yunnan, China)66 
G. subelliptica (Shenzhen, Guangdong, China)66 
G. xanthochymus (Xishuangbanna, Yunnan, China)66 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)66 
G. yunnanensis (Dehong, Yunnan, China)66 
 
(NMR, UV, IR)65 [α]D = +336.0º (CHCl3)65 
garcimultiflorone A 
(40) 
 
Garcinia multiflora (Mudan, Taiwan)68 
 
(NMR, UV, IR, CD)68 [α]D = –173º (CHCl3)68 
garcimultiflorone B 
(41) 
 
Garcinia multiflora (Mudan, Taiwan)68 
 
(NMR, UV, IR, CD)68 [α]D = –132º (CHCl3)68 
13-hydroxy-
garcimultiflorone B 
(42) 
 
Garcinia multiflora (Mudan, Taiwan)68 
 
(NMR, UV, IR, CD)68 [α]D = –115º (CHCl3)68 
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garcimultiflorone C 
(43) 
 
Garcinia multiflora (Mudan, Taiwan)68 
 
(NMR, UV, IR, CD)68 [α]D = –25.3º (CHCl3)68 
garcimultiflorone D 
(44) 
 
Garcinia multiflora (Diaoluo Mountain, Hainan, 
China)18 
 
(NMR, UV, IR)18 [α]D = –53.6º (MeOH)18 
garcimultiflorone D2 
(45) 
 
 
Garcinia multiflora (Mudan, Pingtung, Taiwan)69 
 
(NMR, UV, IR)69 [α]D = +5.6º (CHCl3) 
18-hydroxy-
garcimultiflorone D 
(46) 
 
Garcinia multiflora (Diaoluo Mountain, Hainan, 
China)18 
 
(NMR, UV, IR)18 [α]D = –33.3º (MeOH)18 
garcimultiflorone E 
(47) 
 
Garcinia multiflora (Diaoluo Mountain, Hainan, 
China)18 
 
(NMR, UV, IR)18 [α]D = –43.6º (MeOH)18 
garcimultiflorone F 
(48) 
 
Garcinia multiflora (Diaoluo Mountain, Hainan, 
China)18 
 
(NMR, UV, IR)18 [α]D = –48.7º (MeOH)18 
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isogarcimultiflorone F 
(49) 
 
Garcinia multiflora (Diaoluo Mountain, Hainan, 
China)18 
 
(NMR, UV, IR)18 [α]D = –46.0º (MeOH)18 
garciniagifolone A 
(50) 
 
Garcinia oblongifolia (Hainan, China)70 
 
(NMR, UV, IR)70 [α]D = +7.0º (MeOH)70 
garcinialiptone A 
(51) 
 
Garcinia subelliptica (northern mountains, Taiwan)52 
 
(NMR, UV, IR)52 [α]D = +12.1º (MeOH)52 
ent-garcinialiptone A  
(52) 
 
 
Garcinia cochinchinensis (southern Vietnam)71 
G. nujiangensis (Nujiang, Yunnan, China)49  
G. subelliptica (northern mountains, Taiwan)52 
 
(NMR, UV, IR)52 [α]D = –17.3º (MeOH)52 
garcinialiptone B 
(53) 
 
Garcinia nujiangensis (Nujiang, Yunnan, China)49 
G. subelliptica (northern mountains, Taiwan)52 
 
(NMR, UV, IR)52 [α]D = +84.8º (MeOH)52 
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garcinialiptone C 
(54) 
 
Garcinia subelliptica (northern mountains, Taiwan)52 
 
(NMR, UV, IR)52 [α]D = –94.0º (MeOH)52 
garcinialiptone D 
(55) 
 
Garcinia subelliptica (northern mountains, Taiwan)52 
 
(NMR, UV, IR)52 [α]D = –79.1º (MeOH)52 
garcinialone 
(56) 
 
Garcinia multiflora (Taiwan)72 
 
(NMR, UV, IR)72 [α]D = –2.0º (MeOH)72 
garciniaphenone 
(57) 
 
Garcinia brasiliensis (Viçosa, Minas Gerais, Brazil)34,35 
 
(NMR, UV, IR)34 [α]D = –52.8 (CHCl3)34  
crystal structure35 
garcinielliptone A 
(58) 
 
Garcinia subelliptica (Kaohsiung, Taiwan)73,74 
 
(NMR, UV, IR)73 [α]D = –33º (CHCl3)73 
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garcinielliptone B 
(59) 
 
Garcinia subelliptica (Kaohsiung, Taiwan)73 
 
(NMR, UV, IR)73 [α]D = –23º (CHCl3)73 
garcinielliptone C 
(60) 
 
Garcinia subelliptica (Kaohsiung, Taiwan)73 
 
(NMR, UV, IR)73 [α]D = –40º (CHCl3)73 
garcinielliptone D 
(61) 
 
Garcinia subelliptica (Kaohsiung, Taiwan)73 
 
(NMR, UV, IR)73 [α]D = –22º (CHCl3)73 
garcinielliptone F 
(62) 
 
Garcinia subelliptica (Kaohsiung, Taiwan)74,75 
 
(NMR, UV, IR)73 [α]D = –23º (CHCl3)73 
garcinielliptone FB 
(63) 
 
Garcinia subelliptica (Kaohsiung, Taiwan)76 
 
(NMR, UV, IR)76 [α]D = –66º (CHCl3)76 
garcinielliptone FC 
(64) 
 
Garcinia subelliptica 
 Kaohsiung, Taiwan74 
 Ping-Tung Hsien, Taiwan77 
Platonia insignis (Barras, Piauí, Brazil)78 
 
NMR77,78 (UV, IR)77 [α]D = +12.6º (CHCl3)77 
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garcinielliptone H 
(65) 
 
Garcinia subelliptica (Kaohsiung, Taiwan)75 
 
(NMR, UV, IR)75 [α]D = –143º (CHCl3)75 
garcinielliptone I 
ent-hyperibone A 
(66) 
 
Clusia minor (Havana, Cuba)79 
Garcinia subelliptica (Kaohsiung, Taiwan)75 
propolis (Guantanamo, Cuba)80 
 
NMR75,79 (UV, IR)75 [α]D = +57º,75 +63.7º79,80 (CHCl3) 
garcinielliptone K 
(67) 
 
Garcinia subelliptica (Kaohsiung, Taiwan)81 
 
(NMR, UV, IR)81 [α]D = +27º (CHCl3)81 
garcinielliptone L 
(68) 
 
Garcinia subelliptica (Kaohsiung, Taiwan)81 
 
(NMR, UV, IR)81 [α]D = –41º (CHCl3)81 
garcinielliptone M 
(69) 
 
Garcinia subelliptica (Kaohsiung, Taiwan)81 
 
(NMR, UV, IR)81 [α]D = +73º (CHCl3)81 
garcinielliptone P 
(70) 
 
Garcinia subelliptica (Ping-Tung Hsien, Taiwan)82 
 
(NMR, UV, IR)82 [α]D = –2º (CHCl3)82 
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garcinielliptone R 
(71) 
 
Garcinia subelliptica (Kaohsiung, Taiwan)74 
 
(NMR, UV, IR)74 [α]D = –38º (CHCl3)74 
garcinol 
camboginol 
ent-guttiferone E 
(72) 
 
Allanblackia monticola (West Province, Cameroon)83 
Garcinia assigu (Central Province, Papua New 
Guinea)29 
G. bancana (Naratiwath, Thailand)84 
G. brevipedicellata (Cameroon)30 
G. cambogia 
 Dapoli,85 Maharastra, India86,87 
 Sri Lanka88,89 
G. cowa (Yunnan, China)65,90 
G. dulcis (Songkhla, Thailand)91 
G. huillensis (western Democratic Republic of the 
Congo)92 
G. indica (Kerela,85 India93,94) 
G. maingayii (Riau Islands, Indonesia)95 
G. oblongifolia 
 Hainan, China70 
 Nhu Xuan, Vietnam96 
G. paucinervis (Xishuangbanna, Yunnan, China)67 
G. pedunculata (Jorhat, Assam, India)97 
G. preussii (Cameroon)30 
G. purpurea (Japan)51 
G. tetrandra (West Kalimantan, Indonesia)98 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
 
1H NMR86,90,92,95,97,98,99 13C NMR86,90,92,95,98,99  
(UV, IR) 46,51,86, 90,92,93,97 CD29,90  
[α]D = –135º,46 –138º,51 –132.9º,86 –143º,93 –125.3º,92  
–142º97 (CHCl3) –192.0º,90 –128.5º,91 –149.2º94 (MeOH)  
–125.3º (EtOH)92  
garcinol  
13-O-methyl ether 
(73) 
 
Garcinia assigu (Central Province, Papua New 
Guinea)29 
 
(NMR, UV, IR, CD)29 [α]D = –117º (CHCl3)29 
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7-epi-garcinol 
(74) 
 
Garcinia brevipedicellata (Cameroon)30 
G. nujiangensis (Nujiang, Yunnan, China)49 
G. preussii (Cameroon)30 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
NMR46 (UV, IR)46,47 [α]D = –86º (CHCl3)46,47 
no name 
cyclogarcinol  
(75) 
 
Garcinia indica (Bengaluru, India)94 
 
(NMR, UV, IR)94 [α]D = +18.9 (MeOH)94 
14-deoxygarcinol 
(76) 
 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
 
(NMR, UV, IR)46 [α]D = –42º (CHCl3)46 
garciyunnanin B 
(77) 
 
Garcinia lancilimba (Xishuangbanna, Yunnan, China)66 
G. multiflora (Wanning, China)66 
G. xanthochymus (Xishuangbanna, Yunnan, China)66 
G. yunnanensis (Dehong, Yunnan, China)66,100  
 
(NMR, UV, IR)100 [α]D = +18.1º (CHCl3)100 
garsubellin A 
(78) 
 
Garcinia subelliptica 
 Ishigaki Island, Japan101,102 
 Kaohsiung, Taiwan73,74 
 
NMR101,102 (UV, IR)101 [α]D = –21.3º (EtOH)101 
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garsubellin B 
(79) 
 
Garcinia subelliptica (Ishigaki Island, Japan)102 
 
(NMR, UV, IR)102 [α]D = –36º (EtOH)102 
garsubellin C 
(80) 
 
Garcinia subelliptica (Ishigaki Island, Japan)102 
 
(NMR, UV, IR)102 [α]D = +39º (EtOH)102 
garsubellin D 
(81) 
 
Garcinia subelliptica 
 Ishigaki Island, Japan102 
 Kaohsiung, Taiwan73 
 
(NMR, UV, IR)102 [α]D = –12º (EtOH)102 
garsubellin E 
(82) 
 
Garcinia subelliptica (Ishigaki Island, Japan)102 
 
(NMR, UV, IR)102 [α]D = –7º (EtOH)102 
guttiferone A 
(83) 
 
Clusia rosea (Havana, Cuba)103 
Garcinia achachairu (Camboriú, Santa Catarina, 
Brazil)104 
G. aristata (Homestead, Florida, USA)105 
G. brasiliensis (Viçosa, Minas Gerais, Brazil) 36,35  
G. cowa (Xishuangbanna, Yunnan, China)65 
G. intermedia (Ejido Benigno Mendoza, Veracruz, 
Mexico)105,106 
G. livingstonei 
 Iringa, Mufindi, Tanzania107  
 Southeastern Florida, USA48,105 
G. macrophylla (Supaliwini, Suriname)108 
G. semseii (Morogoro, Tanzania)109 
G. spicata (Homestead, Florida, USA)105 
Rheedia edulis (Broward County, Florida, USA)41 
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Symphonia globulifera 
 Fundong, Northwest Province, Cameroon110,111 
 West Province, Cameroon83 
 Ndakan Gorilla Study Area, Central African 
Republic107 
S. pauciflora (Zahamena National Park, Madagascar)112 
 
NMR107,113,114 IR107,113 UV41,107,113 [α]D = +34º,107 
+32º,108 +47.6º113 (CHCl3) +31.4º (MeOH)41 
crystal structure113,115 
guttiferone B 
(84) 
 
Garcinia cowa (Yunnan, China)65,66 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. multiflora (Wanning, China)66 
G. oblongifolia 
 Bobai, Guangxi, China66,116 
 Nhu Xuan, Vietnam96 
G. subelliptica (Shenzhen, Guangdong, China)66 
G. xanthochymus (Xishuangbanna, Yunnan, China)66 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)66 
G. yunnanensis (Dehong, Yunnan, China)66 
Symphonia globulifera (Ndakan Gorilla Study Area, 
Central African Republic)107 
 
(NMR, UV, IR)107 [α]D = –44º (CHCl3)107 
guttiferone C 
(85) 
 
Symphonia globulifera (Ndakan Gorilla Study Area, 
Central African Republic)107 
 
characterized as mixture with 86 (NMR, UV, IR)107  
[α]D = +92º (CHCl3)107 
guttiferone D 
(86) 
 
Symphonia globulifera (Ndakan Gorilla Study Area, 
Central African Republic)107 
 
characterized as mixture with 85 (NMR, UV, IR)107  
[α]D = +92º (CHCl3)107 
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 guttiferone E 
ent-garcinol 
(87) 
 
Clusia rosea (Dominican Republic)107 
Garcinia afzelii (Mt. Eloumdem, Centre Province, 
Cameroon)117 
G. intermedia (Homestead, Florida, USA)105 
G. livingstonei (Homestead, Florida, USA)48 
G. multiflora (Diaoluo Mountain, Hainan, China)18 
G. ovalifolia (Ndakan Gorilla Study Area, Central 
African Republic)107 
G. paucinervis (Xishuangbanna, Yunnan, China)67 
G. pyrifera (Sungai Petani, Kedah, Malaysia)50 
G. spicata (Homestead, Florida, USA)105 
G. xanthochymus (Homestead, Florida, USA)19,105 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)118 
G. virgata (Aoupinié, New Caledonia)119 
Rheedia edulis (Broward County, Florida, USA)41 
propolis (throughout Cuba)120 
red propolis (Maceio City, Alagoas, Brazil)121 
 
NMR50,107 UV41,107 IR107 [α]D = +106º,19 +104º,50  
+101º107 (CHCl3) +120º (EtOH)19 
absolute configuration107 
guttiferone F 
(88) 
 
Allanblackia monticola (West Province, Cameroon)83 
A. gabonensis (Mbankomo, Centre Province, 
Cameroon)122 
A. stuhlmannii (Mufundi, Tanzania)123 
A. ulugurensis (Morningside, Morogoro, Tanzania)124 
Calophyllum thorelii (central Vietnam)33 
Garcinia bancana (West Kalimantan, Indonesia)125 
G. cowa (Yunnan, China)65,66 
G. esculenta (Dehong, Yunnan, China)66 
G. multiflora 
 Diaoluo Mountain, Hainan, China18 
 Wanning, China66 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. oblongifolia 
 Bobai, Guangxi, China66 
 Vietnam126 
G. paucinervis (Xishuangbanna, Yunnan, China)66 
G. subelliptica (Shenzhen, Guangdong, China)66 
G. xanthochymus (Xishuangbanna, Yunnan, China)66 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)66 
G. yunnanensis (Dehong, Yunnan, China)66 
 
(NMR, IR)123,125 UV123 [α]D = –293º (CHCl3)123 
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 guttiferone G 
guttiferone I2 
ent-oblongifolin C 
(89) 
 
Calophyllum thorelii (central Vietnam)33 
Garcinia cambogia (Sri Lanka)88 
G. cochinchinensis (southern Vietnam)71,127 
G. griffithii (Lembah Arau, West Sumatra, Indonesia)128 
G. humilis (Dominica)129 
G. macrophylla (Supaliwini, Suriname)108 
G. paucinervis (Xishuangbanna, Yunnan, China)67 
G. smeathmannii (Cheffou-Baham, West Province, 
Cameroon)130,131 
G. virgata (Aoupinié, New Caledonia)119 
 
(NMR, UV, IR)108,119,129 [α]D = –25º,108 –14.3º119 
(CHCl3)  
+8.7 (MeOH)129 
structural revision132 
guttiferone H 
(90) 
 
Garcinia xanthochymus (Homestead, Florida, USA)19 
 
(NMR, UV)19 [α]D = +94º (CHCl3)19 +57º (MeOH)19 
guttiferone I 
(91) 
 
Garcinia cochinchinensis (Dong Nai, Vietnam)133 
G. giffithii (Singapore)134 
Symphonia pauciflora (Zahamena National Park, 
Madagascar)112 
 
(NMR, UV, IR)134 [α]D = –68º (CHCl3)134 
oxy-guttiferone I 
(92) 
 
Garcinia cambogia (Sri Lanka)135  
 
(NMR, UV, IR)135 [α]D = +23.8º (MeOH)134 
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 guttiferone J 
garciyunnanin A 
(93) 
 
Garcinia cambogia (Sri Lanka)88 
Garcinia cowa (Xishuangbanna, Yunnan, China)66 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. multiflora (Wanning, China)66 
G. oblongifolia (Bobai, Guangxi, China)66 
G. paucinervis (Xishuangbanna, Yunnan, China)66 
G. subelliptica (Shenzhen, Guangdong, China)66 
G. xanthochymus (Xishuangbanna, Yunnan, China)66 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)66 
G. virgata (Aoupinié, New Caledonia)119 
G. yunnanensis (Yunnan, China)66,100 
 
(NMR, UV, IR)100,119  
[α]D = –3º (CHCl3)100 –34.3º (MeOH)119 
7-epi-guttiferone J 
(94) 
 
Rheedia edulis (Broward County, Florida, USA)41 
 
(NMR, UV, IR, CD)41 [α]D = +10.8º (MeOH)41 
absolute configuration41 
guttiferone K 
(95) 
 
Garcinia cambogia (Sri Lanka)88,89,135 
G. cowa (Yunnan, China)65,66 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. livingstonei (Homestead, Florida, USA)48 
G. multiflora (Wanning, China)66 
G. oblongifolia (Bobai, Guangxi, China)66 
G. paucinervis (Xishuangbanna, Yunnan, China)66,67 
G. semseii (Morogoro, Tanzania)109 
G. subelliptica (Shenzhen, Guangdong, China)66 
G. xanthochymus (Xishuangbanna, Yunnan, China)66 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)66 
G. yunnanensis 
 Dehong, Yunnan, China66 
 Luxi, Yunnan, China100 
Rheedia calcicola (Antsiranana, Madagascar)136 
 
(NMR, UV, IR)136 [α]D = –2º (CHCl3)136 
guttiferone K2 
coccinone A 
(96) 
 
Garcinia cowa (Yunnan, China)90 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
Rheedia acuminata (La Paz, Bolivia)1 
 
NMR1,46,90 (UV, IR)46,90 CD90  
[α]D = +28º (CHCl3)46 +106.45 (MeOH)90
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oxy-guttiferone K 
(97) 
 
Garcinia cambogia (Sri Lanka)88,135 
 
(NMR, UV, IR)88 [α]D = +20.9º (CHCl3)88 
absolute configuration135 
 
oxy-guttiferone K2 
(98) 
 
Garcinia cambogia (Sri Lanka)135 
 
(NMR, UV, IR)135 +12.2 [α]D = +12.2º (MeOH)135 
guttiferone L 
(99) 
 
Rheedia calcicola (Antsiranana, Madagascar)136 
 
(NMR, UV, IR)136 [α]D = –8º (CHCl3)136 
guttiferone M 
(100) 
 
Garcinia cambogia (Sri Lanka)88,135 
 
(NMR, UV, IR)88 [α]D = –29.8º (MeOH)88 
absolute configuration135 
oxy-guttiferone M 
(101) 
 
Garcinia cambogia (Sri Lanka)135 
 
(NMR, UV, IR)135 [α]D = –96.2º (MeOH)135 
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32-hydroxy-ent-
guttiferone M 
(102) 
 
Rheedia edulis (Broward County, Florida, USA)41 
 
(NMR, UV, IR, CD)41 [α]D = +9.6º (MeOH)41 
absolute configuration41 
guttiferone N 
(103) 
 
Garcinia cambogia (Sri Lanka)88 
 
(NMR, UV, IR)88 [α]D = –34.5º (MeOH)88 
guttiferone O 
(104) 
 
Garcinia solomonensis (Central Province, Papua New 
Guinea)137 
 
(NMR, UV, IR)137 [α]D = +30.7º (CHCl3)137 
guttiferone O2 
ent-oblongifolin F 
(105) 
 
Garcinia afzelii (Mt. Eloumdem, Centre Province, 
Cameroon)117 
 
(NMR, UV, IR)117 [α]D = +45º (acetone)117 
guttiferone P 
(106) 
 
Garcinia solomonensis (Central Province, Papua New 
Guinea)137 
 
(NMR, UV, IR)137 [α]D = +18.2º (CHCl3)137 
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guttiferone Q 
ent-chamuangone 
ent-cowanone 
(107) 
 
Garcinia cochinchinensis (Dong Nai, Vietnam)133 
 
(NMR, UV, IR)133 [α]D = –50.0º (MeOH)133 
guttiferone R 
(108) 
 
Garcinia cochinchinensis (Dong Nai, Vietnam)133 
 
(NMR, UV, IR)133 [α]D = –57.5º (MeOH)133 
guttiferone S 
(109) 
 
Garcinia cochinchinensis (Dong Nai, Vietnam)133 
 
(NMR, UV, IR)133 [α]D = –10.0º (MeOH)133 
guttiferone T 
(110) 
 
Garcinia cochinchinensis (southern Vietnam)71 
 
(NMR, UV, IR)71 [α]D = –14.0º (CHCl3)71 
hydroperoxycadiforin 
(111) 
 
Hypericum perforatum (Bonn-Beuel, Germany)138 
 
(NMR, UV, IR)138 [α]D = +26.5º (hexane)138 
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hyperandrone A 
(112) 
 
Hypericum androsaemum (Yunnan, China)15 
 
(NMR, UV, IR)15 [α]D = +20.9º (MeOH)15 
hyperatomarin 
(113) 
 
Hypericum annulatum (Rhodope Mountains, 
Bulgaria)139,140 
H. atomarium (Nišava District, Serbia)141 
 
(NMR, UV, IR)141 [α]D = +19.4º (CH2Cl2)141 
hyperevolutin A 
(114) 
 
Hypericum revolutum (Zomba, Malawi)142 
 
(NMR, UV, IR)142 [α]D = +84.4º (MeOH)142 
crystal structure142 
hyperevolutin B 
(115) 
 
Hypericum revolutum (Zomba, Malawi)142 
 
(NMR, UV)142 
hyperfirin 
(116) 
 
Hypericum perforatum 
 Germany3  
 Epirus, Greece4  
 Cemernik Mountain, southern Serbia5 
H. reflexum (Halle-Wittenberg, Germany)3 
H. triquetrifolium (Al-Mafraq, Jordan)6 
 
1H NMR4 
hyperfoliatin 
hyperibone J 
(117) 
 
Hypericum perfoliatum (Jijel, Algeria)143 
H. perforatum (Tokushima, Japan)59 
H. scabrum (Chimgan, Uzbekistan)38 
H. tomentosum (Bekira-Constantine, eastern Algeria)144 
 
(NMR, IR)143,38 UV143  
[α]D = +17 (MeOH)143 +16.9 (CHCl3)38 
O
O
O
O
O
O
O
OH
O
O
O
OH
O
O
O
OH
O
O
O
OH
O
O
OH
O
O
O
368
hyperforin 
(118) 
 
Hypericum androsaemum (northern Turkey)145 
H. aviculariifolium (northern Turkey)145 
H. barbatum (throughout Macedonia and Serbia)146,147 
H. bithynicum (northern Turkey)145 
H. bupleuroides (Maçka district, Trabzon, Turkey)148 
H. calabricum (Calabria, Italy)149 
H. calycinum (Bonn, Germany)7 
H. confertum (Uludağ Mountain, Bursa, Turkey)150 
H. elodes (Umbrian-Marchean Apennines, Italy)8,151 
H. empetrifolium (Irbid, northern Jordan)152 
H. ericoides (El Feidja, northwestern Tunisia)10  
H. grandifolium (Pedro Álvarez, Tenerife, Canary 
Islands)153 
H. heterophyllum (northern Turkey)145 
H. hircinum (Umbrian-Marchean Apennines, Italy)154 
H. hirsutum 
 Umbrian-Marchean Apennines, Italy154 
 Throughout Macedonia and Serbia146,147  
 Spisska Tomašovca, Slovakia155 
 Northern Turkey145 
H. hyssopifolium  
 Umbrian-Marchean Apennines, Italy151,154 
 Northern Turkey145 
H. leschenaultii (Indonesia)156 
H. leptophyllum (Yozgat, Turkey)157 
H. linarioides (throughout Macedonia and Serbia)146,147 
H. maculatum 
 Prakovce, Slovakia9 
 Spisska Tomašovca, Slovakia155 
 Throughout Macedonia and Serbia146,147 
H. microsepalum (southeastern USA)156 
H. montanum (Umbrian-Marchean Apennines, 
Italy)151,154 
H. montbretii (Cakalli,158 Samsun, Turkey145) 
H. nummularioides (northern Turkey)145 
H. olympicum (throughout Macedonia and Serbia)146 
H. orientale (northern Turkey)145,159 
H. perfoliatum 
 Northern Turkey145 
 El Feidja, northwestern Tunisia10 
H. perforatum  
 Yerevan,160 Armenia161 
 Mt. Taylor, Canberra, Australia11  
 Ontario, Canada161 
 Longxi, Gansu, China162 
 Throughout Estonia163 
 Alpirsbach, Black Forest,12 Germany3  
 Epirus, Greece4 
 Throughout India155,164 
 Throughout Italy13,151,154,165,166  
 Throughout Macedonia and Serbia146 
 Russia167 
 Cemernik Mountain, southern Serbia5  
 Nová Ľubovňa, Slovakia14 
 Slovenia168 
 Throughout Switzerland169 
 Throughout northern Turkey145,170 
 El Feidja, northwestern Tunisia10 
 Western Montana, USA161 
 Ithaca, New York, USA161 
 Southeastern USA156 
O
O
OH
O
369
hyperforin 
(continued) 
(118) 
 
H. pruinatum (northern Turkey)145 
H. reflexum (Halle-Wittenberg, Germany)3 
H. richeri 
 Umbrian-Marchean Apennines, Italy151 
 Throughout Macedonia and Serbia146 
H. rumeliacum (throughout Macedonia and Serbia)146,147 
H. scabrum (northern Turkey)145 
H. sinaicum (northern Jordan)2,152  
H. tetrapterum 
 Umbrian-Marchean Apennines, Italy151,154 
 Throughout Macedonia and Serbia146,147 
 Nová Sedlica, Slovakia155 
H. triquetrifolium 
 Ajloun Nature Preserve, northern Jordan152 
 Northern Turkey145 
H. venustum (throughout Turkey)145,171 
Apocynum venetum (Apocynaceae)172 
Scutellaria baicalensis (Lamiaceae)173 
 
1H NMR4,9,167,174,175,176,177 13C NMR11,174,175,176,177  
(UV, IR)167,174 [α]D = +41º (EtOH)167 
structural elucidation;178,179 crystal structure179,180 
absolute configuration180 
hyperibone A  
ent-garcinielliptone I 
(119) 
 
Hypericum scabrum (Chimgan, Uzbekistan)181  
propolis, type 6 (Atlantic forest, Bahia, Brazil)182 
 
(NMR, IR)181,182 UV181 [α]D = –37.7º (CHCl3)181 
hyperibone B 
 (120) 
 
Clusia minor (Havana, Cuba)79 
Hypericum scabrum (Chimgan, Uzbekistan)181 
propolis (Guantanamo, Cuba)80 
 
NMR79,181 (UV, IR)181  
[α]D = –42.2º,79,80 –20.8º181 (CHCl3) 
hyperibone C 
(121) 
 
Hypericum scabrum (Chimgan, Uzbekistan)181 
 
(NMR, UV, IR)181 [α]D = –27.3º (CHCl3)181 
structural revision132 
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hyperibone D 
(122) 
 
Hypericum scabrum (Chimgan, Uzbekistan)181 
 
(NMR, UV, IR)181 [α]D = –61.9º (CHCl3)181 
hyperibone E 
(123) 
 
Hypericum scabrum (Chimgan, Uzbekistan)181 
 
(NMR, UV, IR)181 [α]D = –56.0º (CHCl3)181 
structural revision132 
hyperibone F 
(124) 
 
Hypericum scabrum (Chimgan, Uzbekistan)181 
 
(NMR, UV, IR)181 [α]D = –31.0º (CHCl3)181 
structural revision132 
hyperibone G 
(125) 
 
Hypericum scabrum (Chimgan, Uzbekistan)181 
 
(NMR, UV, IR)181 [α]D = –29.3º (CHCl3)181 
hyperibone H 
(126) 
 
Hypericum scabrum (Chimgan, Uzbekistan)181 
 
(NMR, UV, IR)181 [α]D = +12.4º (CHCl3)181 
structural revision132 
hyperibone I 
(127) 
 
Hypericum scabrum (Chimgan, Uzbekistan)181 
 
(NMR, UV, IR)181 [α]D = +13.3º (CHCl3)181 
structural revision132 
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hyperibone K 
(128) 
 
Hypericum scabrum (Chimgan, Uzbekistan)38 
 
(NMR, UV, IR)38 [α]D = +22.3º (CHCl3)38 
absolute configuration183 
18-hydroxyhyperibone 
K 
(129) 
 
Hypericum hypericoides (St. Andrew, Jamaica)31 
 
(NMR, IR)31  
hyperibone L 
(130) 
 
Hypericum scabrum (Chimgan, Uzbekistan)38 
 
(NMR, UV, IR)38 [α]D = +69.5º (CHCl3)38 
hyperpapuanone 
(131) 
 
Hypericum papuanum (Ialibu, Papua New Guinea)184 
 
(NMR, UV)184 [α]D = +15º (MeOH)184 
hypersampsone A 
(132) 
 
Hypericum sampsonii (Chia-Yi, Taiwan)185 
 
(NMR, IR)185 [α]D = +21º (CHCl3)185 
hypersampsone B 
(133) 
 
Hypericum sampsonii (Chia-Yi, Taiwan)185 
 
(NMR, IR)185 [α]D = +12º (CHCl3)185 
hypersampsone C 
(134) 
 
Hypericum sampsonii (Chia-Yi, Taiwan)185 
 
(NMR, IR)185 [α]D = +14.3º (CHCl3)185 
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hypersampsone D 
(135) 
 
Hypericum sampsonii (Chia-Yi, Taiwan)185 
 
(NMR, UV, IR)185 [α]D = –35º (CHCl3)185 
hypersampsone E 
(136) 
 
Hypericum sampsonii (Chia-Yi, Taiwan)185 
 
(NMR, UV, IR)185 [α]D = +39º (CHCl3)185 
hypersampsone F 
(137) 
 
Hypericum sampsonii (Chia-Yi, Taiwan)185 
 
(NMR, UV, IR)185 [α]D = +30.0º (CHCl3)185 
structural revision132 
hypersampsone G 
(138) 
 
Hypericum sampsonii (China)186 
 
IR186 [α]D = +10.25º (CHCl3)186 
crystal structure186 
hypersampsone H 
(139) 
 
Hypericum sampsonii (China)186  
 
(NMR, IR)186 [α]D = +44.37º (CHCl3)186 
hypersampsone I 
(140) 
 
Hypericum sampsonii (Chalin, Hunan, China)187 
 
(NMR, UV, IR)187 [α]D = +18.6º (CHCl3)187 
crystal structure187 
hypersampsone J 
(141) 
 
Hypericum sampsonii (Chalin, Hunan, China)187 
 
(NMR, UV, IR)187 [α]D = +11.4º (CHCl3)187 
crystal structure187 
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hypersampsone K 
(142) 
 
Hypericum sampsonii (Chalin, Hunan, China)187 
 
(NMR, UV, IR)187 [α]D = +31.7º (CHCl3)187 
hypersampsone L 
(143) 
 
Hypericum sampsonii (Chalin, Hunan, China)187 
 
(NMR, UV, IR)187 [α]D = –67.4º (CHCl3)187 
insignone 
(144) 
 
Clusia insignis (Campinas, São Paulo, Brazil)24 
 
O-Me ether (1H NMR, UV)24 [α]D = +92.7º (CHCl3)24  
methyl insignone 
(145) 
 
propolis (Manaus, Brazil)20 
 
(1H NMR, UV)24 [α]D = +92.7º (CHCl3)24 
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 isogarcinol  
cambogin 
ent-isoxanthochymol 
(146) 
 
Allanblackia monticola (West Province, Cameroon)83 
Calophyllum enervosum (Bukitinggi, West Sumatra, 
Indonesia)54 
C. thorelii (central Vietnam)33 
Hypericum lanceolatum (Mt. Bamboutos, West 
Province, Cameroon)188,189 
Garcinia assigu (Central Province, Papua New 
Guinea)29 
G. bancana (Naratiwath, Thailand)84 
G. brevipedicellata (Cameroon)30 
G. cambogia (India)86,87 
G. cowa (Yunnan, China)65,66 
G. esculenta (Dehong, Yunnan, China)66 
G. giffithii (Singapore)134 
G. indica (India)93,94 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. latissimia (Central Province, Papua New Guinea)190 
G. multiflora 
 Wanning, China66 
 Mudan, Taiwan68 
G. nujiangensis (Nujiang, Yunnan, China)49 
G. oblongifolia (Bobai, Guangxi, China)66 
G. paucinervis (Xishuangbanna, Yunnan, China)66 
G. pedunculata (Jorhat, Assam, India)97 
G. preussii (Cameroon)30 
G. purpurea (Japan)51 
G. subelliptica (Shenzhen, Guangdong, China)66 
G. tetrandra (West Kalimantan, Indonesia)98 
G. xanthochymus (Xishuangbanna, Yunnan, China)66 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)66 
G. yunnanensis (Dehong, Yunnan, China)66 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
Rheedia acuminata (French Guyana)191 
 
1H NMR46,97,98,191 13C NMR46,86,98,191  
(UV, IR) 46,51,93,94,97,191 CD29  
[α]D = –158º,46 –160º191 (CHCl3) –224º,51 –209.9º,86  
–269.8º94 (MeOH) –203º,93 –211º97 (EtOH) 
structural revision;192 crystal structure192 
absolute configuration46 
isogarcinol  
13-O-methyl ether 
(147) 
 
Garcinia assigu (Central Province, Papua New 
Guinea)29 
 
(NMR, UV, IR, CD)29 [α]D = –199º (EtOH)29 
absolute configuration29 
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7-epi-isogarcinol 
(148) 
 
Garcinia nujiangensis (Nujiang, Yunnan, China)49 
Moronobea coccinea (dense rain forest, French 
Guyana)46 
Rheedia acuminata (French Guyana)191 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
(NMR, UV, IR)46,47,191 [α]D = –158º (CHCl3)46,47,191 
30-epi-isogarcinol 
(149) 
 
Allanblackia ulugurensis (Morningside, Morogoro, 
Tanzania)124 
Garcinia cochinchinensis (southern Vietnam)71 
G. cowa (Yunnan, China)65,66 
G. esculenta (Dehong, Yunnan, China)66 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. multiflora (Wanning, China)66 
G. oblongifolia (Vietnam)126 
G. paucinervis (Xishuangbanna, Yunnan, China)66,67 
G. subelliptica (Shenzhen, Guangdong, China)66 
G. xanthochymus (Xishuangbanna, Yunnan, China)66 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)66 
G. yunnanensis (Dehong, Yunnan, China)66 
 
(NMR, UV)123 [α]D = –125º (CHCl3)123 
14-deoxyisogarcinol 
(150) 
 
Garcinia indica (Bengaluru, India)94 
 
(NMR, UV, IR)94 [α]D = –178.0º (MeOH)94 
crystal structure193 
14-deoxy-7-epi-
isogarcinol 
(151) 
 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
(NMR, UV, IR)47 [α]D = –77º (CHCl3)47 
13,14-didehydroxy-
isogarcinol 
(152) 
 
Garcinia multiflora (Mudan, Taiwan)68 
 
(NMR, UV, IR, CD)68 [α]D = –185º (CHCl3)68 
absolute configuration68 
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isoxanthochymol 
ent-isogarcinol 
(153) 
 
Garcinia afzelii (Mt. Eloumdem, Centre Province, 
Cameroon)117 
G. cambogia (Kerela, India)85 
G. griffithii (Lembah Arau, West Sumatra, Indonesia)194 
G. indica (Dapoli,85 Maharastra, India195) 
G. livingstonei (Homestead, Florida, USA)48 
G. maingayii 
 Riau Islands, Indonesia95 
 Pahang, Malaysia196 
G. multiflora 
 Diaoluo Mountain, Hainan, China18 
 Taiwan72 
G. ovalifolia 
 Douala-Edea Reserve, Cameroon197,198 
 Ndakan Gorilla Study Area, Central African 
Republic107 
G. polyantha (Cheffou-Baham, West Province, 
Cameroon)199 
G. pyrifera (Sungai Petani, Kedah, Malaysia)50 
G. smeathmannii (Cheffou-Baham, West Province, 
Cameroon)130,131 
G. subelliptica (Okinawa, Japan)51 
G. xanthochymus 
 South Canara,200 India201,202 
 Homestead, Florida, USA19 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)203 
Rheedia acuminata (La Paz, Bolivia)1 
R. edulis (Broward County, Florida, USA)41 
 
(1H NMR, IR)95,107,202,203 13C NMR95,107,203  
IR95,203 UV41,107,202 
[α]D = +181º,107 +208º,204 (MeOH)  
+208º,202 +207.6º205 (EtOH) 
characterized as mixture with 21 (NMR, UV, IR)50,51  
[α]D = +142º (CHCl3)50 [α]D = +158º (MeOH)51 
absolute configuration;205 crystal structure95 
structural revision204 
lathrophytoic acid B 
(154) 
 
Kielmeyera lathrophyton (Chapada Diamantina, 
Brazil)206 
 
O-Me ether (NMR, IR)206 
laxifloranone 
(155) 
 
Marila laxiflora (Guatemala)207 
 
(NMR, UV, IR)207 [α]D = +23.6º (MeOH)207 
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makandechamone 
(156) 
 
Garcinia punctata (northern Gabon)208 
 
(NMR, UV)208 
nemorosone 
(157) 
 
Clusia rosea 
 Campinas, São Paulo, Brazil209 
 Havana, Cuba103,210 
C. grandiflora 
 Campinas, São Paulo, Brazil28 
 Canaima, Venezuela21 
C. hilariana 
 Campinas, São Paulo, Brazil24 
 Jurubatiba, Brazil211 
C. insignis (Campinas, São Paulo, Brazil)28 
C. nemorosa (Campinas, São Paulo, Brazil)28 
C. rosea 
 Campinas, São Paulo, Brazil28 
 Havana, Cuba103 
brown propolis (throughout Cuba)120,212,213 
 
(NMR, UV, IR)210,211 UV210 [α]D = +112.8 (CHCl3)210 
O-Me ether (NMR, IR)28,209 UV28  
[α]D = +150º (MeOH)28 +48.6º (CHCl3)209 
structural revision;210 crystal structure214 
hydroxynemorosone 
(158) 
 
Clusia nemorosa (Campinas, São Paulo, Brazil)28 
 
O-Me ether (NMR, IR)28 [α]D = +142.8º (MeOH)28 
nujiangefolin A 
(159) 
 
Garcinia nujiangensis (Nujiang, Yunnan, China)49 
 
(NMR, UV, IR)49 [α]D = –2º (MeOH)49 
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nujiangefolin B 
(160) 
 
Garcinia nujiangensis (Nujiang, Yunnan, China)49 
 
(NMR, UV, IR)49 [α]D = +5º (MeOH)49 
nujiangefolin C 
(161) 
 
Garcinia nujiangensis (Nujiang, Yunnan, China)49 
 
(NMR, UV, IR)49 [α]D = +20º (MeOH)49 
no name 
obdeltifolin A 
(162) 
 
Clusia obdeltifolia (Chapada Diamantina, Brazil)215 
 
NMR215 [α]D = +30.9º (CHCl3)215 
no name 
obdeltifolin B 
(163) 
 
Clusia obdeltifolia (Chapada Diamantina, Brazil)215 
 
NMR215 [α]D = +10.0º (CHCl3)215 
no name 
obdeltifolin C 
(164) 
 
Clusia obdeltifolia (Chapada Diamantina, Brazil)216 
 
(NMR, IR)216  
no name 
obdeltifolin D 
(165) 
 
Clusia obdeltifolia (Chapada Diamantina, Brazil)216 
 
(NMR, IR)216 [α]D = –5.1º (CHCl3)216 
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oblongifolin A 
(166) 
 
Garcinia cowa (Yunnan, China)65,66 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. multiflora (Wanning, China)66 
G. oblongifolia 
 Bobai, Guangxi, China66,116 
 Nhu Xuan, Vietnam96,126 
G. paucinervis (Xishuangbanna, Yunnan, China)66 
G. xanthochymus (Xishuangbanna, Yunnan, China)66 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)66 
G. yunnanensis 
 Dehong, Yunnan, China66 
 Luxi, Yunnan, China100 
 
(NMR, UV, IR)96 [α]D = +23º (CHCl3)96 
oblongifolin B 
(167) 
 
Garcinia cowa (Yunnan, China)65,66 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. multiflora (Wanning, China)66 
G. oblongifolia 
 Bobai, Guangxi, China66,116 
 Nhu Xuan, Vietnam96 
G. paucinervis (Xishuangbanna, Yunnan, China)66 
G. subelliptica (Shenzhen, Guangdong, China)66 
G. xanthochymus (Xishuangbanna, Yunnan, China)66 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)66 
G. yunnanensis 
 Dehong, Yunnan, China)66 
 Luxi, Yunnan, China100 
 
(NMR, UV, IR)96 [α]D = +17.6º (CHCl3)96 
oblongifolin C 
ent-guttiferone G 
(168) 
 
Garcinia cowa (Yunnan, China)65,66 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. multiflora (Wanning, China)66 
G. oblongifolia 
 Bobai, Guangxi, China66,116 
 Nhu Xuan, Vietnam96 
G. paucinervis (Xishuangbanna, Yunnan, China)66 
G. subelliptica (Shenzhen, Guangdong, China)66 
G. xanthochymus (Xishuangbanna, Yunnan, China)66 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)66 
G. yunnanensis 
 Dehong, Yunnan, China66 
 Luxi, Yunnan, China100 
 
(NMR, UV, IR)96 [α]D = +14.5º (CHCl3)96 
oblongifolin D 
(169) 
 
Garcinia cowa (Yunnan, China)65,66 
G. lancilimba (Xishuangbanna, Yunnan, China)66 
G. multiflora (Wanning, China)66 
G. oblongifolia 
 Bobai, Guangxi, China66,116 
 Nhu Xuan, Vietnam96 
G. subelliptica (Shenzhen, Guangdong, China)66 
G. yunnanensis 
 Dehong, Yunnan, China66 
 Luxi, Yunnan, China100 
 
(NMR, UV, IR)96 [α]D = +44.6º (CHCl3)96 
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oblongifolin E 
(170) 
 
Garcinia oblongifolia (Bobai, Guangxi, China)116 
 
(NMR, UV, IR)116 [α]D = +65.1º (CHCl3)116 
oblongifolin F 
ent-guttiferone O2 
(171) 
 
Garcinia multiflora (Wanning, China)66 
G. oblongifolia (Bobai, Guangxi, China)116 
G. subelliptica (Shenzhen, Guangdong, China)66 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)66 
G. yunnanensis (Dehong, Yunnan, China)66   
 
(NMR, UV, IR)116 [α]D = –85.6º (CHCl3)116 
oblongifolin G 
(172) 
 
Garcinia oblongifolia (Bobai, Guangxi, China)66 
G. oblongifolia (Bobai, Guangxi, China)116 
G. paucinervis (Xishuangbanna, Yunnan, China)66 
G. subelliptica (Shenzhen, Guangdong, China)66 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)66 
G. yunnanensis (Dehong, Yunnan, China)66 
 
(NMR, UV, IR)116 [α]D = +5.9º (CHCl3)116 
oblongifolin H 
(173) 
 
Garcinia oblongifolia (Bobai, Guangxi, China)66 
 
oblongifolin I 
(174) 
 
Garcinia oblongifolia (Bobai, Guangxi, China)66 
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ochrocarpinone A 
(175) 
 
Ochrocarpos punctatus (Mahajanga, Madagascar)217 
 
(NMR, UV, IR)217 [α]D = +8.7º (CHCl3)217 
ochrocarpinone B 
 (176) 
 
Ochrocarpos punctatus (Mahajanga, Madagascar)217 
 
(NMR, UV, IR)217 [α]D = –3.5º (CHCl3)217 
ochrocarpinone C 
ent-hyperibone B 
(177) 
 
Ochrocarpos punctatus (Mahajanga, Madagascar)217 
 
(NMR, UV, IR)217 [α]D = +10.2º (CHCl3)217 
otogirinin A 
(178) 
 
Hypericum erectum (Japan)218 
 
(NMR, UV, IR, CD)218 [α]D = –8.1º (MeOH)218 
otogirinin B 
(179) 
 
Hypericum erectum (Japan)218 
 
(NMR, UV, IR, CD)218 [α]D = +12.0º (MeOH)218 
otogirinin C 
(180) 
 
Hypericum erectum (Japan)218 
 
NMR218  
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otogirinin D 
(181) 
 
Hypericum erectum (Japan)218 
 
(NMR, UV, IR)218 [α]D = +160.0º (MeOH)218 
otogirinin E 
(182) 
 
Hypericum erectum (Japan)218 
 
NMR218 
oxepahyperforin 
(183) 
 
Hypericum perforatum (Chile)64 
 
(NMR, UV, IR, CD)64 [α]D = –73.7º (CHCl3) 
oxyhyperforin  
8-hydroxyhyperforin 
8,1-hemiacetal 
(184) 
 
Hypericum perforatum 
 Chile64 
 Italy13 
 Tokushima, Japan59 
 
(NMR, UV, IR, CD)64 [α]D = +34.0º (CHCl3) 
 
papuaforin A 
(185) 
 
Hypericum papuanum (Ialibu, Papua New Guinea)184 
 
(NMR, UV)184 [α]D = +13º (MeOH)184 
papuaforin B 
(186) 
 
Hypericum papuanum (Ialibu, Papua New Guinea)184 
 
NMR184 
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papuaforin C 
(187) 
 
Hypericum papuanum (Ialibu, Papua New Guinea)184 
 
(NMR, UV)184 [α]D = +23º (MeOH)184 
papuaforin D 
(188) 
 
Hypericum papuanum (Ialibu, Papua New Guinea)184 
 
(NMR, UV)184 [α]D = +64º (MeOH)184 
papuaforin E 
(189) 
 
Hypericum papuanum (Ialibu, Papua New Guinea)184 
 
(NMR, UV)184 [α]D = +41º (MeOH)184 
paucinone A 
(190) 
 
Garcinia paucinervis (Xishuangbanna, Yunnan, 
China)219,220 
 
(NMR, UV, IR)219,220 [α]D = –6.2º (MeOH)219,220 
paucinone B 
(191) 
 
Garcinia paucinervis (Xishuangbanna, Yunnan, 
China)219,220 
 
(NMR, UV, IR)219,220 [α]D = +58.7º (MeOH)219,220 
paucinone C 
(192) 
 
Garcinia paucinervis (Xishuangbanna, Yunnan, 
China)219,220 
 
(NMR, UV, IR)219,220 [α]D = +19.2º (MeOH)219,220 
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paucinone D 
(193) 
 
Garcinia paucinervis (Xishuangbanna, Yunnan, 
China)219,220 
 
(NMR, UV, IR)219,220 [α]D = +41.6º (MeOH)219,220 
pedunculol 
(194) 
 
Garcinia pedunculata (Jorhat, Assam, India)97 
 
(NMR, UV, IR)97 [α]D = –159º (EtOH)97 
peroxysampsone A 
(195) 
 
Hypericum sampsonii (Cha Lin, Hunan, China)221 
 
(NMR, UV, IR)221 [α]D = +17.0º (CHCl3)221 
peroxysampsone B 
(196) 
 
Hypericum sampsonii (Cha Lin, Hunan, China)221 
 
(NMR, UV, IR)221 [α]D = –41.2º (CHCl3)221 
plukenetione A 
(197) 
 
Clusia plukenetii (Barbados)222 
propolis (throughout Cuba)212 
 
(NMR, UV, IR)222 [α]D = +1º (CHCl3)222 
28,29-
epoxyplukenetione A 
(198) 
 
Clusia havetiodes (Ecclesdown, Portland, Jamaica)223 
C. obdeltifolia (Chapada Diamantina, Brazil)215 
 
(NMR, UV, IR)223 [α]D = –4.4º (CHCl3)223 
plukenetione B 
(199) 
 
Clusia plukenetii (St. Thomas, Barbados)224 
 
(NMR, UV, IR)224 [α]D = +17.2º (CHCl3)224 
structural revision225 
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plukenetione C 
(200) 
 
Clusia havetiodes (Ecclesdown, Portland, Jamaica)223 
C. plukenetii (St. Thomas, Barbados)224 
Hypericum sampsonii (Cha Lin, Hunan, China)221 
 
(NMR, UV, IR)221,223,224  
[α]D = +27.5º,221 +15.0º,223 +65.9º224 (CHCl3) 
33-hydroxyperoxyiso-
plukenetione C 
(201) 
 
Clusia havetiodes (Ecclesdown, Portland, Jamaica)223 
 
(NMR, UV, IR)223 [α]D = –3.9º (CHCl3)223 
plukenetione D/E 
7-epi-nemorosone  
(202) 
 
Clusia hilariana (Campinas, São Paulo, Brazil)24 
C. nemorosa (Campinas, São Paulo, Brazil)209 
C. plukenetii (St. Thomas, Barbados)224 
C. rosea (Florida, USA)226 
Tovomitopsis saldanhae (southeastern Brazil)227 
Propolis 
 Carribean226 
 Manaus, Brazil20 
 
NMR20,227 (UV, IR)20 
O-Me ether (NMR, IR)209 [α]D = +140.7 (CHCl3)209 
acetate ester (NMR, UV, IR)224  
[α]D = +34.5º (D), –37.6º (E) (CHCl3)224 
structural revision225,227 
plukenetione F 
(203) 
 
Clusia plukenetii (St. Thomas, Barbados)224 
 
(NMR, UV, IR)224 [α]D = –53.6º (CHCl3)224 
characterized as mixture with 205 (NMR, UV, IR)223 
structural revision132 
15,16-dihydro-16-
hydroperoxy-
plukenetione F 
(204) 
 
Clusia havetiodes (Ecclesdown, Portland, Jamaica)223 
Ochrocarpos punctatus (Mahajanga, Madagascar)217 
 
(NMR, UV, IR)223 [α]D = +24.7º (CHCl3)223 
structural revision132 
plukenetione G 
(205) 
 
Clusia havetiodes (Ecclesdown, Portland, Jamaica)223 
C. plukenetii (St. Thomas, Barbados)224 
 
(NMR, UV, IR)224 
characterized as mixture with 203 (NMR, UV, IR)223 
structural revision132 
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prolifenone A 
(206) 
 
Hypericum prolificum (Lawrence County, Pennsylvania, 
USA)228 
 
(NMR, UV, IR)228 [α]D = +13.3º (MeOH)228 
prolifenone B 
(207) 
 
Hypericum prolificum (Lawrence County, Pennsylvania, 
USA)228 
 
(NMR, UV, IR)228 [α]D = –0.58º (MeOH)228 
propolone A 
(208) 
 
propolis (Nuevitas, Cuba)229 
 
(NMR, UV, IR)229 [α]D = +40º (CHCl3)229 
propolone B 
(209) 
 
propolis (Guantanamo, Cuba)80 
 
(NMR, UV, IR)80 [α]D = +38.2º (CHCl3)80 
propolone C 
(210) 
 
propolis (Guantanamo, Cuba)80 
 
(NMR, UV, IR)80 [α]D = +35.7º (CHCl3)80 
propolone D 
ent-hyperibone G 
(211) 
 
Clusia minor (Havana, Cuba)79 
propolis (Guantanamo, Cuba)80 
 
NMR79 [α]D = +48.5º (CHCl3)79,80 
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pyrohyperforin 
pyrano[7,28-
b]hyperforin  
(212) 
 
Hypericum perforatum 
 Longxi, Gansu, China162,230 
 Tokushima, Japan59 
 Mt. Orzen, southeast Serbia58 
 
(NMR, UV, IR)162,230 [α]D = +83.5 (CHCl3)162,230  
sampsonione A 
(213) 
 
Hypericum erectum (Japan)218 
H. sampsonii  
 Jinhua, Zhejiang, China32,231 
 Yunnan, China232 
 
(NMR, UV, IR)231,232 [α]D = –49.10º (CHCl3)231 
sampsonione B 
(214) 
 
Clusia obdeltifolia (Chapada Diamantina, Brazil)216 
Hypericum sampsonii 
 Hunan, China37 
 Jinhua, Zhejiang, China32,231 
 
NMR231 IR216 [α]D = +10.0 (CHCl3)216 
sampsonione C 
(215) 
 
Hypericum sampsonii (Jinhua, Zhejiang, China)32,233 
 
(NMR, UV, IR)233 [α]D = +13.39º (CHCl3)233 
sampsonione D 
(216) 
 
Hypericum sampsonii 
 Jinhua, Zhejiang, China32,233 
 Chia-Yi, Taiwan185 
 
(NMR, UV, IR)233 [α]D = +12.27º (CHCl3)233 
sampsonione E 
(217) 
 
Hypericum sampsonii (Jinhua, Zhejiang, China)32,233 
 
(NMR, UV, IR)233 [α]D = +57.69º (CHCl3)233 
sampsonione F 
(218) 
 
Hypericum sampsonii 
 Jinhua, Zhejiang, China32,233 
 Yunnan, China232 
 
(NMR, UV, IR)232,233 [α]D = +14.52º (CHCl3)233 
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sampsonione G 
(219) 
 
Clusia obdeltifolia (Chapada Diamantina, Brazil)216 
Hypericum sampsonii (Jinhua, Zhejiang, China)32,233 
 
(NMR, UV)233 IR216,233 [α]D = +10.00º (CHCl3)233 
ent-sampsonione G 
(220) 
 
Clusia havetiodes (Ecclesdown, Portland, Jamaica)223 
 
(NMR, UV, IR)223 [α]D = –3.5º (CHCl3)223 
sampsonione H 
(221) 
 
Hypericum sampsonii 
 Jinhua, Zhejiang, China233 
 Chia-Yi, Taiwan185 
 
(NMR, UV, IR)233 [α]D = +5.15º (CHCl3)233 
sampsonione I 
(222) 
 
Hypericum sampsonii (Jinhua, Zhejiang, China)32,234 
 
(NMR, UV, IR)234 [α]D = +16.88º (CHCl3)234 
sampsonione J 
(223) 
 
Garcinia multiflora (Mudan, Pingtung, Taiwan)69 
Hypericum sampsonii (Jinhua, Zhejiang, China)32,234 
 
(NMR, UV, IR)234 [α]D = +1.48º (CHCl3)234 
sampsonione K 
(224) 
 
Hypericum sampsonii 
 Jinhua, Zhejiang, China32 
 Yunnan, China232 
 
(NMR, UV, IR)32,232 [α]D = –5.60º (CHCl3)32 
sampsonione L 
(225) 
 
Hypericum sampsonii  
 Hunan, China37 
 Jinhua, Zhejiang, China32 
 
(NMR, UV, IR)32 [α]D = +55.00º (CHCl3)32 
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sampsonione M 
(226) 
 
Hypericum sampsonii (Jinhua, Zhejiang, China)32 
 
(NMR, UV, IR)32 [α]D = +54.77º (CHCl3)32 
sampsonione N 
(227) 
 
Hypericum sampsonii (Hunan, China)37 
 
(NMR, UV, IR)37 [α]D = +22.0º (CHCl3)37 
sampsonione O 
(228) 
 
Hypericum sampsonii (Hunan, China)37 
 
(NMR, UV, IR)37 [α]D = +87.9º (CHCl3)37 
sampsonione P 
(229) 
 
Hypericum sampsonii (Hunan, China)37 
 
(NMR, UV, IR)37 [α]D = +18.6º (CHCl3)37 
sampsonione Q 
(230) 
 
Hypericum sampsonii (Hunan, China)37 
 
(NMR, UV, IR)37 [α]D = –9.65º (CHCl3)37 
crystal structure37 
no name 
sampsonione R  
(231) 
 
Clusia obdeltifolia (Chapada Diamantina, Brazil)216 
Hypericum sampsonii (Hunan, China)37 
 
(NMR, IR)216 [α]D = +10.8º (CHCl3)216 
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scrobiculatone A 
(232) 
 
Clusia scrobiculata (Campinas, São Paulo, Brazil)24 
propolis (Andes Trujillo, Venezuela)235 
brown propolis (throughout Cuba)212 
 
(1H NMR, UV, IR)24 [α]D = +44.7º (CHCl3)24 
18-ethyloxy-17-
hydroxy-17,18-
dihydro-
scrobiculatone A 
(233) 
 
propolis (Andes Trujillo, Venezuela)235 
 
(NMR, UV)235 
scrobiculatone B 
(234) 
 
Clusia scrobiculata (Campinas, São Paulo, Brazil)24 
propolis (Andes Trujillo, Venezuela)235 
brown propolis (throughout Cuba)212 
 
(1H NMR, UV, IR)24 [α]D = +44.7º (CHCl3)24 
18-ethyloxy-17-
hydroxy-17,18-
dihydro-
scrobiculatone B 
(235) 
 
Propolis 
 Manaus, Brazil20 
 Andes Trujillo, Venezuela235 
 
(NMR, UV)235 
secohyperforin 
(236) 
 
Hypericum perforatum (Yerevan, Armenia)160 
 
NMR160 
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semsinone A 
(237) 
 
Garcinia semseii (Morogoro, Tanzania)109,236 
 
(NMR, UV, IR)236 [α]D = +52º (CHCl3)236 
sinaicinone 
(238) 
 
Hypericum sinaicum (Sinai peninsula, Egypt)237 
 
(NMR, UV, IR)237 [α]D = +37.5º (CH2Cl2)237 
absolute configuration237 
spiranthenone A 
(239) 
 
Spiranthera odoratissima (Rutaceae; Brasilia, Brazil)238 
 
(NMR, IR)238 [α]D = +11º (CHCl3)238 
spiranthenone B 
(240) 
 
Spiranthera odoratissima (Rutaceae; Brasilia, Brazil)238 
 
(NMR, IR)238 [α]D = +13º (CHCl3)238 
spiritone 
(241) 
 
Clusia burchellii (Campinas, São Paulo, Brazil)24 
C. fluminensis (Campinas, São Paulo, Brazil)24 
C. pana-panari (Campinas, São Paulo, Brazil)24 
C. pernambucensis (Campinas, São Paulo, Brazil)24 
C. spiritu-sanctensis (Campinas, São Paulo, Brazil)24 
C. weddelliana (Campinas, São Paulo, Brazil)24 
 
O-Me ether (1H NMR, UV, IR)24 
subellinone 
(242) 
 
Garcinia subelliptica (Ishigaki Island, Japan)239 
 
(NMR, IR)239 [α]D = –2.8º (EtOH)239 
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sundaicumone A 
(243) 
 
Calophyllum sundaicum (Singapore)240 
 
(NMR, UV, IR)240 [α]D = +52º (EtOH)240  
sundaicumone B 
(244) 
 
Calophyllum sundaicum (Singapore)240 
 
(NMR, UV, IR)240 [α]D = +48º (EtOH)240 
symphonone A 
(245) 
 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
(NMR, UV, IR)47 [α]D = –37º (CHCl3)47 
symphonone B 
(246) 
 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
(NMR, UV, IR)47 [α]D = –81º (CHCl3)47 
symphonone C 
(247) 
 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
(NMR, UV, IR)47 [α]D = –67º (CHCl3)47 
O
O O OH
O
HO
OH
OHO
O
O O OH
O
OHO
O
O
O
O
OH
OH
O
O
O
O
OH
OH
O
O
O
O
OH
OH
OH
393
symphonone D 
(248) 
 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
(NMR, UV, IR)47 [α]D = –41º (CHCl3)47 
symphonone E 
(249) 
 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
(NMR, UV, IR)47 [α]D = –50º (CHCl3)47 
symphonone F 
(250) 
 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
(NMR, UV, IR)47 [α]D = –9º (CHCl3)47 
symphonone G 
(251) 
 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
(NMR, UV, IR)47 [α]D = –4º (CHCl3)47 
symphonone H 
(252) 
 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
(NMR, UV, IR)47 [α]D = –37º (CHCl3)47 
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symphonone I 
(253) 
 
Symphonia globulifera (dense rain forest, French 
Guyana)47 
 
(NMR, UV, IR)47 [α]D = –22º (CHCl3)47 
thorelione A 
(254) 
 
Calophyllum thorelii (central Vietnam)33 
 
(NMR, UV, IR)33 [α]D = +91.9º (MeOH)33 
oxy-thorelione A 
(255) 
 
Calophyllum thorelii (central Vietnam)33 
 
(NMR, UV, IR)33 [α]D = +323.0º (MeOH)33 
thorelione B 
(256) 
 
Calophyllum thorelii (central Vietnam)33 
 
(NMR, UV, IR)33 [α]D = +412.0º (MeOH)33 
uralodin A 
(257) 
 
Hypericum henryi 
 Jinping, Yunnan, China241 
 Lünchun, Yunnan, China60 
 
(NMR, UV, IR)241 [α]D = –55º (MeOH)241 
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uralodin B 
(258) 
 
Hypericum henryi (Lünchun, Yunnan, China)60  
 
(NMR, UV, IR)60 [α]D = –24.6º (MeOH)60 
uralodin C 
(259) 
 
Hypericum henryi (Lünchun, Yunnan, China)60  
 
(NMR, UV, IR)60 [α]D = –55.0º (MeOH)60 
xanthochymol 
(260) 
 
Clusia rosea 
 Dominican Republic107 
 Hilo, Hawaii, USA242 
Endodesmia calophylloides (Calophyllaceae; Balmayo, 
Centre Province, Cameroon)243 
Garcinia densivenia  (Douala-Edea Reserve, 
Cameroon)198 
G. indica (India)195 
G. intermedia (Homestead, Florida, USA)105 
G. livingstonei (Homestead, Florida, USA)48 
G. mannii (Douala-Edea Reserve, Cameroon)198,244 
G. ovalifolia (Douala-Edea Reserve, Cameroon)197,198 
G. pyrifera (Sungai Petani, Kedah, Malaysia)50 
G. spicata (Homestead, Florida, USA)105 
G. staudtii (Douala-Edea Reserve, Cameroon)245 
G. subelliptica 
 northern mountains, Taiwan52 
 Okinawa, Japan51 
G. xanthochymus 
 South Canara,200 India201,202,246 
 Homestead, Florida, USA19,105 
G. xipshuangbannaensis (Xishuangbanna, Yunnan, 
China)118,203 
G. virgata (Aoupinié, New Caledonia)119 
Rheedia edulis (Broward County, Florida, USA)41 
R. madrunno (Caracas, Venezuela)247 
propolis 
 Manaus, Brazil20 
 throughout Cuba120 
red propolis (Maceio City, Alagoas, Brazil)121 
 
1H NMR20,50,51,201,202,203,242,248 13C NMR20,50,51, 203,242,248 
UV20,41,51,201,202,242 IR20,51,201,202,203,242 [α]D = +141º,50 
+138º,51  +143.5º202,205 (CHCl3) +209.9º (MeOH)204 
structural revision;248 crystal structure248 
absolute configuration205,248 
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